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Families with an autosomal dominant predisposition to benign or
malignant tumours were identified in Newfoundland in the 1980s, including
families with von Hippel·lindau disease (VHl). the multiple endocrine
neoplasias, type 1 (MEN-1), and type 2 (MEN-2). and the hereditary colon
cancers. familial adenomatous polyposis (FAP), and hereditary non-polyposis
colon cancer (HNPCC). Each family was identified because of an excess of
early deaths and disabilities in family members who had presented with
symptomatic disease, and an increased anxiety in affected and unaffected
family members.
The medical team recognized that a multidisciplinary approach to the
disease in each family was necessary to improve the prognosis. and that a
screening program might be central to this type of care.
Successful genetic screening programs had been developed since the
1960s for severe or lethal hereditary diseases with neonatal or early childhood
onset: for early identification and treatment of affected infants. or for
identification of those at risk of having an affected child with provision of
counselling to allow informed.reproductive decisions. Subsequently predictive
testing for incurable late-onset diseases, such as Huntington disease, was
introduced to reduce uncertainty. Many lessons were learned from these early
screening programs. about the ethical requirements of screening for hereditary
disease, and the need for coordination with pre-screening and post-screening
education. counselling, and follow-up.
In the 1980s there were recommendations for screening programs for
hereditary tumour syndromes, for early identification of gene carriers to provide
reproductive counselling, and for early identification and treatment of tumours
to improve the prognosis. At the same time there were concerns that more
harm than good might result from this type of program. The large
Newfoundland families with VHL. MEN-1, MEN-2, FAP and HNPCC provided an
opportunity to develop, implement, and then evaluate clinical and genetic
screening programs for these hereditary tumour syndromes.
For each fthereditarycancerft an extended pedigree was documented and
medical records reviewed. A clinical screening protocol was developed based
on the type of tumours and ages at which they occurred. Educational materials
were prepared, counselling was provided, and clinical screening was offered to
affected and at-risk family members. Medical and psychosocial results of
screening were documented. Genetic testing by linkage analysis or mutation
detection was developed in collaboration with molecular geneticists in
Newfoundland and elsewhere, and predictive testing was offered to at-risk
family members. Affected and unaffected members of the VHL family were
interviewed to assess the psychosocial implications of the disease and the
screening program, and a formal health care evaluation was completed for the
VHLscreening program, including a cost-benefit analysis.
For VHL, an earlier age at diagnosis. an improved prognosis (reduced
morbidityandmortalityl,andabetterqualityoflife(reducedanxiety,and more
informed reproductive decisions) were demonstrated for those identified by
screening, compared with those presenting symptomatically. The overall cost
to society of screening and management of presymptomatic disease was less
than the combined costs of treatment of symptomatic disease and the costs
related to early deaths and disabilities. Screening programs for the other
hereditary tumour syndromes were less formally reviewed, but provided similar
Asagroupthese hereditarycancers differed from untreatable adult-onset
disordersbecausetheharmfuleffectsofthediseasegenescouldbemitigated.
At the same time, important differences were identified within this group of
diseases (the age at onset, severity of disease. the spectrum of disease
expression, the potential for treatment, and the state of genetic knowledge)
which influenced the development of specific screening programs, and the
attitudes of family members towards participation in the clinical and genetic
components of screening.
It was concluded that screening programs combining clinical and genetic
testing methods to identify and provide reproductive counselling for gene
carriers, and to identify and treat presymptomatic tumours, provide appropriate
management for hereditary tumour syndromes. and that this approach reduces
monetary costs to the health care system. as well as monetary and
psychosocial costs to individual family members.
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RATIONALE AND OBJECTIVES OF THESIS
Screening has been defined as the investigation of asymptomatic
members of a population at risk to identify those who are affected by. or
carriers of, a particular disease. Early screening programs were directed at
endemic or epidemic infectious disease (Mausner and Kramer 1985). A
population or sub-population at risk was screened to provide early treatment for
those identified to reduce morbidity and mortality and prevent spread of
disease. Screening subsequently was introduced fora widevarietyofdiseases,
including hypertension, diabetes, and cancer, to discover and treat disorders
not yet clinically recognizable (Fost 1992).
The rationale for development of screening programs as outlined by
Wilson and Jungner (1968) is based on the following requirements:
that there isa recognized burden of disease
that the populati.on at risk can be identified
that the natural history of disease is known
that a presymptomatic stage of disease can be identified by a
simple. non-invasive test
that treatment is available
and that early treatment improves prognosis and/orquality of life.
The screening testIs) used should be valid and reliable, as well as simple
and inexpensive, and should have high sensitivity and specificity (Mausnerand
Kramer 1985, Report of the Royal College of Physicians 1989, Holtzman
1992). Since the positive predictive value depends on the prevalence of the
condition in the population, the population to be screened should be chosen
with care. ie, there should bea high prevalence of the condition (Mausnerand
Kramer 1985, Thompson et al 1991). The screening tests should be part of a
complete program (Scriver 1980, Modell and Petrou 1988) with education and
counselling about the goals of the screening program before testing, and
appropriate follow-up after testing. including confidential reporting of results,
and diagnostic investigations to confirm positive screening results. Facilities
for treatment should be available without financial restrictions for all those
testing positive (Committee for the Study of Inborn Errors of Metabolism 1975,
Assessing Genetic Risk 1994).
Although the original aim of screening programs was to permit earlier
treatment,screeninghasalsobeenusedforresearchparticularIytodetermine
the frequency or natural history of disease, and to develop new screening
programs,and,inthecontextofscreeningforcarriersofhereditarydisease.for
reproductive counselling (Scriver 1980, Report of the Royal College of
Physicians 1989).
iii) f1b.ig
Because screening, by definition, is directed at asymptomatic individuals
rather than those seeking medical attention for recognized symptoms, there is
a responsibility to do more than just practice good medicine by treating those
identified (Sackett et al1991, Fost 1992). Particularly there is a requirement
to maximize the benefits and minimize any harm. There is a danger that those
identified by screening may be discriminated against socially, or in terms of
health or life insurance, or employment (Billings and Beckwith 1992a, Ostrer
et al 1993). Screening should, therefore, be offered rather than imposed on
society, and informed consent required from each individual to be tested.
Results of testing must also be given confidentially only to the person screened
(Knoppers and Chadwick 1994).
There is also a risk that when a "weU" person is classified as "affeeted",
this labelling (Sackett et al 1991) may precipitate the onset of symptoms.
Screening may thus take away health (Fost 1992). This may be acceptable if
early identification and treatment ultimately improves the medical outcome.
But it is not acceptable if screening only lengthens the illness by advancing the
onset of disease (Sackett et al 1991). Screening programs must therefore be
evaluatedtoensurethatthegoalsareachieved,andthatbiases(eg,lead-time
bias learlierdiagnosis with no change in ultimate survival), and length bias
lbetterprognosisinthescreenedgroupbecauseofidentification of those with
more indolent disease)) do not confound the results (Sackett et al 1991).
Screening programs should also be evaluated economically. to determine
whether the costs are appropriate for the benefits (both medical and
psychosocial) that are obtained (Drummond 1980).
6.0.1Ie Ser.enlng
Screening has been applied to genetic disorders since the 1960s when
screening programs for neonatal detection and treatment of phenylketonuria
(PKUI and other inborn errors of metabolism were introduced (Erbe and Boss
19901. Genetic screening programs have now been developed to detect and
treat other hereditary diseases. The goal of many genetic screening programs.
however. is to identify those at high risk of having a child with a severe or
lethal untreatable disorder. and to provide genetic counsell ingtoassistwith
reproductive decisions (Cao et al 1981. Kaback et al 1993).
Genetic screening is defined as the search within a population for
persons with certain genotypes that cause or predispose to geneticdisease.in
those persons themselves, or in their descendants (Thompson et aI1991). This
screening is aimed at a whole population. or a defined segment. of the
population. when there isa recognized riskofaparticulardisease. and there is
a simple buteffeetive screening technique to identify those with the specific
genotype (Assessing Genetic Risk 19941.
The rationale for the first population-based genetic screening programs
was that early identification would allow early treatment to prevent the harmful
consequences of the particular mutation. Neonatal screening for detection of
PKU in the early 1960s was the prototype of this type of program (Fost 19921.
Although neonatal screening for PKU and possibly other inborn errors of
metabolism is now used in most developed countries. the concept of genetic
screening was under intense scrutiny before its value was widely accepted
(Committee for the Study of Inborn Errors of Metabolism 1975).
It is now acknowledged that early treatment is not the only acceptable
objective of genetic screening. Some screening programs are undertaken to
permit informed reproductive decisions (Report of the Royal College of
Physicians 1989). This includes prenatal screening for age-related
chromosomal disorders by amniocentesis or chorionic villus sampling and
cytogenetic analysis (eg. Down syndrome screening which was introduced in
the late 196Osl. and for neural tube defects. originally by amniotic fluid alpha-
fetoprotein measurement. and more recently by maternal serum alpha-
fetoprotein (MSAFP) measurement. It also includes carrier detection programs
in specific high-risk groups. Screening programs that identify carriers and
carrier couples for Tay-Sachs disease in Ashkenazi Jewish populations. or for
a or ,8-thalassemia in southeast Asian or Mediterranean populations. have
significantly reduced the incidence of these serious or fatal diseases and have
allowed carrier couples to have the normal children that they desired (Modell
and Kuliev 1991). Screening programs for sickle cell anemia carriers in black
populations were not originally as well accepted (Committee for the Study of
Inborn Errors of Metabolism 1975) (since the programs were less successful in
educating the population at risk and their health care workersI,and popUlation
screening for cystic fibrosis carriers is thought by most to be premature
(Biesecker et al 1992, Statement of the American Society of Human Genetics
1992).
Screening programs whose initial objective is enumeration orresearch
(Scriver 1980) may result in other successful population-based screening
programs for treatment or reproductive counselling, through:
identification of other high-risk groups,
development of effective screening techniques
biochemical,radiologicalormolecular,or
development of treatments for identifiable diseases.
Screening programs for presymptomatic identification of carriers of
autosomal dominant (AD) dis~ase, such as Huntington disease (HO), myotonic
dystrophy, or polycystic kidney disease (ADPKDI, to allow reproductive
planning and to reduce uncertainty, have also been suggested (Assessing
Genetic Risk 1994, Elias and Annas 19941, but few areas would have "a
sufficiently high incidence for population-based screening. However,predictive
testing or presymptomatic diagnosis in members of identified families could be
considered family screening. The HD predictive testing/presymptomatic
diagnosis programs have some lessons for other screening programs (Ball and
Harper 1992, Wexler .19921. particularly those for other adult-onset diseases.
The HD programs have been highly structured and have emphasized the need
for counselling and support before and after testing because of the possible
negative psychosocial aspects associated with predictionofboth increased and
decreased risk of an incurable disease (Wiggins et al 19921.
With the rapid expansion of genetic information resulting from the
Human Genome Project. new areas are rapidly opening up where genetic
screening may be introduced (Holtzman 1992. Caskey 1993b. Editorial 1994a.
Motulsky 19941. It has been stated that "It will soon be considered malpractice
if preventable disorders are not discovered early enough by established
screening programs" (Bickel 19801. However, even if genetic screening
programs are desirable and technically possible, they must be developedand
introduced only when the medical and psychosocial implications of the
programs have been properly considered and evaluated (Croyle and Lerman
1993b. Assessing Genetic Risk 19941.
ScrgDlnp fpr ".,odillry Tumour pradiSQQ.itigo
The AD tumour predisposition syndromes such as von Hippel-Lindau
disease. the multiple endocrine neoplasias. and the hereditary colon cancers,
are characterized by a variable age at onset. and variable type and order of
manifestations. They are potentially lethal but treatable if identified early. In
the genetics literature. a program for the identification of genetic disease
amongst those known to be at risk because of family history. has been
considered testing rather than screening (Scriver and Fujiwara 1992).
However. within the medical literature for these conditions. the term
·screening" has been used for the identification of gene carriers among
patients' relatives. and more particularly. for the identification of individual
manifestations in those known (or at risk) to carry the gene (Vasen et al 1989b.
Vasen et a11990a. Fost 1992. Eng et al 1994b).
In the past. patients with hereditary tumours frequently presented
symptomatically with advanced disease that was difficult to treat. resulting in
significant morbidity and mortality (8ussey 1975. Lamiell et al 19891. 8ecause
of the late age of onset. many of these patients hadseveralchildren before the
diagnosis was made and the 50% risk of recurrence to any offspring was
recognized. Since those at risk can be identified from the pedigree. screening
for these syndromes would seem indicated to facilitate early diagnosis of
disease.
al so that particular manifestations can be identified and treated at
an early stage. and
bl so that genetic counselling can be given prior to the reproductive
period.
This screening may consist of:
clinical testing, to identify an early stage of particular
manifestations if the natural history of disease is well
characterized,and presymptomatic disease can be identified by
acceptable investigations (Skogseid 1991a, Vasen et al 19941,
with, or without,
bl genetic testing to identify gene carriers by linkage analysis if
informative closely-linked markers have been identified, or by
mutation analysis if the gene has been cloned and the mutation
identified (Glenn et al 1992, Petersen et al 19931.
Once the components ofa screening protocol (the type and timing of
investigations) have been established, and the screening program has been
instituted, it is necessary to evaluate the program (Shortell and Richardson
1978) to determine whether the objectives have been met (earlier identification
and more successful treatment of individual manifestations, identification of
gene carriers at a pre-reproductive age, and reduced anxiety and increased
understandingaboutthedisease),andwhetherthebenefitsoftheseoutcomes
outweigh the costs to the individuals in these families and to the medical care
system (Drummond et aI1986).
There are a number of large families in Newfoundland with these
variable AD diseases, including families with von Hippe.-Lindau disease (VHL),
the multiple endocrine neoplasias (MEN-1 and MEN-21, and the hereditary colon
cancer syndromes, familial adenomatous polyposis (FAPI, and hereditary non-
polyposis colon cancer (HNPCCI or Lynch syndrome.
The experience with these families can be used:
to investigate the feasibility of instituting a screening program,
to determine the appropriate components ofascreening protocol,
iiil to compare the medical and genetic outcome for family members
who have been screened with those who were not screened, and
iv) to determine the cost, both financial and non-financial, of
maintaining such a screening program.
UTERATURE REVIEW
There is extensive literature on all aspects of screening for hereditary
disease, including the rationale for screening, the implementation and results
of previous screening programs, and ethical concerns regarding screening. This
literature is briefly reviewed for the lessons to be learned and applied to the
development of new programs. The emphasis is on the successes and
problems of earlier programs, and the ethical issues such as autonomy,
confidentiality,equityanddiscriminationwhichmustbeconsidered.
Scr••nfng to Allow Early Id,ntffleaJign .ad Trt,tmlnt Of Gla.tic; PIu'"
Neonatal§cr@enjog
Genetic screening was first introduced in the early 1960s with programs
for neonatal identification and treatment of infants with phenylketonuria (PKUI
(Committee for the Study of Inborn Errors of Metabolism 1975, Erbe and Boss
19901. A burden of disease had been recognized (untreated PKU causes severe
mental retardation requiring costly institutionalized care [Scriver 198011, a
simple test had been developed (the Guthrie bacterial inhibition assay measures
phenylalanine concentration in a dried blood spot on filter papercollectedfrom
a neonate [Guthrie 1961)), and a treatment was available (early institution of
a phenylalanine restricted diet prevents mental retardation [Committee for the
Study of Inborn Errors of Metabolism 197511.
Although there was opposition from the beginning, including from some
who denied that elevated phenylalanine caused mental retardation (Bessman
1966), a strong lobby promoted newborn screening for inborn errors of
metabolism, particularly PKU, as an innovation in public health to prevent
mental retardation (Scriver 1~80, Fost 19921. It became clear later that the
clinical and genetic features of PKU, the validity of testing, and the
effectiveness of treatment were not as well understood as was thought when
the screening program began (Wilfond and Fost 1990). There was also much
variation in the implementation of screening and in the integration into an
overall program including education, informed consent, and foilow-up (Scriver
19801. All features of the PKU screening program, and other screening
programs initiated subsequently were extensively reviewed in 1975 by the
National Academy of Sciences (Committee for the Study of Inborn Errors of
Metabolism 19751. and the lessons learned have been instructive in the
development of other programs.
Since a positive screening test is not necessarily diagnostic, screening
tests must be followed up by appropriate investigations to confirm or reject a
specific diagnosis (Report of the Royal College of Physicians 19891. The failure
toappreciatetheheterogeneityofthehyperphenylalaninemiasin the early days
of the PKU screening programs, meant that some infants were incorrectly
identified as having PKU and unnecessarily, and sometimes detrimentally,
treated (Erbe and 80ss 1990, Fost 1992). The Guthrie assay identified
transient hyperphenylalaninemia. persistent non-PKU hyperphenyfalaninemia
(both benign conditions not requiring treatmentl, and tetrahydrabiopterin
deficiency (requiring a different treatmentl, as well as classic PKU. Even within
families with classic PKU, there can be variation in clinical expression so
treatment must be monitored closely.
The timing of testing was found to be important (American Academy of
Pediatrics 19651. For PKU, a false negative result could occur if the test was
done too early (eg, on the first day or two of life before there was sufficient
intake of phenylalanine). But hospital stays were short and unless screening
was done before infants left hospital. there was a danger that itwouIdnotbe
done at all. and some affected infants could be missed.
The appropriate duration of dietary treatment for PKU was also not clear
in the 1960s when screening began (Committee for the Study of Inborn Errors
of Metabolism 19751. Because the diet is quite unpalatable, it was desirable
to minimize the time that it was required. However. intellectual deficits have
subsequently been identified in some of those whose dietary restrictions were
stopped in late childhood or early teens. The most serious unanticipated result
of stopping the diet early was the occurrence of maternal PKU: severe mental
retardation in the non-PKU offspring of mothers with previously treated PKU
(Hansen 1973). It is now recognized that dietary restrictions are necessary
during and. preferably. prior to pregnancy for women with treated PKU to allow
normal development of the fetus.
Ethical principles require that informed consent be given by those
participating in a screening program (or by parents or guardians if below the
age of consent) (Fast 1992. Assessing Genetic Risk 19941. Some of the
original PKU and other screening programs were mandatory (Farlel and
Holtzman 1984) to avoid missing affected individuals. It is now agreed by
most that screening should be offered to all. but that participation should be
voluntary (Report of Royal College of Physicians 1989. Assessing Genetic Risk
19941. Adequate education and counselling about a program are important for
increasing understanding and compliance (Farlel and Holtzman 1984, Wilfond
and Fost 1990).
Guthrie spot tests similar to the test for PKU were developed for neonatal
detection of a number of other inborn errors of metabolism, including
tyrosinemia, histidinemia, maple syrup urine disease and some forms of
homocystinuria (Committee for the Study of Inborn Errors of Metabolism 1975).
There was some impetus to use the dried blood spots for as many screening
tests as possible, whether or not treatment was available, and whether or not
the frequency of the specific disease warranted it (Assessing Genetic Risk
1994). Multiplex testing is now discouraged unless each program is
independently evaluated (American Academy of Pediatrics 1965, Fost 1992,
Assessing Genetic Risk 19941.
Even when mUltiplex testing is appropriate, there are differing opinions
on how much information should be provided about each test. Elias and Annas
(19941 believe that general information about similar tests is adequate because
too much detail about individual risks (particularly when these risks are low)
would cause unnecessary anxiety. Others (Fost 1992. Assessing Genetic Risk
1994) recommend more detailed counselling about each test. Because of the
restrictions on multiplex testing, the number of neonatal screening programs in
some countries or states has been reduced. Treatment for maple syrup urine
disease (MSUD) is very difficult even when started early, so screening for
MSUD. which is very rare. may be inappropriate (Erbe and Boss 1990).
Newborn screening for tyrosinemia is appropriate in certain sub-populations
such as the Lac St. Jean region of Quebec where the incidence is high (1/650
births) (Demers et a11994, Grompe et aI1994). but not generally. Screening
for congenital hypothyroidism, a severe but treatable disease, is recommended
(American Academy of Pediatrics 19771. although the disorder is not always
genetic in etiology.
New neonatal screening programs should be developed rationally, not
just because a test is available. Programs are appropriate for severe imminent
diseases if diagnostic testing, successful treatment, and follow-up are all
available for infants that test positive (Assessing Genetic Risk 19941. Neonatal
screening for Duchenne muscular dystrophy has been criticized for providing
"unwanted" information on an untreatable disease (Marshall 1993) and
therefore causing unnecessary anxiety for the parents, butalsorecommended
on the basis that it provides information for future reproductive decisions (for
the parents. or other relatives who might also be at risk of havinganaffected
child) and, therefore. may prevent subsequent affected children (Thompson et
a119911.
Neonatal screening programs for cystic fibrosis (CF), one of the most
common autosomal recessive diseases in the white population, have also been
considered. When the CF ge,1e was cloned in 1989 it was anticipated that a
DNA-based test for CF would soon become available (Goodfellow 1989). The
diversity of CF mutations now identified means that this is not feasible;
although the ~F508mutation is present on 70,*, of CF chromosomes, over 300
other mutations have been identified, and there is no simple method to detect
all mutations (Scriver and Fujiwara 19921. There is no direct biochemical test
for CF, but immunoreactive trypsinogen is secondarily elevated in the blood of
CF neonates, and Guthrie cards can be used for this testing (Ranieri et al
19941. The randomized controlled trial in Wisconsin (Fost and Farrell 1989),
however, has not established that early diagnosis and treatment reduce
morbidity and mortality from CF (Hammond et al 1991, Farrell and Mischler
19921. This should be clarified before neonatal screening for CF is expanded.
Scuta.oe to "'rmit Infgrmtd R.prgdugtiva ptA'lpn.
Screening to permit informed reproductive decisions is offered to
individuals in specific populations or sUb-populations who are at risk to produce
a child with a severe or lethal genetic disorder (Charrow et al 1990, Modell
19901. This includes prenatal screening for Down syndrome or for neural tube
defects (NTD), and heterozygote screening in high-risk populations to identify
carrier couples for specific al,ltosomal recessive diseases.
prenatal SGfflftojng
Prenatal screening for Down syndrome (Trisomy 211 and other less
common trisomies, by amniocentesis and cytogenetic analysis, was first offered
in the early 1970s to older pregnant women because of the increased risk of
non-disjunction with late maternal age (Hook et al 1983, 0'Alton and
DeCherney 1993): in 1988 in the USA, 25-30% of Down syndrome infants
were born to mothers over 35 years of age, although only 8% of births
occurred in women of this age group (Haddow et al 19921. Early
amnio<::entesis before 15 weeks gestation, or chorionic villus sampling at 9-10
weeks are increasingly used instead of traditional "'ate"amniocentesissothat
an earlier decision can be made about the outcome of the pregnancy if
abnormal cytogenetic results are received (D'Alton and DeCherney 1993). For
the majority of women tested, a normal screening result is obtained resulting
in reassurance and reduced anxiety (Report of the Royal College of Physicians
19891. For those identified to be carrying an affected fetus, most
(approximately 85% [Report of the Royal Commission on New Reproductive
Technologies 1994)) choose therapeutic abortion, although others use the
information to prepare for the birth and management of an affected child
(Charrow et al 1990, Platt and Carlson 1992).
Because screening for Down syndrome in pregnant women over the age
of 35 was shown to be cost-effective, for economic reasons this has been
established as the cut-off age (Henderson 1991, Hagard and Carter 1976).
But, although the highest risk of a Down syndrome child is in women over 35
years of age, the greatest number of Down syndrome infants are born to
women less than 35 years of age since the majority of births are in this age
group (Platt and Carlson 1992). The standard screening for Down syndrome
therefore misses the majority of affected fetuses (D'Alton and DeCherney
1993). Advances in prenatal diagnosis have provided new screening tests for
this younger age group. It has been recognized that maternal serum alpha-
fetoprotein (MSAFP) and unconjugated estriol are decreased, and human
chorionic gonadotropin (hCG) increased in Down pregnancies (all measured at
15-17 weeks of gestation) (Wald et al 1988, Haddow et al 1992).
Amniocentesis and cytogenetic analysis can be offered to all women with these
abnormal values. When all pregnant women are screened with maternal serum
testing, 35% of Down pregnancies can be identified by decreased MSAFP
alone, and 60% of Down pregnancies can be identified by the combined results
(decreased MSAFP and unconjugated esteriol, and increased hCG) (Haddowet
al 1992). Anxiety because of a positive result may be greater in those
identified by this population screening, since the result was not anticipated
(Editorial 1992b, Croyle and Lerman 1993b, Assessing Genetic Risk 1994),
than in those screened for late maternal age where the high risk is recognized.
Since the sensitivity and specificity of ~he MSAFP, unconjugated estriol
and hCG assays are low, both false negative and false positive values occur.
Those with a false negative result may have a false sense of security, and
those with a false positive result may have significant anxiety that is difficult
to resolve (Marteau 1989). Thus, there are trade-offs: screening only the high-
risk population reduces false positives but misses many Down syndrome
infants, whereas screening the whole population detects most Down
pregnancies but increases the number of false positives because of the number
of individuals being screened.
Prenatal screening for NTO (ie, spina bifida and anencephaly) by
amniocentesis and measurement of amniotic fluid AFP (increased in the
presence of fetal NTDI was first offered to women with a previous affected
child; these women having about a 3% recurrence risk (0'Alton and DeCherney
19931. This screening, however, can only detect about 10% of fetuses with
NTDs since about 90% occur in women with no previous history. Increasingly,
MSAFP screening is offered to all pregnant women. Detection of increased
MSAFP followed by prenatal ultrasound will identify 80-90,*, of all NTD fetuses
(D'Alton and DeCherney 19931. As with prenatal screening for Down
syndrome, the majority of women will receive a normal screening result
(Charrow et al 19901. For those who were screened because of a previously
affected child,this will provide reassurance and reduction inanxiety. Forthose
receiving an abnormal result,adecision is made either to arrange for expert
care at a high-risk birth, or to have a therapeutic abortion.
HAtAwzvgntftSGrAAning
Heterozygote screening programs have been employed with varying
degrees of success for severe or lethal autosomal recessive disorders.
(Tsukahara and Kadota 1977, Mouzouras et a119801. The goal is to identify
carrier couples and provide information relevant to their reproductive decisions
(Kaback 19901. These screening programs should only be implemented when
the disease is at high frequency at least in a specific population, there is a
sensitive and specific test for mass screening, and education and genetic
counselling are available to explain the program and interpret the results
(Thompson et al 1991). Prenatal diagnosis should be possible or treatment
should be available, and the programs should be voluntary with informed
consent obtained prior to testing (Fost 1992).
Mandatory screening for carriers of sickle cell anemia, in the American
black population. was introduced in various states of the USA in the early
1970s even though these conditions for development of a screening program
did not all apply (Committee for the Study of Inborn Errors of Metabolism 1975,
Farfel and Holtzman 1984). Sickle cell anemia is an extremely variable
condition but with severe disease and early lethality in manyaffeeted. Carriers
were identified by hematological testing but prenatal diagnosis was not
available, nor was treatment possible. Reproductive options for carrier couples
were therefore limited to ignoring the risk, or avoidance of pregnancy
(Committee for the Study of Inborn Errors of Metabolism 1975). Since it was
the black population that was at risk (carrier frequency of approximately 9%)
and therefore screened for sickle cell anemia, these options wereseenbysome
as racial genocide (Fost 19921. Because of poor planning. and poor education
ofboththosebeingscreenedandthehealthcareworkers,therewas confusion
about the meaning of carrier status, and stigmatization and frequent
discrimination against those identified (Wilfond and Fost 1990). This
emphasizes the need for strict confidentiality in a screening program. Results
should not be given to a third party without prior consent, whether this is
another family member, an employer, or an insurance company (Knoppers and
Chadwick 1994).
A similar attempt at sickle cell anemia screening in Greece in 1973
resulted mainly in social ostracism of the carriers identified (Petrou et al 1992).
Many of the problems encountered with sickle cell anemia screeningresulted
from the fact that it was imposed on a population rather than planned with that
population - indicating the harm that can occur even when screening is
initiated with the best intentions (Committee for the Study of Inborn Errors of
Metabolism 1975).
Carrier screening for Tay Sachs disease (TSD) in those of Ashkenazi-
Jewish descent (Kaback et al 1993), and for the thalassemias, particularly in
Mediterranean populations (Mouzouras et al 1980, Scriver et al 1984), also
introduced in the 19705, met with much greater success because prenatal
diagnosis was available and the programs were planned with leaders of the
communities involved. Thert~was extensive education of health care workers
and potential participants, and testing of pilot projects (eg, for Tay Sachs
disease in the Washington/Baltimore area in 1970-71 [Kaback 19721. and for
p-thalassemia in Sardinia in 1976-1978 [Cao et al 19811 and in Montreal in
1978 [Scriver et al 198411 before implementation of voluntary screening
programs. Prenatal diagnosis and therapeutic abortion was considered an
option by many carriers because of the uniformly severe burden of disease (Cao
et al 1989, Kaback et al 1993) - (the burden of disease being a subjective
measure of the impact of a disease on an individual or family, comprising
concepts of degree of risk, and severity of medical and psychosocial effects of
the disease). British Pakistani couples at risk for p-thalassemia, however, were
much less likely to panicipate in screening until first trimester diagnosis (by
chorionic villus sampling and molecular techniques), and, thus, early therapeutic
abonion became possible (Modell and Modell 1990).
While decreased incidence of disease should not be the primary goal of
screening, this may be one of the results of such a program. The high uptake
of prenatal diagnosis and selective therapeutic abonion for both TSD and P-
thalassemiahasresultedinasignificantdeclineinbinhsofaffectedindividuals
and therefore a reduced burden of disease to the family and to the community.
For example, there has been a 90% reduction in incidence of TSD in the Jewish
population of the USA and Canada (1970-1993) (Kabacket a11993), and also
a 90% decrease in thalassemia major binhs in Sardinia where the carrier
frequency is 1/9, and 1/80 couples are at risk (Cao et aI1989). Carriers have
not only been able to avoid the binh of an affected child, but they (and those
identified as non-earriers) have been able to have the normal children that they
desired but would previously have been afraid to have (Modell and Kuliev
1993).
Screening for TSD was originally based on an enzymatic assay
(measurement of serum hexosaminidase levels) (Kaback et aI1993). a test that
required precisely controlled conditions. The genetic defect causing TSD has
now been recognized. and three mutations identified which account for
approximately 95% of mutant alleles in Ashkenazi-Jewish populations. A more
specific DNA-based assay for TSD carrier status in these populations has
therefore been developed (Triggs-Raine et al 1990). However. if not all
mutations have been identified. or if the clinical and genetic heterogeneityof
a particular disease have not been characterized. DNA-based screening is not
appropriate (Motulsky 1994).
Recently. voluntary sickle cell anemia screening programs in the United
Kingdom have been more acceptable than earlier programs (Petrou et al 1992.
Modell and Modell 19901. Midtrimester prenatal diagnosis of sickle cell anemia
has been available since 1977 but there was little demand for screening until
first trimester prenatal diagnosis and early therapeutic abortion became possible
in the early 1980s. The decision for or against prenatal diagnosis and
therapeutic abortion can be more difficult for many sickle cell anemia carrier
couples than for TSD or thalassemia carrier couples because of the variable
severity of the disease. Approximately 50% of all carrier couples. however.
request prenatal diagnosis. and this increases to greater than 90% of those
with a previously affected child (Petrou et al 1992). If prenatal screening is not
desired.neonataldiagnosisandprophylactictreatmentofaffectedinfantswith
penicillin and folic acid are now recommended to reduce morbidity by
preventing infections (Modell and Modell 19901.
Carrier screening for cystic fibrosis, the most common severe, autosomal
recessive disease in Europeans, has been extensively discussed, particularly
since the cystic fibrosis transmembrane receptor (CFTR) gene was cloned
(Rommens et al 19891. However, there still is no direct biochemical or
physiological carrier testing available for CF, as was available for TSD and p-
thalassemia when those screening programs began (Scriver and Fujiwara
19921. Carrier screening is therefore only possible by mutation analysis, and
the sensitivity of this testing is not yet sufficient for population-based carrier
screening, except in certain sub-populations such as Ashkenazi Jewish
populations where few different mutations occur.
As stated previously, the most common mutation, ~F508, is present on
70% of CF chromosomes but over 300 other mutations are known, and some
mutations have not yet been identified. There is no single test or efficient
combined testing to identify all mutations (Serre et al 1991). The cost of
population-based screening is also extremely high - an estimated $2.2 million
per CF birth prevented (Wilfond and Fost 19901. Until 90-95% of carriers can
be accurately identified. CF popUlation-based carrier screening is considered
premature (Biesecker et al 1992, Scriver and Fujiwara 1992, Workshop on
Population Screening for the Cystic Fibrosis Gene 1990). Meanwhile, the
genetic basis for the wide phenotypic variability ofCFis being workedout,and
improved therapies for both the pancreatic and pulmonary features of the
disorder are being developed. thus increasing the life-span and improving the
quality of life of those with CF (Wilfond and Fast 1990. Kaback et al 1993.
Statement of the ASHG on Cystic Fibrosis Carrier Screening 1992).
Even when carrier screening fora particular disease is appropriate,the
coordination of this screening with educational and genetic counselling
components of a program is necessary (Farfel and Holtzman 1984). There is,
however. a severe shortage of geneticists and genetic counsellors to provide
this service (Ball and Harper 1992. Editorial 1994a1. If population screening for
CF carriers were introduced. there would be an even greater strain on genetic
The fact that heterozygote screening programs until now have been
targeted to particular ethnic groups has had both positive and negative
consequences (Zeesman et al 1984. Modell and Petrou 1988, Report of the
Royal College of Physicians 1989. Holtzman 1992). In some cases this has
meant that a screening program has been tailored to the needs of the specific
community (Kaback et al 19931. but in other situations, discrimination or
stigmatization of participants has been the result (Farfel and Holtzman 1984).
Heterozygote screening frequently takes place early in pregnancy.
because it is perceived as a reproduction-related test (Kaback et al 1993). This
is not the ideal timing for carrier testing since it reduces the 0 ptionsavailable
to carrier couples identified (Workshop on Population Screening for the Cystic
Fibrosis Gene 1990. Report of the Royal College of Physicians 1989). In order
to reach those who could benefit from carrier screening at an earlier stage.
improved education and communication is necessary (Modell and Petrou 1988.
Williamson 1993). This has been conducted by community or church groups
of the relevant populations. or through pilot studies in high schools.
Particularly with regard to screening for CF carriers. several different
approaches have been considered. including offering this screening to high
school students (Cobb et al 1991. Mitchell et al 19931. to all adults in a family
practice clinic (Modell 1993)ortoallparentsinapediatricpractice (Watson et
a119921, to relatives of known CF carriers in a ·cascade" strategy (Super et
al 19941. to prenatal couples (Livingstone et al 1994). or to pregnant women
followed by the partner only if the woman is a carrier (Mennie et al 1992).
Each method has advantages and disadvantages and the choice between them
is complex (Editorial 1992a, Editorial 1994b, Raeburn 1994).
Carrier screening for the fragile X syndrome. one of the most common
singlegenecausesofmentalretardation.hasalsobeenconsidered. particularly
since the mutation was ide!ltified to be an expanded trinucleotide repeat
(Sutherland and Richards 19931. Carrier females can be identified. and offered
genetic counselling and prenatal diagnosis. Currently the diagnostic techniques
are used for screening for the fragile X premutation and mutation within
families at risk. and pilot projects are evaluating the efficacy of population-
based screening programs (Caskey 1993b. Rousseau et al 19941.
It was previously stated that one of the pre-eonditions for development
of a new genetic screening program was the availability of a reliable and
sensitive test to detect individuals with a specific genotype. For many genetic
diseases, valid biochemical or physiological tests were not available; it was not
until molecular genetic techniques were developed for mapping and cloning
genes, and identifying linked markers or specific mutations, that screening
became possible. Because of the significance of advances in molecular
genetics to the development of new screening programs, I will briefly review
this progress before discussing screening programs for late-onset hereditary
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The rapid advances in molecular genetics in the 1980s, and even more
so since the Human Genome Projects were initiated in 1990. have resulted in
identification of DNA alterations. whether linked markers or actual mutations
of specific genes. that can be used for population and family screening for an
increasing number of genetic diseases (Report of the Royal College of
Physicians 1989. Collins and Galas 1993. Sutherland and Richards 1994).
Restriction fragment length polymorphism (RFLP) markers are heritable changes
of DNA base sequence which alter the ability of restriction enzymes to cut DNA
(Botstein et al 1980). As such they can be identified by laboratory techniques:
the appropriate restriction enzyme is added to a DNA sample, and the
fragments produced then separated by electrophoresis and identified by a
specific radioactively-labelled probe.
RFLPs are rarely the cause of a genetic disease but are distributed
throughout the genome, and have been used extensively as the markers for
linkage mapping of disease genes. After a gene is mapped. these markers can
also be used to follow a disease gene through a family. to allow predictive
testing for those at risk (Botstein et al 1980). RFLP markers have some
disadvantages. however. Their distribution throughout the genome is not
random. and they usually have relatively few alleles, therefore, may be
uninformative for mapping or predictive testing in a particular family.
Short tandem repeat (STR) markers (di-. tri- or tetra-nucleotide repeat
sequences, of which the most commonly used are the 'CA' repeat markers)
are randomly distributed and are much more numerous than RFLP markers (Lin
and Luty 1989, Dausset and Cann 1994). These STR markers have the
additional advantage that there are frequently multiple alleles (each with a
different number of copies of the repeated unit) which are readily
distinguishable on the basis of size (Weber and May 1989. Sutherland and
Richards 1994). The use of STR markers is frequently coupled with the
technique of polymerase chain reaction (PCR) (Sakai et al 1985) which allows
the amplification (production of multiple copies) of only the stretch of DNA of
interest. and detection of marker alleles within this segment of DNA. This
combination of the use of STR markers with PCR reduces the amount of DNA
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required, simplifies the laboratory procedure, and reduces the time required for
testing, all of which are important for development of a screening test for a
genetic disease (Assessing Genetic Risk 19941.
The number of specifically located genetic markers identified has
increased rapidly over the past few years (Ward and Davies 1993, Assessing
Genetic Risk 1994). The increased number of markers has in turn resulted in
an acceleration of the mapping and cloning of disease genes (CollinsandGalas
1993). It was initially expected that there would be relatively few different
mutationsofaspecificdiseasegene,and,therefore,thatcloning such a gene
would rapidly lead to direct mutation analysis for those at risk within known
families (Goodfellow 1989). For a few conditions this is the case, particularly
for the group of diseases caused byexpansionofatripletrepeatsequdnce(eg,
Huntington disease, myotonic dystrophy, and spinocerebellar ataxia) where
identifying a mutation is based on determination of the size of the repeated
sequence (Mahadevan et al 1992, Sutherland and Richards 1993, Benjamin et
al 1994). For other conditions such as tyrosinemia in eastern Quebec (Demers
et al 1994, Grompe et al 199~), only one or a few mutations occur in a specific
population, and in other situations such as for cystic fibrosis (CF),onemutation
may be particularly common (the ~F508 mutation occurring on 70% of CF
chromosomes) but many other mutations (over 300) also occur (Verlingue ilt
a119941.
For most genes the mutations are extremely diverse and many families
have unique mutations (eg, VHL [Crossey et al 1994), neurofibromatosis, type
2 (NF2) [MacColiin et al 1994), or FAP [Powell et a11993)}. For some genes
(eg, Marlan syndrome [Sutherland and Richard 1994) and neurofibromatosis,
type 1 (NF1) [Upadhyaya et al 1994]}, mutations are very difficult to identify
with the commonly used techniques such as single strand conformation
analysis (SSCP), and denaturing gradient gel electrophoresis (DGGE), (Caskey
1993a),oreven by sequencing the gene. For these diseases, genetic screening
by direct mutation analysis is possible in relativelyfewfamilieS,andpredictive
testing by linkage analysis is necessary for the majority of families where the
mutation has not been identified (Sutherland and Richards 1994).
Thus diagnostic tools are available to detect those who are at high risk
for many genetic diseases, whether through family studies or by population
screening. This information, however, must be used with care so that more
good than harm results (Assessing Genetic Risk 1994, Caskey 1993b).
$sr.,ningto RldyS' Uns'nainty
Huntingtgn djSfl8$A predictive tAsting
Few of the adult-onset AD diseases are frequent enough in the
population asa whole, orin a geographic or ethnic subgroup, for population
screening to be appropriate, but because of the AD inheritance pattern there
may be many relatives at risk who could benefit from family screening: the
families where these AD diseases occur can be considered the "populationat
risk". Because the primary defect for most of these diseases is unknown, the
identification of gene carriers by biochemical or physiological testing is not
possible. The identification of RFLP markers, however, provided the
technological basis for DNA-based family screening, the first example of this
being the predictive testing programs for Huntington disease (HOI (Harper and
Morris 1989).
HD is an incurable autosomal dominant neurodegenerative disorder
presenting in adult life. Family members at risk frequently have a great deal of
anxiety because of the inevitable physical and psychiatric decline of those who
inherit the gene, and the ramifications for close family members (Hayes 1992).
Many of those at risk expressed a desire to know their fate so that they could
plan for the future with or without the HD gene.
The HD gene was mapped to the short arm of chromosome 4 in 1983
by linkage to an RFLP marker (Gusella et al 1983), and predictive testing
became possible after other RFLP, and later, STR markers were identified in the
region. There was concern, however, among the professionals involved with
HD families about the potential costs and benefits of such testing (Harper
1992).
Previous population or family screening for genetic disease had been
directed towards severe diseases that were imminent, either at birth or in early
childhood. to permit early identification and treatment of those who were
affected; or to provide reproductive options which could prevent, or allow
preparation for, the birth of a child with a severe disorder (Bloch and Hayden
19901.
Even though the technology was available, there were concerns about
the appropriateness of predictive testing for an incurable disease such as HD
presenting in adult life (Bloch and Hayden 19901. There were fears that the
psychosocial costs from increased anxiety or depression, or discrimination
regarding insurance or employment would outweigh the benefits (Billings and
Beckwith 1992a. Natowicz et al1992, Cstrer et a119931. Family members at
risk were surveyed to identify the demand for this testing. In different studies,
50'*' to 70,*, of those responding expressed-an interest in predictive testing,
particularly to reduce the uncertainty under which they were living (Hayes
1992, Codori and Brandt 1994a1. Up to 65,*, of those surveyed desired
prenatal testing.
Strict guidelines were developed by geneticists. ethicists, and mental
health professionals before the first HD predictive testing programs were
initiated in the mid-1980s under carefully controlled research protocols
(Craufurd et al 1992). The predictive test was only offered to those over 18
years of age, informed consent was required, extensive pre- and post-test
counselling were included for all participants, and results were provided
confidentially (Bloch and Hayden 1990, Benjamin et a119941.
Predictive testing for HD by linkage analysis was thus made available,
but the uptake was much lower than expected for both adult and prenatal
testing. Only 9.5% of those eligible participated in the Canadian adult
predictive testing program (Quaid and Morris 1993), and only 5% worldwide
(HarperetaI1993).
The majoritY of those who declined testing when it was offered. stated
that the perceived costs (psychological stress. potential discrimination regarding
insurance or employment, "being unable to "undo" the testing") were too great
for the possible benefits (Quaid and Morris 1993). Many felt that they would
be interested in testing in the future, if treatment became available. if the test
were more accurate lie. if direet testing rather than linkage analysis were
possible). or if the testing process was simplified. Recently the gene was
cloned (Huntington's Disease Collaborative Research Group 1993) and because
of the tYpe of mutation (an expanded triplet repeat) a direct test is now
possible for most family members, including those at 25% risk, without the
need for samples from other relatives (Simpson et al 19931. Still. less than half
of those at risk request direct testing for the HD mutation. Overall. the high
psychosocial cost with Iinle or no perceived benefit is the major deterrent to
participation (Babul et al 1993).
There have also been fewer requests for prenatal diagnosis than
expected from previous questionnaires (18% in the Vancouver program
compared with 65% expected [Adam et al 199311. The main reason given by
eligible persons declining prenatal testing was the hope for a cure in time to
benefit their children. Underlying this was a strong desire to have children
despite the risk,andthefactthattermination of pregnancy was unacceptable
to many, particularly for future rather than imminent disease (Babul et a119931.
The majority of those tested, particularly those with increased risk, have
suffered less psychological trauma than expected (Wiggins et al 1992, Codori
and Brandt 1994a1. Unexpectedly, however, about 10% of those with
decreased risk, had difficulty accepting the results (Huggins et al 19921. The
fact that the overall response to HD predictive testing was good may be
attributable to the extensive pre-and post-test counselling (Wigginsetal1992,
Kessler 19941; or to self-selection of participants (Codori et al 1994b, Kessler
1994, van der Steenstraten et al19941, so that those perceiving an inability to
cope with an increased risk result did not take part in predictive testing. TIbben
et al (19931 suggest, however, that the apparent favourable response is in fact
denial of the undesirable results.
There is concern that psychosocial responses may not be as favourable
in the future if unsuitable candidates are persuaded by well-meaning
professionals to take the test, or if the extensive counselling, whichsupports
thosebeingtested,decreasell,eitherbecauseofthegoodoutcomespreviously
demonstrated,orbecausedemandforallformsofgeneticscreeningincreases
beyond the capacity of geneticists to provide the necessary counselling
(Craufurd et al1992, Wexler 1992, Codori et al1994b, Kessler 19941.
The cloning of the gene and possibility of direct testing for the mutation,
even for those at 25% risk, facilitates testing for some who could not be tested
previously, but raises new issues such as the conflict of interest between one
person's ·right to know·, and another's ·right not to know· IBall and Harper
1992, MacMillan and Quinn 1993, Simpson et al1993, Benjamin et al19941,
since identifying the mutation in one person may at the same time identify
another individual as an obligate gene carrier.
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Genetic testing, or screening, is being recommended for an increasing
number of adult-onset hereditary disorders, as more and more genes are
mapped and cloned (Editorial 1994a1. Some, like HD, are untreatable, for
instance, spinocerebellar ataxia, type 1 (SCA-1), another ultimately fatal
neurodegenerative disorder generally presenting in adulthood. Here, also,
predictive testing is requested to end the uncertainty of being at 50% risk. The
desire for predictive testing, and the use of this knowledge, arecorrelatedwith
theperceivedburdenofdisease-althoughprenataldiagnosisandtermination
of pregnancy are generally unacceptable, those who consider SCA-1 to be a
severe burden do not plan to reproduce unless found to be non-carriers INance
et a119941. Since the SCA-1 mutation is an expanded triplet repeat as in HD,
direct mutation testing is possible.
Screenjng tortrftatabl, adult-ooHtdjs,aIR
Other late-onset autosomal dominant disorders are treatable, and the
results of screening investigations lwhetherclinical or genetic) are used for
clinical management. as well as for reproductive decisions and reduction of
uncertainty. For both Marfan disease and NF2. the likelihood of successful
treatment is enhanced by early diagnosis of specific manifestations (Bridges et
al 1992, MacCollin et al 1993. The age at onset and severity of disease are
extremely variable. and for Marfan disease. particularly, includes those severely
affectedatbirth,andadultswithmildmanifestationsunrecognized except by
careful examination. Clinical screening of those at risk using specific
investigations to detect known manifestations has been used within families to
identify and treat pre-symptomatic disease. For these disorders, a major benefit
of screening is improved medical outcome (Bridges et al 1992, MacCollin et al
1993). Because of the variable age of onset, however, clinical screening must
be continued indefinitely for those with negative investigations. The addition
of molecular genetic testing to identify gene carriers could refine the clinical
screening programs.
For NF2, no genetic heterogeneity has been recognized, and even though
about 50% of NF2 families have a new mutation, the mutation can be identified
in the majority of families (MacCollin et a119941. When this presymptomatic
diagnosis is added to a clinical screening program there is minimal additional
psychologicalburden,andcostlyclinicalscreeningcanberestricted to gene
carriers. Because the typical age of onset of acoustic neuromas {the most
common manifestation of NF21 is in the twenties or later, genetic testing before
age 18 is not recommended.
For Marfan disease, on the other hand, extensive clinical and genetic
heterogeneity has been recognized (Franke and Furthmayr 1994) and a
mutation of the major gene, fibrillin, can only be identified in a minority of
families (even in those linked to the fibrillin locus on chromosome 15)
(Sutherland and Richards 1994). Although family members have expressed
interestinadefinitivemolecularscreeningtestforthemselveS,orforprenatal
diagnosis (Bridges et al 19921. predictive testing by mutation detection or
linkage analysis is only available fora few families.
Predictive testing for NF1 has also been considered. however the gene
is large. and until protein truncation testing {PTTI (Roest et al 1993) was used
recently (Heim et al 1994). relatively few mutations were detected. The
phenotype is also extremely variable with many gene carriers having skin
manifestations only, and the severity of disease cannot be predicted. Prenatal
diagnosis is, however. desired by some gene carriers, for preparation for the
birth of an affected child rather than for termination (Benjamin et aI1993).
Tuberous sclerosis is another AD disorder with variable age at onset and
variable manifestations (Smalley et al 1994). Very mild disease expression or
non-penetrance may be seen. Thus, even with comprehensive clinical
investigations, it may be difficult to make a diagnosis (AI-Guzali et al 19891.
A DNA diagnostic test to identify gene carriers would, therefore, be desirable;
but there are at least two loci for tuberous sclerosis, and frequently the gene
involved ina particular family is unknown.
Autosomal dominant polycystic kidney disease (ADPKD) is one of the
most common hereditary diseases with an incidence of approximately 1/1.000,
therefore, more common than cystic fibrosis or Huntington disease (Elles et al
1994). Although up to 30% of patients with ADPKD have mild or
unrecognized disease. 45% develop end-stage renal disease (thereforerequiring
dialysis or kidney transplant) by age 60 (Gabow 1993).
The PKD1 gene was mapped to chromosome (chr) 16 in 1985 (Reeders
et aI1985), and a second locus was subsequently identified on chromosome
4 (Peters et al 1993). Because of this heterogeneity, predictive testing by
linkage analysis was only available to families where chr16 linkage could be
demonstrated. The request for predictive testing. in any case, was not high.
The majority of gene carriers could be identified by symptomatic disease. or
positive ultrasound testing by age 30 (Parfrey eta11990, Bearet aI1992). and
many family members did not desire a definitive diagnosis before this age
(Gabow 1993). Prenatal diagnosis and termination were rarely requested
(Hodgkinson et al 1990) because of the late onset and unpredictable severity
of the disease, and because of the availability of treatment.butgenetictesting
is used to identify non-carriers for potential organ donation (Gabow et al 1993).
Although the disease is treatable. there still is no evidence that presymptomatic
diagnosis and treatment delays or prevents end-stage renal disease (Gabow
1993). The demand for predictive testing for ADPKD is unlikely to change
dramatically even though the PKD1 gene was recently cloned (European
Polycystic Kidney Disease Consortium 1994). Few mutations have so far been
identified, and the PKD1 gene is difficult to screen for mutations because of
extensive homologies to neighbouring regions.
Screening has also been recommended for early diagnosis and
prophylactic treatment of hemochromatosis (Edwards and Kushner 1993), a
common autosomal recessive disorder that is associated with significant
morbidity and mortality in symptomatic patients. The gene has been mapped
to the HLA region of chromosome 6 and, within families, homozygotes can be
identified by linkage analysis, but for population screening a transferrin assay
is necessary. Prophylactic phlebotomy is then recommended to reduce the
excessive iron stores and prevent future disease (Edwards and Kushner 1993,
Phatak et a119941.
iii) Screening for hereditary cancers
The most recent class. of diseases where genetic screening has been
proposed is the group of hereditary cancers, including hereditary colon and
breast cancers (Biesecker et al 1993, King et al 1993. National Advisory
Council for Human Genome Research 1994, Evans 1995), and the less
common cancer predisposition syndromes such as von Hippel-Lindau disease,
Li-Fraumeni syndrome (Li et al 1992), and hereditary retinoblastoma
(Knudson71. DNA·based predictive testing for the hereditary cancers has only
been available recently (Lynch et al 1993d. Weber et al 1994. van de Water
1994). since the mapping and cloning of genes. for example, for familial
adenomatous polyposis (FAP) (Nishisho et al 1991). hereditary non-polyposis
colon cancer (HNPCC) (Leach et a11993, Bronner et aI1994), and hereditary
breast or breast-ovarian cancer (Miki etaI1994), and the identification of
mutations in some families. But even if genetic screening is possible in a
particular family, ther!!:5 concern whether predictive testing for hereditary
cancer does more harm than good (Statement of the American Society of
Human Genetics 1994, Weber et aI1994). The quotation from Sophocles, "It
is sorrow to be wise when wisdom profits not" (quoted in Wexler 1992)
expresses the sentiment of some opponents of this type of screening. It is not
always known whether the medical outcome is improved for those identified
presymptomatically to carry the particular mutation (li et al 1992, King et al
1993), and psychosocial problems including increased anxiety. discrimination.
and stigmatization have been documented (Lerman et al 1991. Roberts 1991.
Lynch et al 19948. National Advisory Council for Human Genome Research
1994).
Clinical screening programs for FAP have proceeded successfully for
some time (Bussey 1975. Bulow 19911 because there is a consistent
premalignant marker (multiple coloreetal polyps) to identify gene carriers. and.
more important, to identify those requiring prophylactic surgery (Jarvinen
1985). Predictive testing with linked markers or mutation analysis has more
recently been available in families at risk to distinguish gene carriers and non-
carriers, and therefore to reduce the number requiring clinical screening
(Petersen et aI1993). FAP, however, accounts for only a small proportion of
hereditary colon cancer. The more common HNPCC does not have a reliable
premalignant marker, and colon cancer may not be the first or only cancer.
Besides the variable expression of HNPCC. there is genetic heterogeneity with
at least four genes predisposing to clinically indistinguishable phenotypes
(Nystrom-Lahti et al 1994a, Nicolaides et al 1994); this complicates
identification of the gene or mutation in a particular family. The reliability of
recommended clinical screening programs for those who are mutation-positive
or at high risk, is only now being evaluated (Vasen et al 1994).
Similarly for hereditary breast cancer, two loci, BRCA1 and BRCA2
(which produce phenotypes that are only partially clinically distinguishable)
have already been identified (Miki et al1994, Wooster et aI1994). There is
also variable expression of BRCA1 and BRCA2, so that gene carriers may
develop other cancers (Biesecker et al1993, Ford et al 1994) before. or as well
as, breast cancer (particularly ovarian cancer in BRCA1 families). To add to the
difficulties of predictive testing, age of onset is extremely variable for both
hereditarycolonandhereditarybreastcancer,andnon-penetranceoccursinat
least 5-10% of gene carriers (National Advisory Council for Human Genome
Research 1994, Goldgar et al 1994, Rowell et al 19941.
Despite these problems. there is a demand from the public for screening
programs to define cancer risk (Croyle and Lerman 1993al. Some of those
requesting predictive testing. however. may be from families with sporadic
cancer. where there is not a significant increased risk to relatives (King et al
1993. Rowell et al 19941. Geneticists may have difficulty distinguishing
families with hereditary cancer from families with coincidental sporadic cancers,
and the public may not recognize the need for this distinction (Motulsky 1994).
Screening programs for hereditary cancers require extensive pre- and
post-test education and counselling components (Biesecker et al 1993, Lynch
et al 1993dl, as in the Huntington disease predictive testing programs, because
of the psychosocial implications of predictive testing for cancer (Croyle and
Lerman 1993b, Lynch et al 1994a). But, to repeat, there are probably not
enough geneticists or genetic counsellors to provide all this counselling
(Holtzman 1992, Assessing Genetic Risk 1994, Warner 1994, Weber et al
1994).
It is generally agreed that screening programs for hereditary cancers
should be conducted under well-controlled research settings until more
information is available on the medical and psychosocial outcomes of screening,
and appropriate clinical surveillance for gene carriers is defined (National
Advisory Council for Human Genome Research 1994, Statement of the
American Society of Human Genetics 1994, NIH Guide 19941. More
information is also needed on the spectrum of mutations for each hereditary
cancer. and any differences in the risk of cancer(s) from these different
mutations (Statement of the American Society of Human Genetics 19941.
Finally. safeguards against discrimination. particularly with regard to insurance.
are also necessary for those with a presymptomatic genetic diagnosis (Billings
et al 1992b. Caskey 1993b. Ostrer et al 19931. since this may be considered
a pre-existing condition.
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Health care programs need to be evaluated in a number of ways to
ensure that they do more good than harm to those who require these services.
and to ensure that the use of resources is appropriate (Sackett 19BO). The first
question to be answered is whether the health care program can workinideaJ
circumstances (a question of efficacy (Stoddart and Drummond 1984a)). The
second question is whether the program does work under normal circumstances
(a question of effectiveness). This combines efficacy with both the availability
and acceptability of the program to those who need it (Sackett 1980). The
third question is whether the resources allocated to allow the program to
proceed are better used in this way than in some other way. This question of
efficiency is assessed by one of the forms of economic evaluation of health
care (Drummond et a119871. usually after the efficacy and effectiveness have
been established (Stoddart and Drummond 1984a1.
Efficacy and effectiveness pf health gBm programs
The first step in evaluation of efficacy and effectiveness of health care
programs is to establish the need for the program (Needs Assessment [Scriven
1990)). A health care program should only be developed or implemented after
a burden of disability or death from the disease in question has been
established. The needs assessment should indicate whether this unmet need
is for the population as a whole, or for a specific segment of the population.
This needs assessment should initially be done before the program is planned,
but should also be repeated subsequently to determine whether the need still
exists (Canadian Evaluation Society 1989). The objectives of a health care
program should then relate to the established need.
The second step is to determine whether the objectives of the program
are being met, and, if so, whether these results, or outcomes, can be attributed
to the program rather than to some other variable (Summative Evaluation
[Shortell and Richardson 1978, FitzGibbon and Morris 1987]). The third step
is to determine whether or not there is a better way to achieve the same results
(Formative Evaluation [Short,,11 and Richardson 1978]). Summative evaluation
relates to both the efficacy and effectiveness of the health care program
whereas formative evaluation relates more specifically to the effectiveness of
the program given that efficacy has been demonstrated.
Ideally, efficacy and effectiveness should be established experimentally
through a randomized control trial (Sackett 1980), in which the medical
outcome in an experimental group receiving the investigation or treatment is
compared with the outcome in a control group not re~eiving the intervention.
or receiving a different intervention. However there are certain circumstances
where randomization is either not possible or unethical (Shortell and Richardson
19781. Determining the appropriate evaluation method therefore includes
choices of evaluation design. data type. and data analysis (Patton 1987).
The evaluation design provides the method of gathering comparative
information and ruling out the effect of other variables on the outcome. to
reduce the chance of alternative interpretations of the results(FitzGibbonand
Morris 19871. The evaluation design may be a randomized control trial with
equivalent experimental and untreated. or differently treated. control groups;
a quasi-experimental design with non-equivalent control (orcomparisonlgroups
(Cook and Campbell 1979. FitzGibbon and Morris 1987); or a naturalistic
design where the experimental and control groups are chosen for their
information content (Patton 1987).
Ideally a randomized control trial is used to insure that the effect seen is
due to the treatment and not some other variable. but this is not always
possible. It may. for example. be unethical to withhold treatment for a severe
or letha' disease by assigning patients to an untreated control group (FitzGibbon
and Morris 1987). In other studies the numbers may be too small to allow
randomization. particularly when individuals are stratified according to socio-
demographic factors or disease severity. This is likely to be the situation when
evaluating screening programs for extremely variable tumour predisposition
syndromes.
When a quasi-experimental design is used, the differences between the
experimental and comparison groups should be documented, and any
demonstrated effects considered in light of these differences. The comparison
groups may be previous cohorts, or similar groups treated differently at another
centre (Cook and Campbell 1979, FitzGibbon and Morris 1987). Threats to
internal validity of the results should then be ruled out (Shortell and Richardson
1978), particularly whether there is selection bias in establishing the
experimental or comparison groups, and, if historical comparison groups are
used,whethertheeffectisduetoimprovedmedicalcareingeneral,rather than
to the specific treatment. Threats to external validity are also considered to
determine the extent to which the results can be generalized to other situations
(FitzGibbon and Morris 1987), eg, when evaluating screening programs for
hereditary tumour predisposition syndromes, will the results apply to other
families, to other locations, and to other similar diseases?
Naturalistic design is particularly suited to evaluation of programs with
individualized outcomes, to those dealing with unique situations, and to
evaluation of quality of life aspects rather than purely medical effects of
programs (Patton 1987). Data (usually qualitative) is collected from
"information-rich" cases or situations for comparison of program effects at a
personal level.
Ingeneral,datatobecollectedcanbequantitativeandobtainedthrough
valid and reliable measurement of a specific operational indicator of the program
objective (Shortell and Richardson 1978); or qualitative, and obtained by
observation. interviews. or questionnaires (Patton 1987). These data are then
analyzed either by statistical analysis (usually of quantitative datal. or by
content or case analysis to search for patterns in in-depth qualitativedata. The
evaluation design. data type. and data analysis are chosen to suit the specific
evaluation. and may be matched in different ways (Patton 19871.
The deductive approach with experimental or quasi-experimental design.
qualitative data. and statistical analysis is used to test a pre-formulated
hypothesis. An inductive approach with naturalistic design. qualitative data.
and content or case analysis. on the other hand. is particularly suited to
evaluation of programs where individualized (lutcomes are important because
of variable disease. to evaluation of psychosocial effects of programs. and to
formative evaluation of all programs. The inductive approach may also identify
unanticipated results and lead to generation of new hypotheses.
The summative evaluation will frequently combine deductive and
inductive approaches in order to assess both the specific medical objectives of
the health care program. and the related psychosocial outcomes. For the
formative evaluation. generally the inductive approach. alone. is used since this
evaluation requires a detailed description of the program. including ·who does
what to whom with what resources· on a day to day basis (Sackett 1980). in
order to look for areas for improvement.
ECQogmicftyalyationofhAalthcarftpcngraml
Health care economic evaluation methods have been developed to assist
indecision-making because there are insufficient funds for all demandsonthe
health care budget (Williams 1974, Drummond 1980). Choices, therefore.
have to be made (Stoddart and Drummond 1984a, Robinson 1993a). An
economic evaluation can help with these decisions by organizing information
about costs and benefits in a systematic way (Henderson 1991, Robinson
1993al. The methods used are similar to economic evaluation techniques used
in other areas such as education, transportation or town planning (Robinson
1993a). The relevant advantages of a particular course of action or program
areweighedagainstthedisadvantages,insuchawaythatdifferentprograms
can be compared and prioritised. the overall goal being to use the available
resources to obtain maximum benefits in terms of the health of the population
as a whole (Williams 1974, Sackett 1980. Henderson 1991).
Health care programs should be evaluated to determine whether to offer
a service (Chapple et al 1987). how much of a service to offer (Henderson
1991, Robinson 1993b), or to whom to offer a service lie. universally, or
selectively to a particular high-risk population [Hagard and Carter 1976. Phatak
et al 1994)). The economic evaluation is not concerned with the ethics or
efficacy of a particular health care program but these should be established
before the economic evaluation is undertaken (Stoddart and Drummond 1984a.
Chappleetal1987. Henderson 1991).
Different forms of economic evaluation can be used in different situations
(Stoddart and Drummond 1984a, Robinson 1993a. Sackett 1980). depending
on whether the goals and outcomes of the programs to be compared are the
same or different:
a) Gost-minimization aoa'Ylil in which the outcomes of the programs being
compared are the same and the aim of the analysis is to identify the least
costly option (Robinson 1993b),
b) GOlt-@ffectiV@"'I! aoalYlia in which the outcomes to be compared,
although similar, are different at least in degree, and the outcomes are
measured in common (natural) units such as "lives saved" or "pain free days"
(Robinson 1993c),
c) GQlt-'1tilityjlOjlIY$js in which the outcomes vary and are converted into
quality of life units for comparison (Robinson 1993dl, and
d) GQ$t-bAOAfi!jlojlIY$j$ in which costs and benefits are all converted into
monetary units (Hook 1991, Robinson 1993el.
Economic evaluations differ depending on the point of view taken,
whether of the patient, the hospital or health care unit, the government, or
society in general (Stoddart and Drummond 1984b, Phatak et al 1994), the
most appropriate being the assessment of costs and benefits from a societal
perspective (Robinson 1993b). However, defining the limits of the effect of the
program can be difficult.
Evaluations also differ in the methods used to identify and measure costs
and benefits (either in the units used or the values given) (Sackett 1980,
Phatak et aI1994). More important, significantly different assumptions can be
made about which costs or benefits to include (Hagard and Carter 1976,
Stoddart and Drummond 1984a, Modell and Kuliev 1991).
It is important to determine all the consequences of a program and to
identify all the potential costs and benefits (direct. indirect, and externalI
(Drummond et al 1987). even if these costs and benefits are outside the health
sector. The costs and benefits will include tangible (or direct) costs
(Drummond et al 1987) which are easy to affix a monetary value to (costs for
procedures,counselling.patient·stravell.andalsointangible(orindirect)costs
and benefits such as increased or decreased productivity. or quality of life of
unaffected family members (Henderson 1991) which are more difficult to
quantify (Modell and Kuliev 1993). Intangible costs and benefits also include
psychosocial factors: either costs (such as discomfort during a procedure,or
anxiety about the risk of disease or the results of testing or treatment). or
benefits (such as reassurance about the absence of disease, or reduction of
uncertaintyl (Stoddart and Drummond 1984b).
One attempt to measure such intangible effects is the use of "quality
adjusted life years" (OALYs) (Henderson 1991, Hook 1991) which takes into
account the improved quality of life as well as the years of life lost or gained
because of an intervention. However. a QALY is more useful for assessing
physical symptoms or handicaps. than for assessing psychosocial factors
(Henderson 1991).
Not all costs and benefits are in the present. Because it is generally
assumed that benefits in the immediate future are of greater value than those
in the distant future. and costs are preferablydelayed,a methodofdiscounting
may be used to convert future costs and benefits to their present value
(Williams 1974, Robinson 1993b, Phatak et aI19941.
The way these different methods of economic evaluation are used can
be demonstrated in a series of examples. For cost-minimization analysis, the
assumption is that the interventions being compared have identical outcomes,
and the analysis is to determine the least expensive option (Robinson 1993b).
Outcomes, however, are rarely identical; even if the outcomes differ only in
degree of effect, a cost-effectiveness approach should be used in order to
compare the consequences as well as the costs.
Walker et al (19911 present their analysis of costs of diagnostic
procedures for colorectal cancer detection as a cost-minimization study (the
minimizationofexpectedcostpercanceridentifiedl,butqualifythis because
clinical trials have not established the relative effectiveness 0 fcolonoscopyand
double contrast barium enema in the detection of colon cancer. A cost-
effectiveness analysis would be more appropriate for this study.
In cost-effectiveness analysis, outcomes are similar and are measured in
natural units such as "lives saved· or ·pain free days" (Robinson 1993cl. This
may be a comparison of two different treatments, or of the proposed treatment
and the "status quo option" (either no treatment, or treatment at the time of
presentation with symptomatic disease).
Phatak et al (1994) used a decision analysis method for a cost-
effectiveness evaluation of early or late treatment of patients with
hemochromatosis. The comparison was between al early identification and
preventive treatment facilitated by screening healthy 30-year-olds. and bl late
identification and treatment of symptomatic patients. Information from the
literature was used to construet a decision tree to compare the possibilitvof
life-threatening complications and their costs. depending on whether
hemochromatosis was identified early or late. In order to prevent bias from
incorrectassumptions aboutseveral variables (prevalenceofdisease. probabilitv
of different disease manifestations. the cost of the screening test, and the
discount rate). asensitivitv analysis was conducted with different values for
each of these conditions (Phatak et al 1994. Robinson 1993c). A set of
circumstances was thereby determined over which screening 30-year-old males
to allow early treatment of hemochromatosis was considered cost-effective.
In cost-utilitv analysis, outcomes of procedures are measured in units
relating to a person·ssenseofwell-being. ie. reflecting their qualitv of life as
well as length of life resulting from the intervention. the most common unit
being the OALY (Robinson 1993d). The intention is that by using QALYs. the
outcomes of different treatments for one disease. or of treatments of different
diseases can be compared. However, OALYs have proven difficult to measure
even using health profile questionnaires such as the Rosser index (Rosseretal
19821 which describe health status in terms of ·perceived disabilitv and
Cost benefit analysis is the most comprehensive economic analysis but
is difficult to apply since human life must be given a monetary value (Williams
1974, Robinson 1993e). Two approaches have been used: a) the human
capital approach where a person's value is related to his or her normal wage
(since by death or disability this wage is lost), and b) the stated preference
approach where a person's value is based on what he/she is willing to pay for
a particular service. The capital approach ignores any costs of ·pain and
suffering·, and both methods give greater value to a person with greater
financial resources (Robinson 1993e).
Many economic analyses called ·cost-benefit analyses· have been
published but the methods used to identify, measure. and value costs and
benefits vary greatly (including using non-monetary units for some costs or
benefitsl.makingthemdifficulttocompare.
Henderson (1991). and Hagard and Carter (1976) consider both the
question of whether prenatal diagnosis is cost-beneficial and the level at which
this service should be provided. They demonstrated an economic advantage
in providing prenatal screening for Down syndrome at least for women over 35
years of age. However, by expanding the program to individuals below this
cut-off risk in terms of maternal age. the costs would outweigh the benefits.
The cost of the program included the cost of genetic counselling. and of
diagnosticprocedurestoallowprenatalidentificationandtherapeuticabortion
of affected fetuses. The economic benefit is defined as the costs for the care
of Down syndrome children avoided. for the family and community. because
affected births are prevented. Similarly, Chapple et al (1987) estimate the
benefit of DNA diagnostic testing as the costs not incurred for treating the
relevant disorders. and Henderson (1991) calculates the benefit of screening
for neural tube defects in specific populations of pregnant women, as the
avoided costs of health care, education, and extra family expenses associated
with birth of an affected child.
Modell and Kuliev (1991 and 1993) disagree with this approach. In their
cost-benefit analysis of a comprehensive program for treatment and prevention
of thalassemia, therapeutic abortion of an affected individual is considered a
cost of the program not a benefit. Since the goal of at-risk families is to have
the desired number of normal children, not to abort affected ones, a non-
monetary unit, genetic fitness, is used as the unit for benefits of this program
or the less comprehensive programs to which it is compared. For each level of
geneticservicesprovided,thecostoftheprogramiscalculatedin terms of both
the treatment of the appropriate number of affected children, and the services
(education, counselling, prenatal diagnosis and terminationI necessary to
achieve a healthy family. Highest genetic fitness is achieved with the most
comprehensive service. Initially this is the most expensive program, but over
a short period of less than 5 years, it becomes the least costly complete
program of prevention and treatment.
The dollar value of health care programs can be compared with that of
other programs even outside the health care field when monetary units are used
for both costs and benefits (Robinson 1993e). This is appropriate since the nial
costofa program is the opportunity cost, ie, the achievable outcomes of
another (unfunded) program, forgone (Henderson 1991, Williams 1974, Sackett
19801.
Once the evaluation process is complete, it is important to communicate
the findings to interested groups, whether the funding agencies, program
administrators, participants, or community groups. Although the basic message
is the same, the presentation of this message should be tailored to each
audience (MorrisetaI1987).
RATIONALE AND OBJECTIVES OF THESIS
As stated previously, large families with hereditary tumour syndromes
(VHL, MEN-1, MEN-2, FAP, and HNPCC) were identified in Newfoundland in the
1980s, the diagnosis being made when family members were referred for
genetic counselling or clinical care. During the initial work-up of each family,
a burden of disease was recognized; ie, there were early deaths anddisabilities,
and increased anxiety in affected and unaffected family members.
The physicians and geneticist (Jane Green) originally involved with each
family recognized that family members would benefit from a coordinated
approach to their medical management, and that introducing a screening
program (for early identification and treatment of individual tumourstoreduce
morbidity and mortality; for early identification of gene carriers to allow
informed reproductive decisions; and for provision of genetic counselling to
increase understanding and reduce anxiety) could be central to this type of
care. Asdescribedabove,screeningprogramshadbeenusedsuccessfulIyfor
other types of hereditary disease, particularly those with neonatal or early
childhood onset, to allow early treatment or to provide information for
reproductive decisions. Predictive testing orpresymptomatic diagnosis had also
been offered to those at risk for severe. late-onset untreatable disorders such
as HD. to reduce uncertainty. The recommendation of clinical and genetic
screening programs for hereditary tumour syndromes. to improve the prognosis
and quality of life of family members. however, was recent and screening
programs had not been fully evaluated.
Because of the large Newfoundland MEN-1. MEN-2. FAP. HNPCC and
VHL families identified, there was an opportunity to develop, implement. and
evaluate screening programs for these hereditary tumour syndromes. As
previously stated. I proposed:
to investigate the feasibility of instituting each screening program.
to determine the appropriate components of the screening
protocols.
iii) to compare the medical. genetic. and psychosocial outcomes for
family members who had been screened with those who had not
been screened. and
iv) to determine the cost. both monetary and non-monetary. of
maintaining such screening programs.
I could then use this experience to identify and define the factors that must be
considered for successful development and implementation of clinical and
genetic screening programs for similar late-onset multisystem disorders: for
other families, for other locations, and for other diseases.
The same approach was taken for each hereditary tumour syndrome:
a) an extended pedigree was prepared by interviewing family
members and searching archival records,
bl the type of tumours, and age at which they occurred were
documented by retrospective and prospective studies,
c) a preliminary screening protocol, based on the natural history of
the disease thus described, was developed with appropriate
medical specialists, and offered to family members,
d) collaborative molecular genetic studies were initiated to map the
relevant gene and/or to identify specific mutations,
el genetic testing by linkage analysis or mutation detection was
offered to family members at risk,
educational materials about the disease, about the screening
program. and about predictive testing were provided for family
members and their physicians, and genetic counselling was given
when appropriate,
gl the medical and psychosocial outcomes of the clinical and genetic
screeningprogramswerereviewed,and
hi the VHL screening program was formally evaluated, including a
cost-benefit analysis.
Consent was obtained from family members for participation in each
stage of these studies.
Although the objectives of the screening programs were the same, the
programs differed in important details because of the differences inthenatural
history and severity ofthe five hereditary tumour syndromes, and in the present
state of knowledge regarding the medical management, and the molecular
genetics of each disorder.
In Chapters 2 to 6, I discuss in detail the development, implementation,
and informal evaluation of each of the five clinical and genetic screening
programs, and in Chapter 7 present the formal health care evaluation of the
VHLscreening program. In the final chapter, I summarize the recommendations
of this approach to management of hereditary tumour syndromes and other
late-onset multisystem diseases; and the benefits to family members, and to
society,ingeneral,whichcanresult.
CHAPTER 2 - CLINICAL AND GENETIC SCREENING
ENDOCRINE NEOPLASIA, TYPE 1
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Present study
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Impact of the Screen Program
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This chapter describes the identification of a group of Newfoundland
families with multiple endocrine neoplasia. type 1 (MEN-l); the documentation
of an atypical natural history of disease in these families and comparison with
typical MEN-1; and the development. implementation. and review of a clinical
and genetic screening program for these families.
including hyperparathyroidism. and tumours of the pancreatic islet cells and the
anterior pituitary gland (Wermer 1954. Ballard et al 1964. Schimke 1976. Bone
19901. Tumours of the adrenal cortex (Skogseid et al 1992) and thyroid gland
(Wermer 1963. Ballard et al 1964). as well as carcinoid tumours of the lung
and thymus (Rosai et al 1972. Farid et al 1980. Duh et al 19811 may also
occur. Hyperplasia of the parathyroid glands is found in at least 90% of those
affected with MEN-l (Marx et al 1982. Betts et al 1980. Benson et a11987.
Samaan et al 1989) but is not necessarily the initial manifestation (Shepherd
et al 1991. Skogseid et al 1991b). Pancreatic tumours (usually gastrinomas.
insulinomas. or glucagonomasl have been reported in 32 - 75% of patients in
different series (Marx et al 1982. Vasen et al 1989b. Skogseid et al 1991 a) and
are a major cause of morbidity and mortality in most MEN-1 families (Schimke
1976. Oberg et al 1982. Lips et al 1984. Pipeleers-Marichal et al 1993).
Pituitary tumours (usually prolactin [Carlson et al 1978. Levine et al 1979.
Prosser et al 1979. Veldhuis et al 19791 or growth hormone-secreting [Ballard
et al 19641. but also including non-functioning adenomas1are less common in
most families having been reported in 16 - 40% of patients (Farid et al 1980,
Marx et a11982, Hershon et a119831. Carcinoid tumours are rare in most series
but are a significant cause of morbidity and mortality in some large MEN-1
families (Bear et a11985. Green et a11992. Wilkinson et a119931.
Some of the difference in reported frequency of gland involvement is
because of difference in ascertainment (whether autopsy series. or
symptomatic or screened patients [Ballard et al 1964, Johnson et al 1967,
Majewski and Wilson 1979. Marx et al 1982)). Some. however. apparently
reflects a difference in disease expression in certain families (Faridetal1980.
Hershon et al 1983. Brandi et al 1987. Vasen et al 1989b. Skogseid et al
1991a. Shepherd 1991 I. Whether this difference is because there is more than
one gene for MEN-1; because of variable expression ~f different mutations at
one genetic locus. as with the MEN-2A and MEN-2B mutations of the RET
proto-oncogene (Mulligan et al 1993. Donis-Keller et al 1993, Eng et al 1994a.
Carlson et a119941; or because of modifying genes, is not yet determined.
The age at onset and severity of disease varies even within families
(Schimke 1976. Shepherd 1991, Thakker 1993al. ranging from patients
symptomatic in their teens. to those in their 60s or 70s who are asymptomatic
and only identified by screening following diagnosis in a younger family
member. In most MEN-1 families the major morbidity and mortality is because
of pancreatic islet cell tumours (Majewski and Wilson 1979. Vasen et al 1989b.
Skogseid et a11991al. in the past associated with intractable ulcer disease
(Zollinger-Ellison Syndrome [Zollinger and Ellison 195511 in patients with
gastrinomas (Werrner 1963. Van Heerden et al 19861. and more recently
associated with pancreatic malignancies (Wolfe and Jensen 1987. Eriksson et
al 1990. Pipeleers-Marichal et al 19931. Periodic screening (primarily
biochemical screening to detect hyperactivity of the parathyroid.pituitaryor
pancreasl has been recommended for family members at risk because early
identification and treatment of individual manifestations is thought to improve
prognosis (Marx et a11986. Samaan et a11989. Vasen et a11989b. Skogseid
eta11991al.
An understanding of the natural history of the disease (particularly the
frequency of different manifestations. and the age and order in which they
occurI is necessary to plan the appropriate screening protocol for those at risk
and for those already known to be affected (Vasen et al 19871. Because some
authors suggested that hyperparathyroidism was a prerequisite to the
involvement of other glands (Bens et al 1980. Benson et al 1987. Thakker
1993al. screening of those at risk in some families was limited to testing for
hyperparathyroidism (Marx et a11986. Brandi et al1987, Vasen et a11989bl.
with screening for other manifestations concentrated on those identified by this
testing. It is now recognized. however. that hyperparathyroidism is not
necessarily the first manifestation (Shepherd 1991. Skogseid et al 1991 b). and
that the order of gland involvement can be quite variable. so that a more
extensive screening protocol may be necessary for all families (Brunt and Wells
1985). However. if clinical heterogeneity can be identified. different screening
protocols maybe appropriate for different families.
The mapping of the MEN-l gene to chromosome llq13 in 1988
(Larsson et al 1988. Bale et al 1989. Thakker et a11989) and identification of
closely-linked informative markers (Nakamura et al 1989, Julier et al 1990.
Fujimori et al 1992, Larsson et al 1992b, Thakker et al 1993bl now permits
predictive testing in some families.
Four Newfoundland families with an atypical presentation of MEN-l were
identified in the late 1970s by Farid (Farid et al 1980). Prolactinomas were
more frequent than in most MEN-1 families and were often the presenting
feature. Carcinoid tumours of the lung and thymus were also more frequent,
whereas pancreatic islet cell. tumours were not identified in the first study.
Because of the different pattern of manifestations in the Newfoundland
kindreds. they were referred to as atypical MEN-l, or MEN-1(Burin) (Bear et al
1985), and, with a similar family from the northwestern USA (Hershon et·al
1983). called the prolactinoma variant of MEN-1.
Clinical screening was introduced for some members of the MEN-l (Burin)
kindreds in the early 1980s but the full extent of the affected and at-risk
members of the families was not yet delineated. and the frequency and age at
onset of different manifestations was therefore incomplete. The impetus for
further study was the mapping of the MEN-l gene in 1988.
The following sections describe the results of a retrospective and
prospective medical review of the MEN-1 (Burin) families. and of genetic linkage
studies. carried out to determine whether MEN-l (Burin) could be distinguished
from typical MEN-l by clinical expression of disease or by the genetic locus.
This has led to a better understanding of the natural history of the disease
which can be used to determine the optimal type and timing of tests for the
appropriate clinical screening program for this large group of patients. It has
also led to the development of predictive testing by linkage analysis to
determine who requires the clinical screening.
PATIENTS AND METHODS
AIG'r!llnm.ntg'Ftmlllt·
The four separately-identified families were each from small coastal
communities (outports) in the Burin Peninsula/Fortune Bay area of the south
coast of Newfoundland. By 1988 there were 42 documented affected
individuals. of whom 35 were still living. Family members were interviewed by
Jane Green to extend the pedigrees (Figure 2.11 and to search for a connection
Figur.2.1. MEN-1 (Burin) pedigrees with manifestations for each affected
member.
Typeofmanifestation(s) and age at diagnosis are given for each
affected family member. Presentageorageatdeath(inbracketsl
is also indicated.
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between the kindreds. After consent was obtained, medical records, including
any autopsy records, of affected and apparently unaffected family members
were reviewed. Records of some individuals were very limited because of the
isolated area. without medical facilities. where these families had previously
Results were recorded for any previous biochemical testing or
investigations, and the details and outcome of surgical procedures and
pathology were documented. Because there was no established protocol for the
screening of MEN-1 families when this program began. knowledge of the
presentation of MEN-1 (Burin) patients and recommendations from the literature
(Oberg et al 1982. Ups et al 1984. Marx et al 1986) were used as guidelines
for implementation of a screening protocol which was then modified as new
information became available {see laterl. This screening protocol was offered
to known MEN-1 patients and their first degree relatives over 14 years of age.
In some circumstances, second degree relatives were also included,particularly
whenfirstdegreerelativeswereunavailableoruninterestedinparticipating.
Clinics with a physician. geneticist and laboratory personnel inattendancewere
held in the outport communities where the majority of family members now
Genetic counselling was provided concerning the manifestations of
MEN-1{Burin). the inheritance pattern and risk of recurrence ofthe condition.
and the recommended clinical screening. The potential for genetic screening if
the location of the MEN-1 (Burinl gene could be identified was also described,
and family members were asked about their willingness to participate in linkage
For family members living in other parts of Canada, contact was made
through their relatives in Newfoundland. Information on MEN-1 (Burin) and
recommendations for screening were sent to those at risk, and to their family
doctors,ifrequested.
CliolqlSqllolng
Participants were examined by the endocrinologist. medical and family
histories taken by Jane Green, and blood drawn for measurement of serum
calcium. parathyroid hormone (PTH1, prolactin and gastrin. Patients with any
abnormal screening test results were followed up by investigations at the
Clinical Investigation Unit (CIUI of the General Hospital in St. John's. In the
CIU. blood work was repeated. and ionized calcium, and fasting gastrin and
glucose levels were determined. Other investigations included combined
pituitary function testing, CT (computerized tomography) scan of the sella
turcicaandvisualfieldtestingifprolactinwaselevated,secretin stimulation
test and pancreatic ultrasound if gastrin was elevated, and a chest x-ray, in all
family members, for evidence of carcinoid tumours. Until 1993 measurement
of glucagon and pancreatic polypeptide were only available under special
circumstances but these are now included for patients seen in St. John's. Also,
all known affected persons now have a CT scan or MRI (magnetic resonance
imaging) of the sella turcica. and pancreatic ultrasound for baseline studies
even if prolactin and gastrin are normal (Figure 2.21.
Results of all screening tests and follow up investigations were recorded.
along with the diagnosis. and age of occurrence of each manifestation for each
affected individual. The type of treatment required. and the outcome of this
In this group of high-risk individuals. the diagnosis of MEN-1 was made
if one or more of the following criteria were met (Shepherd 1985, Vasen et al
1989b):
a) confirmed hypercalcemia with elevated or inappropriately normal
PTH level.
b) confirmed hyperprolactinemia (> 5X normal) and/orenlarged sella
turcica.
c) elevated gastrin level with positive secretin test. elevated
glucagon level. or pancreatic mass demonstrated by ultrasound.
d) radiological or h.istological identification of a carcinoid tumour.
All persons with documented MEN-1 manifestations were screened
annually for evidence of subsequent manifestations. Those at risk (at 50% risk
or in certain circumstances at 25% risk) were screened every 1 - 2 years with
blood work done in their local hospital, this screening being coordinated by the
geneticist and the family doctor.
Figure 2.2. Screening protocol for affected and at-risk members of MEN-1
(Burin) families.
SCREENING PROTOCOL FOR AFFECTED AND AT·RISK MEMBERS OF
MEN-1(Burin) FAMIUES
PRIMARY SCREENING'
1. serum total and/orionized
calcium
PTH
2. serum prolactin
3. fasting gastrin
4. (chest x-ray)
FOllOW-UP INVESTIGATIONS
"repeat ionized calcium with serum
PTHandphosphate
24hrurinecalcium
parathyroid scan
combined pituitary function testing
visual fields
"CTscan/MRI of pituitary fossa
secretin stimulation test
"fasting glucose
"glucagon
"pancreatic polypeptide
"ultrasound/CTscan of pancreas
72 hour fast
"chest x·ray
• everyl-2yearsfromage12
•• allpatientslotherfollow-upinvestigationsareperformedasindicated
by results of primary screeningl
Pr.die;tjyaT.,ting
At the time of initial screening a blood sample was also taken from
consenting family members for DNA extraction by standard procedures (Miller
et a/ 1988) in Dr. Roger Green's laboratory at the Health Sciences Centre in St.
John's. In 1991, aliquots of DNA from 171 members of the families (including
65 known to be affected) were sent to Dr. Allen Bale, Department of Genetics,
School of Medicine, Yale University, for linkage analysis with a series of
markers closely linked to the chromosome 11 q13 map location of the gene for
typical MEN-1 (Figure 2.31. The markers 0115288, PGA, PYGM, 0115971,
0115970, 0115146, INT2 and 0115533 were used (Table 2.1) (Petty et al
19941, although not all probes were used on every sample. Sased on the age
at diagnosis in this group of Newfoundland families, family members over 50
years of age were considered unaffected if all screening values were negative.
Unscreened family members over 50, or younger at-risk family members,
whether screened or not, were categorized as unknown. For each marker at
were analyzed with the program MLINK from the LINKAGE package to
determine the LOO scores for linkage of MEN-1(Burinl to individual markers.
When linkage to chromosome 11 q13 markers was demonstrated in the
studies with known affected family members (Petty et a119941, counselling
was given to all family members participating in the clinical screening program,
and to any others at risk who could be contacted, regarding predictive testing
Figure 2.3. MEN-1IMEN-1 (Burin) region of chromosome 11.
The map location of the MEN-1/MEN-1 (Burin) gene(sl is shown
in relation to the position of the markers used for linkage analysis.
The percent recombination between markers is also given. This
figure is based on published data (JulieretaI1990, Fujimorietal
1992).
MEN 1IMEN-1(BURIN) region of Chromosome 11
0115288
PGA
PYGM
0115971
0115970
0115533
IMEN0 1MEN-1(BURIN)
TABLE 2.1. MARKERS AND ALLELES USED FOR LINKAGE ANALYSIS IN
MEN-1IBurln) K1NDREDS: FOR MAPPING THE GENE AND FOR
PREDICTIVE TESTING
POLYMORPHIC LOCI ON CHROMOSOME 11
Restriction
Enzyme
p12-11.2 011 S288/p3C7 Mspl
q12-13.2 PGA/PGA101 BgllI
q12-13.2 PYGM/pMCMP1 Mspl
q12-13.2 PYGM/IAnrep (VNTR) none
q13 011S971/RC271CATT) none
q13 011S970/RC29 (CATT) none
q12-13.2 011S146/pHB159 Mspl
Taql
q13 Taql
BamHI
q13 011 S533/4F7 (VNTR)
BaI.etal1991
Petty.ta11994
'aU.I.sar.d.toctedbyPCRsizing
PCR-polym.ra..chainr.aetion(.... p.291
VNTII-variabl.numbertand.mrep.at
CATT-t.tranucleotid.r.peat .
by linkage analysis. The method of linkage analysis was described and also the
possible results, including high-risk, low-risk and uninformative status. The
implications of these different results, in terms of possible modification of the
clinical screening recommendations and of the recurrence risks to children,
were also described. It was stressed that linkage analysis gives a probability
that the MEN-1 gene was, or was not, inherited, not a certainty because a
recombinant event between the gene and the markers used cannot always be
detected. Definitive testing by mutation analysis was recommended when the
gene and mutation are identified.
For those wishing to participate in predictive testing (including those who
lived in other provinces), consent was obtained, and arrangements were made
for the testing to proceed at Dr. Bale's laboratory. Haplotypes for the set of
markers used were then determined by Jane Green for all members of each
kindred and the haplotype of affected individuals identified (Figure 2.4). The
risk status of the first degree relatives was modified accordingto comparison
with this haplotype. All results were reviewed with Dr. Bale and Dr. Elizabeth
Petty at Yale University before being delivered to patients.
Results of predictive testing were provided to each at-risk individual in
Newfoundland in genetic counselling sessions at clinics held in their own
communities. The principles of linkage studies were explained as well as the
implications for future medical management based on the specific results
obtained. Visual aids were used during the counselling, and a short pamphlet
Figure 2.4. Haplotype of linked markers segregating with MEN-1 (Burin).
A section of the MEN-1 (Burin) Family A pedigree is shown with
results of initial linkage analysis to map the MEN-1 (Burin) gene to
theMEN-1 region of chromosome 11q13. The haplotype of linked
markers segregating with MEN-1 (Burin) in this family is circled.
The patient indicated (-) received a recombinant chromosome
from his affected mother. The location of the recombination
(cross-over) event is marked with an arrow (..).
Haplotype of linked markers segregating with MEN·1 (Burln)
•• c:inicallyaJfected
00 ===-..
*. :::c,inantctvomosomo
was provided which reinforced the counselling session. When requested,
information on the predictive testing process was given to family doctors, and
a phone number was provided for any subsequent questions or concerns.
Arrangements were made with geneticists in other centres to provide predictive
testing results for family members living outside of Newfoundland.
Imp'etofth,SG",ningPmgrlm
There were no formal interviews about the psychosocial implications of
MEN-l and the screening program, but views expressed during counselling
sessions and phone calls were documented, and 10 family members were
asked informally about the impact of the disease on themselves and their
families, and the value of the screening program to individual family members.
They were asked, particularly, about their views of their own health before and
aftertheclinicalscreeningprogramwasimplemented,theirreasonsforinterest
or disinterest in predictive testing, and their use of the information on revised
risk status provided by the genetic testing.
A'GlrtI'nmlntg'familie•
Ancestors of each of the four kindreds came from a group of very small,
abandoned communities on the north shore of Fortune Bay (Figure 2.51. A
common ancestor could not be identified but few historical records are
Figure 2.5. Present and ancestral location of MEN-1 (Burin) families.
The isolated communities in which the ancestors of the MEN-1
(Burin) families lived have been resettled. A common ancestor
was not identified but review of archival material on births and
marriages demonstrated the inter-relationship of families in this
cluster of communities on the north shore of Fortune Bay.
• Present location
• Ancestrallocatlon
>-< 1SkIn ~ewfound..nd tJohn's~
available. It is suspected that these families are related because there were very
few settlers in this area originally. andthreeofthefourpedigreesconsistof
two separately identified branches that were only linked by pedigree studies
(Figure 2.1. p. 68-71).
Eighty-three members of these families have now been identified as
affected; 34(41 %1 presented symptomatically. and 49(59%1 were identified by
clinical screening, the majority of these since 1988. One hundred andsixty-nine
first degree relatives at 50% risk were also identified in 1989. 108 of these
participated in the clinical screening program, and 121 subsequently
participated in genetic testing (see later).
Nln",. HI,tOry Of DilA'"
Hyperparathyroidism is the mostcommon manifestation, present in 96%,
but hypercalcemia was never detected in three affected patients (age 31-71 at
the time of death). Pituitary tumours have been identified in 39% (all but 2 of
these being prolactinomasl. and carcinoid tumours of the lung or thymus are
present in 13% of affected. Pancreatic islet cell tumours (eithergastrinomas
or glucagonomas) are less common but have been identified in six affected
(7%) (Table 2.2).
The age at diagnosis was extremely variable. age 15-63 years in
symptomatic patients, and age 13-83 years in asymptomatic patients identified
TABLE 2.2. FREQUENCY OF MANIFESTATIONS IN MEN-1(Burin) FAMILIES.
AND IN TYPICAL MEN-1 FAMILIES FROM THE lITERATURE
FREQUENCY OF MANIFESTATIONS
~ I.it!lra1Ynl
MEN-1(Burin) TypicalMEN-1
1980
Vasen- Skogseid-
(1989) (1990)
% (number) %
Parathyroid 88%(22) 96%(80)
0% (0) 7% (6)
Pituitary 40%(10) 39%(32)
16% (41 13%(12)
N = 25 N = 83 N "" 52 N = 80
Vasenetal1989b
Skogseidetal1991a
by screening (Figure 2.6). There has been a shift to an earlier age at diagnosis
in the screened group compared to the symptomatic group (Figure 2.7).
However, since the majority of the screened group were identified at their initial
screening this shift will likely increase as screening forthoseatriskcontinues,
and more gene carriers are identified prospectively.
Although a number of different glands may be involved. just over half of
those with MEN-1 have had only one manifestation of the disease (44/83, or
53%), and the majority of these (41/44) had hyperparathyroidism only.
However, 29 patients (35%) had two manifestations and 10 patients (12%)
had three or more documented manifestations of MEN-1 (Table 2.3, Figure
2.8).
There have been thirteen deaths (age 31 - 881 of the 83 family members
definitely affected with MEN-1 (Table 2.4). Eight of these (age 31 - 73) were
directly related to manifestations of MEN-1: two were due to malignant
carcinoid tumours of the lung or thymus; two due to malignant carcinoid
tumours and another malignancy (breast cancer or renal cell carcinoma); two
due to expanding pituitary tumours; one, in a patient with Zollinger-Ellison
syndrome, due to sepsis from a perforated ulcer; and one, from renal railure,
in a patient with long-standing untreated hyperparathyroidism. Two other
MEN-1 patients died of malignancies (one may have had a malignant
prolactinoma and the other patient died of breast cancer). Three deaths, in
Figure 2.6. Age at diagnosis of symptomatic, screened, and predicted
affected patients in MEN-1 (Burin).
The age at diagnosis, by five year intervals. of symptomatic.
screened and predicted affected family members. is illustrated.
The range of ages at diagnosis for the three groups overlap; for
symptomatic patients (age 15-63),forclinicallyscreened patients
(age 13-831. and for predicted affected patients (age 10-54).
Age at diagnosis of symptomatic, screened
and predicted affected MEN-1(Burin) patients
~ 10
§
Z
1:2:1 predicted affected
n=27o screened
n=49
• symptomatic
n=34
Age (years)
Figure 2.7. Cumulative age at diagnosis for screened and symptomatic MEN-1
(Burin) patients.
The median age at diagnosis of patients detected by screening is
27 years, and of patients identified because of symptoms is 38
years. Because the majority detected by screening were identified
at the first set of investigations, the median age at diagnosis for
this group is expected to decrease. Ninety percent of each group
were identified by 55 years of age.
The youngest patient identified by screening was 12 years of age•
and youngest symptomatic patient was 13 years.
Cumulative age at diagnosis (MEN-1)
50% by age 38
90% by age 55
50% by age 27
90% by age 55
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TABLE 2.3. NUMBER AND COMBINATION OF MANIFESTATIONS IN
MEN-1IBurln) PATIENTS
Number/Combination
HPTH
PRL
PIT·'
CARC
HPTH/PRL
HPTH/PIT·z
HPTH/CARC
HPTH/PANC
HPTH/PRLlCARC
HPTH/PRLlPANC
HPTH/PRLlCARC/PANC
Number(%)
43
1
1
..1
46155.4%)
21
1
4
...z
28(33.7%)
5
...a
8(9.6%)
..1
1 (1.2%)
"one patient in 1975 with a "chromophobe adenoma" lprolactinnotmeasured)
"one patient in 1993 with a non·functioning chromophobe adenoma Iprolactin normal).
(All other pituitary tumours were prolactinomas.)
HPTH·hyperparathyroidism,PRL·prolactinoma, PIT· pituitary adenoma,
CARC • carcinoid tumour, PANC • pancreatic islet cell tumour
Figure 2.8. Combination and order ofoccurrence of manifestations in affected
MEN-1 (Burin) family members.
The age at diagnosis of individual manifestations is indicated on
a timeline for each affected member of the four MEN-1 (Burin)
families. Each family is illustrated separately with family members
ordered by date of birth. Age and cause of death are given where
applicable.
FAMILY A Combination and order of occurrence of manifestations
in affected MEN·1 (Burin) family members
yr. of birth
1976~
1969~ANC
1968 HPTH
1967~
1965 HPTH
1962 __
1961 -_
1958 ___'_~
1957 _
1954 _
1951 - __
195o __
195o _
1948 ~_
1947 -u;;n::r-_
::: p~_LTH_CAR_1....:.;~PTH~
1945 __~~__H:..:,;:*~=-
::=--=--=--=--=--=-~~~------:H~*~fii;-L~
1939 "-
1939 --l
1933-=~ ____+l
1928 ---'-"+'---__
1921 ------~:-----'-o;;:.,
1918 ------t
1910 -=="-----........-.t
AGE
malignant carcinoid
of the thymus
perforated ulcer (Z.E.)
natural causes
heart attack
FAMILY B Combination and order of occurrence of manifestations
in affected MEN·1 (Burin) family members
1966~
1963 PAL p~~
1963 HPIH
"Pi!It
1959 ----'-'~
1959 .....:.=.:.:.:...
::: ~r~AJ~~i
1950 "~P~w.;:""ftL;-
1939 (UPOMA) PANC~I%. HPTH
H~
HPTHcJ6lb HPTH
1933 ~
1930 =--;;;;;+~.;..,;O.
1929 ~CAR=CQl+-i1
1928 ----"O~
malignant carcinoid
of thymus
20 30 40 50 ~ 70 80 :a
AGE (YEARS)
FAMILY C Combination and order of occurrence of
manifestations in affected MEN-1 (Burin)
family members
yr. of birth
1979~
1975~
1973 H_PTH
1970 HPTH_
1969~
1962 HPTH
HPW
tf~ HPTHHPTH
1947PRlMARYAMENORRHEA I
1939 --;:;;;;;:;-'-"-HPTH.,HPTH:'tC
1935 ~~(L! ~~gljlRL
1929 ---"<,.;.;c-.--:=--_
1928_---== ...!!tfPlH!4!RLl......-_
Age (years)
cancerof maxillary sinus
Combination and order of occurrence of
manifestations In affected MEN-1 (Burin) family
members
1953---"""';';~
1946 p_;EA_R_IC(TJ-'4Hprl';';;;~8;;:;71('
1945-----~- -
~~~~~rg~,F~~~~ma
breast cancer
bf~~n"~{carcinOK1
invasi~uenro~uitary
naturaJcauses
10 20 30 ~ 60 70 :0 ~
Age(years)
AGE AND CAUSE OF DEATH IN MEN-11Burlni PATIENTS
MEN-1
MANIFESTATIONS
Age
at
Death
F Ca maxillary sinus
(1malignantprolactinomal
F Malignantcarcinoidlthymusl
M Z-EIPerforationandsepsisl
M Malignantcarcinoidlthymusl
M Invasiveprolactinoma
F Malignant carcinoid lIungl and
renal cell carcinoma
M Invasive pituitary tumor'
F Malignantcarcinoidllungland
breastcancar
inv.stigations +v•• orsymptomaticdi.....
inv.stigations-v.
noinvestiilations
classifiedaschromophobeadenomalprofactinnotm.asuredl
ZoE Zoliinger-EllisonSyndrorne
Ca Csrcinoma
HPTH - hyperparathyroidism. PRL - prolactinorna. PIT· pituitary adenoma, CARC - carcinoid
tumour.PANC-pancreaticisletceUturnour
patients aged 70 - 88, were apparently unrelated to MEN-1. Two obligate
carriers from an earlier generation, for whom no medical records are available,
died at a young age of ·ulcer disease· which may have been MEN-1 related.
Seventy of the affected family members are still living (age 14 - 92 yearsl.
Mprbidity Ind MgUJlity
HypArnarathyrpidism
Of the 83 affected in the MEN-1(Burinl families, 80(96%) had
hyperparathyroidism. Three others had normal calcium levels until the time of
death (age 31- 73 yrs). Hyperparathyroidism was present at the time of
diagnosis in 69 patients (83%), either alone (62 patients) or in combination
with a prolactinoma (7 patients) (Table 2.5). Twenty-seven of these (39%1
were investigated because of symptomatic presentation (kidneystones, ulcer
disease, or fatigue with muscle and bone pain, alone, or in combination with
galactorrhea and amenorrheal. Hypercalcemia with raised or inappropriately
normal PTH level was detected by screening of at-risk family members in 42
others (61%),the majority of these being identified during the pastfiveyears
(Table 2.6).
Hyperparathyroidism developed subsequent to other MEN-1
manifestations in 11 patients (13%). In two of these patients, who presented
with amenorrhea and galactorrhea and have been treated fora prolactinoma
since their mid-teens, hypercalcemia was only detected after 10 years of
regular screening.
TABLE 2.5. INITIAL MANIFESTATION OF MEN-1IBurinl
Glands Involved At
Initial Diagnosis
- HPTH only
- HPTH 8< PRl
- PRLonly
- PRL 8<HPTH
-PITonly
CARCINOID TUMOUR
62174.7%)
7 (8.4%)
9110.8%1
7 (8.4%)
1 (1.2%)
NumberlPercentl"
69 (83.1%1
17 (20.4%1
2 (2.4%)
2 12.4%)
This column does not total to 100% because some patients had two glands
involved at the time of diagnosis.
HPTH - hyperparathyroidism, PRL - prolactinoma. PIT - pituitary adenoma
N.B. 16.9% of patients did not have hyperparathyroidismatthetimeofdiagnosis.
TABLE 2.6. DETECTION OF HYPERPARATHYROIDISM IN MEN-1IBurlnl
Hyperparathyroidism
At Initial Diagnosis of MEN-1
- Symptomatic"
- Screening"
Subsequent Manifestation
- Symptomatic
-Screening
TOTAL WITH MEN-llBurinl
NumberlPercent)
80196%1
69183%1
11113%1
3 14%1
" Kidney stones, ulcer disease, fatigue, bone and muscle pain
'21ncreasedionizedcaicium,andincreasedorinappropriatePTH
The age at development of hyperparathyroidism is extremely variable. At
one extreme, a 14-year-old boy had significant hypercalcemia with raised PTH
at his first screening and passed a kidney stone prior to surgery atage 16. At
the other extreme, two asymptomatic women in their 80s were each screened
when they were recognized to be obligate carriers. Both had mild but confirmed
hyperparathyroidism, but because of their age neither hadsurgery.Onediedat
age 88 of natural causes and the other is now 92-years-old.
Thirty-seven patients (46%) have had a subtotal parathyroidectomy (3 y.
glands removed) or a total parathyroidectomy with forearm implant. Seven of
these required repeat surgery for recurrent hyperparathyroidism 8 -21 years
subsequently. Seventeen patients (21 %) who had surgery prior to the
recognition of MEN-l , had less than 3 glands removed. Seven in this group had
persistence or early recurrence of hypercalcemia post-operatively, and required
repeat surgery within two years. Twenty-three patients (29%) with recently
identified hyperparathyroidism have not yet had surgery, and three others (4%)
died without treatment (Table 2.7).
Two potential complicating factors regarding parathyroidectomy in MEN-
1 patients are the presence of more or less than four parathyroid glands in up
to 6% of individuals, and the risk of persistent hypocalcemia post-operatively.
In this group of families, two patients were documented to have five
parathyroid glands, and in two other patients, only three parathyroid glands
could be identified. The number of parathyroid glands removed was adjusted
TABLE 2.7. METHOD AND OUTCOME OF TREATMENT OF
HYPERPARATHYROIDISM IN MEN-1IBurin)
Number No. Requiring
Treated Repeat Surgery
Type of Treatment
Subtotal parathyroidectomy"
(3% glandsl
Partial parathyroidectomy
(1 or 2 glands)
Not treated
-pending
-deceased
Total with hyperparathyroidism
(%)
(46%)
(21%)
26 (33%)
(23)
(3)
(%1
(19%)'2
(41%)'3
"includesonepatientwithtotalparathyroidectomyandforearmimplant
·2 recurrent HPTH. 8-21 years post-parathyroidectomy
'2 persistent HPTH or recurrence <2 years post-parathyroidectomy
so that half a gland was left in place. Two patients had persistent post-
operative hypocalcemia treated with calcium and vitamin 0 supplementation.
One of these patients had had a total parathyroidectomy with forearm implant,
and the other had had 3% glands removed.
Only one affected family member died of the effects of long-standing
hypercalcemia. He presented with kidney stones in 1960 at age 50, and had
persistent hypercalcemia after one parathyroid "adenoma" was removed. He
declined further surgery and died of renal failure at age 53. Twenty-four
patients, however, have had multiple kidney stones (Table 2.81.
The proband in each of the four MEN-1 (Burin) families presented in the
late 1970s with galactorrhea and amenorrhea, or headaches and visual field
defect. Each of the probands had hypercalcemia identified duringinvestigations
of the prolactinoma, or had a previous history of kidney stones.
Pituitary tumours were identified in thirty-two (39%) of the 83 affected
persons (17 female and 15 male patients) (Table 2.9). Thirty of the pituitary
tumours were prolactinomas although three were originally classified in the
early 1970s as chromophobe adenomas (these patients had amenorrhea and
galactorrhea, and increased prolactin was later measured). Another patient with
a chromophobe adenoma, a male who was identified retrospectively as an
MEN-1 patient, may also have had a prolactinoma, but he died of invasive
pituitary tumour before prolactin assays were available.
MORBIDITY IN AFFECTED MEMBERS OF MEN·1(Burln)
K1NDREDS
GLAND. TYPE OF MORBIDITY
MUltiple kidney stones 24
Ulcers. fatigue. and bone pain 9
Renal failure 1
Multiple surgical procedures 14
Persistant post-operative hypocalcemia 2
Primary amenorrhea
2°amenorrhea/galactorrhea/infertility
Visual field defect
Severe headaches. coma
Panhypopituitarism
Chronic dopamine agonist treatment 15
Surgery/radiation treatment 10
Zollinger-Ellison syndrome
Metastatic disease
Partial pancreatectomy/gastrectomy
OTHER MALIGNANCY
Breast cancer
Renal cell carcinoma
Ca of maxillary sinus
TABLE 2.9. DETECTION OF PITUITARY TUMOURS IN MEN·1(Burinl
PATIENTS
METHOD OF DETECTION
Type of Tumour Symptomatic By Screening
140 ' 1602
-at initial diagnosis ofMEN-l (91 (7) (161
-subsequent manifestation (5) (9) (141
CHROMOPHOBE ADENOMA
-at initial diagnosis (1") (11
-subsequent manifestation (1'4) (1)
" amenorrhea and/orgalaetorrhea in women; visual fielddefeets. headaches or comain
'2 raisedprolaetin(~5xnormal;.all were microadenomas)
" visualfielddefeets;prolaetinnottested(1971)
'. abnormalCTscan; prolaetinnormal(19931
Recently, a macroadenoma of the pituitary was identified by baseline CT
scanning of the sella in a 32-year-old male patient with hyperparathyroidism but
normal prolactin levels. Following surgery, this tumour was classified as a
non-functioning chromophobe adenoma because immunostaining was negative
for prolactin, growth hormone, and ACTH (adrenocorticotropic hormonel.
Fourteen of the 30 patients with prolactinomas (47%1 presented with
symptoms before the screening program was introduced. These symptoms
included amenorrhea and galactorrhea in nine women (two of these with
primary amenorrheal; and visual field defects, severe headaches and coma, or
decreased sexual function in five men (Table 2.81. In nine of these patients.
prolactinoma was the first symptomatic manifestation of MEN-1. In seven of
sixteen others identified by screening, hyperprolactinemia with or without
hypercalcemia was present at the initial diagnosis of MEN-1 (Table 2.51. In two
women who presented symptomatically with prolactinomas in their mid-teens.
hypercalcemia was not identified for 10 years despite annual screening.
Management and outcome differed in patients identified symptomatically
or by screening (Table 2.101. Nine patients presenting symptomatically before
1984 with macroprolactinoma or chromophobe adenoma had surgery by either
a transtrontal or transphenoidal approach. In all of these. there was an
incomplete removal of the tumour. and subsequently radiation therapy and/or
bromocryptine treatment was required. Two of these patients died because of
the mass effect of the remaining invasive tumour. another died of an
METHOD AND OUTCOME OF TREATMENT FOR
PITUITARY TUMOURS IN MEN·l(Burinl
PROLACTINOMA CHROMOPHOBE ADENOMA
bromocryptineonly
bromocryptineand
radiation
deceased
(other causes)
Symp. Asymp.
n = 14 n = 16"
9'2
Symp.
n = 1
1'3
Asymp.
n = 1"
"' alive and well
"2 all had ineomplete removal of tumour and required subsequentmediealand/or
radiation therapy (2 deaths from pituitary tumour. 4 with panhypopituitarism. 3
alivewith.evereMEN-lI
"' diedofinvasivepituitarytumour.19n
symp.-symptomatic
asymp.-asymptomatie
"anaplastic carcinoma" of the maxillary sinus which may have been a malignant
prolactinoma(seelaterJ,andfourpatientshadpanhypopituitarismaftersurgery.
Another patient with a macroprolaetinoma had bromocryptine treatment and
radiation therapy without prior surgery. Two symptomatic patients have been
treated successfully with bromocryptine only, and two died of other causes
Seven of those with hyperprolactinemia recently identified by screening
(prolactin level up to 10x normal) are being treated medically with
bromocryptine, and nine others are not yet requiring treatment but are
beingclosely monitored. The recent patient with a non-functioning
macroadenoma underwent surgery with apparent complete removal of the
iii) PanCrAatjc!"mo'Jr$
Pancreatic islet cell tumours were documented in only 6 of the
MEN-lIBurin) patients (7%1. all male, ages 18-58 at the time of diagnosis
(Table 2.111. Although uncommon, the pancreatic tumour was the first
manifestation of MEN-1 identified in two of these patients, one patient
presenting with severe ulcer disease and the other identified by screening.
As in other MEN-1 families, the pancreatic tumours have been associated
with a poor prognosis. Gastrinomas causing Zollinger-Ellison syndrome (Z-EJ
(intractable ulcer disease) occurred in two men (Table 2.81 with extensive
MEN-1 disease including hyperparathyroidism and macroprolactinoma. One of
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these had a partial gastrectomy at age 35 and later a total gastrectomy
because of severe ulcer disease. He continues to have very high gastrin levels
(>2000 pmolll; N<43 pmollLI. and has slow growing liver metastases
documented with abdominal ultrasound and CT scanning. The second patient
with Z-E. age 44 at diagnosis, was treated with H,-antagonists for 5 years,
only partially successfully, and died of sepsis following perforation of a
duodenalulcer.Neitherpatienthadidentifiablepancreaticlesions on ultrasound
or CT scanning but the first had mUltiple small nodules seen in the pancreas at
the time of gastrectomy; and the second had multiple small gastrinomas of the
pancreas, and metastatic tumours in the liver and in peripancreatic lymph nodes
identified at autopsy.
Tumours were identified by pancreatic ultrasound screening in four other
asymptomatic MEN-1 patients with normal gastrin levels. Each had a partial
pancreatectomy. Increased serum glucagon was measured pre-operatively after
a pancreatic mass was identified in one patient. In two others. one of whom
had had increased serum pancreatic polypeptide pre-operatively. glucagon was
the major peptide identified on immunostaining of the pathology specimen.
None of these patients. however. had symptoms of the glucagonoma
syndrome. Information on the tumour in the fourth patient is unavailable.
Death from ulcer disease was reported in a number of first degree
relatives in previous generations for whom no medical records are available.
Although some may have had a gastrinoma with ZOllinger-Ellison syndrome, it
is more likely that they had untreated hyperparathyroidism. The majority of
family members who presented recently with ulcer disease and were
investigated, had hypercalcemia with normal gastrin levels, and the symptoms
were reversed by parathyroidectomy.
iv) Carcinoid tumours
Carcinoid tumours occurred in eleven patients (13%). Seven of these
(lM:6F) had carcinoid tumours of the lung, three (2M:1F) had carcinoid
tumours of the thymus, and one patient, a 58 year old male, had carcinoid
tumours of both lung and thymus (Table 2.12). All four of the thymic
carcinoids were malignant and in two cases this was the cause of death (Table
2.4). Six of the eight lung carcinoids were also malignant (Table 2.8): three
patients currently have liver metastases, and two others had metastatic
carcinoid of the lung at the time of death as well as another metastatic
malignancy (ie, renal cell carcinoma, or breast cancer). Three other MEN-1
patients (all male) have lung lesions seen on chest x-ray, suggestive of
carcinoidtumours,butnodefinitediagnosishasbeenmade.
None of the patients with carcinoid tumours, of the lung or the thymus,
have had symptoms of carcinoid syndrome or increased 5-hydroxyindoleacetic
acid (5HIAA) (Ouh et al 1987). The majority of the carcinoid tumours of the
lung, were identified coincidentally and initially thought to be benign. Surgery,
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radiation treatment and/or chemotherapy were attempted with little success
when rapid enlargement was seen or symptoms developed. A patient with liver
metastases documented with somatostatin receptor scanning is being treated
with the somatostatin analogue. oetreotide (Arnold et aI1993).
The carcinoid tumours of the thymus were identified because of a neck
mass or symptoms of shortness of breath. Two patients who presented with
a neck mass had incomplete removal of the tumour and died later of
widespread metastatic disease. Another patient who presented with shortness
of breath has an inoperable thymic carcinoid tumour, treated with radiation and
chemotherapy. as his only manifestation o"f MEN-1(Burinl. and the fourth
patient has had surgery but has local metastatic disease.
Carcinoid tumours are not only more common in MEN-1 (Burin) than in
typical MEN·1 families. but have proven difficult to identify by screening and
difficult to treat. A chest x-ray is now recommended every two to three years
for all known MEN-1 (Burin) patients and at least every five years for those at
risk. as an attempt to identify the tumours earlier. This may allow earlier and
more successful treatment. particularly of carcinoid tumours of the thymus.
v)~
Only two adrenal gland tumours have been identified in this family. These
were coincidentally noted on CT scanning of the abdomen. one in a patient
being investigated because of a pancreatic tumour detected on ultrasound
screening. and one ina patient with liver metastases from a bronchialcarcinoid
tumour. These may be coincidental rather than related to MEN-l in these
patients.
vi) OthermalignanciA§
A 32-year-old member of family C died in 1978 of an invasive tumour of
the maxillary sinus. described as a small cell anaplastic carcinoma atbiopsy.
but which may have been a malignant prolactinoma (personal communication.
Dr. Sylvia Asa. Mount Sinai Hospital. Toronto). The patient previously had
primary amenorrhea and galactorrhea but did not present to medicaI care until
age 20. She declined surgery until age 29 when a large "chromophobe
adenoma" was partially removed. She was also treated with radiation therapy.
however she returned 3 years later with an inoperable tumour. This tumour
wasbiopsied.butshediedwithoutfurthertreatmentordefinitivediagnosis.
Breast cancer was identified in four of the affected members of family
o (three sisters and their cousin). and another affected sister had renal cell
carcinoma. All five of these women also had malignant carcinoid tumours
(Table 2.13. Figure 2.9). There are no documented malignancies in non-MEN-l
members of Family D. or non-MEN-l related malignancies in affected or
unaffected members of Families A. Band C.
In 1989. when pedigrees were completed and 42 affected family
members had been identified. there were 169 first-degree relatives at 50% risk
TABLE 2.13. MAUGNANT TUMOURS IN AFFECTED
MEN-1(Burlnl K1NDREDS
NUMBER AFFECTED
TYPE OF TUMOUR Total (Dead)
MEN-l TUMOURS
Pancreatic Islet Cell 3(11
- gastrinoma 2(11
- glucagonoma 1!Ql.
10(41
_ lung"'2 6(2)
- thymus M.Zl
OTHER (POSSIBLY COINCIDENTAL) 6(41
-breastcancer"' 4(2)
- renal cell carcinoma'2
- cancer of maxillary sinus'3 .lill
TOTAL MALIGNANCIES
"onepatientwithcarcinoidofthalungandbraastcancer(daadl
"onepatientwithcarcinoidofthalungandranalcaUcaldeadl
·z possiblemalignantprolactinoma
19(7)""2
Figure 2.9. Malignant tumours in affected members of MEN-1 (Burin) Family
D.
A simplified pedigree is used to illustrate the malignant tumours
identified in Family D. All malignancies, whether characteristic of
MEN-1 (eg, carcinoid tumour), or other malignancies (eg, breast
cancer, renal cell carcinomal, were in family members affected
with MEN-1 (Burinl.
Malignant tumours in MEN·1 (Burin) family D
l!!
[iI
"*@) Carcin"idlumou,(m',lignantJ
O~Breastcanc8r
O~Renalc8l1carcinoma
of having inherited MEN-l. On questioning, 143 of these (85%1 stated that
they were interested in participating in a linkage study, and werealso interested
in predictive testing if this became available. After appropriate consent forms
were signed, DNA samples were obtained from those interested and from
relevant affected relatives.
Initially, proximal chromosome 11 p and 11 q markers linked to the gene
for typical MEN-l were used to determine whether the gene for MEN-l (Burin)
also mapped to this region. All ofthe markers used (0115288, PGA, 0115971,
0115970,0115146, INT-2, 0115533) (Table 2.1) gave positive LOo scores
(Petty et al 1994), and no cross-overs were seen with PYGM a marker
tightly-linked to typical MEN-l. Using the MLINK program a LOo score of
13.65 at 8 = 0.0 was obtained for linkage of MEN-1(Burin) to PYGM. Thus
the differences between the MEN-l (Burin) and typical MEN-l phenotype are not
likely to be due to mutations of different genes. All affected individuals in the
four kindreds shared the same uncommon PYGM allele, and other closely-linked
markers were in linkage disequilibrium with MEN-1(Burin) (Figure 2.10),
supporting the geographic evidence for a common ancestor (Petty et al 19941.
Predictive testing could then proceed and is now complete for 121 of
those at risk (Figure 2.11, Table 2.141. Several family members had blood
collected for DNA extraction at the same time as their first clinical screening
tests, so for 23 (19%) of those tested (age 13-52), the high-risk predictive
testing results and positiveclinicalscreeningresultswereobtainedatthesame
Figure 2.10. Haplotypes of affected members of individual MEN-1 (Burinl
families.
All haplotypes for the set of linked markers that are found in
affected members of the four MEN-1 (Burin) kindreds are shown.
The most common haplotype in each family is indicated as
subgroup Ii). and haplotypes generated by cross-overs are
indicated as subgroups (ii) or (iii). In one branch of Family B,
designated B", the MEN-1 (Burin) gene is now known to be
inherited from an unrelated spouse who is from the same
ancestral community"as Family D. All affected individuals share
the same uncommon PYGM allele.
Haplotypes of affected members of individual MEN-1 (Burin) families
MARKER ALLELES
Families
Loci
A --.!...- ~ c
ii'iiii i ii i ii Ii
o
iii
0115288
PGA
PYGM
0115971
0115970
0115146
INT2
::~ ~~~~ ~2~2 ~~ ~2~2
2212222222
2222222222
2221121221
1 3 1
0115533 450580700 480580 470 - 470 "4" "3"
Figure 2.11. Results of predictive testing for at-risk members of MEN-1 (Burin)
families.
The marker data from linkage analysis is given for each family
member who requested predictive testing, and also for relevant
affected relatives. The haplotype associated with MEN-1 (Burin)
is circled. Family members with high-risk results are indicated
(-I. Those with low risk (LR), or uninformative IU) results are
also indicated. Whenhaplotypescould not be determined, the
allelesofaparticularmarkerareseparatedbyacommalie, 1,2).
FAMILY A MULTIPLE ENDOCRINE NEOPLASIA, •
~,TYPE 1
FAMILYB MULTIPLE ENDOCRINE NEOPLASIA, n
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TABLE 2.14. PARTlCIPAnON IN PREDlcnVE TE5nNG. AND RESULTS OF
UNKAGE ANALYSIS FOR MEN-1(Burinl
PARTlClPATlQN IN PREDICTIVE TESTING
At 50% Risk (1990)
Testing incomplete
Clinical diagnosis
(before predictive testing)
121
RESULTS Of LINKAGE ANALYSIS
High Risk
With positive clinical screening
With negative clinical screening
23(19%)
27(22%1
50(41%)
43(36%)
28(23%)
time. For those with negative clinical screening, high-risk results
(>95%->98% probability of carrying the MEN-1 genel were given to 27
others (22%), nine of whom were subsequently identified as affected by clinical
screening, and low-risk results « 2%- <5% probability) were given to 43(36%)
of those tested. Genetic testing was uninformative for 28 of those tested
(23%) because of recombination, homozygosity of markers. heterozygosity in
both parents. or unavailable DNA samples from key relatives.
Thus. eighteen family members (age 9 to 42) have high-risk results from
predictive testing but have no abnormalities as yet on clinical screening. This
includes a 42-year-old woman predicted to be homozygous for the MEN-1
(Burin) gene. having inherited the haplotype associated withthe disease from
each of her affected parents (Figure 2.12). This high-risk group. family
members already affected, and those for whom predictive testing was
uninformative require continued annual clinical screening to identify and treat
any endocrine tumours at an early stage. The,low-risk group (n = 43) requires
less frequent clinical screening, and will be screened everythreeyears.
Imp.C;!g'tb.$t;....ningp'ogr.m
Some members of the MEN-llBurin) families were previously very
apprehensive about MEN-1 because of the early deaths or severe disease in
close relatives. and because they and their doctors had very little information
about MEN-1. They expected a poor outcome for all affected family members.
Figure 2.12. Presumed homozygote for MEN-1 (Burin) identified by linkage
analysis.
There was one marriage between two affected persons (#204
from Family A, and #205 from Family D). Their daughter, #302,
inherited the haplotype associated with MEN-1 (Burin) from each
parent. She is therefore presumed to be homozygous for the
MEN-1 (Burin) gene. Although the haplotype of each parent was
inferred, in each case it was based on the haplotype of affected
and unaffected siblings, the daughter, grandchildren, and
multiple affected relatives. At age 42, #302 has no
manifestations of MEN-1 (Burin) identified by screening.
Results of predictive testing by linkage analysis indicating
presumed homozygote for MEN-1 (Burin)
26 22 15
~m ~m
andnowappreciatetheinformationprovidedontheclinicalandgeneticaspects
of MEN-1(Burin), and the organization of specialized care, as part of the
screening program. Many of these feel that family members are much better
off medically and psychologically than before. As a result, they comply with
clinical screening recommendations, and have been interested in predictive
testing to determine whether they and their children should continue with this
screening. However none of these family members were interested in prenatal
diagnosis, nor would they reduce the size of their families because of the risk
ofMEN-llBurinl.
Other family members had little previous interest or knowledge about
MEN-llBurin). Typically these had no close relatives who were severely
affected, and had no expectation of any adverse effects of MEN-llBurin).
Some of these were not interested in the screening program, and others
participated on an irregular basis. Many of this group also requested predictive
testing when it was available, to clarify their risk but not to alterreproductive
planning.
DISCUSSION
This group of MEN-1 (Burinl kindreds was of particular interest because.
atypically, each proband presented with a symptomatic prolactinoma (Farid at
al 19BOI, and because of the high frequency of prolactinomas and carcinoid
tumours and low frequency of pancreatic islet cell tumours compared to typical
MEN-1 families (Marx et al 1986. Brunt and Wells 1985, Vasen et al 1989b).
These kindreds also presented a significant problem for clinical management
because of the large number of affected and at-risk members within the original
pedigrees. the significant morbidity and mortality in those originally identified.
and the independent identification of other distantly related MEN-1 patients
from that geographic region which suggested that the full extent of the problem
was not yet defined. In addition. because the families reside ina rural area,
access to the necessary medical care is difficult. It was felt that a coordinated
screening program was necessary to allow early identification and treatment of
manifestations of disease (Brunt and Wells 1985. Vasen et al 1989b), and to
provide appropriate genetic counselling for affected and at risk family members.
The present study was undertaken to define the clinical phenotype of
MEN-' (Burin) so that appropriate clinical screening could be instituted, to map
the gene for MEN-1 (Burin) so that predictive testing by linkage analysis or direct
mutation detection could be offered to those at risk, and to implement and
evaluatetheclinicalandgeneticscreeningprogramrecommended; but first. a
few words about the identification of MEN-1 (Burinl families.
A,s9rtalnm.nt p' MEN-111ydo' Ftmili••
Ancestors of each of the four independently-identified MEN-lIBurinl
families came from a group of very small. isolated. now abandoned
communities within a 20-mile radius on the north shore of Fortune Bay. No
single common ancestor was identified. However, three of the pedigrees
consist of two separately identified branches joined by pedigree studies, and
the small communities in this isolated area of the south coast of Newfoundland
were populated by a small number of settlers from southwest England in the
middle 18oos. There are no written records to extend the pedigrees beyond the
four or five generations documented but there are common surnames in the
earliest generations recorded. The fact that all affected in the four families have
the same allele of PYGM (a closely-linked marker for which recombination with
theMEN-110cushas not been recorded I supports the inference that a single
founder introduced the mutant gene.
ClioI."" Pheootype of MEN-1IBurlnl
Our studies confirmed that MEN-1 (Burinl is distinct from typical MEN-1
in the characteristic presentation of disease, and also in the 0verallfrequencies
of manifestations detected by comprehensive screening (Table 2.2, p. 881. The
high frequency of prolactinomas and carcinoid tumours, and low frequency of
pancreatic involvement is not just a bias of ascertainment based on the
dramatic presentation of the probandsandotherearlyaffected individuals.Even
though pancreatic islet cell tumours are rare, functional gastrinomascausing
Zollinger-Ellison syndrome, and non-functional glucagonomas have occurred.
The most difficult manifestations to identify and treat, however, are the
carcinoid tumours of the lung and thymus. and these have caused both
morbidity and mortality.
Although the overall pattern of disease in MEN-1 (Burin) is different from
that in typical MEN-1. there is an extremely variable disease presentation even
among close relatives: in age of onset. in number and order of occurrence of
manifestations. and in severity of disease. Just over 50% of affected members
have hyperparathyroidism only. as in typical MEN-1 families. but 34% have two
manifestations, and 11 % have three or more. Identification of atypical MEN-1
families depends on having enough patients documented to recognize the
atypical statistical distribution of manifestations. Branches of these families
seen elsewhere, or small families with a similar genetic defect, might therefore
not be immediately recognized as having a different pattern of tumour
predisposition. This suggests that a broad screening protocol (Figure 2.2. p. 76)
would be desirable for all MEN-1 families, inclUding testing for parathyroid,
pituitary. pancreatic and carcinoid tumours. Compliance will be greatest if
primary screening is available locally rather than requiring travel to a tertiary
care facility. Because of variable availability of medical care for families in
different areas of one country or in different countries. the exact set of
screening tests used may have to be a compromise.
Miggins Of MEN-1IBurlnl
The MEN-l (Burinl gene maps to the same chromosome llq13 region as
the gene for typical MEN-l (Petty et al1994, Larsson et aI1988). However,
until the gene(s) is cloned and specific mutations identified, it will not be
possible to determine the basis for the differences in MEN-l and MEN-l (Burin).
Are they different genes (which is unlikely); or different mutations within the
same gene, as with the distinct types of mutation in the RET proto-oncogene
causing MEN-2A and MEN-2B (van Heyningen 1994); or does the difference
reside in factors modifying a common genetic defect as in the different
phenotypes of MEN-2 (MEN-2A and familial medullary carcinoma of the thyroidI
arising from identical mutations of the RET oncogene (Mulligan et al 1994,
Donis Keller et a11993)7
AlIylll Of Clln;eal $"',,n;n9 fo, MEN-lIBy,lnl
The clinical screening program has identified 41
MEN-1lBurinl patients since 1989. Although many have had
hyperparathyroidism only, as in typical MEN-l families (Marx et al 1986, van
Heerden 1986, Shepherd et al 1991), others have had prolactinomas or
carcinoid tumours only which is not characteristic of typical MEN-l.
It is obviously not possible, as yet, to provide precise data on the
long-term medical benefits of the screening program. This and other MEN-l
families must be monitored over a longer time period before appropriate
comparisons can be made. However, as one would expect, the patients who
presented symptomatically have had greater morbidity and mortality than those
identified by screening, and many had symptoms from at least two involved
glands at the time of diagnosis: particularly kidney stones, fatigue andfor
muscle pain secondary to hyperparathyroidism; and amenorrhea, galactorrhea,
headachesorvisualfielddefectssecondarytoaprolactinoma.Sincescreening
for most patients is relatively recent, and screening identifies gland involvement
at an earlier stage, patients identified by screening have not been affected as
long as most symptomatic patients. However, patients with hyper-
parathyroidism,orhyperprolactinemiaidentifiedbyscreening are being treated,
by surgery (Brunt and Wells 1985, Malmaeus et al 1986), or medically with
bromocryptine (Dalkin and Marshall 19891, respectively, at an early stage.
Since the disease is not progressing, the morbidity or mortality previously seen
for these manifestations is less likely to occur.
Surgery is still the treatment of choice for MEN-1-related hyper-
parathyroidism; however, recognition of MEN-l is important so that the
appropriate type of surgery is done (subtotal parathyroidectomy, or total
thyroidectomy with forearm implant) because in MEN-1 (Burin) patients as well
as in MEN-1 patients described in the literature, there is typically hyperplasia
of all four glands rather than a single adenoma. In the past, removal of only
one gland frequently resulted in persistence or early recurrence of symptoms,
and the need for repeat surgery at an early stage (Rizzoli et al 1985, Malmene
et aI1987).
No macroprolactinomas have been identified in the MEN-1 (Burin)
patients sincehyperprolactinemia has been detected by screening and treated
medically. Not only have patients not required a difficult surgical procedure,
but they also have not developed the severe symptoms caused by a large
prolactinoma (galactorrhea, amenorrhea, visual field defects. or severe
headaches).
Although two patients had Zollinger-Ellison syndrome with very high
gastrin levels and multiple small gastrinomas (as previously described [van
Heerden et al 1986. Pipeleers-Marichal et a11993)), elevated gastrin has not
been detected by screening in any other affected oratrislcfamilymembers.
There is evidence from other families with frequent pancreatic islet cell
tumours. that treatment of early gastrinomas with H.·receptor antagonists or
ATPase inhibitors (Brunt and Wells 1985, van Heerden et al 1986. Wolfe and
Jensen 1987) can prevent Zollinger-Ellison syndrome, but not necessarily the
malignant potential of the gastrinoma (Wolfe and Jensen 1987.
Pipeleers-Marichal et aI1993). The MEN-1 (Burin) patient who died of sepsis
from a perforated ulcer. had liver and lymph node metastases detected at
autopsy, and the second ZoE patient has documented slow-growing liver
metastases. but the malignant nature of the pancreatic tumours has not been
the main concern in the clinical management of these two patients. Both
patients had severe uncontrollable symptoms because of hypergastrinemia.
The patients with non-functioning glucagonomas have been identified recently
and their long term clinical course remains to be seen.
In many MEN-1 families described in the literature, pancreatic tumours
caused the greatest morbidity and mortality, previously because of untractable
ulcer disease, and currently because of pancreatic islet cell malignancies
(Ballard et a11964, Vasen et al1989b, Skogseid et aI1991a). Shepherd etal
(19931, however, have described a large Tasmanian family where the majority
of patients with radiological or biochemical evidence of pancreaticisletcell
disease are asymptomatic. Only 28% of those with pancreatic involvement
had symptomatic pancreatic lesions, and deaths from pancreatic disease were
Carcinoid tumours of the lung and thymus cause the greatest problem for
clinical management in the MEN-1(Burin) kindreds, and a similar situation is
described in the Tasmanian family (Wilkinson et al 1993). Unlike other studies
wherecarcinoidofthelunghasbeenfoundonlyinwomenandcarcinoidofthe
thymus only in men (Shepherd et al 1991, Zeiger et al 1992, Economopoulos
et al 1990), we have seen carcinoid tumours in both locations in both sexes,
and one male patient has had carcinoid of the lung and carcinoid 0 fthethymus.
Carcinoid tumours of the thymus are frequently malignant when identified and
are associated with a poor prognosis (Economopoulos et al 1990, Wilkinson et
aI1993). Surgery is difficult because of their location (Teh et aI1994a), and
chemotherapy and radiation may not be helpful.
These carcinoid tumours have not secreted 5HIAA as sporadic carcinoid
tumours usually do (Duh et al 1987), so have been detectable only by chest
x-ray, or the symptoms of advanced inoperable disease. However, there is a
concern that annual chest x-ray (or, particularly the diagnostically more useful
CT scanning) from an early age may increase the risk of malignancy in a patient
with a genetic predisposition to tumours (personal communication, Dr. CE
Jackson, Henry Ford Hospital, Detroit, Michigan).
MQrbidity lod MOn'IiN
Only eight deaths definitely related to MEN-1 have been recorded in the
83 affected members of these kindreds (three other deaths were unrelated, and
two were from other malignancies), but some of the MEN-1-related deaths
were at an early age (Table 2.41. Four of these eight deceased patients had
malignant carcinoid tumours; two deaths were caused by malignant carcinoid
of the thymus, and two other. patients had metastatic carcinoid of the lung as
well as a second metastatic tumour (renal cell carcinoma or breast cancer) as
the cause of death. Five of the seven living patients with carcinoid tumours
also have malignant tumours, with either local invasion from carcinoid of the
thymus, or rapidly enlarging lung and liver metastases from carcinoid tumours
of the lung. Various combinations of surgery, radiation and chemotherapy have
been tried with only limited success. Since some of the carcinoid tumours or
their metastases have somatostatin receptors, one suggestion has been that
somatostatin receptor scanning, and treatment of those with a positive scan
with the somatostatin analogue, octreotide, may offer a solution to both the
difficulty of detection and the difficulty of treatment of these tumours (Arnold
et al 19931. However this is costly (approximately $l000/scan). A limited
clinical trial is now being conducted by Dr. Ehud Ur (Endocrinology) and Dr.
Peter Hollett (Nuclear Medicinel at St. John's General Hospital to determine the
efficacy of this procedure.
Deaths from renal failure (one previously), Zollinger-Ellison syndrome (one
previously), and invasive pituitary tumours (two previously) are less likely to
occur now because of the early detection and treatment of
hyperparathyroidism, hypergastrinemia, and prolactinomas, or other pituitary
tumours. because of the screening program.
The relation of other malignancies to MEN-1 (Burin), in five patients from
one of the kindreds. is not known. Four breast cancers and a renal cell
carcinoma were identified in four sisters and their cousin with MEN-l(Burin)
(four of whom also had malignant carcinoid tumours). No malignancies have
been identified in the non-MEN-1 members of any of the four kindreds, raising
the possibility that breast cancer may be a rare manifestation of the MEN-1
(Burin) gene, or that MEN-1(Burin) increases the overall risk of various
malignancies including breast cancer and renal cell carcinoma.
The potential for malignancies in MEN-1 other than of pancreatic islet cell
or carcinoid tumours has not been described except in the family reported by
Johnson and Sawicki (1993) which has a number of atypical features including
childhood onset, dysmorphic features and hematological malignancies. In fact,
this family may have a contiguous gene syndrome associated with a small
deletion rather than variable manifestations of the MEN-1 gene (personal
communication, Dr. Carey Johnson, Alberta Children's Hospital, Calgary).
Although some MEN-1 patients in the Newfoundland families have severe
disease, there is very mild late-onset disease in other gene carriers. most
notably two women (first cousins) identified in their 80s with hypercalcemia.
one of whom later developed mild hyperprolactinemia also. Both had severely
affected siblings, children or grandchildren who predeceased them. Older
patients who are asymptomatic or with very mild disease have also been
described by Shepherd (1991) in the large Tasmanian MEN-1 family.
The family member predicted by linkage analysis to be homozygous for
the MEN-1 gene has no symptoms of MEN-1 at age 42. and continues to have
normal results for all screening investigations. Two other patients predicted to
be homozygous for MEN-1 have been reported (Brandi et al 1993). They
express manifestations of MEN-1 (age 35 and 40), but are no more severely
affected than their heterozygous relatives.
Fifty-two per cent of those who are affected have had
hyperparathyroidism only, successfully treated surgically in most cases,
whether identified clinically or by laboratory screening. Because of this mild or
easily treatable disease in some family members, some of those at risk have not
been interested in the clinical or genetic screening programs, or have been
non-compliant following initial screening. Unfortunately, it is not possible to
predict the severity of disease in any particular gene carrier, and, as described
above, children of mildly affected MEN-1 patients will not necessarily have mild
A••yl" Q'pr.distlv. ,.,'tjng
The mapping of MEN-1 IBurin) to chromosome 11 q13 allowed predictive
testing with a set of markers flanking the MEN-1 region to distinguish those at
low or high risk of having inherited the MEN-1 IBurin) gene. Discussions during
genetic counselling sessions showed that the majority of family members were
interested in predictive testing forthemselvesorfortheirchi1dren, but this was
usually to determine whether they required clinical screening, rather than to
influence their reproductive decisions.
Nineteenpercentofthosetestedl23/1211hadpositiveclinicalscreening
results at the same time as high-risk predictive testing results. These will have
annual screening, and treatment as necessary. Those who had high-risk
predictive testing results (22% [age 10-42 yearsll with normal clinical
screening results also require annual screening.
Twenty-three per cent of those for whom linkage studies are completed
had uninformative results because of unavailable DNA samples from key
individuals, homozygosity of markers (a potential problem with inbred
populations in genetic isolates), or recombination between flanking markers.
This group also requires continued annual clinical screening until the genetic
status can be clarified when more informative markers are available (Larsson et
al 1992a, Teh et a11994b), or the MEN-1 gene is cloned and the mutation in
this family identified.
For 36% of those at risk who are participating in the clinical screening
program and have had negative screening results up to the present time, clinical
SCreening can be reduced because of the low-risk linkage results. Similar
predictive testing programs for typical MEN-1 families have been described
(Larsson et al 1992a, Teh et al 1994b). When the recommended biochemical
testing can be directed to the high-risk group identified bylinkageanalysis, the
screening program is more efficient with reduced costs to individual family
members, and to the medical care system.
Co,t! end "nlfit! Of $,(.tnlng
The clinical screening has been organized in such a way that the primarv
testing can be done at the local hospital or clinic, and this is coordinated by the
geneticist in St. John's and the various family doctors. For most family
members who live in small communities on the Burin Peninsula or Fortune Bay,
this means a 5-60 km drive for screening rather than a drive of at least 400 km
to the tertiary care centre in St. John's, and therefore saves both time and
money. Follow-up of abnormal screening, however. is done at the Clinical
Investigation Unit in St. John's.
Because of the late diagnosis of very mild disease in some family
members. it is not known how long biochemical screening should continue if
all biochemical screening results are negative. We have seen that compliance
with screening decreases with repeated normal results so some patients may
be lost to follow up before diagnosis. The addition of genetic testing by linkage
analysis to the screening protocol provides a means to identify those at high
risk who should be encouraged to continue with regular clinical screening
despite negative testing. The genetic testing also identifies non-carriers who
require much less frequent screening (Figure 2.131, Because these are large
families. there were over 100 affected and at-risk family members in the
screening program in Newfoundland. Clarifying those who require this
screening, by genetic testing, is therefore beneficial to the health care system
and to the family members. .
Satilfl";t!on with Sq..nlng
Family members have expressed their satisfaction with the clinical arid
genetic screening program because of the early identification andtreatmentof
family members. and the better understanding of the disease. both by
themselves and by their family doctors.
Figure 2.13. Management plan for MEN-1 (Burin).
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They have greater confidence than previously that their special needs are
recognized, and that specialists are available, if necessary, to investigate any
symptoms or abnormal screening results. Their interest and participation in
both the clinical and genetic components of the screening program is correlated
with their perception of the burden of MEN-l(Burinl, and this, in turn, is
correlated with the degree of relationship to those who have had severe disease
in the past. or died young of the disease - similar to the situation reported for
members of spinocerebellar ataxia (SCA-1) families (Nance et aI1994). The
results of predictive testing are used to determine their need tocontinuewith
clinical screening or to have their children- screened, rather than to alter
reproductive planning, unlike in more severe late-onset hereditary diseases
where high-risk or affected individuals often choose not to reproduce (Nance
et aI1994). Overall, family members feel that they are more healthy and less
anxious than before the screening program was offered.
CHAPTER 3 - DEVELOPMENT OF A CLINICAL AND GENETIC SCREENING
PROGRAM FOR MULTIPLE ENDOCRINE NEOPLASIA, TYPE 2
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This chapter will describe the identification of a Newfoundland family
with multiple endocrine neoplasia. type 2. the implementation ofaclinical
screening program, the difficulties in classification of this family based on the
results of clinical screening, the development of genetic testing. and the impact
of this screening program on family members.
Multiple endocrine neoplasia. type 2 (MEN-2} is a dominantly inherited
cancer predisposition syndrome characterized by medullary carcinoma of the
thyroid, pheochromocytoma and hyperparathyroidism (Sipple 1961, Steiner et
al 1968, Chong et al 19751. In the classic form of MEN-2. MEN-2A, medullary
carcinoma of the thyroid (MTCI. or its precursor state C-cell hyperplasia (CCH),
occurs in almost 100% of gene carriers but the age of onset is extremely
variable (Easton eta11989), including patients symptomatic in the teens or
childhood (Telander et al 19891, and asymptomatic gene carriers in the 6th or
7th decade (Ponder et al 19881. Pheochromocytoma or adrenal medullary
hyperplasia occurs in about 50% of gene carriers and may precede thyroid
gland involvement (Carney et al 1975. Gagel et al 1988. Howe et aI1993).
Parathyroid hyperplasia is present in approximately 20% of those affected, but
is rarely associated with significant clinical disease (Gagel et al 1988, Kraimps
et a11992. Decker 1992. Howe et al 1993).
Patients presenting symptomatically typically have advanced disease,
with almost half dying of MEN-2 (Calmenes et al 1992, Telenius-Berg et al
1984). In families studied retrospectively, the causes of death have been
related equally to metastatic spread from malignant MTC, and to hypertensive
crisis due to an undetected pheochromocytoma (Telenius-Berg et al 1984,
Vasen etaI1987).
Clinical screening programs (Graze et al 1978, Telenius-Berg et al 1984,
Vasen et al 1987, Gagel et al 1988, Calmenes et al 1992) using a pentagastrin
and/or calcium-stimulated calcitonin test (Guilloteau et al 1990, Weissel et al
1991, Barbot et al 1994) for identification of thyroid disease, and 24-hour urine
measurement of catecholamines and metanephrines for evidence of adrenal
disease (Gagel et al 1988, Lairmore et al 1993), allow early detection and
treatment of manifestations (Wells et al 1985, Jannson et a11988, Telander
et al 1989, Barry et al 1991), and have resulted in reduced morbidity and
mortality (Vasen et al 1987, Gagel et al 1988, Decker 1992. Calmenes et al
1992). Although only 60% of patients have symptomatic evidence of MTC or
C-cell hyperplasia by age 70. 93% of those with the MEN-2 gene can be
detected by biochemical screening by age 31 (Ponder et a11988, Easton et al
1989). Those who are detected by prospective screening and have a
thyroidlJlctomy as soon as the increased serum calcitonin is confirmed usually
have C-cell hyperplasia only and have the best prognosis (Vasen et al 1987).
The European Collaborative Group has therefore recommended that screening
should start by age 3 to allow prospective detection of even the earliest onset
disease (Calmettes et al 1992', and other groups recommend even earlier
screening (TelanderetaI1989,.
A related but clinically distinct syndrome, MEN-2B (Gorlin et al 1968,
Schimke et al 1968, Norton et al 1979', has also been described, with
particularly early onset and rapid progression of medullary carcinoma and
pheochromocytoma. Hyperparathyroidism is not described in MEN-2B, but
associated features including Marfanoid habitus, mucosal neuromas, and
intestinal ganglioneuromatosis are often present (Vasen et al 1992). MEN-2B
is less common than MEN-2A. Because of 'the early lethality, often before
reproduction, many MEN-2B patients are the result of a new mutation
(Montgomery et al 1987. Lairmore et al 1991). but the associated features
present in early life may allow early diagnosis (Vasen et aI1992).
It has also been recognized that some MEN-2 families have thyroid
disease only. either MTC or C-cell hyperplasia (Noll et al1984, Farndon et al
1986'. In these families with familial MTC (FMTCI. the typical age of onset of
medullary carcinoma is significantly later than in MEN-2A families and the
thyroid disease usually more slowly progressive (Farndon et al 1986). Because
ofthelaterageofonset,screeningforthesefamiliesmaybeginatalater age.
The gene for MEN-2A was mapped to the centromeric region of
chromosome 10 in 1987 (Simpson et al 1987, Matthew et al 1987', and
subsequently MEN-2B (Norum et al 1990, Lairmore et al 1991) and FMTC
(Narod et al 1989. Lairmore et al 1991) were also mapped to this region.
Closely-linked markers have been used for predictive testing in MEN-2A. MEN-
2B. and FMTC families (Sobol et al 1989. Telenius et al 1990. Mathew et al
1991. Howe et al 1992. Lichter et al 1992. Shimotake et al 1992. Thakker et
al 1993a. Barbot et al 1994). to identify those at high risk of carrying the
disease gene and requiring clinical screening.
In 1993. mutations in the RET proto-oncogene were identified in affected
members of MEN-2A (Mulligan et a11993. Donis-Keller et a11993) and FMTC
families (Donis-Keller et al 1993. Mulligan et aI1994). These mutations cluster
in five cysteine residues near the transmembrane boundary of the extracellular
domain of the RET protein (Eng et al 1994b. Lips et al 1994. Mulligan et al
1994). A missense mutation in this group of cysteine codons has been
identified in over 80% of families studied ( Mulligan et al 1994. Schuffenecker
et al 1994. Xue et al 1994) with the majority of mutations. particularly in
MEN2-A families. affecting codon 634 (McMahon et al 1994. Mulligan et al
1994. Schuffenecker et aI1994). Subsequently. missense mutations of codon
918 in the tyrosine kinase domain of the RET proto-oncogene were identified
in MEN-2B patients (Carlson et a11994. Eng et aI19948. Hofstra et a11994)
and in sporadic MTC (Hofstra et al 1994). Interestingly. inactivating mutations
in the intra- and extracellular domains of the RET gene cause a usually
unrelated disease. autosomal dominant Hirschsprung disease (Edery 1994.
Romeo et al 1994).
This specificity of the site of mutations increases the likelihood of
mutation detection for an MEN-2 family. or even for an individual presenting
with MEN-28 without family history. and facilitates the identification of gene
carriers amongst at-risk relatives by direct mutation analysis (lipsetaI1994,
McMahon et al 1994, Tsai et al 1994, Xue et al 1994). Clinical screening to
detect thyroid and/or adrenal disease can then be reserved for those identified
as gene carriers.
While there is evidence that the clinical screening programs have reduced
the morbidity and mortality from MEN-2A, MEN-28 and FMTC (Vasen et al
1987. Gagel et a11988. Decker 1992). there is some concern about apparent
false positive results of calcitonin stimulation testing leading to inappropriate
thyroidectomy in unaffected individuals (Simpson et al 1990, Landsvater et al
1993). Use of genetic testing to identify gene carriers, however, will lessen
the possibility of this problem.
A Newfoundland famil.y with MEN-2. with 4 affected family members
and 19 first degree relatives at 50% risk. was referred to genetics in 1989.
Clinical screening was organized by Jane Green for all affected or at risk.
Genetic screening (initially linkage studies and latera search for the mutationI
was undertaken in collaboration with other laboratories in an attempt to
identify gene carriers so that biochemical screening could be restricted to this
The results of the clinical and genetic screening are nowpresented with
a preliminary comment on the impact of the screening program on members of
the family.
PATIENTS AND METHODS
A,c;.rtlinmlntgfF.mlly
The Newfoundland MEN-2 family was first recognized by the Pathology
Department of the General Hospital, St. John's, Newfoundland in 1984 when
they identified two patients with medullary carcinoma of the thyroid. A 44-
year-old patient (Patient 1) who had presented four years earlier with a neck
mass, and had biopsy proven MTC, died of metastatic disease. His 67-year-old
uncle (Patient 2) died suddenly, and at autopsy a small MTC was identified
coincidentally as well as a ruptured aortic aneurysm which was the cause of his
death. Screening was instituted for some family members and, in 1985, the
19-year-old grandson of Patient 2 had increased urinary catecholamines. as well
as increased blood pressure and tachycardia. After further investigations,
including CT scan of the abdomen, MIBG (13l1-metaiodobenzylguanidinel scan
and venous sampling, he had a bilateral adrenalectomy. The pathology was
consistent with bilateral adrenal medullary hyperplasia.
In 1989, screening of a 50-year-old daughter of Patient 2 revealed
increasedbasalandpentagastrin-stimulatedcalcitoninleveIs and she underwent
a total thyroidectomy. A very small «2 mm) medullary carcinoma was
identified in the pathology specimen. At this time genetics was consulted to
assist in the development of a comprehensive screening program for members
of the family.
Cliniql SGMlnlng
Family members were interviewed by Jane Green to complete the
pedigree and, after consent was obtained, medical records of living and
deceased relatives were reviewed to identify affected family members and their
first degree relatives at risk (Figure 3.1 - 19891. Genetic counselling was
provided for affected and at-risk family members, including education about the
clinical and genetic features of MEN-2, and the recommendation for annual
clinical screening from the early teens. Information on MEN-2 was also sent to
the family doctors.
Because of the variability in age at diagnosis, and the skipped generation
in those already identified as "affected" in this family, a screening program was
institutedforfirstandseconddegreerelativesofaffectedpatients,andforfirst
degree relatives of deceased family members who could have been affected
based on family history or medical record review. The screening started at age
Figure 3.1. Initial (1989) and current (19931 pedigrees of a Newfoundland
MEN-2 family.
Clinical status of family members. as known in 1989 or in 1993.
is indicated on the respective pedigrees.
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11 andincludedannualcalciumandpentagastrin-stimulatedcalcitonintesting
at the Outpatient Department (OPD) of the General Hospital in St. John's, and
annual collection of a 24-hour urine sample for measurement of catecholamines
and metanephrines (Figure 3.2).
Appointments were booked with the OPD nurse, and patients contacted
about their appointments. When testing was completed, results were reported
to patients and their family doctors. Repeattesting and referral to the Endocrine
Service was arranged if results were abnormal, and a 1-year recall appointment
scheduled if results were normal. Patients with confirmed abnormal stimulated
calcitonin or urinary catecholamine levels were referred to the Department of
Surgery for pre-operative management and surgery. Annual screening resumed
following surgery. Radiological, surgical and pathology reports were reviewed,
andageatdiagnosis,presentageorageatdeath,andcurrentstatus,including
outcome of surgery, were recorded for all family members.
Later, a computerized system of recall, booking, and reporting of
screening investigations was developed by Dr. Marshall Godwin and managed
by the Family Practice Unit at the General Hospital. As more family members
wereidentifiedasaffected,thescreeningwasextendedtoincludefirst degree
relatives of these newly identified patients.
Flgure3.2. Clinical screening protocol for multiple endocrine neoplasia type
2 (MEN-21.
CUNICAl SCREENING PROTOCOL FOR MUlTlPLE ENDOCRINE NEOPLASIA,
TYPE 2 IMEN-21
ANNUAL CALCIUM AND PENTAGASTRIN-STIMULATED CALCITONIN
LEVEL'
N < 15pmoi/L
N < 30pmollL
if confirmed abnormal.
i) rule out pheochromocytoma
iiI total thyroidectomy
ANNUAL 24-HOUR URINE CATECHOLAMINE AND METANEPHRINE
LEVEL'
Urinarycatecholamines
Urinary metanephrines N < 7pmol/d
if confirmed abnormal,
il abdominal CT scan and MIBG scan
ii) if pheochromocytomaIs) identified
- alpha-adrenergic blockade
- unilateral or bilateral adrenalectomy
" beginning at age 11
G.n.tig&q••ninq
In 1990-1991 ,geneticcounsellingregarding predictive testing bylinkage
analysis was given to 34 family members known to be at risk and over 12
years of age. Consent was obtained from those requesting predictive testing
(and from their parents if less than 18-years-oldl, and blood samples were
obtained for DNA extraction in the laboratory of Dr. Roger Green. Aliquots of
DNA from affected and at-risk family members and from unaffected spouses
were sent to Dr. Nancy Carson at the Molecular Diagnostic Testing Laboratory
at Queen's University, Kingston, Ontario, for linkage studies with RFLP markers
in the centromeric region of chromosome 10 (FNR8, 010534, 01 OZ1. 010594,
R8P3 [Goodfellow et al 1990, Narod et al 1992]).
In 1992-93, DNA samples from eleven consenting at-risk members of a
recently identified branch of the family were sent to Queen's University for
PCR-based linkage testing with the marker 010594 which had been informative
in this family. Although an informative flanking marker was not available, no
recombination between 010594 and MEN-2 has been identified in other
families (Goodfellow et al1990, Narod et a119921. Results of linkage analysis
with this marker were tested with the MLINK program of the LINKAGE
package.
In 1994, DNA samples from three affected individuals were sent to
Dr. Lois Mulligan at Queen's University, to search for the mutation.
Imp'stgfSsr••ninggnth'Flmlly
There has been extensive contact in person or by telephone with all
family members over the five years of the screening program, during
counselling sessions and while arranging appointments or reporting results.
Although formal interviews were not carried out, family members talked about
the significance of the screening program to themselves and their children,and
RESULTS
Clinic,' S«;r,.0109
~
a) Thyroid pathology
Sixteen members of this family have pathological evidence of thyroid
disease (Figure 3.1 - 1993, p. 160), ten with medullary carcinoma (MTC) and
six with C-cell hyperplasia (CCH). A seventeenth family member underwent
thyroidectomy because ofelevated stimulated calcitonin levels, but only normal
thyroid tissue was identified (Table 3.1). The age range of those with CCH
(18-75 years, median 38 years) overlapped that of the MTC patients (18-74
years, median 42.5yearsl.
b) Method ofdlagnosi.
The proband, age 40, was symptomatic with a neck mass at the time of
diagnosis and died at age 44, a 67-year-old was identified coincidentally at
PATHOLOGY
SURGICAL PATHOLOGY IN NINETEEN MEN-2
PATIENTS
AGE AT DIAGNOSIS
NUMBER OF (years)
PATIENTS Mean (range)
Thyroid gland
Medullary carcinoma
C-cellhyperplasia
"Normal"
Adrenal gland
Adrenal medullary
hyperplasia
10'
6
1
42.5 (18-74)
38 (18-75)
19
• Two pdiems with metastatic disease
- 1 symptomatic, age 40; deceased. age 44
-1 identified by screening. age 50; asymptomatic. age 53
autopsy, and 15 other asymptomatic family members, age 18-75, were
identified by screening with calcium and pentagastrin-stimulated calcitonin
testing (Table 3.2). Eight of those identified by initial screening had MTC, but
only one, a 50-year-old woman who is still asymptomatic at age 53, has
evidence of metastatic disease (markedly elevated basal and stimulated
calcitonin post-operatively). Four others identified at initial screening, and two
who converted from normal to elevated stimulated calcitonin levels, had CCH
only, and in the final patient, identified on subsequent screening, no MTCor
CCH was identified at pathology. Screening has identified those with the MEN-
2 gene at an early stage when surgery is curative.
c) Ag.etdlegnosis
The three affected members of the earliest generation were 67,74, and
75 years of age at diagnosis, identified either coincidentally, or by screening
after their children were affected. Although all three are now deceased, none
died of MEN-2. Seven of 15 at risk in the second generation are affected, with
diagnosis at age 40-50 years of age; four with MTC (including the proband who
died at age 44 of metastatic disease and a 53-year-old with biochemical
evidence of metastatic disease), and three with CCH. Seventeen at risk in the
youngest generation have been screened,and seven of these were identified
as affected (age 18-26). Four had MTC confined to the thyroid, two had CCH
only, and one had normal thyroid gland histology. There appears to be an
METHOO OF IDENTIRCAnON OF MEN-2 THYROID DISEASE
(SYMPTOMAnC. COINCIDENTAL. OR BY SCREENING). AND
PAnENT OUTCOME
METHOD OF NUMBER OF AGE AT
IDENTIFICATION PATIENTS DIAGNOSIS
Symptomatic Deceased. age 44
Diagnosis at autopsy
Initial
screening·
Metastatic MTC
(increased post-operative
calcitonin)
MTCconfinedtothyroid
(normal post-operative
calcitonin)
Subsequent
screening·
iii) C-cel! hyperplasia
(normal post-operative
calcitoninI
C-cel! hyperplasia
(normal post-operative
calcitoninI
Norma/thyroid tissue
earlier age at onset with successive generations (Figure 3.3), however, this
maybeabiasofascertainment.
~
Two family members, brothers, had a diagnosis of adrenal gland disease
(Figure 3.1, p. 160); one presented with increased blood pressure and cardiac
arrhythmias,andthesecondwasidentifiedbyurinarycatecholaminescreening.
Both underwent bilateral adrenalectomy because of elevated urinary
catecholamines, and evidence from venous sampling or MIBG scanning of
bilateraladrenalinvolvement.lneach,thepathologicaldiagnosis was adrenal
medullary hyperplasia. Both patients have had normal calcitonin testing, and
none of the patients with MTC or CCH (or any of those at 50% risk) have had
evidence of adrenal involvement. The uncertainty of whether these brothers
have MEN-2 creates problems with interpretation of the genetic testing.
Glnltiri$Gr,.ning
~
The RFLP markers FNRB, 010534, 01 OZ1, RBP3 were uninformative for
the majority of family members (data not shown), however the marker 010594
was informative in this family. All family members with MTC or CCH have the
same allele with the marker 010594, but the two patients with adrenal
medullary hyperplasia (and their clinically normal fatherl do not have this allele
(Figure 3.41. Are they crossovers, or is their adrenal diseasecoincidental7 If
Figure 3.3. Age at diagnosis by decade, and thyioid pathology in an MEN-2
family.
Age at diagnosis of MEN-2 thyroid disease is extremely variable
in this family. The age ranges of those with MTC (18-74 years),
and with CCH only (18-75 years) overlap. Patients who are
older at the time of diagnosis do not necessarily have more
severe disease.
Age at diagnosis by decade, and thyroid
pathology in an MEN-2 family
Generation III Generation II
.....------I'-- .....------I'--
Generation I
~
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AGE (YEARS)
o ~~c'll:'~'it~~
EZI ~~~~f~t~II~~in.
Ei]l C-<:ellhyperplasia(CCH)
•
Medullary carcinoma of
thethyrood(MTC)
• * Metastatic MTC
Figure 3.4. Newfoundland MEN-2 pedigree with results of linkage analysis.
The RFLP markers FNRB, 010534, 010Z1, and RBP3 were
uninformative in the majority of family members (data not
shown). The marker 010594 was informative. Allele "2" of
010594 co-segregated with the presence of MTC or CCH (LOO
score of 2.596 or greater, see text). The brothers with adrenal
medullary hyperplasia did not inherit allele "2", and are predicted
to be unaffected with MEN-2. Four family members, age 13-23,
are predicted to be affected; all have had normal clinical
screening results so far. The late age at diagnosis, and presence
of thyroid pathology only in those with the high-risk allele of
010594 suggest that this family has FMTC, not MEN-2A.
Newfoundland MEN-2 pedigree with results of linkage analysis
m1 11 12I1 11 1Zl11Zl11Zl1
#306 #310
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o [] Normalclinicalscreening #306 Pedigree number
f linkage analysis
~(MTC)
)lasia 121. D10Sg4allelesegregalirigwllhMEN-2
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·2 -consistentwithmatemal-2-
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·3 -Iowriskpredictivetestingresults
these two family members are considered to be affected. the LOD score is
2.596 at 8 = 0.1; but if their status is classified as unknown. the peak LOD
score is 3.608 at 8 = 0.05 satisfying the criteria for linkage to chromosome
10qll.2. The brothers would then be predicted to be at low risk of carrying
the gene for MEN-2. Despite the evidence for linkage to the chr 10q11.2
region as in other MEN-2A and FMTC families. a mutation in the RET oncogene
has not been identified in this family.
~
There are 20 clinically unaffected first degree relatives (age 9-64) in this
family. Nineteen (all except the nine-year-old) have had regular clinical
screening with negative results; 17 of these have had DNA extracted for
predictive testing. Thirteen family members (age 18-64) have low-risk
predictive testing results with the informative marker 010594. and four family
members (age 13-23) have high-risk results (Table 3.3a and 3.3bl. Calcitonin
values of those with high-risk results are within normal limits. but each has had
detectable or high-normal basal or stimulated calcitonin levels (Table 3.4). This
group will continue to have calcium and pentagastrin-stimulated calcitonin
testing at 6 month intervals. and will be referred for thyroidectomy if the basal
or peak calcitonin levels increase.
Because of the uncertainty of the status of the brothers with adrenal
disease (or the cause of their bilateral adrenal medullaryhyperplasia if not due
to MEN-2I, and the implications of this uncertainty to other family members.
CATEGORY
IDENTlFICAnON OF AFFECTED AND HIGH-RISK MEMBERS
OF A NEWFOUNDLAND MEN-2 FAMILY BY CUNICAL
SCREENING AND BY UNKAGE ANALYSlS
NUMBER OF
FAMILY
MEMBERS
IDENnFIED AFFECTED (1989)
(thyroid disease - 3, adrenal disease - 1)
FIRST AND SECOND DEGREE RELAnVES
AT RISK
PARTICIPAnON IN CLINICAL SCREENING'
- POSmVE CLINICAL SCREENING 15
- high-risk genetic screening (14)
-Iow-riskgeneticscreening (1)
- NEGAnVE CLINICAL SCREENING 30
PARTICIPATION IN GENETIC SCREENING'
- HIGH RISK 18
- positive clinical screening (14)
- negative clinical screening (4)
-~WRl~ ~
- (includes 2 brothers with
"bilateral adrenal medullary
hyperplasia")
IDENnFIED AFFECTED (1993)
(thyroiddisease-17,adrenaldisease
[possibly coincidental) - 2)
'Stimulatlldcak:itoninassayandurinarycataeholaminaasaay
'UnkageanalysiswithchrlOqrnarkers
CATEGORY
SUMMARY OF INFORMAnON ON IDENnACAnON OF
AFFECTED AND HIGH-RISK MEMBERS OF A
NEWFOUNDLAND MEN-2 FAMILY BY CLINICAL
SCREENING AND BY LINKAGE ANALYSIS
NUMBER OF
FAMILY MEMBERS
-High-riskgenetic screening with
positive clinical screening
(effected)
-High-risk genetic screening with
negative clinical screening
(presymptomatlc)
-Low-riskgeneticscreeningwith
positive clinical screening
(false positive'
-Low-riskgeneticscreeningwith
negative clinical screening
(uneffected)
TABlE 3.4. AGE AND SCREENING RESULTS OF THOSE PREDICTED
AFFECTED BY LINKAGE ANALYSIS
AGE
RECENT SCREENING
RESULTS
Detectable basal and
stimulated calcitonin·
Detectable basal and
stimulated calcitonin·
Borderline stimulated
calcitonin
Detectable stimulated
calcitonin"
those with low-risk predictive testing results are continuing to be screened, at
less frequent intervals, until the MEN-2 mutation is identified and their status
The ratio (4:13) of high-risk to low-risk family members identified by
linkage analysis is not 50:50 because clinical screening had already identified
15 gene carriers.
Impact of Sq..njng on the Family
Most members of the first two generations of this family lived in one
small community at the time of the proband's illness, and were very aware of
the diagnosis of "thyroid cancer" and the early death of the proband. They also
knew the autopsy results of the proband's uncle (patient 2), and that the
identification ofa similar thyroid cancer marked this as a "family disease".
While they knew that this was called MEN-2. they had found it very difficult to
obtain information about the disease before the screening program was
implemented.
The two affected members of generation I identified by screening were
elderly and did not understand the implications of MEN-2, particularly since
neither they nor the third affected member of generation I (patient 2 who was
identified coincidentally at autopsy) had had any symptoms or clinical effect
from MEN-2. In contrast, the widow of patient 2, now 75 years old. has a very
good understanding of all aspects of MEN-2 and provides a supportive role for
children and grandchildren.
The fourteen living affected and at-risk members of generation II all
appreciated both the information on MEN-2 provided during genetic counselling,
and the organization of the screening program. The six identified as affected
by the program were all very grateful for early diagnosis and treatment, since
they did not experience symptoms of cancer nor require chemotherapy or
radiation treatment, and since (except for one with biochemical evidence, only,
of metastatic disease) they have a very good prognosis.
Fourofthesehavechildrenthathavealsobeenidentifiedasaffectedand
treated. Three of the four affected parents have stated that they regret having
passed this disease on to their children, and one has specifically said that she
would not have had children if she had known the risks.
The seventeen members of generation III originally identified as at risk,
also appreciated the information they have received, and have been compliant
with screening. Ingeneral,thesevennowaffected have accepted diagnosis
andsurgeryasa"factoflife",butbecausetheywereyoungatthetimetheir
father/uncle/cousin was sick and died, they do not have such personal
experience with the disease as their parents do. One of the seven, who was
26 and had small children at the time of her diagnosis, has more difficulty than
the others with accepting the fact that she has a hereditary disease. None of
the others have children, but three, who are married or engaged, say that the
MEN-2 gene will not alter their reproductive planning since they expect that the
screening program will be available for their future children for earIydiagnosis
and treatment of any thyroid disease.
DISCUSSION
Clinical SR••ning
MEN-2 is a potentially lethal hereditary disease with families frequently
recognized because of symptomatic presentation or early death of one or more
family members from medullary carcinoma of the thyroid, or
pheochromocytoma (Vasen et al 1987). Once a family has been ascertained,
clinical screening of first degree relatives at risk has allowed early identification
and curative treatment of the thyroid and adrenal disease in many gene carriers
(Vasen et al 1987, Gagel et a11988, Calmettes et aI1992).
The goal of clinical screening programs in MEN-2 families (MEN-2A,
MEN-2B or FMTCI is the presymptomatic identification of thyroid or adrenal
involvement so that early treatment by total thyroidectomy (Wells et al 1985,
Barry et al 1991, Decker 1992). or unilateral or bilateral adrenalectomy
(Jansson et 81 1988. Howe et al 1993. Lairmore et al 19931 can prevent the
morbidity and mortality often seen with symptomatic disease. The elevation
of calcitonin levels after stimulation with pentagastrin and/or calcium has been
used to identify early MTC or C-cell hyperplasia, and the elevation of
catecholamines in a 24-hour urine collection has been used to identify presymp-
tomatic pheochromocytoma, or adrenal medullary hyperplasia.
TImingnfC'injcalSGreAoioq
In classical MEN-2A families it is recommended that this screening begin
at least by age 3 because of the very early age that metastatic MTC has been
identified (Calmettes et al 1992). Clinical screening begins at age 11 in our
family, however, since the earliest detection of CCH/MTC. even with
prospective screening, has been at 18 years of age. This fits with
recommendations for other hereditary cancers (eg, the hereditary colon cancers)
where the recommended age to begin screening is five years before the earliest
age at diagnosis in the family (Fitzgibbons et al 1987).
As in previous studies in which the majority of symptomatic patients had
incurable disease (Vasen et a11987. Calmettes et a11992), the proband in the
Newfoundland family died of metastatic MTC within a few years of diagnosis.
Patients identified at their initial screening may also have advanced disease
which is difficult to treat. even if asymptomatic at the time of identification
(Telander et al 1989). However, many of those with abnormal values at initial
screening, and all with normal values converting subsequently to elevated
calcitonin levels. have thyroid disease (either early MTC or the precursor stage
CCHI. that is curable surgically (Wells et al 1985. Vasen et al 1987. Decker
1992). One Newfoundland patient identified at initial screening has significantly
elevated calcitonin levels post-thyroidectomy, and, although asymptomatic,
presumably has metastatic disease. Despite extensive investigations, the
location of this metastatic disease has not been identified.
Nine patients identified at initial screening and three identified
subsequently, all have had reversion to undetectable calcitonin levels post-
operatively. The early detection and treatment of thyroid disease facilitated by
the screening program has been potentially life-saVing for these twelve
individuals. Eleven of these had small MTC tumours, or nodules of CCH
identified at pathology; in one patient, only normal thyroid tissue was identified.
This 18-year-old patient, with confirmed, but minimally positive,
calcitonin stimulation testing and no CCH or MTC identified at pathology
illustrates a problem of interpretation sometimes seen in such families - the
possibility of false positive tests (Landsvater et al 1993, Barbot et al 1994).
This patient did, concurrently, have genetic evidence from linkage analysis that
he was a gene carrier and so most likely would have progressed to malignancy,
however, members of other families in the literature have had conflicting clinical
and genetic screening results (Landsvater et al 1993). Some patients have
been identified by abnormal calcitonin test results, and have had CCH identified
after total thyroidectomy, but later by linkage studies or direct mutation testing
have been shown not to carry the MEN-2 gene (Barbot et al 1994, McMahon
eta119941.
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Although presymptomatic thyroid C-cell disease can be identified by a
positive pentagastrin stimulation test. it is not possible clinically or
biochemically to distinguish early MTC from the precursor stage CCH (Wells et
al 19851. For this reason, total thyroidectomy is recommended as soon as a
positive pentagastrin stimulation test is obtained (Decker 1992. Telander et al
1989). The recognition that MTC can metastasize when very small emphasizes
the need for early thyroidectomy lTelander et al1989, Calmette et al 19921.
However, there is not a clear cut-off between normal and abnormal calcitonin
values. The concern is that by setting a low threshold level for abnormal
stimulatedcalcitoninvaluestoincreasethesensitivityofthescreeningtest,the
specificity is decreased, and some patients may have inappropriate
thyroidectomy. At the lower limits of the assay. elevations of calcitonin may
result from greater variation in normal values than expected (Simpson et al
1990, Kempter & Ritter et al19911, or from C-cell hyperplasia unrelated to the
MEN-2A or FMTC gene (Libbey et al 1989. Landsvater et al 1993. Lips et al
19941.
The possibility of directly identifying gene carriers in many MEN-2A or
FMTC families (Donis-Keller et al 1993, McMahon et al 1994, Mulligan et al
1994. Tsai et al 1994, Xue et al 1994), because of the clustering of mutations
in a group of cysteine residues at the transmembrane boundary of the extra-
cellular domain of the RET protein. and in MEN-2B (Carlson et al 1994. Eng et
al 19941. Hofstra et al 1994) where the mutation in the majority of families
studied has been at codon 918 in the tyrosine kinase domain of this protein.
will reduce the risk of inappropriate thyroidectomy or adrenalectomy since in
informative families only gene carriers will be clinically screened. or proceed
directly to surgery (Barbot et al 1994. lips et al 1994. McMahon et al 1994.
Tsai etaI1994).
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There has been less discussion of false positive values in screening for
adrenal medullary disease. However. this was a concern in our family. About
50% of MEN-2A gene carriers are predicted to have unilateral or bilateral
adrenal involvement with pheochromocytoma or adrenal medullary hyperplasia.
and this may precede thyroid disease. Large families with MTC only (Noll et al
1984. Farndon et al 1986) have been recognized. but the distinction between
MEN-2A and FMTC cannot be made in small families. Genetic testing also will
proto-oncogene have been found to cause either MEN-2A or FMTC in different
families (Donis-Keller et a11993. Mulligan et al 1994. Xue et aI1994). Because
of the dangers of surgery wi~h an unrecognized pheochromocytoma. and the
variability in frequency of pheochromocytomas (from 5% - 75%1 in different
MEN-2A families (Narod et al 1989. Narod et a11992. Xue et al 19941.
screening for pheochromocytoma is recommended for all families (except when
there is a very large family with thyroid disease only).
The Newfoundland family was originally thought to be a typical MEN-2A
family with thyroid and adrenal disease. After symptomatic and coincidental
presentation of MTC in the initial two affected members, the first patient
identified by screening in this family had increased urinary catecholamines
confirmed on several occasions. On further investigation, there was a bilaterally
positive MIBG scan with a negative CT scan, these results being compatible
with adrenal medullary hyperplasia. Genetic testing to identify or exclude gene
carriers was not yet possible and the patient underwent bilateral
adrenalectomy. The pathology report indicated bilateral adrenal medullary
hyperplasia, a recognized precursor of pheochromocytoma in MEN-2A (Carney
et al 19751. Subsequently, this patient's brother, also at age 19, had similar
clinical test results and also had a bilateral adrenalectomy.
No other persons with adrenal disease have been detected in this family,
either in those at risk, or in the seventeen members with documented MTC or
CCH, despite the fact that all affected and at-risk family members have annual
24-hour urine catecholamine testing. However, if the increased catecholamines
in the brothers had been due to stress or interfering substances, there should
not have been radiological or nuclear medicine evidence of adrenal disease.
The genetic linkage studies, when available, also conflicted with the clinical
screening evidence since these brothers did not inherit the same chromosome
10q marker allele as affected family members. This raised the question of
whether there had been a cross-over between the MEN-2 gene and the marker,
but recombination in males in the centromeric region of chromosome 10 has
not been observed (Goodfellow et a11990. Narod et aI1992).
Thepossibilityofgeneticheterogeneitywasconsidered,butthereis no
strong support in the literature for non-linkage of "MEN-2" to chromosome
1Oq11.2 markers. Also, there is now evidence of linkage of the thyroid disease
in this family to the marker 010594 near the RET proto-oncogene (LCD score
of 3.608 at 9 = 0.051, although the mutation within the RET proto-oncogene
for this family has not yet been identified. The Newfoundland family, in fact,
may have FMTC (with medullary carcinoma of the thyroid or C-cell hyperplasia
only), not MEN-2A. The late age at onset of thyroid disease (mean age of
diagnosis of 39.4 years in screened family members, with the youngest
diagnosis at age 18) also supports the classification of this family as FMTC not
MEN-2A. The adrenal medullary hyperplasia may then be unrelated. There is
no evidence, however, for another genetic disease such as von Hippel-Lindau
disease or neurofibromatosis, type 1 predisposing to pheochromocytoma or
adrenal medullary hyperplasia in these brothers or their relatives, yet the
bilateral disease in two brothers suggests a hereditary etiology.
Prophylactic bilateral or unilateral adrenalectomy is considered
inappropriate by most clinicians even in clearly identified MEN-2A families
(Lairmore et al 1993, Utiger 19941, because of the risks associated with long-
term adrenal replacement therapy (Jansson et al 1988), because not all MEN-
2A patients will develop adrenal disease, and because regular biochemical
screening combined with modern scanning techniques can, in most situations,
identify adrenal glands with hyperplasia or pheochromocytoma when
adrenalectomy is necessary.
G,n.tiG$G,··ning
The variable age at onset of MEN-2, and the potentia' false positive or
false negative results of biochemical screening tests, emphasize the importance
of genetic testing whenever possible to identify gene carriers (Barbot et al
1994, Xue et al 1994, McMahon et al 19941. The specificity of the location of
the mutations in the RET proto-oncogene in the majority of MEN-2A, FMTC and
MEN-2B families, increases the probability of identifying the mutation. The
Newfoundland family, however, is one of the few large MEN·2A or FMTC
families, where linkage to chromosome lOq is demonstrated but the specific
mutation has not been identified.
Even though gene carriers cannot be directly detected in this family, the
results of predictive testing by linkage analysis provide guidance in determining
which family members require annual clinical screening, and which require Jess
frequent screening. The four family members with high-risk linkage results
have all had detectable or borderline stimulated calcitonin levels so will have
pentagastrin stimulation testing at six-month intervals, and will be referred for
thyroidectomy if the basal or peak calcitonin levels increase.
Because of the uncertainty of the status of the brothers with adrenal
disease (or the cause of their bilateral adrenal medullaryhyperplasia if not due
to MEN-2), and the implications of this uncertainty to the family members, the
13 family members with low-risk linkage results will have screening every two
years until the MEN-2 mutation in this family is identified, and their status
The ratio of high-risk to low-risk family members identified by linkage
analysis is not 50:50 because clinical screening had alreadyidentified 15gene
Impl'! Of $q••ning gD the F,mily
In the Newfoundland MEN-2 family there has been reduced anxiety, and
very good compliance with the clinical screening program because of the
recognizedbenefitsofearlytreatment,eventhoughithasnotyetbeenpossible
to definitely identify non-carriers of the MEN-2 gene and exclude them from
screening. There will be savings in time, money (for the investigations, and for
travel and lost days at workl. and from the discomfort of the pentagastrin
stimulation test when screening is no longer required for those who are not
gene carriers.
Impllc;atign, Of Squnlnq for Lllt-On••t G.n.tic pi,.,"
Questions have been raised about the appropriateness of predictive
testing for "Iate-onset-geneticdiseases,and,ifappropriate,theageatwhich
this testing should be done (Harper and Clarke 19901. For the hereditary tumour
syndromes, including MEN-2A/ FMTC, which are potentially lethal but also
potentially treatable and possibly curable, clinical screening ofthoseatrisk,to
identify presymptomatic disease, is desirable (Vasen et al 19871. However, for
autosomal dominant diseases, clinical screening of all first degree relatives at
50% risk can be costly in monetary and psychological terms (Eng et a11994bl.
With the identification of mutations in the RET proto-oncogene in the
majority of MEN-2A/FMTC families, predictive testing by direct mutation
detection or by linkage studies will frequently permit the distinction of gene
carriers who would benefit from clinical screening and management, and those
who are not gene carriers and therefore require no screening (Utiger 19941. If
the group without the MEN-2 mutation no longer require clinical screening, this
would result in considerable savings to the health care system, as well as
financially and psychologicall.y to the individual family members (Gagel 1993,
Eng et al 1994b1. Gene carriers and non-carriers would both benefit from
knowledge of their status when making reproductive decisions.
It is now clear that MEN-2A and MEN-2B are not "adult-onset" diseases
- the mean age at diagnosis in prospectively studied families is 10 years of
age (Easton et a119891. Metastatic MTC has been identified at 6 months of
age in MEN2-B and at 3 years of age in MEN-2A. Large FMTC families with
late age at onset (mean 40 years) and slowly progressive disease in the
majority of affected members have been described (Farndon et al 1986, and
possibly the Newfoundland family), but other large families with FMTC and
early aggressive disease have also recently been documented (Xue et al 1994).
If clinical screening for MEN2-A and MEN2-B (which is acknowledged to be
unpleasant, and is costly to the health care system and to family members) is
recommended to begin by 3 years of age by many clinicians, and by 1 year of
age by others (and by early teens even for FMTC families) predictive testing
should be available before this age (Gagel 1991). Clinical screening or
immediate prophylaeticsurgerycanthen be reserved forthoseidentifled by
mutation detection or linkage studies to be at high risk (Gagel et al 1993, Eng
et al 1994b). If genetic testing is uninformative in the family or a family
member chooses not to participate in genetic testing, then clinicalscreening
should still be available (Gagel et al 1993). Whether prenatal diagnosis should
be offered (or is desired for a treatable conditionI is a different question, but
members of the Newfoundland family were not interested in this option.
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The most efficient screening for MEN-2A/FMTC families would begin
with a search for a mutation within the cysteine codons of the transmembrane
domain of the RET proto-oncogene (codons 609, 611, 618, 620, 634) where
mutations have been identified in approximately 85% of families. If a mutation
is found, gene carriers can be identified directly, and clinical screening or
immediate surgery arranged for these individuals. Those without the mutation
would not require clinical screening. If a mutation is not identified, then linkage
analysisusing10qcentromericmarkersshouldbeutilized,firstto clarify linkage
to this region, then to predict those who are carrying the MEN-2A/FMTC gene.
Those with high-risk results, all first degree relatives of an affected person if
linkage analysis is uninformative. and anyone not wishing to participate in
genetic screening, would be offered clinical screening annually from childhood.
Persons predicted to be at low risk would require less frequent clinical
screening (Figure 3.5), With the appropriate combination of genetic and clinical
screening, medical care can be maximized, and costs (monetary and
psychosocial) can be minimized.
Figure 3.5. Management plan for MEN-2A/FMTC families.
The mutation has been identified in > 90% of MEN-2A
families.and in >80% of FMTC families. No MEN-2 families
have been identified with confirmed linkage to another locus.
Annual clinical screening from age 3 or earlier is recommended
for MEN-2A families. and for MEN-2 families not yet classified.
For a large MEN-2 family with late age at onset (particularly an
FMTC familyl. clinical screening may begin later, but at least 5
years before the earliest age at diagnosis in the family. Fora
well·documented FMTC family. annual catecholamine
measurement may be excluded.
Management plan for MEN2A1FMTC families
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CHAPTER 4 - CLINICAL AND GENETIC SCREENING IN A FAMILY WITH
ATYPICAL FAMIUAl ADENOMATOUS POLYPOSIS
PATIENTS AND METHODS
Ascertainment of Family, and Medical Record Review
Clinical Screening
Genetic Screening
Ascertainment of Family
Clinical Phenotype
i) Number of polyps
ii) Site of polyps
iii) Natural history and course of disease
iv) Upper gastrointestinal neoplasm
v) Associated features
Genetic Screening
i) Identification of family members at risk
ii) Linkage analysis
iii) Predictive testing
iv) Unexpected results
vI Delivery of results
Clinical Screening
i) Screening for typical FAP
ii) Screening for atypical FAP
iii) Extracolonicmanifestations
Genetic Screening
Implementation and Acceptance of the Screening Program
INTRODUCTION
This chapter describes the ascertainment of a Newfoundland family with
familial adenomatous polyposis (FAPI, the recognition of an atypical natural
history of disease and the revisions of the clinical screening protocol
necessitated by this clinical phenotype, the development of genetic screening,
and a comparison I)f the impact and acceptance of the combined screening
program by two geographically separated branches of the family.
FAP is an autosomal dominant condition characterized by colon cancer
preceded by mUltiple bowel polyps typically concentrated in the sigmoid colon
and rectum (Bulow 1986, Rustgi 1994). Traditionally the diagnosis has required
the presence of greater than 100 polyps and often thousands are present
(Bussey 1975, Bulow 1991). These polyps usually develop in the teens, with
the majority of FAP patients being positive by the end of the third decade. The
polyps progress to malignancy, often without symptoms, FAP patients typically
developing colon cancer in their 40s or 50s - at a significantly younger age
than patients with sporadic colon cancer (Bussey 1987, Rustgi 19941. Before
the value of screening was recognized, the majority of FAP patients died of
colorectal cancer (Bussey 1975, Arvanitis et al 1990a, Bulow 19911.. With
appropriate screening and early treatment, the incidence of cancer and the
mortality caused by FAP can be markedly reduced (Vasen et al1990a, Jarvinen
1992, Rhodes and Bradburn 19921.
Because of the characteristic age at onset and location of polyps in FAP,
the usual screening protocol recommended for those at risk is a flexible
sigmoidoscopy every one to two years from the early teens until the mid
thirties, then every 3-5 years until at least 50 years of age (Bark et al 1987,
Herrera et al 1990, Jarvinen 1992). The identification of those at risk is
initially determined by the pedigree but is modified ifpossiblebygenetictesting
(Petersen et a11991, Maher et al 1993, Petersen et al 1993).
In some families originally designated as Gardner's syndrome, extra-
colonic features have also been described, including osteomas, epidermoid
cysts, dental abnormalities, desmoid tumours (Naylor and Gardner 1977,
Jagelman 19871, and retinal pigmentation (congenital hypertrophy of the retinal
pigment epithelium or CHRPE [Lewis et al 1984, Baba et al 1988, Bark et al
1988b, Romania et aI1992]) which may provide early evidence of the presence
of the FAPgene.
Once multiple polyps have been identified, allowing a clinical diagnosis
of FAP to be made, sub-total colectomy is recommended (Serk et al 1988a,
Skinner et a11990, Jarvinen 1985) to prevent the development of colon cancer
and thus to improve survival. Because FAP patients are also at risk for
adenomatous polyps and cancer of the segment of rectum remaining after the
usual surgery, and of the upper gastrointestinal (Gil tract (particularly the
duodenum) (Jarvinen et al 1983, Sarre et al 1987, Jagelman et al 1988, Lynch
et al 1993b), continued follow-up with sigmoidoscopy of the rectal stump
(Sarre et al 19871, and with upper GI endoscopy (Arvanitis et al 1990, Bulow
19911 is recommended. If only a partial colectomy has been done then
surveillance of the remaining colon is also necessary.
In 1987 the gene for FAP was mapped to the long arm of chromosome
5 (Bodmer et al 1987, Leppert et al 1987, Solomon et al 1987) and by 1991
predictive testing by linkage analysis was available for those at risk in some
families (Tops et al 1989, Burn et al 1991, Dunlop et al 1991, Petersen et al
1991, Macdonald et al 1992). In 1990, a Utah family was described by
Leppert with autosomal dominant colon cancer and a variable number of polyps
(from a few polyps to florid polyposis) that was also linked to the 5q21 markers
(Leppert et aI19901. This disease presentation was later designated atypical
FAP, attenuated adenomatous polyposis coli (Spirio et al 19921, or flat
adenoma syndrome (Lynch et al 1992).
In 1991 the adenomatous polyposis coli (APC) gene, responsible for FAP,
was identified and cloned (Groden et al1991, Joslyn et al1991, Kinzler et al
1991, Nishisho et al 1991). Mutations within the APC gene have been
identified for typical FAP, for. Gardner's syndrome, and for some families with
the atypical FAP presentation (eg, Miyoshi et al 1992, Spirio et al 1992,
Olschwang et al 1993al. The variability of disease expression is not entirely
explained by allelic heterogeneity, however,sincethesamebasechangehas
been identified in patients originally described as either FAP or Gardner's
syndrome (Nishisho et al1991, Groden et al 1993, Paul et al 19931.
The APe gene is very large with 15 exons spanning greater than 8.5kb,
the 15th exon itself being over 6500 nucleotides in length (Groden et aI1991).
Although the mutations cluster at the 5' end of exon 15 and some mutation hot
spots have been identified (Miyoshi et al 1992, Groden et al 1993, Mandl et al
19941, the majority of families have unique mutations, and up to 30% of FAP
patients have a new mutation (Rustin et al 1990. Maher et al 19931. Thus.
identification of the specific mutation within a family in order to allow direct
identification of gene carriers has only been successful in about 30-60% of
families in most studies (Fodde et al 1992, Miyoshi et al 1992. Olschwang et
a11993al.
In this rapidly evolving field, it is necessary to consider carefully the
approach to screening and management for a particular familial polyposis
family. In some families, particularly those that fit the criteria for typical FAP,
either direct mutation analysis for identification of gene carriers, or linkage
analysis for predictive testing is possible. Mutation-positive or high-risk
individuals are then followed throughout life with a clinical screening protocol
and surgical intervention as appropriate, and relatives shown to be mutation-
negative or at low risk are freed from the need for follow-up. or require less
frequent screening, respectively. In other situations, particularly for small
familiesorwherelinkaget05q21 cannot be proven. linkage analysis or direct
mutation detection may not be possible, and the clinical screening protocol is
the only screening available for identification of gene carriers, as well as for
clinical management. This clinical screening must be appropriate for the disease
presentation in the family if it is to identify a premalignant stage of disease
when treatment is most likely to be successful.
PATIENTS AND METHODS
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In 1985, a large family from the Notre Dame say area of Newfoundland
was identified by the family doctor as probably having FAP after several related
patients presented with colon cancer and multiple polyps. An initialpedigree
was drawn, screening with annual sigmoidoscopy was initiated and a request
was made to Medical Genetics in 1989 for assistance in the development of an
overall management plan for the extended family.
Family members were interviewed by Jane Green and an extended
pedigree was drawn (Figure 4.1). Medical records were reviewed in order to
confirm the diagnosis in apparently affected members of previous generations.
Several family members were noted to have colon cancer but fewer than the
expected number of polyps for a diagnosis of FAP. Consent was obtained from
family members, and a more detailed review of all medical records was
undertaken in 1991 with particular attention to the surgical and pathological
records and the reports of screening investigations. The number and location
of polyps, location of cancer, age at onset of bowel-related symptoms, and age
at diagnosis of polyps or cancer were recorded. The outcome of surgery, the
Figure 4.1. Pedigree of a Newfoundland family with atypical familial
adenomatous polyposis.
The pedigree has been simplified to emphasize those with FAP
(polyps :t: colon cancer). The number of polyps. and presence
or absence of colon cancer are indicated for each family member.
Newfoundland family with atypical familial adenomatous polyposis
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development of subsequent manifestations, and the age and cause of death
were also documented.
Because of the right-sided location of polyps in many family members,
recommendations were made for use of colonoscopy instead of sigmoidoscopy
for screening. Screening was offered to newly identified at-risk family members
including a branch of the family in central Newfoundland. Advice was given on
establishing a registry of affected and at-risk family members at the Notre
Dame Bay Regional Hospital in Twillingate, and, for the central Newfoundland
branch of the family, at the Hugh Twomey Health Care Centre in Botwood.
An Ophthalmology clinic was organized at the Notre Dame Bay Regional
Hospital in 1991, and 50 affected and at-risk family members were examined
by Dr. Craig Beattie with direct and indirect ophthalmoscopy for evidence of
CHRPE. The group examined included nine already affected family members
but the status of each individual was not known by the ophthalmologist at the
time of examination. At the same clinic an information session was provided
by Jane Green on the characteristics of the disease in the family, the
inheritance pattern, the recommended clinical screening, and the possibilityof
genetic screening by linkage analysis if the location of the gene could be
confirmed. Blood samples were obtained for DNA extraction from consenting
family members including those at risk, affected family members, and spouses.
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Because of the atypical clinical expression of disease, linkage studies
with DNA from known affected and older screening-negative family members
were carried out with chromosome 5q markers linked to the APC gene before
predictive testing was attempted. The RFLP markers used initially (pi 227 and
YN5.48) were uninformative because of homozygosity of alleles in many
affected family members. However a CA repeat marker (055346) which is 50-
70 kb from the APC locus became available ISpirio et al 1991, Spirio et al
1993a), and linkage was demonstrated to this informative marker. One
hundred and thirty first degree relatives at 50% risk were then identified from
the pedigree.
Predictive testing by linkage analysis was offered to those at 50% risk,
and in some circumstances to those at 25% risk, eg, if a parent at 50% risk
was deceased or otherwise unavailable for testing, or if the parent had never
been screened clinically and for geographic reasons it was easier to collect and
test both samples simultaneously. Ninety-six family members were interested
in participating in this genetic. testing. Blood samples were collected from any
remaining at-risk family members, and key affected family members and
spouses. DNA extraction and linkage analysis were carried out by Or. Roger
Green's laboratory at the Health Sciences Centre, St. John's, Newfoundland.
A pamphlet was written by Jane Green describing the disease
presentation and recommended clinical screening for the family, and also the
method of predictive testing and the meaning of the possible results. This was
given to family members when predictive testing results were provided
individually in St. John's or at special clinics at the Notre Dame Bay Regional
Hospital in Twillingate. The appointments were arranged by the nurse in charge
of the registry in consultation with Jane Green, and a team of four geneticists
and genetic counsellors travelled from St. John's and Gander to provide
individual counselling for each family member. The team also met with the
doctors and nurses involved with the family, and Jane Green provided them
with information on the methods of genetic testing and the implication of the
possible results. The recommendations for clinical screening were then revised
for those with low-risk results, but remained unchanged for those with high-risk
RESULTS
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Medical records were available for documentation of polyps andfor
cancer of the gastrointestinal tract in 38 family members, 21 of whom had
colorectal cancer. Seven others were deemed affected by verbal history but
no records were available for confirmation (Figure 4.11. Nineteen of 38
documented affected (50%) were ascertained because of symptoms, and
nineteen (50%) by clinical screening.
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The numbers of polyps in the 32 family members with a documented
number of polyps are presented in Table 4.1. Twenty-one (66%) had over 100
polyps and some of these had thousands of polyps, while 11 (34%) had fewer
than twenty polyps including four who already had colon cancer. The
diagnostic criteria for FAP of the presence of at least 100 polyps is not valid
for this family.
Polyps were clustered in the cecum and ascending colon (right-sided
polyps) in nine of 21 patients (42.8%) with mUltiple polyps, rather than in the
sigmoid colon and rectum (left-sided polypsI as in typical FAP (Figure 4.21. In
six patients, including three with cancer in the cecum or ascending colon,
sigmoidoscopy revealed no polyps in the sigmoid colon or rectum. Therefore,
annual screening for those at risk by sigmoidoscopy is notappropriateforthis
family.
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The mean age at diagnosis of polyps in the Newfoundland family is 39
years (range, 18-68 years) and at diagnosis of cancer is 49 years (range, 19-69
years) (Table 4.2); later than in typical FAP where mean age at diagnosis of
polyps is 33 years, and at diagnosis of cancer is 36 years (Bulow 1986).
Diagnosis of FAP was 15 years earlier on average in patients identified by
NUMBER OF POLVPS. AND PRESENCE OR ABSENCE OF
COLON CANCER IN A NEWFOUNDLAND FAMILV WITH
ATYPICAL FAP
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'Obligate carrier; documented cancer of the stomach or duodenum, bowel status unknown.
Figure 4.2. Location of colorectal polyps in typical and atypical familial
adenomatous polyposis.
Patients with typical FAP have polyps throughout the colon,
increasing in density towards the sigmoid colon and rectum. In
the Newfoundland atypical FAP family, 9 of 21 patients with
multiple polyps had the greatest density of polyps in the
ascending colon or cecum. Six had no polyps visible by
sigmoidoscopy, including three with right-sided colon cancer.
The location of polyps in typical and atypical FAP determines the
type of screening required.
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TABLE 4.2. NATURAL HISTORY OF DISEASE IN TYPICAL AND
ATYPICAL FAMIUAL ADENOMATOUS POLYPOSIS
TYPICAL FAP' ATYPICAL FAP
(Nfld Kindred)
Mean age Mean age Range
(yrs) (yrs)
Known onset of polyps· 16 25 (18-28)
Onset of symptoms 29 45 (31-65)
Diagnosis of FAP" 33 39 (18-68)
Diagnosis of cancer 36 49 (19-691
Death due to cancer 40 54 (42-721
° Patients with previous negative sigmoidoscopy or calonascopy
00 Identification of polyps in those at risk
screening than in those who became symptomatic (at a mean age of 32 years
for the screened group compared with 47 years for the symptomatic group).
All 19 patients diagnosed through screening had disease limited to polyps or
carcinoma in situ (CISI. In contrast, 17 of 19 (90%1 of the symptomatic
patients had invasive cancer at the time of diagnosis (Table 4.3). All twelve
cancer deaths (mean age 54 years; range 42-72 years) were in patients who
presented with symptoms. Screening resulted in diagnosis at an earlier stage
of FAP, and in reduction in mortality from the disease. However, polyps and
cancer occur at a later age in this kindred than in typical FAP.
iv) UpQflrgastmintflstjnal neoplasms
The presence of frequent upper GI polyps, and of upper GI cancer in
about 5% of patients with FAP (Jagelman et a11988) means that screening of
these areas is necessary as well as of the colon. Of the 38 patients with
documented colonic polyps or cancer in the Newfoundland family, 5 (13%) had
neoplasms of the stomach or duodenum at an average age of 44 years (Table
4.41, however, some of the earlier patients who presented with advanced
cancer were not investigated forupperGI polyps or cancer. In three patients
the gastric or duodenal neoplasms (multiple gastricadenomatous polyps, gastric
polyps with CIS. or duodenal cancer) were identified as a result of screening
by upper GI endoscopy after the identification of bowel polyps or cancer.
The first two of these patients had successful subtotal colectomy and partial
TABlE 4.3. EFFECT OF SCREENING ON AGE AT DIAGNOSIS AND
SEVERITY OF DISEASE IN A FAMilY WITH ATYPICAL
FAMIUAl ADENOMATOUS POLYPOSIS
CATEGORY
SYMPTOMATIC SCREENING
# #
Polyps only
Carcinoma in situ (CIS)
Mean age at diagnosis
(Range)
II
19
47 years
(19-68 years)
16
3
J2
32 years
(18-57 years)
TABLE 4.4. UPPER GASTROINTESTINAL IGII PATHOLOGY IN AFFECTED
AND AT RISK MEMBERS OF AN ATYPICAL FAP FAMILY
UpperGI
Pathology
Gastric polyps
Gastric adenomatous
polyps
Gastric polyps with
carcinoma-In-situ
ICIS)
Cancer of the
Ampulla of Vater
Age at
Diagnosis
(yrsl
Bowel
Pathology
No polyps or cancer
(athighriskl
Multiple polyps
Multiple polyps and
cancer of the
sigmoid colon
Multiple polyps and
cancer of the cecum
Bowel status
unknownldeceasedl
Bowel status
unknownldeceasedl
(obligate carrier)
gastrectomy. but the third patient died of metastatic colon and duodenal
cancer. Two patients in an earlier generation presented with symptomatic end-
stage stomach or duodenal carcinoma.
A 16-year-old. examined because of abdominal pain (and later found to
be at high genetic risk). was also found to have multiple gastric polyps but no
intestinal polyps.
v) ASSQciated fealu[@§
Congenital hypertrophy of the retinal pigment epithelium ICHRPE) is
present as an expression of the FAP gene in 65-80% of kindreds (Saba et al
1988. Heyen et al 1990. Olschwang et al 1993b). and can be a useful
presymptomatic marker of the gene in these families. However. CHRPE was
not found in the 9 affected or 41 at-risk Newfoundland family members
examined by an ophthalmologist. Affected family members were not routinely
screened for osteomas. epidermoid cysts or other manifestations of Gardner
syndrome. However. large sE:baceous cysts were noted by the family doctor
on the scalp and neck of several affected members in one branch of the
pedigree.
GlOttic; SsN.nlng
IdAotjficatioogffamjlymAmbe(latrjsk
As stated previously. thirty-eight members of this family have
documented tamilial adenomatous polyposis. and another seven family
members, including three obligate carriers, were reported to be affected. One
hundred and thirty (130) first degree relatives at 50% risk were then identified
from the pedigree. After genetic counselling about predictive testing by linkage
analysis was given to this family, 96 of those at risk were interested in
participation in linkage studies. The majority requesting predictive testing
(66/961 were at 50% risk, but those at 25% risk were included in some
circumstances such as when the clinical status of the parent at risk was
The original linkage studies with RFLP markers were uninformative
because of homozygosity of alleles in many affected family members.
However, linkage to a CA repeat marker (0553461 closely-linked to the APC
locus was demonstrated (LOO score of 3.2 at B = 0.01. Although an
informativeflankingmarkerwasnotavailablefortesting,recombinationhasnot
been demonstrated between 055346 and the APC gene (5pirio et aI1993a).
iiil~
Eighty predictive testing results have been obtained and provided to
family members. The results delivered include 11 high-risk results (>99.9%
probability of carrying the FAP gene) in family members age 10-29, and 64
low-risk results «0.1 % probability of carrying the FAP genel: 36 low-risk
results in those at 50% risk, and 28 low-risk results where the parent was
determined by linkage analysis to be at low risk (Table 4.5, Figure 4.3). Five
TABLE 4.5. RESULTS OF PREOICTIVE TESTING FOR ATYPICAL
FAP IN A NEWFOUNDLAND KINDRED
PREDICIIVE TESTING RESULT
TOTAL RESULTS
resultspending-16
> 99.9% probability of having inherited the FAPgene
< O.l%probabilityofhavinginheritedtheFAPgene
Figure 4.3. Pedigree of a Newfoundland atypical FAP family with results of
linkage analysis.
Clinically affected family members (polyps ± colon cancer) are
indicated by solid symbols.
The CA repeat marker 055346. 50 kb from the APC gene (5pirio
et al 19911. was used for linkage analysis. Ten alleles were
identified. Allele "1" is segregating with atypical FAP in this
family. Genotypes are indicated below each pedigree symbol;
inferred genotypes are given in brackets. Predicted affected
family members are indicated on the pedigree. Family members
with colon or other GI cancer who are predicted to be unaffected
with FAParealso indicated (see keyl.
Newfoundland atypical FAP family with results of linkage analysis
•• Familial adenomatous polyposis (polyps ± colon cancer)
o S Predicted affected
,. Alleles of CA repeat marker
ill D5S346allelesegregatingwithatypicalFAP
,. Parentaloriginofallele'1',unknown
~ ~ Colon or stomach cancer, unrelated to atypical FAP

results were uninformative because both parents were deceased and it was not
possible to reconstruct the parental genotypes; the "high-risk" allele could have
come from the affected or the unaffected parent. However, there is only one
documented instance, of this allele (allele 1) entering the family independently
through a spouse.
In those at 50% risk, the ratio of high risk:low risk results (11 :36)
appears skewed because many gene carriers had already been identified by
clinical screening.
iv) UnexpeCtld rellll!$
Unexpectedly two brothers with early onset colon cancer who died at
age 40 and 56 were at low risk for FAP since their at-risk mother had not
inherited the high-risk allele. Therefore their 12 first degree relatives (siblings
and children) who were tested were all determined to be at low risk for FAP.
Nevertheless, this branch of the family, may be at increased risk of colon
cancer for reasons other than the FAP gene. Also, a 37-year-old woman who
died of stomach cancer (and whose mother and sisters were affected with
FAP), apparently did not carry the FAP gene, based on the alleles present in her
husband and children.
v) DeliveNg'results
The majority of results (n = 56) were delivered at one clinic in Twillingate
in November 1992, and the remainder either at a second clinic in Twillingate
in October 1993 (n=16), or at individual counselling sessions (n=8) in St.
John's or Corner Brook. When the majority of family members live in one
community or a group of communities some distance from St. John's, it is
more efficient for the geneticist(s) to organize a special clinic at a regional
hospital and see the patients there, than for many family members to travel to
the tertiary care centre in St. John's.
C1ini«;,' $Gr.,ning
Clinical screening and prophylactic surgery for first degree relatives of
patients with FAP was introduced as early as 1925 at St. Mark's Hospital,
London (Bussey 1975), and has been shown to be an extremely effective
means of preventing cancer and prolonging life. This is demonstrated in the
Newfoundland family as well as in families described previously in the literature
(Berk et al 19B7, Vasen et al 1990a, Rhodes and Bradburn 1992). For the
family members presenting symptomatically before screening was introduced,
90% (17/19) had invasive cancer, and 12 of 17 died of cancer within 6 years
of diagnosis. In contrast, nooe of those diagnosed as a result of screening had
invasive bowel cancer and none have died of the disease. Thus, there has been
a dramatic reduction in morbidity and mortality because of the clinical screening
Screening fortypipal FAP
Standard clinical screening protocols for FAPare based on the features
of FAP described in patients followed by large polyposis registries (Bussey
1975, Bulow 1991), Typically, multiple polyps (often hundreds or thousands)
occur throughout the colon, with increasing numbers towards the sigmoid colon
and rectum. Diagnosis of FAP is made when over 100 polyps are seen. Polyps
usually appear in the teens or early twenties and the majority of gene carriers
can be identified as affected by the early thirties (summarized in Bulow 1991).
Screening protocols, therefore, usually consist of flexible sigmoidoscopy (to
view the region of colon where the maximum number of polyps occur) every
1-3 years from teens to fifties, for those at risk; and review of the rectum and
any remaining colon semi-annually, and upper GI endoscopy every 3-5 years,
for those already affected.
Screening fgratypipal FAP
For families with atypical or attenuated FAP such as the Newfoundland
kindred, modification of this screening protocol is necessary (Figure 4.41. The
number of polyps in the Newfoundland kindred is highly variable. Therefore any
number of polyps must be considered significant and followed closely, or
prophylactic subtotal colectomy planned, rather than using the typical FAP
diagnostic criteria of "greater than 100 polyps", There is frequent clustering
of polyps in the cecum and ascending colon (in 43% of those with multiple
Figure 4.4. Recommended screening protocol for atypical familial
adenomatous polyposis.
RECOMMENDED SCREENING PROTOCOL FOR ATYPICAL FAMILIAL
ADENOMATOUS POLYPOSIS
Flr.tdegree relative. of tho.. who ere effected
a) Predietivetesting by linkage analysis in early teens (or direct mutation
detection if this becomes available)
b) Clinical screening
High risk group
-annualcolonoscopy
- upper GI endoscopy every 3-~ years
iiI Low risk group
-colonoscopyin late teens and in mid-thirties
iiil Uninformative group. or those declining
predictive testing
Age 15-45 years - annual screening with flexible
sigmoidoscopy or colonoscopy (colonoscopy should be used at
least every 3rd year); upper GI endoscopy every 3-5 years
After age 45 - colonoscopy every three years
c) Subtotal colectomy with i1eorectal anastomosis when polyps identified
Affected patients (following Inltlal.urgery)
- sigmoidoscopy of any remaining colon and rectum every 6-12 months
- upperGI endoscopy every 3-5 years
polyps), and absence of rectal polyps in some affected members in this kindred.
A recent patient, for example, had only two polyps in the sigmoid colon but
hundreds of polyps in the ascending colon and cecum. Therefore, colonoscopy
rather than flexible sigmoidoscopy is recommended for families with this
disease presentation (Smith-Ravin etaI1994).
The age at onset is highly variable in the Newfoundland kindred and on
average older than for typical FAP. Therefore, if identification of gene carriers
by genetic testing is not possible, clinical screening of those at risk must be
continued to a later age than for typical FAP.
As in typical FAP families, those who have had prior colectomy require
screening of any remaining colon and rectum every 6-12 months for life. Polyps
and cancer of the stomach and duodenum have also been identified in members
of the Newfoundland kindred, as in other FAP families; therefore regular upper
GI endoscopy (every 3-5 years) is recommended for all affected family
members. This is of particular concern for those who have had prophylactic
bowel surgery and remain at somewhat elevated risk of duodenal or stomach
cancer (Jagelman et a11988, Arvanitis et al 1990). (It was only when early
death from colon cancer was prevented by surveillance and treatment that the
full extent of the subsequent extracolonic expression of the APe gene was
recognized [Jagelman 1987)).
iii) Extraco'gniC manifestations
The benign but invasive desmoid tumour (Gurbuz et al 1994) found in
some FAP patients following colectomy. and hepatoblastoma (Li et al 1987) or
brain tumours (Hamilton et al 1995), which occur rarely in FAP gene carriers
in childhood. have not yet been seen in this family. nor have CHRPE been
identified. These benign pigmented lesions of the retina area sensitive marker
for the development of polyps in about 70% of FAP families (8erk et al 1988b.
Heyen et al 1990, Romania et al 1992). but typically occur in FAP families with
early rather than late development of polyps (Romania et al 1992) and a more
classic presentation ofFAP.
A correlation has recently been recognized between the presence of
CHRPE and the location of the mutation within the APC gene (CHRPE are only
present when the mutation is between exon 9 and codon 1444 in the very
large exon 15 [Caspari et al 199511. and this correlation can be used to
facilitate detection of the mutation in specific families (Wallis et al 1994.
OlschwangetaI1993b).
A variable number an~ location of polyps. an older age of onset. and
variable age at onset within a kindred have recently beendescribedinseveral
other kindreds (Nagase et al 1992. Evans et al 1993. Spirio et al 1993b. Smith-
Ravin et a11994. Varesco et aI1994); thus. familial polyposis may be a more
variable disease than previously recognized. Since the different phenotypes will
only be obvious in large kindreds with many affected members. more extensive
screening than previously recommended may also be important for smaller
kindredswhichlacksufficient numbers to define the characteristics of the
disease within their own family.
Even though genetic testing by direct mutation detection or by Iinkage
analysis is possible for many families, clinical screening is still necessary to
identify the onset of polyp formation and to plan surgery in identified gene
carriers. Furthermore, clinical screening will be the only option for families
where the specific mutation has not been found and linked markers are
uninformative. Therefore clinical screening protocols should be revised as new
clinical or genetic information accumulates, or new technology becomes
glo.tic; $Gr,.ning
The mapping of the gene for FAP to chromosome 5q21, the cloning of
the APC gene, and the identification of mutations within the APC gene for
many FAP families allows direct identification of gene carriers in these families
(Petersen et al 19931. But the very large size of the APC gene, the many
different mutations so far identified, and the high mutation rate increase the
difficulty of finding the mutation in each family (Groden et a119931. There is
clustering of mutations at the 5'endofexon 15, particularly in families with
·classic· early-onset disease and profuse polyps (Nagase et al 1992, Nagase
and Nakamura 1993, Caspari et al 1994, Gayther et al 19941, and several
mutations have occurred more than once. (mutation hotspots have been
identified at bp 1061 and 1309 [Miyoshi et al 1992. Nagase and Nakamura
1993. Bhapat et a11994. Mandl et a11994)). but the majority of families have
a unique mutation (Nagase and Nakamura 1993. Powell et aI1993). Because
many of the APC mutations lead to stop codons (large deletions. 4-5bp
deletions or nonsense mutations). protein truncation testing by a linked in vitro
transcription-translation method has recently been developed to increase the
efficiency of identifying the APC gene mutation in individual families (Powell et
a11993. Van der Luijt et aI1994). This method is reported to be successful
in greater than 80% of families for identification of the specific APC mutation
(Liu 1993bl. but is not widely available.
Even using these newer methods. and knowing that APC mutations in
families with similar phenotype to the Newfoundland family cluster at the 5'
end of the APC gene (in exons 1-4) (Spirio et al 1993bl. the mutation for the
Twillingate family has not yet been identified, Because genetic heterogeneity
for FAP has been reported, with linkage to 5q21 being excluded in at least one
large family with typical FAP (Tops et al 19931. and also in a family with an
atypical expression of FAP (Stella et al 1993'. predictive testing by linkage
analysis should be used with caution unless linkage to the APCgeneregioncan
be demonstrated. The identification of several highly informative closely-linked
CA repeat markers. however, has increased the possibility that linkage to the
APC gene region can be demonstrated, and used for predictive testing when
the mutation is not identified (Spirio et a11993a, Eckert et aI1994).
Unkage to one of these CA repeat markers has been established for the
Newfoundland family. Predictive testing by linkage analysis has therefore been
used for modification of the clinical screening protocol for those at risk (Figure
4.51. Recommendations regarding clinical screening remain unchanged for
those with high-risk or uninformative linkage analysis results. For those with
low-risk results, a much reduced screening protocol with colonoscopy in the
late teens and late thirties is recommended (Petersen et al 1991).
Unexpectedly, the low-risk group includes two brothers with early colon
cancer. Colon cancer is frequent enough in the general population that the
occurrence of sporadic colon cancer in an older member of a large FAP kindred
would not be surprising, but it was unexpected that two brothers who died at
a young age of colon cancer (one of whom had several polyps) had not
inherited the marker associated with FAP in this family. Because of the early
age at onset, they may have had another form of hereditary colon cancer such
as HNPCC. Their relatives may have an increased risk of GI cancer, but FAP
linkage studies cannot predict the risk of cancer in this part of the pedigree.
The presence of individuals within an FAP kindred with GI cancers for other
reasons than the APC gene can cause problems with linkage analysis, as well
as problems for clinical management.
Figure 4.5. Management plan for FAP families.
Different methods are used for mutation detection by different
laboratories (including SSCP. DGGE. RNase protection assay,
heteroduplex analysis. and protein truncation testing [PTTl). The
mutation is identified in 30-60% of families by most laboratories,
and may be identified in over 80% of families if PTT is available
(Powell et al 1993. van der Luijt et al 1994). If mutation
detection is not available, the management plan begins with
linkage analysis.
SSCP - single strand conformation analysis
DGGE-denaturing gradient gel electrophoresis
Management plan for FAP families
" annual colonoscopyis recommended for
atypicalFAPfamilieswithrlght-sided
cluslerlngofpolyps
Although these brothers with colon cancer (and few or an unknown
number of polyps) apparently did not have atypical FAP, other family members
with colon cancer and only a few polyps did inherit the marker associated with
familial polyposis in this family.
Impltm,oytion Iud ACG'ptanG. of thl 'Gr.tning Pmqr.m
Between 1985, when it was first recognized that a type of hereditary
colon cancer was responsible for several colon cancer deaths in an extended
Notre Dame Bay family, and 1989, a number of family members participated
in clinical screening initiated by the family doctor. Because a diagnosis of
familial adenomatous polyposis had been made, the FAP guidelines for
screening were followed with annual sigmoidoscopy recommended for those
at risk. Screening, however, had been offered to "thefamily"asawhole rather
than according to degree of risk, so that some of those participating in this
screening program were at 25% risk or less. When Genetics was asked to
assist with management of this family in 1989, the degree of risk was
established for each individual from pedigree and medical record review. The
pedigree was then extended to include another large branch of the family in
Members of the Notre Dame Bay branch live in many small communities
on the islands of Twillingate and New World Island. Their health care has
always been centred on the regional hospital in Twillingate, and two established
family doctors know the family and the condition very well. In collaboration
with the geneticist involved, a registry of affected and at-risk family members
was developed at the hospital and is monitored by one of the nurses. A
surgeon at the hospital provides the screening by colonoscopy and upper GI
endoscopy.
There has been a good understanding by the majority of members of this
branchofthefamilyaboutthedisease,theinheritancepattern,therecurrence
risk, and the rationale for screening since the information session was held at
Twillingate Hospital in 1991, and since educational pamphlets and individual
genetic counselling were provided. Compliance with screening
recommendations has generally been good, and the majority of those identified
as affected by clinical screening have been in this branch of the family. The
interest in genetic testing has also been high. Some family members, males
more often than females, declined clinicalscreeningbutexpressedan interest
in genetic testing when this became available. Two men at 50% risk refused
any screening or genetic testing for themselves or for their children until an 18-
year-old son of one of these developed symptomatic disease. All this branch
of the family now participate in clinical screening and have recentIyhadblood
samples collected for predictive testing.
The central Newfoundland branch of the family live in a number of
communities in the Botwood - Phillips Head region, and more members of this
part of the family than of the Notre Dame Bay branch have moved to other
parts of Canada. Several different family doctors have clinics in these
communities, and over the years there have been frequent changes in the
doctors in practice, so that there is no key individual who knows the whole
family. The regional hospital in Botwood has become a chronic care facility; as
a result, travel to Grand Falls (35 km) or St. John's (300 km) is necessary for
any screening procedures or surgery. An attempt to establish a registry similar
tothatinTwiliingatewasnotsuccessful,partlybecauseofthelesscentralized
care and partly because of the pressures of other work on nurses who originally
expressed interest. Relatively few of those at risk in this area have been
clinically screened ona regular basis, and it has been moredifficulttocontact
and to provide information for them. However, there has now been a request
for information, and for clinical screening and genetic testing from some of
these family members. This may provide the impetus for an improved screening
program for this section of the family.
As has been demonstrated with other screening programs, such as for
carriers of Tay Sachs disease or p-thalassemia, education of the families at risk
and of the health care workers is necessary for a successful program (Kaback
1990, Scriver et a11984, Cao et a11989, Modell and Kuliev 1991). Genetic
registers can also be very beneficial, particularly when on-going screening is
required, to facilitate record keeping, regular follow-up, and communication
with family members (Bussey 1975, Berk et al 1981, Jarvinen et al 1984,
Bulow 1986, Vasen et al1990a, Rhodes and Bradburn 1992). The registry can
also be used to coordinate the complete management of FAP familv members
including molecular genetic diagnosis, ophthalmic examination, clinical
screening, and treatment (Burn et al1991, Maher et aI1993).
CHAPTER 5 - DEVELOPMENT OF A SCREENING PROGRAM
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INTRODUCTION
This chapter describes the ascertainment of two families with hereditary
non-polyposis colon cancer (HNPCC), the documentation of the clinical
phenotype, the recognition that these were two branches of one large HNPCC
family (Family C), the collaborative linkage studies that lead to mapping and
subsequent cloning of a gene for HNPCC, the development of a clinical
screening program, and a discussion of some of the ethical issues associated
with screening for hereditary cancers.
Familial clusters of non-polyposis colon cancer either alone (Lynch I
syndrome) or associated with extra-colonic cancers such as endometrial, other
gastrointestinal, or genitourinary cancers (Cancer Family Syndrome or Lynch II
syndrome) have been recognized for years, (Warthin 1913, Lynch et al 1966,
Lynch and Krush 1971, Mecklin 1987, Orrom et al 1990, Lynch and Lynch
1993a), but until recently these clusters were often explained on the basis of
common environmental factors rather than inheritance (Peltomaki et al 1993,
Editorial 1993a). In some families, Lynch I or Lynch II syndrome (now referred
to as hereditary non-polyposis colon cancer or HNPCC [Fitzgibbons et al 1987,
Vasen et al 1990b, Vasen et al 1991b, Lynch et al 1994]) was apparently
inherited in an autosomal dominant pattern with variable age of onset, variable
types of cancer and reduced penetrance (Mecklin and Jarvinen 1986a. Vasen
et al 1990b. Lynch et al 1993c. Watson and Lynch 19931.
This variability and the lack of a premalignant marker (Lynch and Lynch
1993a. Lynch et al 1993c) made it more difficult to implement a clinical
screening program for HNPCC than for familial adenomatous polyposis.
discussed in the previous chapter. where the natural historyofdisease is better
known and multiple polyps typically precede the development of cancer.
HNPCC is. however. responsible for up to 15% of colon cancer (Vasen et al
1991 b. Hamilton 1993. Peltomaki et a/1993). as well as extra-colonic cancers.
and. therefore. considerably morecommon than FAP (responsible for only about
1% of all colon cancerl. Clinical screening protocols have therefore been
introduced by various groups. recommending colonoscopy at from one to five
year intervals. beginning five years before theearliestdiagnosisofcoloncancer
in the family (Mecklin et a11986b. Fitzgibbons et a11987. Vasen et a11989a.
Houlston et a11990. Vasen et al 1993). Women in these families may also be
screened for endometrial cancer with endometrial biopsy or dilatation and
curettage (0 & CI. and pelvic.ultrasound (Fitzgibbons et a11987. Watson et al
1994).
Until 1993 efforts to map the gene or genes for HNPCe had been
unsuccessful. Several candidate genes known to influence hereditary or
sporadic colon cancer progression (APe and MCe on chr 5. Dee on chr 18.
and pS3 onchr 17) had been excluded (PeltomakietaI1991. Peltomakietal
1992), and a search of the whole genome was necessary. DNA was often not
available for linkage studies from enough affected individuals to obtain a
significant LCD score because HNPCC families are frequently recognized by
multiple early cancer deaths (Peltomaki et al 1991). There was concern,
however, about combining LOD scores from several families because of the
possibility of genetic heterogeneity of HNPCC (Peltomaki et al 1993), or the
possibility of lumping families with hereditary and with sporadic caneers.
One attempt to solve this dilemma was the definition of the Amsterdam
criteria (Vasen et al 1991a, Vasen et al 1991bl to increase uniformity of
families included in linkage studies. Research families were to have at least
three first-degree relatives in two generations affected with colon (or
endometrial) cancer, and at least one of these persons diagnosed under 50
years of age. Another approach was to study a single HNPCC family, large
enough to generateasignificantLOD score if there was Iinkagetoa particular
map location.
In 1990, two Newfoundland patients were referred to Jane Green in
Medical Genetics because of their personal and family history of mUltiple colon
and other cancers (Figure 5.1), and their concern about the risk of these
cancers to relatives. A family history was taken and medical records reviewed
Figur. 5.1. Original pedigrees of branch A and branch B of a Newfoundland
HNPCC family.
Two probands. each indicated by an arrow. were independently
referred to Genetics. Affected family members. as reported by
each proband. are indicated by solid symbols.
Subsequent pedigree studies and archival review demonstrated
that these original families were from separate branches of one
large HNPCC family (Figure 5.4).
Original pedigrees of Branch A and B
of Newfoundland HNPCC Family
Branch A
Branch B
(by Jane Green) in order to establish the diagnosis. to identify those at risk. and
to determine whether screening was appropriate in either family.
Each family documented fit the diagnosis of lynch II Syndrome (HNPCC
with extra-eolonic cancers). Extending the pedigrees back six generations
identified a common ancestor. and these families were recognized to be two
branches of one large HNPCC family.
This family. Family C. was key to mapping the first gene for HNPCC to
chromosome 2p (Marshall 1993. Peltomaki et al 1993) and subsequent cloning
of a DNA repair gene (hMSH2) by a collaboration between Jane Green and the
laboratories of Dr. Bert Vogelstein at Johns Hopkins University and Dr. Albert
de la Chapelle at the University of Helsinki (leach et al 1993). and
independently by Fishel and colleagues (Fishel et al 1993. Editorial 1993c).
disease in each of three large HNPCC families including Family C (see below).
Subsequently a second gene for HNPCC was mapped to chromosome 3p
(Lindblom et al 1993. Nystrom-Lahti et aI1994b). and mutations identified in
another DNA repair gene (hMlH1) mapping to this locus (Bronner et al 1994.
Papadopoulos et a11994. Service 1994).
The documentation of the natural history of HNPCC in the Newfoundland
family provides the basis for development of a clinical screening program for
this family. and the identification of the mutation predisposing to HNPCC
provides the basis for genetic screening. As with screening for other cancer
predisposition syndromes, there are ethical, legal and social concerns about the
best method of implementation of this type of screening (National Advisory
Council for Human Genome Research 1994). The approach taken in
Newfoundland is described below.
METHODS
pedigr•• in,di,. end MediCI' R,cord R'viAw
The probands (Appendix, p. 2851 were interviewed by Jane Green to
obtain details of their family histories. They provided introductions to other
family members to extend the pedigrees, and to determine the ancestral
geographic location of each family within Newfoundland.
reported to be affected. Detailsoftype(s) of cancer, age at diagnosis, age at
onset of any symptoms, type and outcome of treatment, and current age, or
age and cause of death were recorded for each individual.
Because of the very similar pattern of cancers in the two families, the
English origins of each family, and the geographic location of the ancestorsof
each family in communities on the northeast coast of Newfoundland, provincial
archival information on births, deaths, and marriages was searched for a
Family members were approached about participation in a linkage study
to try to map the gene predisposing to colon and other cancers in this family.
After consent was obtained, blood samples were collected for establishment
of cell lines and for DNA extraction from all living affected and older unaffected
family members. Tissue blocks were collected, if available, from affected
family members who were deceased, to be used as a source of DNA.
Blood samples, tissue blocks and a pedigree indicating disease status
were sent to Dr. Vogelstein's laboratory at The Johns Hopkins University for
collaborative linkage studies with Dr. de la Chapelle's laboratory in Helsinki,
Genetic counselling regarding Lynch syndrome (now called HNPCCl was
offered to all affected and at-risk family members because of the anxiety
expressed by the probands and many other family members about the excess
and early age of cancer deaths in the family. This counselling was requested
by the majority of family members, and counselling sessions were arranged for
73 individuals at their convenience - in their homes, in local hospitals (in
Botwood or Grand Fallsl, or at the General Hospital in St. John's. The features
of HNPCC (inclUding the types of cancers and the age range over which they
occur, the panern of inheritance, and the risk of recurrence to relatives of
the affected members), and the clinical screening that is recommended for
those at risk (Figure 5.2),weredescribed by Jane Green. Whenrequested,a
Figure 5.2. Recommended screening protocol for hereditary non-polyposis
colon cancer (HNPCC).
RECOMMENDED SCREENING PROTOCOL FOR HEREDITARY NON-POLYPOSIS
COLON CANCER (HNPCCI
Screening for effected. and at risk In HNPCC families
annual or biennial (2-yearty) colonoscopy (beginning 5 years
beforeearliestonsetofcoloncancerinthefamilyl
double contrast barium enema and flexible sigmoidoscopyasa
~.ifcolonoscopyimpossibleorunavailable.
For families in which female genital cancers occur
annual pelvic examination. endometrial aspiration biopsy, and
pelvic ultrasound
annual clinical examination and endoscopic or radiological
investigation of organs at risk every 20r 3 years.
For patients with previous colonic surgery
semi-annual or annual endoscopic evaluation of remaining colon
or rectum.
NOTE:Subtotal colectomy with ileorectal anastomosis is the treatment of choice
for colon cancers in these families because of high risk of synchronous or
metachronouscancers.
summary of this information was also sent (by Jane Green) to each family
doctor. Surgeons and gastroenterologists, in St. John's and in central
Newfoundland, were alerted to the extent of this large family so that screening
or treatment offered would be appropriate, and appointments for colonoscopy
and/orendometrial biopsy and pelvic ultrasound were arranged when requested.
When the mutation was identified in the Newfoundland family, more
detailed counselling was provided to family members about predictive testing
by direct mutation analysis. The counselling included information on the
variability of disease in this family, and the unpredictable age at which tumours
might occur in those identified to be gene carriers. Family members were
reminded that regular screening was recommended for those shown to carry
the HNPCC mutation, and would remain available for those who declined
predictive testing. The possibility of discrimination regarding life insurance,
once gene carrier status was known. was also raised by the geneticist. A
consent form was signed and DNA banked for family members requesting
genetic testing.
RESULTS
A,c9rtainm9ntgfF.mili••
Initial pedigree studies and medical record review delineated two families,
each fitting the criteria for Lynch II syndrome. There were multiple affected
individuals with non-polyposis colon cancer, and extra-colonic cancers including
other gastrointestinal cancers. and endometrial and ovarian cancer in the
affected women. The cancers followed an autosomal dominant inheritance
pattern in each family, and many affected members had early onset cancers,
bilateral cancers and/or multiple primaries.
The families were both from small communities on the northeast coast
of Newfoundland, one from the Wesleyville area on the west side of Bonavista
Bay, and the other from Point Leamington at the head of South West Arm,
further west in Notre Dame Bay (Figure 5.31. Although these communities are
approximately 175 km apart, the Wesleyville area is known to have been
settled earlier by immigrants from England, and in a later wave of migration,
families moved westward along the coast line towards and past the Point
Leamington area (Mannion 1977, Encyclopedia of Newfoundland and Labrador
19811.
By examining archival records including those collected by proband 1
before he died, and old marriage records saved by members of the family of
proband 2, a common ancestor of the two families was identified (Figure 5.4),
an immigrant from Hampshire, England who settled in 1790 on Greenspond
Island, Bonavista Bay, the merchant centre for the Wesleyville area.
Twenty-six affected family members and four obligate carriers were
identified by pedigree studies and medical record review. Two of the obligate
carriers had died young (age 45 and 531 of other causes, and the others were
· Figure 5.3. Geographic location of two branches of a Newfoundland HNPCC
family.
Original Newfoundland settlements were along the coastline and
transportation between them was by sea. The Greenspond
Island area was settled in the 1690s, and the Point Leamington
area was settled in the late 17oos.
Geographic location of two branches
of Newfoundland HNPCC Family
LABRADOR
Figure 5.4. Pedigree of a Newfoundland family (Family C) with HNPCC.
The complete pedigree illustrates the connection between the
two independently-identified branches of Family C. The types of
cancerandageatdiagnosisforeachaffeetedindividualare
indicated on the pedigree.
Pedigree of a Newfoundland family (Family C) with HNPCC
pedlg... number
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IPCC
1---------------------'
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a 42-year-old identical twin and a 78-year-old woman with affected siblings.
children and grandchildren. Ninety-four first degree relatives at 50% risk were
identified from the pedigree. 75 of whom were over 20 years of age. Another
153 family members were at 25% risk.
N'ty,,'Hi,tgrv gf Dil,a.,
In the combined family. twenty-six (12 males and 14 females) were
identified as affected (Figure 5.4). The median age at diagnosis of the initial
cancer in all affected was 38 years (range. 27-67 years); in affected males. 33
years (range. 27-54 years); and in affected females. 45 years (range. 32-67
years) (Table 5.1. Figure 5.5). There were also four obligate carriers with no
evidence of cancer; two men who died of other causes at age 45 and 53. and
two women age 42 and 78 still living.
The twenty-six affected members had a total of 40 cancers typical of the
Lynch II classification. with one to four primary cancers in each affected
individual. The most frequent cancers were colon cancer (57.5%1. endometrial
cancer (22.5% of the total cancers. or 39% of the cancers in affected women).
and stomach cancer (10%1 (Table 5.2. Figure 5.6). Ovarian and duodenal
cancer also occurred. and bladder cancer has since been identifiedinonefamily
member who was at 50% risk. Ten of 20 colorectal cancers (50%1. and 2 of
TABLE 5.1. AGE AT DIAGNOSIS, AGE AT DEATH, AND
SURVIVAL nME OF MALE AND FEMALE
PAnENTS IN A NEWFOUNDLAND HNPCC
FAMILY
AGE IN YEARS
median (range)
number
Age at diagnosis 33 (27-54) 45 (32-67)
n=12 n=14
Age at death 41 (29-69) 54 (38-67)
n=10 n=5
Survival time
-deceased only 1 (0-31) 2 (0-16)
n=10 n=5
-all patients 1 (0-311 6 (0-34)
n=12 n=14
Figure 5.5. Time to diagnosis and to disease-specific death for male and
female patients in a NewfoundlilOd HNPCC family.
The Kaplan-Meier method was used to estimate the probability of
diagnosisorofdisease-specificdeathformaleandfemalepatients
with HNPCC. Data was censored for those dying of other causes
or remaining alive.
The mean age at diagnosis of male (x, 36.1) and female {x, 45.41
patients was significantly different (p <0.051. However, the mean
age at death of male (x, 42.8) and female {x, 53.81 patients was
not significantly different (p>O.051.
Time to diagnosis and to disease·specific death for male and
female patients in a Newfoundland HNPCC family
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TABLE 5.2. SPECTRUM AND FREQUENCY OF TUMOURS
NEWFOUNDLAND FAMILY WITH HNPCC
FREQUENCY
INITIAL TUMOUR ALL TUMOURS
Number (%) Number (%)
Uposarcoma·
Malignant
Schwannoma·
• May be coincidental tumours
Figure 5.6. Combination and order of occurrence of tumours in individual
patients with HNPCC.
Thetype(s) of cancer, age at diagnosis of each cancer, and age
at death are indicated on a time line for each patient. Colon,
endometrial, ovarian, stomach, duodenal and pancreatic cancer
are recognized HNPCC tumours; prostrate cancer and
schwannoma are not typical of HNPCC and may be coincidental.
Keratoacanthoma is a premalignant skin lesion common in the
Muir-Torre variant of HNPCC. Colonic polyps are indicated
because they may be premalignant manifestations of HNPCC. For
women, coincidental hysterectomy is indicated, since this
removes the risk of endometrial and possibly ovarian cancer.
Type of Cancer, Age at Diagnosis and Age at Death for Individual Patients
1965~
1949 --"'-_
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1926~
1922 C'i
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1908~
1899 OBUGATECARRlERMI
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1955 ---"'-_
1951 OBUGATECAAAJEA E(~)
1951-----"-O-=-E
1918 --"!<--.lii1fT
191308UGATECARAIER
o 10 20 30 60 70
Years
ICOLONE eNDOMETRIUMo OVARYS SlOMACHo DUODENUMP PANCREASPr PROSTATESchSCHWANNOMA• KERATOACANniOMAP COLONIC POLYPS1"1 HYSTEREClOMY(ooncidenlaJ)
8 colorectal polyps (25%) of known location, were right-sided (Table 5.3,
Figure 5.7). Several skin cancers (basal cell carcinoma, sebaceous cell
carcinoma, squamous cell carcinoma, and melanoma) were also identified in
affected family members as has been seen in some other Lynch II-like families
in the literature, designated as Muir-Torre syndrome (Lynch et al 1985a, Hall
et al 1994b). Prostate cancer and a malignant schwannoma, identified in
affected family members, and a liposarcoma in a 26-year-old at 50% risk, are
not typical of Lynch II syndrome; these may be less common cancers of the
Lynch I( phenotype, or may be coincidental.
iii)~
The initial cancer in 10/12 males (83.3%) was colorectal cancer,
whereas the initial cancer in 7/14 females (50%) was endometrial cancer, and
in two other women was ovarian cancer (Table 5.2). All patients originally
documented were identified because of symptoms, most commonly abdominal
pain, bleeding or diarrhea in those with colon or stomach cancer.andmenstrual
abnormalities or post-menopausal bleeding in those with endometrial or ovarian
iv) M2!:Iil.!ir£
Ten of the 12 affected men have died; the median age at death was 41
years (range 29-69) and the median survival time was 1 year (range 0-31
years). Five of the 14 affected women have died; their median age at death
was 54 years (range 38-67 years) and the median survival time was 2 years
TABLE 5.3. LOCATION OF COLORECTAL NEOPLASTIC
LESIONS IN AFFECTED MEMBERS OF A
NEWFOUNDLAND HNPCC FAMILY
TUMOURS POLYPS
(number) (number)
Right-sided
Ascending colon
(101 (2)
Descending colon
Sigmoid colon
(7) (3)
Figure 5.7. Location ofcolorectal cancer and polyps in patients with HNPCC.
Location of colorectal cancer and
polyps in patients with HNPCC
:
~~
~~~i~:~~~~n
rectum
unknown
10
7
3
3
(range 0-16 years) (Table 5.1, p. 253; Figure 5.8). The two living affected men
have survived 10and 2 years since diagnosis, but the second of these, a 27-
year-old, has terminal colon cancer. The nine living affected women have
survived 4-34 years (median, 10 years) since diagnosis, and their current
median age is 57 years (38-78 yearsl. All deaths of known affected family
members were due to cancer. Two male obligate carriers in a previous
generation, however, died at ages 45 and 53 of heart attack without evidence
of having cancer, although no investigations had been carried out.
CllnlSAISc;r"nlng
Participatjooinscreening
Forty-three of those at 50% risk and over 20 years of age (28/42 female,
and 15/33 male) have been screened with colonoscopy (35 with normal results,
and eight with polyps). Eighteen women have also had pelvicultrasound,and
endometrial biopsy or 0 8< C (fourteen with normal examinations, and four with
abnormal results including one with endometrial cancer). Ten women had had
a previous unrelated hysterectomy with bilateral oophorectomy (thus, are no
longer at risk for endometrial cancer, and have very reduced risk for ovarian
cancer). Eight of 11 affected family members have been screened for
subsequent cancers, and one of two obligate carriers was also screened (Table
5.4).
Rgure 5.8. Kaplan-Meier survival curves for male' and female patients with
HNPCC in a Newfoundland family.
The Kaplan-Meier method was used to construct survival curves,
using age at disease-related death,and censoring data for
unrelated deaths and for persons remaining alive. Ten of 12
affected male patients died of HNPCC-related cancers and two are
still alive; two obligate carriers died of other causes. Five of 14
affected female patients died of HNPCC-related cancers and nine
are still alive; two obligate carriers are living at ages 42 and 79.
Kaplan-Meier survival curves for male and female
patients with HNPCC
male survival ._.
(n=12)
female survival .--.
(n=14)
40 50 60
AGE (YEARS)
TABlE 5.4. PARTICIPATION, AND RESULTS OF CUNICAL SCREENING
FOR AFFECTED AND AT·RISK MEMBERS OF A
NEWFOUNDLAND HNPCC FAMILY
PARTICIPATION RESULTS OF SCREENING
----
No. Screened I
Endometrium OtherCategory Total
8/11 4(C-2.P-21
Obligate Carrier 1/2 1(C) 1"
Age~20 0/19 ............ Screening Not Offered ......
21-30 6/14 5 1(PI
31-40 15/26 11 3(PI 1"
14/22 10 3(P) 1(P)
51-60 6/9 3 1(P) l(P,C) 1'3
260 2/4 0 1'4
'normalcolon(301.normalendometriumI141.previoushystereetomy(101
"keratoacanthoma (coincidentaldet8etion); "'endometrialthickening;
"'transitional cell cancer of the bladder;'4enlargeduurus
Re§lIlt$Qf$creening
Rvecancers have been identified since this screening was introduced
two years ago: three colon cancers, in two previously affected women, and in
the 42-year-old obligate carrier; and endometrial cancer and bladder cancer,
each in a family member at 50% risk (Table 5.5). One or more adenomatous
colonic polyps were also identified and biopsied in eight at-risk family members,
and in two women with previous endometrial or ovarian cancer. These
individuals will be screened more frequently than those with a normal colon.
Thirty five at-risk and four affected family members had a normal colonoscopy.
Fourteen women had normal pelvic ultrasound and endometrial biopsy. Three
women with endometrial polyps or thickened endometrium will also be
screened more frequently than those with normal examinations.
Mapping pf a gene fpr HNPCC
The HNPCC gene in Family C was mapped to chromosome 2p1 5-16 after
an extensive search of the genome for linked markers (Peltomaki et al 19931
(Figure 5.91. A LOD score of 6.39 was obtained for linkage to the anonymous
marker 025123 and this linkage was confirmed in a large New Zealand family
{Peltomaki et al 19931. Deletions of chromosome 2p or loss of heterozygosity
(LOHI were not identified in the tumours from this and other HNPCC families,
as would be expected if the gene were a tumour suppressor. However,
TABlE 5.5. DETECTION OF CANCER BY CUNICAL SCREENING
IN AFFECTED AND AT-RISK MEMBERS OF A
NEWFOUNDLAND HNPCC FAMILY
Affected"'
Obligatecarrier'2
1.3
.Z Monozygotic twin affected.
• , Transitional cell bladder cancer in 54vearoldmale.
(Hemawria was identified and investigatedfol/owing
referral to Intemal Medicine for screening forHNPCC.1
Figure 5.9. Linkage of HNPCC with anonymous markers on chromosome 2p
in a Newfoundland family (Family CI.
The pedigree of Family C is simplified to highlight those from
whom DNA samples were available. Type(sl of cancer and age
at diagnosis are given for each affected individual as on the
previous pedigree (Figure 5.41. Linkage to three markers on
chromosome 2p (025119. 025123. 0251361 was identified by
Peltomaki. Aaltonen and colleagues (Peltomaki et a119931. and
data on the alleles present for each marker were provided for
each family member tested. Haplotypes were constructed and
are indicated on the pedigree. Assumedhaplotypesofdeceased
family members are given in brackets. All affected family
members have inherited allele "6" of marker 025123.
Crossovers occurred between 025123 and flanking markers in
some affected individuals as indicated on the pedigree.
Linkage of HNPCC with anonymous markers on chromosome 2p
IV
VI
VII
'kers on chromosome 2p
~~
instability of microsatellite DNA was demonstrated with accumulation of
mutations at chromosome 2p and throughout the genome (Aaltonen et a11993,
Thibodeau et al 1993), suggesting a different mechanism of cancer
predisposition, possibly a defect in DNA repair (Strand et al 1993, Palombo et
al 1994, Parsons et al 1993).
Microsatelliteinstabilitywasidentifiedserendipitouslybecauseofthe use
of CA repeat (microsatellitel markers in testing for LOH; instead of loss of an
allele of markers at chr 2p15-16, multiple new alleles (mutations) of altered CA
repeat size were identified for loci on all chromosomes. Slippage during DNA
replication can result in this type of mutation, but the mutations are normally
repaired. In HNPCC patients the ability to detect and repair these mutations
during DNA replication was apparently reduced.
Cloning of a gene fpr HNPCC
Subsequently, by studying recombinants in Family C and other families,
and by using physical mapping methods, the critical region of chromosome
2p16 was defined, and the human homologue, hMSH2, of the bacterial
mismatch repair gene, MutS (which corrects errors in microsatellite allele size),
was identified in this region (Fishel et a11993, Leach et a119931. Mutations of
hMSH2 were identified in three HNPCC families including a splice site mutation
in Family C which coincided with the disease in this family (Leach et al 1993,
Liu et al 19941. Although the laboratory work for mapping and cloning the
gene, hMSH2, was done elsewhere, the success of these studies was based
on the large, well-defined Newfoundland family.
iii) RAQtlOS!for predictivetfttiting
There are 94 family members identified from the pedigree at 50% risk.
Nineteen of these are less than 20 years of age; clinical screening has not been
offered to this group, nor was predictive testing offered. Fifty-four of75 family
members over 20 years of age live in Newfoundland, and 36 (66%) of these
have requested predictive testing. DNA has been banked and arrangements
have now been made for a laboratory to conduct this testing. When results are
available, they will be provided in another counselling session in a location
convenient for the family member (ie, at the General Hospital in St. John's, in
the local hospital, or at home).
Natyra' History of HNPCC
Hereditary non-polyposis colon cancer (HNPCC) has been defined as the
autosomal dominant predisposition to colon and extra-colonic cancers,
particularly endometrial cancer in women, without the pre-existence of multiple
polyps (Lynch et al 1988, Vasen et al 1990b). Age at onset is frequently earlier
than for similar sporadic cancers, multiple or bilateral tumours are common, and
colon cancers are frequently right-sided (MecklinandJarvinen 1986a, Lynch
et al 1993c). HNPCC was previously divided into Lynch I and Lynch "II
syndromes depending on whether or not extra-colonic cancers occurred in the
kindred (Lynch et al 1988), but this classification does not seem to have a
genetic basis (Nystrom-Lahti et aI1994a1.
The most common extra-colonic cancers in HNPCC families (Vasen et al
1990b, Watson and Lynch 1993, Lynch et al 1993c) are other gastro-intestinal
cancers (eg, stomach [Cristofaro et al 19871, duodenum [Lynch et al 19891,
pancreas [Lynch et al 1985bll; female genital cancers (eg, endometrium
[Mecklin et al 1986b. Watson et al 19941 and ovary [Lynch and Lynch 1979));
genito-urinary cancers (eg. transitional cell cancer of the kidney, bladder or
ureter [LynchetaI19901l; and skin cancers (eg, sebaceous cell carcinoma.
basal cell carcinoma, and keratoacanthoma [Hall et aI1994a. Hall et aI1994b)).
Although heterogeneity among families is observed in the frequency of specific
extracolonic cancers (Watson and Lynch 1993), there is also significant
intrafamilial variability in the age at onset, site(s) and order of occurrence of
HNPCC cancers. Thus the rarer cancers such as stomach, or pancreatic
cancer,and transitional cell cancers of the genitourinary tract, maybe more
common in some families. but cannot be ignored in any HNPCC family.
Morbidity and Mprtality
Some authors have referred to colon cancers in HNPCC families as less
aggressive and therefore providing a better prognosis than sporadic colon
cancer (Mecklin and Jarvinen 1986a, Hall et al1994b, Jass et aI1994). This
is not the case in the Newfoundland family and some other families in the
literature, that have very aggressive tumours and early death (Lindblometal
1993). Both age at diagnosis and age at death were earlier in men than in
women in the Newfoundland family, with 90% of affected men deceased by
age 54 (Figure 5.5, p. 255).
HNPCC causes a high burden to families because of the early morbidity
and mortality from colon and other cancers (Mecklin and Jarvinen 1986al, and
the resulting anxiety to close relatives at risk (National Advisory Council for
Human Genome Research 1994). Although it is more common than FAP, it has
beenmoredifficulttodevelopclinicalandgeneticscreeningprograms because
of the poorer understanding of the natural history of disease, the variability of
expression including non-penetrance of the gene (Lynch et al 1993cl. the lack
of a consistent pre-malignant biological marker (Lynch et a11993c), and until
very recently, the lack of information on the gene or genes involved (Lynch et
al1993c, p. 1545).
~
Recent advances in the understanding of HNPCC should improve the
management of families. Increased knowledge of the clinical phenotype of
HNPCC has come from retrospective and prospective documentation of age of
onset and frequency of cancers in large families or groups of families (Mecklin
and Jarvinen 1986a. Vasen et al 1990b, Watson and Lynch 19931. For
instance. in affected women, in the Newfoundland and other families,
endometrial cancer is more frequent and occurs earlier than colon cancer. This
must be reflected in the development of appropriate clinical screening (Figure
5.2).
It will not, however, be possible to use routine prophylactic surgery, as
in FAP, to prevent cancer, because of the multiple sites in which cancer may
occur, the lack of premalignant markers (although one or a few colonic polyps
may occur before colon cancer in some patientsl, and the lack of penetrance
in about 10% of gene carriers. Variable age of onset will also continue to be
a problem in clinical screening programs. Early onset of cancer requires early
screening, but persons at risk with late onset may become non-compliant if
early screening investigations are all normal.
The International Collaborative Group on Hereditary Non-Polyposis Colon
Cancer (ICG-HNPCC) has provided screening recommendations (Vasen et al
1993), including a recommendation that screening begin five years before the
earliest age at diagnosis of cancer in the family. Because some interval cancers
(cancers developing between two consecutive investigations) have been
identified when screening was every three years, the recommended timing is
two-yearly (Vasen et al 1994).
M'pping and Cloning th' Gent. for HNpCC
Mutations in the DNA repair genes, hMSH2 on chromosome 2p, and
hMlH1 on chromosome 3p, have now been shown to be responsible for
HNPCC in many families. The large well-characterized Newfoundland family
(Family CI played a key role in mapping hMSH2. Family C was large enough
to convincingly detect linkage to an anonymous marker on chromosome 2p
(Peltomaki et aI1993).
The microsatellite instability (Aaltonen et al 1993. Thibodeau et al 1993.
Aaltonen et a11994. Honchel et al 19941 found in HNPCC tumours from Family
C and other families, rather than loss of heterozygosity characteristic of tumour
suppressor genes, suggested a defective DNA repair mechanism as the
underlying genetic defect. Human homologues of the bacterial mismatch repair
genes MutS and Mutl, were the obvious candidate genes. In fact. hMSH2, the
human homologue of MutS. mapped to chr 2p16 (Leach et al 1993. Fishel et
al 19931. and specific mutations in this gene that co-segregated with the
disease phanotype have been identified in Family C and othar families (Liuet
al19941,astrikingaxampleoftheproductiveinterplayofresearchinhumans
and lower organisms. Subsequently, linkage to chr 3p (Lindblom et al 1993)
was demonstrated in HNPCC families not linked to chr 2p, and hMLH1, the
human homologue of Mutl was mapped to this region and mutations similarly
identified (Bronner et al 1994. Papadopoulos et al 19941.
It is estimated that mutations of hMSH2 or hMLH1 are responsible for
the predisposition to cancer in 80-90% of HNPCC families (Nystrom-Lahti at al
1994a). Two related DNA repair genes, hPMS1 on chr 2 and hPMS2 on chr
7. have recently been identified, with mutations of each of these genes
responsible for predisposition to HNPCC in a few families (Nicolaides et al
1994). Other genes for HNPCC may yet be identified.
H.terQR,neity Of HNpCC
Both clinical and genetic heterogeneity are seen in the HNPCC families.
Families with mutations of different genes (hMSH2. hMLH1, or the less
common genes hPMS1 or hPMS2) cannot be distinguished by a specific clinical
phenotype. At the same time, the disease expression varies both within and
between families with mutations of the same gene (Nystrom-Lahti et aI1994a).
Within one family. some family members may have early onset cancers or
multiple primaries while others have late onset cancers or non-penetrance of
the gene. This is seen in Family C. where a 27-year-old presented
symptomatically with metastatic colon cancer. and his 78-year-old grandmother
with the same mutation has had no cancer identified. Similarly. there is
variability of expression betw.een families with allelic mutations. Nystrom-Lahti
and colleagues (1994a) have recently identified hMSH2 mutations in families
previouslydescribed,becauseofthespectrumofcancersineach family, as
Lynch I syndrome, Lynch II syndrome and Muir-Torre syndrome.
Availability of Pr.dipt1v9 TAlting for HNPCC
Direct presymptomatic identification of gene carriers is now technically
possible for families with an identified mutation of hMSH2, hMLH1, hPMS1, or
hPMS2. and has been reported for a large New Zealand family (van de Water
et al 19941. Identification of the specific mutation for each HNPCC family,
however, is hampered by the number of genes involved and the variability of
the mutations so far identified. Protein truncation testing has been useful in
identifying mutations of hMSH2 (Liu et al 19941, but missense mutations
(mutations in which there is substitution of an amino acid in a normal length
protein. rather than a shortened protein) will not be detected by this method.
Although the majority of HNPCC families for whom mutations have been
identified have unique mutations (Liu et al 1994), there is an interesting cluster
Through archival research, nine of these families were shown to have a
common ancestor in the early 15OOs. The disease phenotype mapped to
chromosome 3p in several of the families and a conserved disease-associated
haplotype was identified (Nystrom-Lahti et al 1994b). When the second
HNPCC gene (hMLHl on chr 3p21) was cloned, the identical mutation was
identified in each of the fourteen families (personal communication, Dr. Albert
de la Chapelle, University of Helsinki. Finland). Another cluster of five families
in southeastern Finland with a second hMLH1 mutation has also been
Because of this founder effect, genetic screening for one or other of
these two mutations is available for the majority of Finnish HNPCC families.
It is possible that in Newfoundland a similar situation will exist, with the Family
C mutation being identified in other families. Recall that Family C was
ascertained through two independentprobands, and the extended pedigree of
a single family was constructed through archival research. Other
Newfoundland HNPCC families with ancestors from the same region of the
northeast coast are known, and may also be branches of Family C with this
same mutation. If this is the case. predictive testing for HNPCC will be
available for a greater number of Newfoundland HNPCC families.
Predictive testing has recently been arranged for members of Family C,
and when this is completed, affected members of other Newfoundland HNPCC
families will be tested for the Family C mutation.
Predictive testing by linkage analysis is possible for some other families
for which the individual mutation has not been identified, but linkage is
demonstrated to either chr 2p (Green et al 1994) or chr 3p (Lindblom et al
19931. Establishing linkage to one of the identified HNPCC loci, however. is
rendered difficult by the lack of DNA from deceased affected family members,
and the difficulty in classifying living family members due to the variable
expression and reduced penetrance of HNPCC genes. If predictive testing by
mutation detection or linkage analysis ispossibleina particular family. then the
clinical screening protocol can be modified according to the results of genetic
testing (Figure 5.101.
Figure 5.10. Management plan for HNPCC families.
Management for HNPCC is compli~ated by the clinical and
genetic heterogeneity demonstrated, the absence of
genotype/phenotype correlations which could guide clinical
screening, and the lack of sensitive and specific tests for some
of the typical cancers.
Depending on family structure, and laboratory facilities available,
linkage analysis and/or mutation analysis may be attempted to
identify the gene involved and/or the specific mutation.
Mutation analysis includes testing for "common" mutations in
the specific population and/or a mutation screen (eg, SSCP,
DGGE, PTT [Caskey 1993a, Roest et al 1993)).
Management plan for HNPCC families
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There is already demand for genetic testing for HNPCC. Originally this
was from members of large families, such as Family C, where there had been
considerable anxiety because of the frequency of cancer and early cancer
deaths. Some members of recognized HNPCC families have had previous
screening with colonoscopy and now request genetic testing to determine
whether they should continue with clinical screening. Others, who were
concerned about their risk of cancer but who had declined unpleasant
investigations such as colonoscopy "unless really necessary", also request
genetic testing. The demand has increased recently because of the publicity
surrounding the recent identification of the HNPCC genes and the suggestion
that a blood test for colon cancer was imminent (Globe and Mail 1993). Many
members of the general public, appropriately or inappropriately, now expect
that a blood test will clarify their risk of colon and other cancers.
Thirty-siX of the 54 at-risk members of Family C to whom predictive
testing has been offered, have requested this testing. All of these family
members were anxious becal!se of the frequency of cancer and cancer deaths
in their family, before the question of predictive testing was raised. The
majority find colonoscopy (and, if female, the endometrial biopsy) to be
unpleasant procedures, and would like to know whether these investigations
are necessary. It is encouraging to others in the family that three family
members with early colon cancer, and one with endometrial cancer, identified
by clinical screening, have done well.
Even for families where presymptomatic diagnosis or predictive testing
is now possible, there are many social, ethical and legal questions to be
answered before genetic testing becomes common usage {Assessing Genetic
Risk 1994, National Advisory Council for Human Genome Research 1994,
Danks 1994, Collins 19941. These concerns have been addressed by the
National Institutes of Health, and National Cancer Institute in the United States
of America who have recommended extensive research into the psychosocial
outcomes of the provision of genetic counselling and testing for heritable
breast, ovarian and colon cancer risks, before implementation of genetic testing
for these cancers as a general clinical service (NIH Guide 19941.
ImplicatiQnl Qf Ser"n!nq fQr HNPCC
It is important to determine the effect of early identification and
treatment of gene carriers by clinical screening on long-term morbidity and
mortality,andtoestablishprotocolsforgenetictesting,sothatbenefitscanbe
maximized and harms minimized {Collins 19941. These protocols must include
methods for education and counselling before genetic testing, for ensuring
informed consent, and for provision of follow-up, whether clinical or
psychological,tothose with increased or decreased risk of cancer. Thereare
fears that there will be discrimination (Billings et al1992b, Ostrer et al 1993),
particularly in terms of employment or insurance coverage (less of a problem
in Canada than in the United States, but still a concern), or stigmatization with
"cancer" risk (which engenders fear in many individuals), without significant
benefit from early diagnosis and treatment. The benefit from clinical screening
is yet to be determined, but it is recognized that HNPCC differs from FAP
where there is a more consistent natural history, with a premalignant marker
(multiple polYPsl and fewer potential tumours, and therefore, a reliable clinical
screening protocol for gene carriers, and an effective prophylactic treatment.
fIIIIn1...1(pedigree/lVI-151
Patient 1. a 68-year-old male. had a history of two primary colon cancers
at ages 38 and 65. and. as well. had prostate cancer at age 67. He died at age
69 of metastatic disease from the colon and prostate cancers. One sister died
at age 54 having had two primary colon cancers. and another sister had
endometrial cancer at age 47 and was well at age 65. Patient 1 was
concerned about the risk of cancer to a third sister age 54. and particularly to
his four children ages 19-35.
fIIIln1..Z (pedigree /lV-8)
Patient 2. a 54-year-old female. had a history of two primary colon
cancers at ages 35 and 44. and endometrial carcinoma at age 43. She
subsequently developed stomach cancer at age 54. Her father died at age 54
of stomach cancer and four paternal uncles died of bowel orstomachcancer
at ages 29. 32. 33 and 39. She had one brother age 49 and four children ages
23 - 28 who were apparently unaffected. and also many more distant relatives.
including children of the deceased affected uncles. Many of these relatives
were very apprehensive about the risk of cancer to themselves or to their
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This chapter will describe the identification of five Newfoundland families
with von Hippel-Lindau (VHL) disease; the development. implementation and
revision of clinical and genetic screening programs; and the review of medical
and psychosocial outcomes of screening.
VHL is a potentially lethal autosomal dominant disorder with multiple
manifestations including benign and malignant tumours of the centralnervous
system and many internal organs. Although over thirty different manifestations
have been described. the major morbidity and monality is caused by retinal
angiomas. cerebellar and spinal cord hemangioblastomas. renal cell carcinomas
and pheochromocytomas (Melmon and Rosen 1964. Honon et al. 1976. Lamiell
et a119891.
The age at onset of VHL is variable; the mean age at diagnosis estimated
from a literature review was 24 years (Lamiell et al 19891. with age at
diagnosis ranging from infancy to the sixth or seventh decade (Jenningsetal
1988. Maheretal1990. Riling-Katz et al 1991bl. However. many patients had
not been investigated previously. and some asymptomatic patients who were
identified at a late age had advanced lesions (Glenn et al 19901. The most
common manifestations of VHL are retinal angiomas and cerebellar
hemangioblastomas. followed by renal cell carcinoma. pheochromocytomas and
spinal cord hemangioblastomas (Lamiell et ai, 1989, Maher et aI199O). but
angiomas, adenomas and cysts of many other organs also occur (Horton et al
1976. Hough et a119941.
Retinal angiomas and cerebellar hemangioblastomas. are also the most
common presenting manifestations for individual patients (Glenn et al 1990,
Maher et al 1990), often in their teens or twenties. Different large families,
however, have different patterns of manifestations. and in some families,
including the large Newfoundland family. pheochromocytomas are particularly
common (Atuk eta11979. Green et al1986, Glenn et al19911, and. in these
families. are frequentlv the first manifestation (Neumann et aI1993). Renal cell
carcinomas were thought to be a late manifestation of VHL occurring after 40
years of age (Horton et al 1976. Lamiell et al 1989. Maher et al 19901, but are
now recognized to occur much earlier (Keeler and Klauber 19921. Besides the
variability of disease expression between families. the combination and order
of occurrence of manifestations within a family is extremely variable (Jennings
et aI1988).
The mean age at death from VHL. as estimated from the literature
review, was 38 years of age (Lamiell et al 1989). The most common causes of
death are cerebellar hemangioblastoma and renal cell carcinoma (Horton et al
1976. Jennings and Gaines 1988, Sato et al1988, Neumann et aI1992). but
in families with frequent pheochromocytomas, hypertensive crisis from an
unrecognized pheochromocytoma has been a frequent cause of death (Rho
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1969, Neumann et al 19931. Retinal angiomas are a frequent cause of
blindness unless detected and treated early (Hardwig and Robertson 1984,
Ridley et a11986, Moore et a119911.
Because of the variability of VHl, and because of the advanced disease
in many symptomatic patients, screening is recommended for early
identification and treatment of individual manifestations to improve the
prognosis of the disease (Green et al 1986, Jennings et al 1988, Choyke et al
1990, Maher 1990). Early identification of gene carriers also allows genetic
counselling to be offered before reproductive decisions are made (Jennings and
Gaines 1988, lamiell et a119891.
A large VHl family from the Bonavista Peninsula of Newfoundland was
identified in the early 1980s when several sisters were referred to the ocular
genetics clinic at the General Hospital, St. John's. Individual family members
had previously seen a number of different physicians when symptomatic but
the relationship of the different presenting symptoms was not well understood
by the family members or their physicians, and coordinated follow-up had not
been arranged for early detection of subsequent manifestations in those already
affected, or for review of first degree relatives. Many of the patients had
advanced disease at the time of diagnosis, and morbidity, including blindness
or neurological deficit, and early deaths were common. Pheochromocytomas
were more common in this family than in most families reported in the
literature, and were a frequent cause of death (Rho 1969, Green et aI1986).
Cerebellar hemangioblastomas were less common than in most families in the
literature. and renal cell carcinoma reported in only one patient. Besides the
medical problems, there was a great deal of anxiety. psychological stress, and
mistrust of the medical system in affected and unaffected family members
because of the deaths and disabilities caused by VHL (Hogan and Sparrow
1972).
Several smaller Newfoundland VHL families were subsequently identified
(see Appendix A, p. 3611. Screening was recommended to improve the clinical
management for these families. Since the location of the VHL gene was
unknown at that time. genetic screening was not possible, but a clinical
screening protocol was developed based on the frequency and age of onset of
manifestations from the literature review and the initial medical record review
for the families. The screening protocol, using clinical examination and
biochemical or radiological investigations to detect the common manifestations
of VHL at a presymptomatic stage, was offered to all affected and at-risk
members of the Newfoundland families over three years of age. Patients with
positive screening tests were referred for diagnostic investigations and. if
necessary, for surgery. Annual screening for subsequent manifestations
resumed following the investigations or treatment.
The clinical screening program has been monitored continuously and
adapted as necessary as data on the natural history of the disease in the
Newfoundland families accumulated, and as new investigative procedures
Although the VHLscreening program was originally developed to improve
the clinical management of family members, the objectives of the program were
early identification of those who are affected to allow informed
reproductive decisions
early identification of specific manifestations to facilitate early
treatment or intervention and to reduce the morbidity and
mortality associated with advanced disease
genetic counselling for affected and at-risk family members to
increase the understanding of all features of VHL disease
collection of data to allow refinement of the screening protocol.
The large Newfoundland family was included in collaborative studies
which localized the gene for yHL to chromosome 3p25-26 in 1988 (Seizinger
et al 1988), but closely-linked informative markers have only been available for
genetic screening since 1991 ISeizinger et al 1991, Glenn et al 1992, Maher
et aI1992). Predictive testing by linkage analysis for the Newfoundland VHL
families was developed in collaboration with Dr. Eamonn Maher at Cambridge
University, Cambridge, UK, and was underway when the VHL gene was
identified and cloned in May 1993 (Latif et al 19931. The specific mutation
responsible for the disease in many families. including three Newfoundland VHL
families. has been identified (Crossey et al 1994. Whaley et al 1994. Chen et
a119951. For these families it is now possible to directly identify those with the
VHL mutation and provide clinical screening for mutation carriers only. sparing
family members without the mutation.
As with other hereditary tumour syndromes there are concerns about the
ethical. legal and social issues associated with this type of screening(Motulsky
19941. It is necessary to weigh the benefits against the possible harms which
might result from VHL screening programs before recommending their general
implementation. As a preliminary approach to review these issues. affected and
unaffected members of VHL families who have participated in the clinical and
genetic screening program were questioned about their views on the benefits
and costs of this program.
An initial description of the natural history of VHL in the large
Newfoundland family and recommendations for clinical screening were reported
previously (Green et al 1986. Green et al 1991 I. This chapter will review the
clinical screening that has been ongoing for over 10 years. the genetic
screening more recently implemented. and the attitudes of family members
towards this screening. The follOWing chapter will evaluate the costs and
benefits of the overall VHLscreening program.
Aac.mlnm.nt Qf Famill••
Five families with von Hippel-Lindau disease have been identified in
Newfoundland. A large family (Family Al from Bonavista Bay, ascertained in
1982, had 24 affected members, some of whom lived in Ontario. Two smaller
families, one from Trinity Bay, and the other originally from Nova Scotia had
three and four affected members respectively, and two other families from Bay
d'Espoir and central Newfoundland had only one definitely affected member
each {Appendix A, p. 361-31.
D.yt'opm.nt and 'mpl.mtntltign Of ellniS" Sq,.ninq
The pedigree studies and initial medical record review to identify affected
and at-risk family members had been completed for Family A in the mid 1980s.
A screening protocol was then developed by a group of specialists (internist,
pediatrician, ophthalmologist, neurosurgeon, radiologist and geneticist) using
the frequency and age at diagnosis of VHL manifestations from a literature
review and from the medical record review for this family as the guidelines for
the type and timing of investigations {Figure 6.11. This screening protocol,
including annual investigations from age three, was implemented for affected
and at-risk members of Family A wishing to participate, and records were kept
of the results of all screening tests. The frequency and age at diagnosis of
Figure 6.1. Clinical screening protocol for von Hippel-Lindau disease.
The clinical screening protocol has been revised as necessary, as
new information on the natural history of VHL, or new
technology became available. The protocol shown was used
from 1986-1994. Since 1994. MRI (instead of CT scan) has
been used to screen for cerebellar hemangioblastomas, and CT
scan of the abdomen (instead of renal ultrasoundI has been used
to screen for renal cell carcinoma.
CUNICAL SCREENING PROTOCOL FOR VON HIPPEL-UNDAU DISEASE
Eye examination with indirect ophthalmoscope annually for those at risk.
and at least every 6 months for those who are affected.
(TREATMENT: laser or cryotherapy)
Annual examination by internist or pediatrician
full physical examination with BP lying and standing
24-hour urine collection for urinary catecholamines and
metanephrines
plasma catecholamines if increased blood pressure or
postural hypotension found but normal urinary
catecholamines
abdominal CT and MIBG scans if biochemical abnormalities
found
(TREATMENT: surgery after adequate blocking)
Annual neurological examination with particular note of any cerebellar
signs
baseline CT or MRI scan in early teens
CT or MRI scan repeated if any suspicious neurological
findings
!TREATMENT: surgery when recommended by the neurosurgeon)
Annual ultrasound of kidneys starting in the teens for evidence of cysts
or renal cell carcinoma.
CT scan of kidneys if any abnormalities seen
Annual CT scan of abdomen for those with previous renal
cell carcinoma
(TREATMENT: surgery for renal cell carcinoma)
manifestations in Family A. initially and after 3 years of screening, have already
been reported (Green et al 19861.
The screening program was expanded to include the other VHL families
as they were identified. When each family was ascertained, family members
were interviewed by Jane Green to extend the pedigrees, and consent was
obtained for medical record review to identify affected and at-risk family
members. Retrospective information was collected from medical records for
each affected individual on the type and age at diagnosis of each manifestation.
reason for diagnosis (screening or symptomatic), treatment given, and outcome
of treatment. Age and cause of death were documented when appropriate.
Genetic counselling was provided for each affected and at-risk family
member by Jane Green. This counselling included a discussion of the features
of VHL, the age at which these might occur, and typical symptoms which these
manifestations might cause; the inheritance pattern and riskofrecurrenceof
disease; and the recommended screening protocol. Similar information was sent
to each family doctor, and a pamphlet was written for family members for
reference. Copies of the protocol and pamphlet were sent to family members
in other provinces when requested.
Appointments were made for the set of investigations for affected and
at-risk family members wishing to participate in the screening program.
Prospective records were kept of the results of all screeningtests, and of the
follow-up investigations and any treatment required when screening tests were
abnormal. The age at diagnosis of each manifestation and the order in which
manifestations occurred were recorded for each affected family member. The
outcome of treatment, and age and cause of death of those who died were also
recorded. Record of the date of each appointment was leept so that those with
normal test results, and others following treatment, could be recalled annually
for repeat screening investigations.
Recently, the appointments have been made as required by one of the
secretaries in the Faculty of Medicine, Health Sciences Centre, St. John's, who
also notifies the family members of the appointment times.
Qtytlgpm.nt Qf G.Ottlc; SCAlDing
In 1992, after the VHL gene was mapped and closely-Iinleed flanleing
marleers identified (Glenn et al 1992, Maher et al 19921, genetic counselling
about predictive testing by linleage analysis was given to each family member
involved in the clinical screening program. This counselling included a
discussion of the method oflinleage analysis, the possible results (high-risle,
low-risleoruninformativel,andanyrevisionsoftheclinicalscreeningprotocol
which would occur because of each possible result. The importance of haVing
blood samples for DNA extraction from affected family members and spouses
was stressed. A pamphlet on predictive testing was written and provided to
family members to reinforce this information.
Consent was obtained from all those wishing to participate in predictive
testing for themselves or for their children, and a blood sample was obtained
for DNA extraction in Dr. Roger Green's laboratory at the Health Sciences
Centre. Arrangements were made for predictive testing by linkage analysis to
be carried out by Dr. Maher, Cambridge University. At the time, there were
only two children at risk under 10 years of age; they were not yet participating
in clinical screening, and predictive testing was not offered to them.
Sixty-one DNA samples were collected from members of families A, B,
C and E, including 15 samples from affected family members and 33 from
those at 50% risk, and these samples sent to Dr. Maher. Initially, RFLP
markers flanking the VHL map location were used (including 03S18, 03S601
and 03S1250) (Table 6.1), and later a microsatellite marker, 03S1038,
identified by Dr. Maher's laboratory, was included. Marker allele data on all
When the VHL gene was cloned and the specific mutation identified in
Family A (a C-T missense mutation at base pair 712 which converts an
arginine to a tryptophan and abolishes a restriction enzyme cutting site
[Crossey et al 199411, detection of gene carriers by direct mutation analysis
was possible in this family. Family members were notified that a direct test for
the VHL gene mutation could be done, and further genetic counselling was
given about the method of testing and the implications of the possible results.
A consent form was signed by those who wished to proceed with this more
TABLE 6.1. CHARACTERISTICS OF RFlP AND MICROSATElllTE
MARKERS USED FOR PREDICTIVE TESTING BY LINKAGE
ANALYSIS IN VHl FAMILIES
lOCUS
03518
035601
035601
0351038
0351250
c-llB-7.1
LIB 19-63
C13-946
c-lIB-56
RESTRICTION
ENZYME
BgllI
Taq1
AllELE
SIZES
8.7,4.7
15.4,13
4.3,3.9
2.8,1.2
FREQUENCY OF
HETEROZYGOSITY
0.43
0.42
0.5
'Microsateliitemarker(CArepeati
Reference: ~=s-:ta~I"~~;
definitive testing. This included family members who had previously been given
results of predictive testing by linkage analysis, and others who had not yet
been tested. The direct mutation analysis was also carried out in Dr. Maher's
laboratory, and results were sent to Jane Green for delivery to family members.
The mutations in Family B (a 2bp deletion in codon 2011, and in Family
C (a G-A transition at base pair 7131 have now been identified (Crossey et al
19941 and direct mutation detection is underway for five at-risk members of
Results of predictive testing by linkage analysis or direct mutationtesting
were given individually to family members in a counselling session, either in
their own homes or at the General Hospital, St. John's.
R.yi'w Qf Sc;r••ning Prggr.m
Todeterminewhetherascreeningprogramshouldbecontinued,revised,
or discontinued, the outcomes of the program should be reviewed. Long-term
follow-up of many families being screened is required in order to demonstrate
statistically significant differences in morbidity and mortality because of the
screening program. It is valuable, nevertheless, to review the program on an
ongoing basis to provide preliminary data: on the screening process, on the
medical and psychosocial outcomes, and on the costs associated with the
program. Revisions to the screening protocol can then be made as new
information and new technology become available, and hypotheses can be
generated. particularly regarding psychosocial outcomes. for more rigorous
testing in a larger number of families and over a longer period of time.
$cre@ninqprotocQI
The specialists involved with the VHL patients met in October 1994 to
review and revise the clinical and genetic screening protocols. Jane Green
provided a summary of the results of clinical screening (see medical outcomes).
and also an overview of genetic screening methods including the possible
results of this screening and the availability of the different methods for the
Newfoundland VHL families. The projected direct costs of clinical screening
with or without the implementation of genetic screening were estimated and
presented (see direct costs). The radiologists reported on the acquisition of
new imaging equipment, including a Magnetic Resonance Imager (MRI) and a
newCTscanner.
MAdjcalglJ!COrnft$
To determine the effect of the clinical screening program on medical
outcomes. the types of tumours detected. the age at diagnosis. the severity of
disease. the type and outcome of treatment. and the age and cause 0 fdeath
were compared for two groups: those who had been identified because of
symptoms, and those who had been identified by screening.
iii) PSYGhoSQcial Qll!cOrnft$
To determine the effeet of the clinical and genetic screening programs
on the well-being of family members. 15 affected and unaffected family
members were interviewed individually about the psychological and social
implications of VHL disease and of the screening program, for themselves and
for other members of their families. The individuals interviewed included males
and females. in both reproductive and post-reproductive age groups. Although
the interviews were only semi-structured, the topics covered (Appendix B, p.
364-51 included:
knowledge and understanding of the disease and of screening
methods;
compliance with screening recommendations;
anxiety and stress because of the disease or because of
screening;
support systems available;
financial implications of the disease and of screening;
discrimination because of the disease;
effect of the disease, or of the availability of genetic screening on
reproductive decisions;
quality of life before and after the screening program began.
These interviews were taped and reviewed to identify common-themes
brought up by different family members. The interviews were supplemented by
relevant information documented during counselling sessions or telephone calls
with affected and at-risk family members over the duration of the screening
program. This method of assessment of psychosocial outcomes was chosen
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(after discussions with Dr. Michael Murray. Division of Community Medicine.
Memorial University of Newfoundland), because of the relatively small number
of family members available. and the preliminary nature of this review.
iv)~
To determine the effect of genetic screening on the direct costs 0 fthe
screening program. the annual costs and projected lifetime costs of clinical
screening for at-risk family members before and after genetic testing was
introduced. were compared.
AlG'minmlnt of Faroili••
One large and 4 smaller VHL families (Figure 6.2) have been identified in
Newfoundland. from different geographic regions of the province. or originally
from another province (Figure 6.3). At the time of ascertainment of the
families. there were 33 affected individuals identified through medical record
review (24 of whom were in Family AI. and 76 first degree relatives at 50%
risk. The mean age at diagnosis was 28 years of age. and all but three patients
were symptomatic at the time of diagnosis. Sixteen of the 33 affected
members had unilateral or bilateral blindness. Sixteen of the 33 affected
members were deceased at a mean age of 37 years (all. except one accidental
death. asaresultofVHLdisease).
Rgure 6.2. Pedigrees of Newfoundland VHL families with manifestations for
each family member.
The common VHL manifestations (retinal angioma,
pheochromocytoma, renal cell carcinoma, cerebellar and spinal
cord hemangioblastoma, and pancreatic islet cell tumour) are
present as indicated by the key. Less common manifestations
(indicated as ·other manifestations·) include AV malformation of
the colon, liver angioma, stomach angioma, carotid body tumour,
cerebral hemangioblastoma, and chordoma.
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Figure 6.3. Geographic distribution of Newfoundland VHL families.
Geographic distribution of Newfoundland VHL families
LABRADOR
ApB at diagnosis and frAQ'Jftncy of manifestations
Since 1982, 21 others 118 from Family AI have been identified as
affected; 19 by the clinical screening program, at a mean age of 16 years, and
2 symptomatic patients age 26 and 49 years. Thus the clinical screening
program resulted in a shift to an earlier age at diagnosis; the mean age at
diagnosis in the screened group was 16 years, compared to 28 years of age in
the previous symptomatic patients IFigure 6.4). This shift to a younger age at
diagnosis is expected to increase, since many of the screened group were
identified at their first investigation, with m-anifestations which would have
been present for some time.
(Table 6.21. In families A and C where pheochromocytomas are frequent,
22/45 family members 149%1 presented with pheochromocytoma at a mean
age of 20.2 years. Twenty-one of 45 147%) presented with retinal angioma
(mean age 21.5 yrs), one presented with cerebellar hemangioblastoma and one
with renal cell carcinoma. In families B, 0 and E where pheochromocytomas
havenotbeenidentified,40f6patientslwhererecordsareavailabIe) presented
with cerebellar or spinal cord hemangioblastomas, and the other patients with
retinal angioma, and with renal cysts.
Since 1982, a total of 96 tumours have been identified as initial or
subsequent manifestations of VHL, 88 of these by screening, and 8 because
Figure 6.4. Cumulative age at diagnosis of VHL in symptomatic and
screened patients.
Before 1982, 30 VHL patients were identified because of
symptoms, at a mean age of 28 (range. 5-55 yrs; SO, 12.051
90% of these patients were identified by age 41. Since 1982,
19 VHL patients were identified by screening, at a mean age of
16 (range, 9-28 yrs; SO, 3.72). Ninety percent of these patients
were identified by age 26. The age at diagnosis by screening is
expected to decrease. since90f19wereidentified as affected
at their first investigation. For comparison, the cumulative age
at diagnosis of 538 VHL patients from the literature is also
shown.
Cumulative age at diagnosis of VHL in symptomatic
and screened patients
~:~~TUREREVIEW -
NEWFOUNDLAND
-SYMPTOMATIC - - - - -
N = 30; xage,28; SD,12.0S
-SCREENED
N = 19; 5i: age.16; SD.3.72
41yrs
30 40
AGE (YEARS)
TABLE 6.2. INITIAL MANIFESTAnON OF VHL IN NEWFOUNDLAND
FAMIUES
NUMBER. AND AGE AT DIAGNOSIS
Number (age)
Family A Family B Family C Family D Family E
Retinal angioma 20(X.21.3)·' 1 (32) 1 (27)
Pheochromocytoma! 19(X.21.1)·2
Paraganglioma
Cerebellar 1 (22)
Hemangioblastoma
Spinal Cord
Hemangioblastoma
Renal Cysts
Renal Cell
Carcinoma
Total Affected in
Family
Range:6-28yra.
Range:9-47yrs.
2 (15.30)
1 (27)
3 (11.17,17)
1 (48)
1 (35)
1(18)
of symptomatic presentation (Table 6.31. Although this is an increase in the
numberoftumoursdeteeted,thediagnosisforthemajorityofthesewasatan
earlier, presymptomatic stage than for the tumours identified before 1982.
In 1992, family A had 42 affected members identified, of whom 30 were
living (mean age of 32 years), and 50 first degree relatives at a priori 50% risk.
(The numbers of affected and at-risk family members are constantly changing
as new diagnoses are made and a new group at risk identified, orasgenetic
screening excludes family members from at-risk status).
Retinal angiomas (70%) and pheochromocytomas (67%) are the most
common manifestations, and frequently the first manifestations diagnosed in
this family (Table 6.4) (and also in Family C, originally from Nova Scotia). Renal
cell carcinoma, which had been identified in only one member of Family A prior
to 1986, is now present in 36% of affected individuals, and also in one
member each of Family 8 and Family C. Cerebellar hemangioblastomas (24%1
and spinal cord tumours (14%1 are less common manifestations in Family A,
but are frequent manifestations in Families Band C.
Morbidjtyandmprtality
At the time of ascertainment of these families, 16 of 33 affected
members were deceased at a mean age of 37 years (range 18-55 years). Only
two patients have died since 1982; one, age 49. who had a malignant
pheochromocytoma at the time of diagnosis. and one. age 28. who presented
symptomatically in 1981 with a cerebellar hemangioblastoma. and died in 1986
TABLE 6.3. DETECTION OF VHL MANIFESTATIONS IN FAMILY A SINCE
1982. BY CLINICAL SCREENING AND BY SYMPTOMATIC
PRESENTATION
METHOD OF IDENTIFICATION
BY SCREENING
MANIFESTATION Initial Subsequent
Diagnosis Manifestation Recurrence
Retinal Angioma
Pheochromocytoma
Hemangioblastoma
Cerebellar
Spinal Cord
Renal Cell
Carcinoma
Pancreatic Islet Cell
Tumour
SUBTOTAL
TOTAL 1961
33
TABLE 6.4. FREQUENCY OF MAJOR CLINICAL MANIFESTATIONS OF VHL
IN AFFECTED MEMBERS OF A NEWFOUNDLAND FAMILY,
AND IN A LITERATURE REVIEW
FREQUENCY
LITERATURE
REVIEW'
NEWFOUNDLAND
FAMILY A
Age at diagnosis
(yrs)
Median (Range)
Retinal angioma
Cerebellar
hemangioblastoma
Pheochromocytoma
Spinal cord
hemangioblastoma
TOTAl NUMBER OF
PATIENTS
70(30)
25 (111
36 (15)
67 (28)
14 (61
(5-42)
(15-55)
(19-55)
(9-55)
(16-55)
of complications of VHL and a concurrent illness (Table 6.51. The majority of
patients. however. have multiple manifestations of VHL. with development of
subsequent tumours following successful treatment or surgery for the initial
tumour (Table 6.6, Figure 6.51. The effect of the screening program on the
medical outcomes related to the different manifestations is described in the
following sections.
al~
Before 1982, eleven patients in family A developed unilateral or bilateral
blindness because of untreated retinal angiomas. Since 1982, small retinal
angiomas detected by annual screening have been successfully treated with
laser or cryotherapy in 18 patients, some of these patients having multiple
recurrences. However, three patients, who were asymptomatic but had large
or multiple angiomas when first examined, developed inoperable retinal
detachments several years after treatment. and have progressed to unilateral
b) PbIQ!jhrgmgsytgm.
Prior to 1982. five oJ 10 deaths in Family A were a result of a
hypenensive crisis from an unrecognized pheochromocytoma and one death in
Family C was the result of a malignant pheochromocytoma. Since 1982,
twenty patients with unilateral or bilateral pheochromocytomas or
paragangliomas detected by screening have had the tumours successfully
TABLE 6.5. AGE AND CAUSE OF DEATH OF AFFECTED MEMBERS OF
NEWFOUNDLAND VHl FAMILIES
NUMBER. AND AGE AT DEATH
Family A
Cerebellarlspinalcord 2 [39.501
hemangioblastoma
Pheochromocytoma
-hypertensive crisis 5[18-551
Number (age)
Family B Family C
3 [21,30,481
-malignancy 1 [491
2 [21,491
2 [28.29)"1."2
1 [311
1 [481
1 [20)"3
-'sepsisandaddisoniancrisis
-'accidental
'3 chordoma
TABLE 6.6. NUMBER AND COMBINATION OF MANIFESTATIONS IN
VHL PATIENTS (FAMILY AI
MANIFESTATIONS
Number/Combination
One'
RA
PHEO
RA, PHEO
RA, RCC
RA, CERES
PHEO, RCC
Three
RA, PHEO, RCC
RA, PHEO, SPC
RA, PHEO, CERES
RA, CERES, SPC
RA, CERES. PANC
PHEO, PANC, other"
RA, PHEO, RCC. CERES
RA, PHEO, RCC. SPC
RA. PHEO. CERES. other"
PHEO, RCC, CERES. other"
RA. PHEO, RCC. CERES. SPC 1
PATIENTS
Number(%)
12(29%)
9(21%)
10(24%)
8 (19%)
1 (2%)
2(5%)
RA - retinal angioma; PHEO - pheochromocytoma;
RCC - renal cell carcinoma; CEREB - cerebellar hemangioblastoma;
SPC - spinal cord hemangioblastoma; PANC - pancreatic islet cell tumour
"stornachangioma;'2arteriovenousmalformationofthecolon
"carotidbodytumour
Figure 6.5. Age at diagnosis. order of manifestations. and age at death of
affected members of a Newfoundland VHL family.
Age at diagnosis of each manifestation. and age at death are
indicated on a time-line for each affected family member. Except
for retinal angiomas which have been multiple in all persons with
this manifestation. each primary tumour that occurred is
indicated (eg. a second pheochromocytoma. or second cerebellar
hemangioblastoma).
Age at Diagnosis, Order of Manifestations, and Age at Death of
Affected Members of a VHL Family
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removed after pre-operative alpha-adrenergic blockade. The youngest of these
was nine years old at the time. One patient lin another province) with long-
standing intractable hypertension had a malignant pheochromocytoma at the
time of diagnosis. and died ofrnetastatic disease.
c) 8.n.'c;I"GI,cinpm.
Renal cell carcinoma had only been detected in one patient prior to 1982.
as a coincidental observation at autopsy in a 55-year-old man with multiple
manifestations of VHL. Since 1986. renal cell carcinomas have been identified
by ultrasound screening in 14 previously affected individuals. 19-45 years of
age. All were treated surgically with partial or total nephrectomy. None had
metastatic disease at the time of surgery. but 6 have had asubsequenttumour
in the second kidney and 4 of these have only part of one kidney remaining.
Because onset of renal cell carcinoma was found to beearlierthanexpected.
the screening protocol was revised. with ultrasound of the kidneys being
introduced in the early rather than the late teens.
d) C'rAblne, .nd ,pin,' end h,mlngigbl"'gml
In the past. two of 10 deaths in Family A. and all three deaths in Family
B for which medical records are available. were due to inoperable cerebellar or
spinal cord hemangioblastomas. Since 1982 five patients had cerebellar
hemangioblastomas detected by screening. Three of these patients have had
successful surgical removal of the tumour. and the other two are being
monitored. Three other patients in families A and B (two in Newfoundland and
one in OntarioI had cerebellar hemangioblastomas identified afterpresentation
with symptoms of headache or ataxia. All have had surgery. The patient in
Ontario is on long-term disability because of his post-operative neurological
Four patients in Family A presented with symptoms of a spinal cord
hemangioblastoma. subsequently confirmed by CT scan or MRI. Two are being
followed by the neurosurgeon. and two have had surgical removal of the
tumour. One of these. living outside of Newfoundland. had late investigation
of symptoms. He required lengthy rehabilitation following surgery and has some
neurological deficit remaining.
In two families with no previous family history of VHL. spinal cord or
cerebellar hemangioblastomas were identified in each proband only after
advanced disease had developed. The proband of Family E. an 18-year-oldgirl.
presented with decreased vision. Five cerebellar hemangioblastomas were
identified and removed. however, she has bilateral blindnessbecause of optic
atrophy secondary to the papilloedema which had developed prior to removal
of the tumors. The proband of Family D. a 40-year-Old. had a stroke-like event
when terminally ill with "polycystic kidney disease". A spinal cord
hemangioblastoma was identified at autopsy.
Before the availability of MRI. screening for spinal cord
hemangioblastomas was not possible. CT scanning was appropriate for
investigation of symptoms. but not for screening. because of the amount of
radiation necessary for visualizing the whole spinal cord. Forthosewithinthe
VHL screening program, however. symptoms were recognized and investigated
at an earlier stage than for those at risk who were not closely monitored, or for
members of new families where the risk was not known.
GIO.tiS Serlln'op
Twenty-four at-risk members of Families A, Band C (age 12-531 with
negative clinical screening results participated in predictive testing by linkage
analysis. Twenty of these received low-risk results « 2% risk of inheriting the
VHL gene from the affected parent); three (ages 12. 13, and 251 received high-
risk results (>98% risk of inheriting the VHL gene); and one, age 15, had an
uninformative result (Table 6.7. Figure 6.6a and 6.6b).
ThefreQuencyofclinicalscreeningwasreducedt03-5yearintervalsfor
the twenty family members who received low-risk results. Continued annual
screening was recommended for the four family members with high-risk or
uninformative results.
p;rectml,tatjooana'YJj,
Twenty-eight members of Family A, including all those with previous
predictive testing by linkage analysis. participated in direct mutation analysis
after the VHL mutation was identified in this family (Table 6.8, Figure 6.7a and
TABLE 6.7. RESULTS OF PREDICTIVE TESTING FOR VHL BY LINKAGE
ANALYSIS
AGE
(VRS)
<10
10-20
21-30
>30
• >98% risk
•• <2% risk
NUMBER
TESTED
HIGH
RISK·
1.0W
RISK··
Figure 6.68. Pedigree of Family A with results of predictive testing for VHl by
linkage analysis.
The pedigree is simplified compared with Figure 6.2, to
emphasize family members who participated in genetic testing.
The alleles for the three chromosome 3p markers used (03518,
035601,0351038) are arranged in haplotypes and indicated for
each family member tested. Inferred genotypes are given in
brackets. The haplotype inherited with VHl is indicated by a
box.
There has been a cross-over between 035601 and 0351038 in
one branch of the family. Allele "1" co-segregates with VHl in
the branch of the family at the left; allele "3" co-segregates with
VHl in the rest of the pedigree. 5ix of 11 affected family
members tested for all three chromosome 3p markers were
homozygous for alleles at 03518 and 035601. Only 0351038
was informative in these persons.
Family members with high-risk (n=3), low-risk (n=16I, and
uninformative (n=1) results are indicated.
MARKERS ALLELES
03S18(c-L1B-1) 4.7,8.7
(VHL)
035601(19-63) 3.9,4.3
0351038(946) 1-8
~
•• affected
6 6 screenedclinicall
J21' o deceased
EJ <:) predictedaffectlll
[] @ uninformative
~
• affected
6 screened clinically
0deceased
o predicted affected
o uninformative
Figure 6.6b. Pedigree of Family A (enlarged) with results of predictive testing
for VHL by linkage analysis.
One branch of the pedigree is enlarged to demonstrate the high-
risk, low-risk, and uninformative results more clearly.
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TABLE 6.8. RESULTS OF PRESYMPTOMATIC DIAGNOSIS FOR
VHL BY MUTATION ANALYSIS
AGE
(YRS)
NUMBER
TESTED
MUTATION- MUTATION
POSITIVE NEGATIVE
o
10-20 10
21-30 7
>30
Figure 6.78. Pedigree of Family A with results of presymptomatic diagnosis
of VHL by mutation detection.
A direct mutation test was possible for Family A. when a C-T
transition at bp 712 of the VHL gene was identified. This
mutation abolishes an Msp1 restriction site.
The same pedigree as in Figure 6.6a is used to demonstrate the
results of direct mutation analysis. Presence of the mutation is
~~~icated by • +. and absence of the mutation is indicated by
MARKERS ALLELES
03S18(C-L1B·1) 4.7,8.7
(VHL)
03S601(19-63) 3.9,4.3
03S1038(946) 1-8
~
• • affected
tJ 6 screened clinically
JZ10deceased
• affected + mutation positive
) screened clinically - mutation negative
Jdeceased * predicted affected
Figure 6.7b. Pedigree of Family A (enlarged) with results of presymptomatic
diagnosis of VHL by mutation analysis.
As in Figure 6.6b. one branch of the pedigree is enlarged to
demonstrate mutation-positive and mutation-negative results
more clearly.
The family member with uninformative results by linkage analysis
did not inherit the VHL mutation. The 25-year-old man with
high-risk linkage analysis results also did not inherit the VHL
mutation (confirmed on two separate DNA samples). Because
DNA was not available from his mother who died many years
previously(seetextl,hishigh-risklinkageresultswerebasedon
inheritance of the same allele from his mother as his affected
sister. His mother could have been homozygous for this allele, or
a cross-over could have occurred.
~i
• ~ -as
• l;::~~l
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6.7b). Twenty-four of those tested, age 11·53. did not have the VHL mutation.
This included the 25-year-old with high-risk linkage analysis results. Four. ages
13-15. did have the mutation. These four have all been screened clinically for
8-10 years with negative screening results so far. The proportion of gene
carriers identified by genetic testing (4/28) is much less than 50% because of
the prior identification of many gene carriers by symptomatic disease or by
clinical screening.
Because of the significance of these predictive testing results for medical
management and reproductive decision making, the mutation analysis is now
being established by Dr. Peter Bridge in St. John's. and all testing is being
repeated with a second DNA sample. Clinical screening will no longer be
required for those confirmed negative for the mutation. Those who are
confirmed to have the mutation will require life-long clinical screening, as will
all of those previously identified as affected by screening or by symptomatic
disease. and any family members who decline predictive testing.
CO!tofCljnleaIScra·ninq
Although two of the goals of the screening program (early diagnosis of
VHL. and early identification and treatment of individual tumours) were being
fulfilled by the clinical screening protocol. the costs to both the health care
system and to individual family members were high because of the number of
investigations required and the number of family members at risk. When
closely-linked flanking markers became available, and laterthegenewascloned
and the mutation identified in three of the Newfoundland families, predictive
testing to identify gene carriers by linkage analysis or mutation detection
became possible. One result of this predictive testing was the reduction in the
number of family members requiring clinical screening.
The cost of clinical screening before and after the availability of genetic
screening can best be evaluated in Family A because the majority participating
in clinical screening are from this family, and only members of this family have
so far received results of mutation analysis.
Forty-two affected members and 50 first degree relatives at 50% risk
had been identified in Family A by 1992 prior to the availability of predictive
testing for VHL. Thirty-one of those at 50% risk lived in Newfoundland, and
participatedregularlyintheclinicalscreeningprogram. Twenty-eight of these
havenowhadpredictivetestingforVHL.
The average cost per person, in 1994, o.f the annual set of investigations
recommended by the VHL clinical screening protocol was $288.00. Before
genetic testing was available, annual clinical screening was recommended for
everyone at risk from age 3 until at least age 50. The lifetime costs of basic
screening for each person at risk were therefore estimated to be at least
$13,800 <using 1994valuesl. Based on their present ages, the projected cost
for the remaining annual screening for these 28 family members was
$186,010. Genetic screening has identified that 24 of the 28 are not gene
Therefore. $145.690 of this cost would have been spent
unnecessarily on those without the VHL mutation (Table 6.91. Costs of the
investigations. however.-are only a portion of the total costs of screening and
management of VHL families. A more extensive discussion of direct and
indirect costs of VHL care and management. before and after screening was
introduced. is presented in the following chapter.
p'YGhO,Qcl.llmp'c;tgfVHLPJ,••,.
From structured interviews with 15 family members. and conversations
during counselling sessions or phone calls with 15 others. it is clear that there
is stress and anxiety associated with the VHL screening program because of
the even greater stress and anxiety caused by VHL itself (Langsley et al 1964.
Yuen et a119841. Even before family members knew the name of the disease
within the family. they were aware of and very apprehensive because of the
early and sudden deaths. the progressive and disabling neurological disease.
and the severe visual loss in many relatives. Those who were already affected
were afraid of developing subsequent manifestations. or of their children also
being affected. and unaffected family members worried that they would be
next to develop some expression of "the disease".
In the past. family members were distrustful of the medical care
system because of the poor outcome of treatment for many affected individuals
(although this was frequently because of severe disease at the time of
TABLE 6.9. ESTIMATED COST OF CLINICAL SCREENING FOR AT·RlSK
FAMILY MEMBERS BEFORE AND AFTER GENETIC TESTING
Cost of annual set of investigations"
Lifetime cost of annual screening from
age 3 to age 50 (at 1994 ratesl
Cost of remaining screening for 28
family members who participated in
genetictesting'2
Cost of remaining screening for 4 gene
carriers identified"2
Savings if 24 non-carriers no longer
require clinical screening
$13,824
$186,010
$40,320
$145,690
., Average cost of ophthalmology appointment, pediatriclintemal medicine appointment,
catecholamine assay, and renal ultrasound lscreeningcosts will be higher when CT
scan of the abdomen replaces renal ultrasound to screen for renal celiearcinomal.
"2 Based on present ages.
presentation and treatment). One of the benefits of the screeningprogramis
that family members now feel that the medical care system is working with and
for them. Although family members are still very apprehensive before their own
or their close relatives' screening appointments and until they receiveresults,
they have greater confidence now that problems will be identified and treated.
For the rest of the year, the majority (14f15) are able to pushthedisease and
the screening out of mind. (Over and over the comment was made, "If I didn't
put it on the back burner, I would go crazy".) One family member is unable to
do this and feels that her life is "under a cloud", or "on hold" because of VHL
The majority of family members (45f54) comply with screening
recommendations because they have seen the improvement in medical
outcomes since the screening program began. Some family members originally
resisted the recommendations for screening, eitherbecausetheydidnottrust
the medical care system which they thought had failed them in the past. or
because they were afraid of what might be found. Non-compliance is less
common now, but when it occurs is attributable to: a) fear of VHL (n =,);
b) lack of understanding or nonchalance about the disease (n=4); or
c) confidence, after years of negative test results, of not being affected(n=4).
Family members feel that they understand the medical and genetic
features of VHL better than before, and the reasons for screening. Most
(13f15) appreciate having the combination of personal geneticcounsellingand
pamphlets for reference, but a few prefer one or the other method of
information delivery.
For support, participants in the screening program primarily turn to other
family members (particularly those who are affected) who have directly or
indirectly experienced the disease. They also depend on the geneticist, and
their key specialist for support regarding medical matters, rather than their
family doctors, who they think do not have sufficient knowledge of VHL.
Persons being screened rarely turn to friends or colleagues for supportbecause
the medical and psychological implications of VHL are unknown to the average
therefore have travel costs associated with screening and treatment. Few have
insurance to cover these costs but consider them to be necessary costs.
("Screening is my life, and this money comes first.") The costs of all screening
tests (and follow-up investigations and treatment if necessary) are covered by
the provincial medical insurance plan. In a medical care system where these
costs are the responsibility of the individual (or the individual's health
insurance), there would be an additional direct financial burden to the patient.
When participants in the screening program were questioned about
discrimination, the immediate answer was that there was no discrimination
because of VHL or the screening program. (One patient looked surprised and
said that there was more discrimination because of her diabetes, than because
of -the disease".1 However. when directly questioned about insurance. family
members acknowledged that this was a problem - they cannot obtain personal
life insurance or extended health care plans once they have VHLdisease. Few
members of the Newfoundland families had group insurance through
employment because they were frequently self-employed. seasonal or part-time
employees. or worked for small fish plants without these benefits. When
applying independently for insurance. it is the disease, not the screening
program, which causes the discrimination. Because of the early age at
diagnosis of VHL (diagnosis of disease requiring treatment. not just
presymptomatic disease to be monitored). few family members would be
applying for insurance before the clinical diagnosis is made.
Although there has been no direct discrimination in terms ofeducation
or employment. one husband lost his job when he would not accept a transfer
to Labrador. He felt that this distance from the tertiary carecentreinSt.John's
VHLdiseasehashadaverysignificantimpactonreproductivedecisions
for all family members, whether affected or unaffected. Almost all family
members (18/20) thought that the disease should be stopped ("stamped out")
and therefore that those who were affected should not have children. Because
of uncertainty about who was affected (before the screening program was
introduced). some non-carriers (n=6) had chosen to have no children. Some
family members have thus had no children. or fewer children than desired.
while others (n = 61, in earlier generations when the diagnosis was made after
reproduction, regretted the number of children that they did have. because of
the occurrence of VHL in their children, or the risk that children would be
affected. The clinical and genetic screening programs now identify those who
did. or did not, inherit the VHL gene, and permit reproductive choices that were
not previously available.
None of the affected family members interviewed (0/15) said that they
would choose prenatal diagnosis and therapeutic abortion of an affected fetus.
This may be a choice in other cultures. but Newfoundlanders have been less
likely to accept this option even in situations where there is a risk of severe
congenital disease. Even though affected and at-risk family members consider
VHL to be a severe burden. the -late- age of onset made the choice of
therapeutic abortion unacceptable. and, if they had the VHL gene, they
preferred not to have any children.
In the past. the morbidity and mortality associated with VHL affected the
quality of life of all family members. Besides the direct medical problems,
psychological and financial stresses sometimes disrupted marriages or family
units. Other family units. however. felt closer because of -the common
enemy-. Overall, the screening program has made family members more
confident and hopeful about the future.
Affected family members think that the genetic testing has provided
major benefits to non-earriers because the non-carriers are freed from the need
for clinical screening and the worry about developing VHL. and can now have
children without fear of the children being affected. Those demonstrated to be
non-carriers. however. have some equivocal feelings because they are
concerned that "enjoying" their mutation-negative status would "hurt" family
members who are affected and. therefore. not so fortunate.
DISCUSSION
FlmilyChlrastlriltiGl
The Newfoundland VHL families were recognized because of the
morbidity and early mortality in mUltiple affected members of previous
generations.orinindividualprobandsofthesmallerfamilies.Theone large and
four small VHL families were from different geographic areas. four from
Newfoundland and one originally from Nova Scotia. with no apparent
connection between them (Figure 6.3). The two families with greatest
geographic proximity (from Bonavista Bay and Trinity Bay) had different clinical
features (Family A with. and Family B without. pheochromocytomas). On the
other hand. the two families with similar clinical presentation (ie. frequent
pheochromocytomasI were from different geographic regions (Family A from
Bonavista Bay. Newfoundland. and Family C from Nova Scotia). Subsequent
molecular analysis has shown that these three families each have a different
mutation. confirming their independent origin.
In family A (with 42 family members now identified as affected),
pheochromocytomas and retinal angiomas are particularly common and
frequently the first manifestations detected, while cerebellar and spinal cord
hemangioblastomas are less common than in many VHL families (Table 6.4).
The suggestion that a particular VHL family will have either
pheochromocytomas or renal cell carcinomas (RCC) (Neumann and Wiestfer
1991),andthereforethatscreeningisnecessaryforonlyoneorotherofthese
tumours. appears to be wrong (Filling-Katz and Choyke 1991a, Maher 1991).
RCC has now been identified in 36% of the affected members of Family A.
including thirteen with both RCC and pheochromocytoma.
RCC has also been identified in this family at an earlier age (mean age of
34 years; range. 19-45 years) than had been predicted by the literature (mean
age of 39-44 years in different studies [Hardwig and Robertson 1984. Lamiell
et al 1989, Maheret aI1990)). This necessitated earlier screening for RCC. A
pancreatic islet cell tumour, a less common manifestation but previously
reported clustered in a few VHL families (Fishman and Bartholomew 1979).
was identified in one 23-year"1)ld family member. Pheochromocytomas have not
been identified in family B. but cerebellar and spinal cord hemangioblastomas
are more frequent than in family A. Family C is similar to family A in the high
frequency of pheochromocytomas, but also has frequent hemangioblastomas
of the cerebellum or spinal cord, as in family B.
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Although different VHL families have different frequencies of the major
manifestations, the combination, age and order of occurrence of manifestations
varies even between individuals within a family (Figure 6.51. In all families VHL
is a complex disease; as patients live longer they develop more tumours, either
bilateral or multifocal tumours of a single type, or other types of tumour of the
VHLspectrum.
Clinical screening has been recommended for affected and at-risk
tumours because of the advanced disease present in many symptomatic
patients (Huson et al 1986). The type and timing of investigations of early
clinical screening protocols were based on the age at diagnosis andfrequency
of manifestations in individual families. Screening for pheochromocytomas was
excluded for some families in the literature because they were thought not to
occur (Neumann and Weistler 1991). However. pheochromocytomas may not
have been identified because of small family size rather than because of
absence of risk. Because of the variability of disease expression even within
families, a comprehensive screening protocol is recommended for all families
(Maher et al 19901. Particularly, the danger of an unrecognized
pheochromocytoma in a patient requiring investigations with administration of
contrast material, or possible surgery for other VHL manifestations (either of
which could precipitate a hypertensive crisis if a pheochromocytoma is
present), outweighs any savings from omitting this testing. Conversely. not
screening for RCC in a family with known pheochromocytomas may delay
diagnosis of RCC until too late for successful surgical treatment, since these
tumours rarely cause symptoms before there is metastatic disease.
The mutation has now been identified in many VHL families. Families
with pheochromocytomas are more likely to have missense mutations. and
families without pheochromocytomas to have inactivating mutations (Crossey
et al 1994. Whaley et al 1994, Chen et al 1995). If the genotype-phenotype
correlation can be more clearly defined, it may become possible to tailor the
clinicalscreeningprotocoltothespecificmutationinanindividualfamily.
RAltJIt& pfeUnicel screening
Since the clinical screening program was introduced in 1982 for the
Newfoundland families, there has been an increase in the number of tumours
identified, either as the initial or subsequent manifestation of VHL. The majority
of patients were asymptomatic at the time of diagnosis and treatment has been
successful. There has been a decrease in mortality and a decrease in adverse
sequelae such as blindness or neurological deficit. Renal cell carcinoma (RCCI
has beendeteeted at an earlier age than expected. None of the patients with
RCC have had metastatic disease, and therefore none have required
chemotherapy or radiotherapy.
The clinical screening program has also resulted in a shift to an earlier
age at initial diagnosis of VHL (the mean age at diagnosis in the screened group
was 16 years, compared to 28 years in the previous symptomatic group). This
allows reproductive decisions to be made based on accurate genetic counselling
about the recurrence risk of the disease. In previous generations, affected
members (n = 6) frequently had many children before being identified as
affected. Other family members (n =4) chose not to have children rather than
risk passing on the VHL gene, and subsequently have been shown to be non-
The mean age at diagnosis of individual tumours has also decreased
because of screening, and the timing of investigations has been revised
because of this. Initial scanning of the head and abdomen, for evidence of
cerebellar hemangioblastoma or renal cell carcinoma respectively, has been
advanced to the early rather than the late teens. Recently an MRI, which
provides better resolution for cerebellar screening and the possibility of spinal
cord screening without excessive radiation (Filling-Katz et al 1989, Nelson et
al 1991, Hoff et al 19931, has been available. The screening protocol has
therefore been revised; MR imaging replaces CT scanning for screening for
central nervous system tumours. A decision has also been made to replace
ultrasound screening of the kidneys by CT scanning now that a higher speed
CT scanner is available, giving better resolution while keeping radiation to
acceptable levels.
Thus, the goals of the screening program (early diagnosis of VHL, and
early identification and treatment of individual tumours) were being fulfilled, by
clinical screening. However, there are costs to both the health care system
and to individual family members, in order to achieve these goals. These will
be outlined here,anddiscussedindetailinthefollowingchapter.
CQ$tofplinjcal scrAAning
Clinical screening for a disease such as VHL with multiple manifestations,
variable age of onset, and variable combination and order of occurrence of
tumours is expensive because of the number of different investigations
required, the early age at which screening must start, and the many years over
which repeat testing is necessary. This is acceptable clinical management
when screening improves the prognosis, as has been demonstrated with the
Newfoundland and other VHL families. However, if identification of those at
high risk is from pedigree analysis, screening necessarilyincludessomefamily
members who did not inherit the gene and therefore do not require screening,
as well as those with the gene who could benefit from clinical screening. If
identification of those at high risk is by genetic testing, the clinical screening
can be provided just for gene carriers, thus reducing the number requiring
screening, and saving money.
Monetary costs are not the onlv costs of screening (see Chapter 71,
however the potential savings in direct costs can be considerable if genetic
screening is combined with clinical screening in an overall VHL screening
program. In Newfoundland, the lifetime screening costs, for a first degree
relative who is subsequently found not to have the VHL gene, have been
estimated at $13,800/person (in 1994 dollars). This is based on the cost of
the recommended annual screening from age 3 (because of the earlyageof
onset in some patients) until at least age 50 (because of the uncertain upper
limit of age of onset) using our current screening protocol ($288/per person per
year). This means that a total of $145.690 could be saved in screening for
Family A by first identifying gene carriers and then applying clinicalscreening
to this group only (Table 6.9). With implementation of the recommendation to
use CTscan of the abdomen instead of renal ultrasound for screeningforrenal
cell carcinoma, the annual cost per person of the scanning investigations would
be $402. and the total cost of screening, and of the sum saved. proportionately
higher.
Screening investigations and their costs will change as technology
changes. and the nature of these changes cannot be foreseen, so the figure is
an estimate only. Allowance for inflation and detailed discounting of the
lifetime costs were therefor~ not done (Robinson 1993b): some costs will
increase because of inflation, others will decrease because diagnostic
equipment such as CT scanners and MR imagers is becoming less expensive,
and costs related to potential new investigations cannot be anticipated.
However, the figure presented does give an indication of the direct savings if
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family members who did not inherit the VHL gene can be identified and
excluded from clinical screening.
O,n·tiG$cr••ning
As noted previously, it became possible to provide genetic screening by
linkage analysis or direct mutation detection for individuals at risk in many VHL
families. This permits the identification of gene carriers (or high-risk individuals)
who require clinical screening, and of those without the VHL mutation (or low-
riskindividualsl who no longer required screening.
Results olgAnA!;' screening
Genetic screening was offered to at-risk members of the Newfoundland
VHL families who were participating in the clinical screening program. All of
these were over 10 years of age. Results of direct mutation detection and/or
linkage analysis have been given to 33 members of Families A, B, and C. This
genetic screening has identified VHLgenecarriers (or those athigh-riskl,and
others who do not carry the gene (or are at low-risk). The clinical screening
recommendations have been modified on the basis of these results; continued
annual screening is recommended for the gene carriers (n = 4) along with family
members previously identified clinically as affected. Clinical screening has been
discontinued for those who did not inherit the VHL gene (n = 241, and has been
reduced in frequency for those with low-risk linkage analysis results (n=5).
(The mutations have now been identified in Families Band C, and direct
mutation testing is underway for the 5 low-risk members of these families).
If genetic testing was not yet available, continued clinical screening
would be recommended for all 33 family members. Thus, the number requiring
clinical screening has been markedly reduced by the genetic testing so far
completed (only 4 of 33 at risk who were previously being screened need to
continue with annual clinical screening, and 5 others requirescreeningevery3
years). First degree relatives who do not have the VHL mutation are freed from
regular screening, with reduction in health care costs, both forthemedicalcare
system and, financially and psychologically, for themselves. The information
provided also allows all family members tested to make informed reproductive
CpmpariSQnofmethgdlgfjdentjfirzatjoo of geoAGarriers
The genetic testing results for the large Newfoundland family have also
allowed a comparison between the methods of identification of VHL gene
carriers: by symptomatic presentation, by clinical screening, by linkage analysis.
and by direct mutation detection, with direct mutation detection being
considered the gold standard.
Twenty-six members of Family A (age 5-551 presented with symptoms,
all prior to 1985. Since 1982, another 16 members (age 9-28) were identified
as affected by clinical screening. Twenty-eight first degree relatives at 50%
geneticriskbutwithnegativeclinicalscreeningparticipatedingenetictesting.
Four of these, all 13-15 years of age, were identified as gene carriers by
mutation analysis, while 24 others age 11-53 do not carry the VHL gene. In
this group that participated in genetic testing. everyone with theVHlgeneover
15 years of age had already been identified because of symptomatic disease or
positive screening tests.
There is linkage information for 20 of those for whom direct mutation
analysis is complete. For 18 of these the linkage analysis and mutation
detection results agreed: sixteen with low-risk results were later confirmed to
be mutation negative. and two with high-risk results were identified as gene
carriers (two others identified as gene carriers had not been includedinlinkage
analysis). For 2 of 20 tested (10%). the linkage information was uninformative
or misleading. One 16-year-old who was uninformative for linkage analysis
because of the combination of alleles in his parents. was later shown not to
carry the mutation. A 25-year-old received high-risk linkage results. but was
later found not to carry the mutation - confirmed on two separate DNA
samples. Because DNA was not available from his affected mother who died
many years ago. his linkage results were based on inheritance of the same
high-risk allele as his affected sister. In this situation. a recombinant event
between the marker and the VHl gene could not be detected. nor could
homozygosity of the high-risk allele in his affected mother.
This comparison of linkage analysis and mutation detection shows the
advantage of direct detection of the mutation where possible. linkage analys'is
is least reliable when not all relevant DNA samples are available. for example.
because of previous deaths from the disease in question. A false positive result
(high-risk predictive testing result in a mutation-negative individual). as in the
25-year-old patient mentioned above. would have meant continuing the clinical
screening program unnecessarily, With a potentially lethal disease. a false
positive result is much less serious than a false negative result (low-risk
predictive testing result in a mutation-positive individual), Even if clinical
screening at reduced frequency were recommended to such a person with false
negative results. it might not have been frequent enough to detect a tumour
early. or it might have been discontinued if the subtle message receivedwas
that low-risk implied being free of the disease.
Although most VHL families have a unique mutation. in three large
studies the VHL mutation has been identified in greater than 60% of families
(Crossey et a11994. Whaley et al 1994. Chen et al 1995) - a much higher
success rate than for diseases such as Martan syndrome or neurofibromatosis,
type 1 (Heim et al 1994. Sutherland and Richards 1994). If members of a VHL
family request predictive testing. it is worth searching for the specific mutation.
because of the likelihood of finding the mutation, and because of the greater
precisionindistinguishingcarriersandnon-carriersifthespecific mutation is
The comparison of genetic testing (either linkage analysis or mutation
detection) and clinical testing demonstrates that manifestations of VHL
frequently occur early. and that regular clinical screening is reliableindeteeting
presymptomatic disease (all gene carriers over age 15 in this family were
already identified by screening or by symptoms}. This is important for those
families where linkage analysis or mutation detection is not possible because
the mutation has not been detected, the family is uninformative for linkage. or
key samples are not available.
The fact that, in this family, there were no gene carriers over age 15 that
had not already been identified by clinical screening or symptomatic disease.
does not imply that every VHL gene carrier will be detected clinically by that
age. Where genetic screening is not possible, regular clinical screening must
continue much longer than this.
Variabll ApI at Qnyt Of VHL
The age at onset of VHL is variable and the upper age limit at which VHL
might initially present is unknown (Jennings et al 1988, Maher et al 1990).
Age at diagnosis in the literature ranges to the sixth or seventh decade(clinical
screening has therefore been recommended until at least 50 years of age). but
many of those with late diagnosis had not been investigated previously and had
advanced disease at the time of diagnosis (Huson et al 1986. Lamiell et al
1989). However. a 65-year-old obligate carrier of the VHL gene with negative
clinical screening. has recently been described (Davies et aI1994). From our
own experience, the latest age at diagnosis of VHL with previous negative
screening was in a member of Family B who developed a retinal angioma at age
33 and. later, a renal cell carcinoma. The variability of age at onset even within
a family is emphasized by the fact that this patient's son had a large cerebellar
hemangioblastoma identified by screening at age 15, just 4 years after his
mother's diagnosis.
In family E, there was no known family history of VHL when the 18-year-
old proband presented. However, a maternal second cousin had had
"arteriovenous (AV) malformations of the cerebellum and spinal cord." When
reviewed by the radiologist, this was considered compatible with the diagnosis
of VHL, but intervening family members were not known to be affected.
Although most were not investigated, the proband's mother, now age 54, has
been extensively investigated and has a complicated renal cyst but no other
evidence of VHL. If this is in fact an expression of VHL, she has very mild, late
onset disease. Identification of the mutation in this family will be necessary to
clarify whether anyone other than the proband isagene carrier.
In Family A, there is no evidence of reduced penetrance or late onset of
disease. Studies in other VHL families, comparing clinical and genetic screening
results and following gene carriers prospectively, are necessary to determine
the upper limit of age at onset of VHL, and the frequency with which non-
penetranceoccurs.
GAogtyp.-phlngtyp. Con"ation
In three recent studies comprising 291 VHL families (Crossey et al 1994.
Whaley et al 1994, Chen et aI1995), specific mutations have been identified
in over 60% of families, including missense, nonsense, and deletion mutations.
Over 90% of families with pheochromocytomas have missense mutations,
whereas nonsense and frame-shift mutations, and rearrangements (all
truncating mutationsl are associated with "non-pheochromocytoma" families.
There are two clusters of missense mutations at bp 505, and bp 712/713,
occurring frequently but not exclusively in families with pheochromocytomas.
However, the frequency of pheochromocytomas in families with missense
mutations varies from 0% to 70%, and pheochromocytomas are also found in
a few families with truncating mutations.
Eventually genotype-phenotype correlations mayallowtailoring ofclinical
screening protocols for carriers of specific VHL mutations. At present, a
comprehensive clinical screening protocol is still recommended for members of
p'yC;hO'QCil' Ey.lultigD
Increasingly, concerns are being voiced about the possible detrimental
aspects of screening, particularly the discrimination and psychological costs
associated with presymptomatic diagnosis for a late-onset condition (Assessing
Genetic Risk 19941. Even if predictive testing is considered appropriate, there
isaquestion as to the age at which this should be done (Harper and Clarke
1990, Working Party of the Clinical Genetics Society (UK) 19941, and there are
objections from some geneticists to any genetic testing of children. However,
others argue that the decision should be based on the age at which clinical
disease occurs. In Newfoundland, VHL, for most patients, is not an adult-onset
disease. Over 50% of patients in our families had clinical disease requiring
treatment before age 18. The demonstration that early diagnosis and treatment
improves prognosis emphasizes the value of early implementation of a
comprehensive clinical and genetic screening program.
Psychosocial evaluation of the clinical and genetic screening programin
the Newfoundland VHL families may answer some of the questions about the
relative benefits and harms of screening for VHL disease and other AD
hereditary predispositions to tumours. Many members of the families
(particularly the large family, FamilyAlhaveundergoneannualclinicalscreening
for over 10 years. and more recently have participated in genetic screening.
Detailed prospective records have been kept of the results of screening, of
follow-up investigations, and of treatment when necessary. Records of
previously affected family members were available for retrospective review.
Some older unaffected family members are still alive who remember the medical
and psychological problems ot earlier generations, and members of the younger
generation were interested and available for interviewing regarding the
psychosocial aspects of screening.
80th affected and unaffected members of VHL families consider VHL to
be a severe disease and one that should not be passed onto children. Family
members experience considerable anxiety now (and even more in the past)
because of the early deaths, disabilities, and recurring medical problems caused
by the disease. Typically they experience increased stress at the time of the
screeningappointmentsforthemselvesorcloserelativesbecause of the fear
that there will be positive results. However, they unanimously agreed that the
clinical screening program has improved their health, both medically and
psychologically, and that the genetic screening program will allow more
appropriate reproductive decisions and will free those without the VHL mutation
from financial and psychological costs associated with clinical screening.
R.cgmm,nd,d Mlnap.mlnt fgr yHL fJrnili'l
An efficient screening program for VHL (Figure 6.8) includes:
genetic testing (ideally by direct mutation detection, otherwise by
Iinkageanalysisl to identify gene carriers, and provide reproductive
counselling to both those who have and those who do not have
aVHLmutation, and
clinicalscreeningofgenecarriersthroughoutlife,usingaclinical
screening protocol based on the natural history of the disease
(revised as necessary) to identify and treat individual tumours.
Distinguishing those with the VHL gene will provide accurate reproductive
information,willconcentratetheclinicalscreeningonthosewhorequire it, and
will reduce psychological and financial costs to family members while reducing
Figure 6.8. Management plan for VHL families.
Management plan for VHL families
~ess~?~~ntscreening
.' mutations have been identified in
~,=mateIY60% ofVHL families
·'no familieshINe been identified wilh
confirmedlinlragetoanotherfocation
costs to the medical care system. Since genetic testing must be voluntary,
some family members at risk may choose not to participate.
The excess of low-risk results in the group at a priori 50% risk but with
negative clinical screening. indicates that in the families described here, there
isahighpenetranceofthegenewithrespecttodisease,andthatclinlcal
screening has been very efficient in identifying those who are affected. This
is important for families where genetic testing is not possible (eg, small
families, or those in which key individuals are deceased orunavailablesothat
linkage studies or mutation detection cannot be donel. In such fami1ies, clinical
screening can be reliably used for early diagnosis of VHL as well as for
identification and treatment of individual tumours.
PredictivetestingforVHLdiseaseinchildhoodisjustified,becauseofthe
early age of onset of VHL and therefore the early age that clinical screening is
required, and the availability of treatment particularly when tumours are
identified early. This approach is supported by the views of members of the
Newfoundland families. This is unlike the situation with Huntington disease
(Ball and Harper 1992), a late-onset and untreatable condition, but may apply
to other hereditary tumour predispositions such as the multiple endocrine
neoplasias (MEN-1 and MEN-21 and FAP, where disease onset is early and
treatment available (Working Party of the Clinical Genetics Society (UK) 1994,
Petersen et al1993, Eng et a11994bl.
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Family A:
Several sisters from the Bonavista Peninsula were referred to the ocular
genetics clinic in 1982 because of a family history of eye, brain and "kidney"
tumours. On examination, two of these sisters had retinal angiomas, and one
had previously had an adrenal tumour (pheochromocytoma). Pedigree studies
and a review of medical records indicated that 24 family members (10 of whom
were deceased) had one or more manifestations of VHL. There were 50 first
degree relatives at 50% risk, many of whom had never been investigated, and
thirty-two relatives at 25% risk. Since the implementation of the clinical
screening program in 1982, VHL disease has been identified in another 18
family members (a total of 42 members are now known to be affected). As
family members continued to be screened, subsequent tumours were identified
in recently and previously affected family members.
FamilyB:
A second Newfoundland VHL family originally from Trinity Bay was
identified when the proband, a 32-year-old man with previously treated retin;:!1
angioma, and cerebellar and spinal cord hemangioblastomas, returned to the
province from Ontario. Pedigree studies and medical record review identified
one definitely and two probably affected first degree relatives, all now
deceased: a brother who died following surgery for cerebellar hemangio-
blastoma, and his mother and sister who died of "brain tumours". Four siblings
at 50% risk and their nine children at 25% risk live in Newfoundland. One of
the four siblings and her son have now been identified as affected.
FamilyC:
A teenage brother and sister who had recently moved to Newfoundland
were referred for VHL screening because their mother had died at age 31 of a
malignant pheochromocytoma. having had a previous pheochromocytoma
removed at age' 7. Two of her brothers in Nova Scotia had VHL: one brother
was blind from bilateral retinal angiomas and has cerebellar and cerebral
hemangioblastomas. and another brother died at age 22 with multiple
manifestations including pheochromocytomas. and spinal cord and cerebellar
hemangioblastomas. The teenage brother. originally referred. has now been
identified as affected.
Family 0:
A 40-year-old female patient with ·polycystickidneys" presented toa
central Newfoundland hospital with renal failure. She suffered a stroke-like
event, her condition deteriorated, and she subsequently died of sepsis. At
autopsy, multiple bilateral kidney cysts. spinal cord hemangioblastoma and liver
angioma were identified and the diagnosis of VHL was made by the pathologist.
She had no family history compatible with VHL disease, but had 5 children (age
10-20) each at 50% risk, and seven siblings. also possibly at risk.
FamilyE:
An 18-year-old girl from central Newfoundland presented to an
ophthalmologist because of decreased vision. She was referred to the Health
Sciences Centre in St. John's because of bilateral papilloedema; further
investigations revealed five cerebellar hemangioblastomas and bilateral retinal
angiomas. The diagnosis of VHL was made by the neurosurgeon. In
retrospect, this patient had had periods of nausea and vomiting and progressive
uncoordination over the previous 9 months, but the significance of these
symptoms had not been recognized.
Her parents and three siblings were well, with no apparent VHL
manifestations. However, pedigree studies and medical record review identified
a maternal second cousin who had been disabled for a number of years
because of "AV malformations of the cerebellum and spinal cord." When
previous scans were reviewed by the radiologists, these lesions were
considered to be compatible with cerebellar and spinal cord
hemangioblastomas, and a diagnosis of "probable VHL· was made. This raises
the possibility that the proband's motherisa carrier and that the proband's
siblings are at 50% risk for VHL disease - genetic and clinical screening are.
therefore,indicated.
Interview topics for psychosocull evaluation of the impact of VHL. and
of the screening program on VHL family members
Knowledge/!!nder$taodjog of VHL and of screening methods
how was it obtained
is it sufficient; would you like to know more (or lessI
how should it be provided
do family doctors. public health nurses. etc. know enough?
~withclinicalscreening;~withtheprogram
reasons for non-compliance (financial. fear. disinterest. lack of
concern)
are there any things that should be done differently?
~becauseofthedisease,orbecauseofscreening
death and disability in the past-
concern for yourself or your children about medical aspects ofVHL
worry at time of screening appointrnents
worry because of false positive/false negative results
negativesideeffeets of screening or treatment
family. spouse, friends
family doctor. publiC health nurse
specialists. geneticists. psychologist/psychiatrist
FinaoGial jmplicatioO$ofthe disease, or of screening
for appointments/treatment (travel. accommodation. etc):
are these expenses covered by insurance?
are there other expenses due to the disease or screening?
~or~becauseofVHlorbecauseofscreening
has the disease or screening affected
-education
-employment
-insurance
-social/marriage relationships
-family life?
(has it affected ¥Ql.I!choices; or other peoples' choices or decisions with
respect to you?)
Effect of the disease, or of availability of genetic screening on
reprQdtJctiy' decisign,
no children, fewer children, worry about children
interest in predictive testing/mutation testing (for self or for
children)
interest in prenatal diagnosis
does possibility of predictive testing/prenatal diagnosis change
approach to reproduction?
Effecton~
of the disease
of screening
CHAPTER 7 - HEALTH CARE EVALUATION OF THE VON HIPPEL-LINDAU
DISEASE SCREENING PROGRAM
i) Evaluation design
ii) Collection and analysis of data
iii) Ongoing analysis of program
Objective/Question 1. Does clinical screening for VHL result in
earlier identification of affected family members?
il Method
ii) Results
Objective/Question 2. Does the screening program cause a
decrease in morbidity and mortality from VHL by facilitating earlier
treatmentorinterventionforspecificmanifestationsofdisease?
i) Method
ii) Results
al Quantitative results
bl Qualitative results (In-depth case studies)
-Retinal angioma
-Pheochromocytoma
- C~rebellar hemangioblastoma
-Renalcellcarcinoma
Objective/Question 3. Has the provision of genetic counselling for
affected and at-risk family members increased their understanding
of VHL. and decreased their anxiety concerning the adverse
aspects of the disease? .
i) Method
ii) Results
Objective/Question 4. Has the screening program been revised
whenappropriate7
i) Method
ii) Results
Selection of control groups
Threats to internal validity
a) Threat of history
b) Threat of maturation
c) Threat of instrumentation
dl Threat of selection
iii) Threats to external validity
FORMATIVE EVALUATION
i) Personnel
ii) Participants
iii) Record keeping
ivl Sensitivity and specificity of investigations
v) Genetic testing
vi) Side effects of screening
COST-BENEFIT ANALYSIS
OVERALL DISCUSSION OF HEALTH CARE EVALUATION
This chapter provides a complete health care evaluation of the von
Hippel-Lindau disease screening program, including Needs Assessment,
Summative Evaluation, Formative Evaluation and Cost-Benefit Analysis.
As previously noted, the impetus to develop a screening program for VHL
was provided when a large Newfoundland family with the disease (Figure 6.2al
was identified in 1982. Individual members of the family had previously been
seen by a variety of specialists for urgent medical treatment of symptomatic
disease. Many had suffered blindness or early death, and yet there had been
no coordinated approach to the management of the multiple manifestations of
the disease. The relationship of the different presenting symptoms was not
well understood by the family members or their physicians, and the frequent
morbidity and mortality in this family, and four smaller VHL families
subsequently identified, caused a great deal of anxiety and mistrust of the
medical system.
It was recognized that a multi-disciplinary approach, with the
development of a screening program, was necessary for improved medical
management of family members identified through pedigree studies and review
of medical records as affected oratrisk (JenningsetaI1988).
The objectives of the VHL screening program were:
- early identification of individual manifestations to facilitate early
treatment or intervention, and to reduce the morbidity and mortality
associated with advanced disease,
- early identification of those who carry the VHL gene to allow informed
reproduetivedecisions,
- genetic counselling foraffeeted and at-risk family members to increase
the understanding of all features of VHLdisease, and to reduce the
anxiety caused by the disease,
- collection of data to allowrefinemeht of the screening protocol,
Since the location of the VHL gene was not known in 1982, the
identification of gene carriers and the early identification of individual
manifestations were both dependent on a clinical screening protocol which
included a set of investigations at least annually to detect presymptomatlc
disease (as described previously, Figure 6.11. After the VHL gene was mapped
(Seizinger et al 19881, and later cloned (Latif et al 1993), methods for direct
identification of gene carriers by linkage analysis and by direct mutation
detection were developed. Comprehensive genetic counselling was provided
for all family members when first identified as affected or at risk and, when
necessary, has been reinforced subsequently. Results of the clinical screening
program and of the genetic testing, and relevant information from recent
literature, have been used to review and revise the program.
From the review of past medical records and documentation of the
results of investigations and treatment since screening was implemented,
several advantageous results of the program have been demonstrated. These
include an earlier age at diagnosis (Figure 6.4), detection of manifestations at
an earlier and more treatable stage (although the number of tumoursdetected
hasincreased),andadecreaseinthemorbidityandmortalityassociatedwith
these manifestations (see Summative Evaluation). It is also our impression,
from interviews and frequent contact with the family, that family members now
have a better understanding of the implications of VHL for themselves and for
their children, and are less anxious than previously about the threats of the
disease to their well-being (see Chapter 6, Psychosocial evaluation).
The purpose of this section is the evaluation of the program:
- to review the objectives of the VHL screening program, including
whether or not the need for the program still exists (The Needs
Assessment);
- to determine whether the objectives have been achieved and, if so,
whether it is appropriate to attribute these results, or outcomes,tothe
screening protocol (Sumrnative Evaluation);
• to determine whether there are better or cheaper ways to meet the
objectives (Formative Evaluation); and
• to identify the costs and benefits, both financial and psychosocial,of
this health care program (Cost-Benefit Analysis).
NEEDS ASSESSMENT (Ooes the problem still e.lst7)
In von Hippel-Lindau disease. as in a number of other hereditary tumour
predisposition syndromes. patients who are symptomatic usually have
advanced disease which is difficult to treat successfully and often leads to
death or severe deficits (Vasen et al 1987. Lamiell et al 19891. To prevent
this. individual manifestations in those who are affected must be identified and
treated earlier. A clinical screening protocol based on the natural history of the
disease was designed for this purpose (see Chapter 6).
The autosomal dominant inheritance pattern means that children of an
affected individual have a high (50%) risk of also being affected. Because of
the severity of VHL. many family members prefer not to risk passing the gene
on to their children. To make appropriate reproductive decisions they must
know whether or not they carry the VHL gene before considering having
children. When the Newfoundland VHL screening program was initiated. the
location of the VHL gene was unknown so that gene carriers could only be
recognized by diagnosis of the initial manifestation of VHL in each individual.
and this was also facilitated.bythe clinical screening protocol.
The recent advances in molecular genetics. including the mapping and
cloningoftheVHLgene. permit the identification of gene carriers by genetic
testing in some families; by linkage analysis with closely-linked flanking markers
or by direct detection of the VHL mutation (Glenn et al 1992. Maher et al
1992. Crossey et a11994. Chen et aI1995). Thus. genetic testing may now
be added to the screening program to allow reproductive planning for affected
and unaffected family members. Genetic testing will also focus clinical
screening on those with the VHL gene, reducing by half the number requiring
clinical screening, and therefore reducing the costs associated with clinical
screening. A clinical screening program, however, continues to benecessary
for early identification and treatment of specific manifestations in all those with
the VHL gene, since the age and order in which manifestations occur in any
particular individual is unknown (Maher et al 1990).
Genetic counselling in its broadest sense is education about the natural
history, management, and risk of inheriting a genetic disease, and about the
options available for dealing with the risk. For VHL, this includes knowledge
of the rationale for screening, of the recommended clinical screening protocol,
of the types of symptoms which should be reported to the family doctor
between screening appointments, and of the availability and implications of
genetic screening. Genetic counselling should also include psychological
support for the patient facing the negative aspects of genetic disease. All of
these components of genetic counselling continue to be necessary for VHL
family members.
Continuous review and refinement of the screening program allow
incorporation of newtechnology, and newclinical and genetic knowledge about
Assuming that benefits of the program can be demonstrated, and
considering that there are 78 known affected or at-risk VHL family members in
Newfoundland, a screening program including clinical testing and genetic
counselling, and with the recommended incfusion of genetic testing,isneeded.
SUMMATIVE EVALUATION (Have the objectives been met?)
If the need for a VHL screening program is accepted, then the
Newfoundland program should be evaluated in terms of its effectiveness. This
is the summative evaluation (Shortell and Richardson 1978, FitzGibbon and
Morris 1987) answering the questions of whether or not the objectives (as
previously stated) have been achieved; if so, whether they can be attributed to
the screening program; and whether there are any unexpected outcomes.
An appropriate evaluation design should gather comparative information
on how things might have been if there had been no program, ora different
program (FitzGibbon and Morris 1987). A good design will rule out the effect
of variables other than the treatment (the screening program) on the outcome
(FitzGibbon and Morris 1987, Shortell and Richardson 19781, to reduce the
possibility of alternative interpretations of the results. There must be an
operational indicator (something to measure) that will tell whether or not each
objective has been achieved (Shortell and Richardson 1978).
Ideally. individuals from the "population" of interest (in this case.
affected and at-risk members of VHL familiesl should be assigned randomly to
experimental and control groups (Shortell and Richardson 1978. FitzGibbon and
Morris 1987). those in the experimental group to have regular clinical screening
according to the designated protocol. and those in the control group to have no
screening or a different screening program. However. the medical literature
now recommends some form of clinical screening for members of VHL families
(Jennings et al 1988. Maher et al 19901. and families with other tumour
predisposition syndromes (Ponder et al 1988. Vasen et al 1990a. Skogseid
1991al. because of the morbidity and mortality in unscreened families. It
would therefore have been unethical to assign those at risk randomly to
screening and non-screening groups and. thereby. to withhold medical care
from the unscreened group (FitzGibbon and Morris 1987. Sackett 19801.
Furthermore any randomization process would be confounded by the fact that
family members communicate. A quasi-experimental rather than a true
experimental design was therefore used (Shortell and Richardson 1978. Cook
and Campbell 19791. Non-equivalent control. or comparison. groups were
chosen that were as similar as possible (members of the family living .in other
provinces where regular screening program has not been implemented. and
members of the family in Newfoundland in previous decades). and the
differences documented (FitzGibbon and Morris 19871. Patient outcomes have
been compared in light of these differences.
CQllection and analysjs gf data
Because VHL is an extremely variable disease even for members of the
same family with the same genetic defect, the screening process must be
individualized according to the results of the primaryinvestigations. Screening
proceeds according to an algorithm rather than a step-by-step protoco!. It is
difficult, therefore, particularly in a small sample, to do any statistical analyses,
except the most basic frequency comparisons. Qualitative data collection is
appropriate, however, for evaluation of this type of program, using
observations, interviews or in-depth chart reviews of "information-rich" cases,
for comparison of the effects of the disease at a very personal level (Patton
1987). The key to this part of the evaluation is the appropriate selection of
cases, or "purposeful sampling" (Patton 1987).
For the VHL program evaluation, typical case sampling, maximum
variation sampling, and deviant case sampling are appropriate. The typical and
extreme cases are the most important ones in the comparison of the medical
outcomes between experimental and comparison groups. The extreme or
deviant cases are particularly significant, because the program cannot facilitate
treatment or intervention for manifestations of VHL which are unknown or for
which the type or timing of screening investigations is inappropriate. The
deviant cases may be difficult to provide for, but it is the prevention of severe
"typical" cases, that is the intent of the screening program.
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Naturalistic inquiry (Patton 1987) based on observations over the
duration of the screening program and recent interviews using open-ended
questions. is appropriate for evaluating the psychosocial outcomes and the
effect of genetic counselling.
The use of different data types (quantitative and qualitative). different
data sources (medical records. direct observations and interviews). and
differentmethodsofinquiry(quasi-experimentalandnaturalisticlisanexample
oftriangulation (Patton 1987). and is used to combine the strengths and offset
the weaknesses of the various approaches.
iii} Qnggjnganalysisgfgcggram
Any screening program will require adaptation over time. To determine
when revisions are appropriate. the results of screening and treatment should
be monitored. and reviewed with the specialists responsible for the medical
management of patients. The relevant literature should also be reviewed to
identify new investigations or treatments which may be appropriate. current
information on the natural history of VHL which may necessitate revision of the
type or timing ofinvestigatiQns. and changes in the status and availability of
rnolecular genetic testing.
Clinical data have been collected retrospectively or prospectively for each
affected family member, including age at diagnosis of initial and subsequent
manifestations of VHL, method of diagnosis (by symptomatic presentation or
by clinical screening), outcome of treatment, and age and cause of death when
appropriate. Specific methods related to individual objectives are discussed in
0bltc;thtt'· Early id.ntifie;etigD Of thO. whQ .r. '"'Sited to I"OW
rAprod"C;tjv. planning (Does clinical screening for VHL result in earlier
identification of affected family members?)
Age at diagnosis was compared in screened and unscreened VHL family
members using a Quasi-experimental design with similar but non-equivalent
control groups. The experimental group was the cohort of members of three
VHL families residing in Newfoundland and participating in the screening
program from 1982-1991. The control groups included untreated cohorts lie,
cohorts of 1962-71 and 1972-81 that were not screened), and a differently
treated group (VHL family members in Ontario and New Brunswick, 1982-
1991) with minimal screening.
The mean age at diagnosis of 16 members of the large VHL family
identified by the clinical screening program (1982-91) was 16 years, compared
with 29 years in five family members presenting with VHL in other provinces
in the same time period, and 27 years in the 24 family members identified
previously because of symptomatic disease presentation (a mean age at
diagnosis of 36 years in those identified in 1962-71, and 19 years in those
identified in 1972-81) (Table 7.11.
Nine of 16 of those identified by screening already had presymptomatic
manifestations of VHl when first investigated. As the clinical screening
program continues and manifestations are detected prospectively in young
family members, it is expected that the mean age at diagnosis will decrease
OblASti" 2- Early id.ntificltiOD Of Individual m,nifl'tltiQn. tg meUila" I.rly
tr••tm'ntor fnt1rv,ntigD Indto imp'QY'th. prggnO"1 (Does thescr••ning
program cause a decrease in morbidity and mortality from VHl by facilitating
earlier treatment or intervention for specific manifestations ofdIsease71
The status at diagnosis (presymptomatic or symptomatic disease
expression); the frequency and age of death from VHl; and the frequency of
unilateral or bilateral blindness,orofdisabillty preventing normaI employment,
were compared in the experimental and comparison groups. In-depth case
studies using observations and descriptive information from medical records
were prepared for patients identified presymptomatically by screening, and
patients who presented symptomatically, to compare medical outcomes and
post-treatment quality of life of screened and unscreened family members.
IDENTIFICATION OF NEW PATIENTS. AND OF NEW
TUMOURS IN AFFECTED MEMBERS OF A VHL FAMILY. BY
SCREENING OR BY SYMPTOMATIC PRESENTATION
Regular Minimal Minimal No
Screening Screening Screening Screening
Nfld Ont./N.B. Nfld./Ont. Nfld.
1982-91 1982-91 1972-81 1962-71
Number of New
Patients
Mean Age at
Diagnosis (yrs.)
Number of Tumours
Identified
-Asymptomatic
- Symptomatic
16 28.8 19
50,3.72 50,12.15 50.6.21
35.9
50,11.14
The m.anag.atdiagnosisforsc:reenedpatients was 16.1 (50. 3.72) and·th.mean
age at diagnosis of all symPtomatic patients was 28.9 (50.13.161. Because the
variancesar.signifieantlydiffe<ent.parametricstatistiesarenotappropriate. How.v.r
with a non-param.trieproeedure. the m.ans ar. signifieantlydiffer.nt Ip<O.OOll.
al Quantitative results
There was a marked increase in the number of VHL tumours detected in
affected family members when the clinical screening program was introduced
(74 tumours identified by screening in Newfoundland in 1982-91 in 18 affected
individuals, compared with 14 tumours in 14 patients identified in other
provinces during the same time period, and 16 tumours in 16 patients [1972-
81) and 19 tumours in 11 patients [1962-71) in unscreened cohorts
previously). However, the majority of tumours (70/74) in the screened group
were identified at a presymptomatic stage, compared to 8/14 tumours detected
presymptomatically in other provinces in the same time period. In the earlier
cohorts only 4 tumours were identified presymptomatically, 31/35 tumours
being identified because of symptoms of advanced disease (Table 7.1).
Oneof 18 patients inthescreenedgroupdied,and 3 developed unilateral
blindness during 1982-91. However, each of these patients had presented
symptomatically prior to the institution of screening, or with advanced disease
at initial screening. Fourteen of the 18 patients in the screened group were
free of debilitating disease. In contrast, during 1962-81, of 24 family members
presenting with symptomatic disease, 10 died at a mean age of 37 years, 10
developed unilateral or bilateral blindness, and 7 had a severe neurological or
other disability preventing employment for several years prior to death (Table
7.2).
TABlE 7.2. MORBIDITY AND MORTAUTY IN COHORTS OF VHL
PATIENTS MANAGED WITH OR WITHOUT A CUNICAL
SCREENING PROGRAM
NUMBER, AND AGE AT DEATH OR DISABILITY
Nfld. Ont.lN.B. Nfld.lOnt. Nfld.
1982-91 1982-91 1972-81 1962-71
Deceased l' 1 1 9
(Age) (28 vrs) (49 vrs) (18Vrsl (21-55 vrs)
Blind
3" 1-Unilateral 8
(Age) (23-26vrs) (5 vrs) (18-45 vrs)
-Bilateral 1 1
(Age) (21yrs) (45 yrs)
Neurological 2 1 6
Disability (27,34yrs) (18yrs) 119-54yrs)
(Age)
Total living
affected
• symptomatiepresentationin1980
•• it id.ntifiedin 1973 and not followed
iii symptomaticpr.sentationb.forescr....ingstarted
iii) large angioma on first examination
b) Qualitative results IIn-depth casa studies)
The in-depth case studies comparing the medical outcomes and quality
of life in those identified with symptomatic or presymptomatic manifestations
of VHL, provide insight into the impact of this disease on individual patients.
-~. In 1981, a 16-year-old girl was seen by an
ophthalmologist because of unilateral loss of vision. She had a retinal
detachment because of mUltiple retinal angiomas (>20). Two attempts at
surgical repair of the detachment were unsuccessful and she is now blind in
one eye. She also had multiple angiomas in the second eye on initial
examination. Laser and cryotherapy have so far kept these under control,
although she has extensive scarring and is at risk of a traction retinal
detachment which would cause loss of vision of the second eye. This patient's
mother died at age 21 of VHL, but the only screening the patient had had was
an annual "water test" (ie, VMA [vanillylmandelic acidI measurement, which
was the previous screening test for pheochromocytoma).
A 19-year-old at-risk family member in Ontario, who had never been
screened, presented similarly with decreased vision and was found to have
multiple bilateral retinal angiomas. Despite extensive laser treatment and
cryotherapy, within two years he had retinal detachments in both eyes and was
registered blind at age 21.
Since 1982, retinal angiomas have been detected by screening in twelve
at-risk family members in Newfoundland. All but one, who had a large angioma
when first seen, have had an excellent outcome with small circumscribed scars
where angiomas have been treated. Except in this one patient, no retinal
detachments and no loss of vision have occurred. Angiomas have recurred in
all patients, but because of the regular screening they were small when
identified, and have been relatively easy to treat.
- PheQchramocytQma. In 1981, before the screening program began, a
17-year-old girl (whose father had died previously of hypertensive crisis from
bilateralpheochromocytomaslhadincreasedbloodpressureduringpregnancy,
attributed to toxemia of pregnancy. The day after delivery of a healthy
daughter she had a hypertensive crisis with subarachnoid hemorrhage and was
comatose until she died 5 months later. No autopsy was done.
When her medical records were reviewed, we suspected that she had
had a pheochromocytoma and was, therefore, affected (an undetected
pheochromocytoma is associated with at least 27% mortality during pregnancy
or delivery [Griffin et al 1984, Freier et al 1993)). Her daughter was assumed
to be at risk and was screened completely from age three. At age nine the
daughter's urinary catecholamines were increased, and a CTscan demonstrated
a unilateral pheochromocytoma. She had a successful adrenalectomy and is
well at the age of 13 years.
Six of the twelve deaths from VHL in the family have been secondary to
pheochromocytoma; five because of hypertensive crisis during surgery or
pregnancy (all before the screening program), and one because of malignancy
in 1983 in another province.
- Cerebellar Hemangioblastgma. In 1983 an 18-year-old girl in central
Newfoundland saw an ophthalmologist because of decreased vision and was
eventually referred to St. John's. She had bilateral papilloedema and was
referred for a CT scan of the head and neck. This showed five cerebellar and
one spinal cord hemangioblastomas for which she had successful surgery. In
the postoperative period, retinal angiomas developed and were successfully
treated. However, she is totally blind because of optic atrophy from the long-
standing preoperative papilloedema caused by"the multiple hemangioblastomas.
In retrospect, she had had nausea and vomiting and decreased coordination
over the previous 9-12 months. Because there was no significant family
history (she was the proband of VHL family E) these symptoms were not
thought to be significant and were not investigated.
A 44-year-old affected memberof the minimally-screened Ontario branch
of VHL family A has a significant neurological deficit, and has not worked since
neurosurgery in 1984 for a cerebellar hemangioblastoma. He had bilateral
pheochromocytomas removed in 1972 but did not have any subsequent
screening. His cerebellar tumour was identified in 1984 after he became
symptomatic with incoordination and ataxia. Surgery was only partially
successful because of the large size of the tumour and the extensionsaround
In contrast, a 15-year-old boy at risk for VHL was in St. John's in 1990
for his annual screening (his mother had retinal angiomas and renal cell
carcinoma). His parents were concerned about the recent occurrence of
morning headaches. Even though he had had a normal CT scan of the head
two years previously and had a normal neurological examination otherwise, he
was referred for a repeat CT scan because of the headaches and the positive
family history. The CT scan showed a very large cerebellar hemangioblastoma
which was removed successfully. He has no visual or neurological deficit post-
operatively.
- Renal Cell Carcjnoma. None of the patients in this family have had
symptomatic renal cell carcinoma (RCC). Prior to 1982 there had been only
one diagnosis of BCC - in a severely affected 55-year-old man at autopsy.
Since 1986, BCC has been identified by routine ultrasound in thirteen
asymptomatic affected family members. They all had unilateral or bilateral
partial or total nephrectomies. None of these tumours extended through the
kidney capsule or into the blood vessels, and no metastatic disease has been
detected, so these patients have not required chemotherapy or radiotherapy.
However,threepatientshavehadsubsequentprimarytumoursinthe second
kidney. In other VHL families documented in the literature, metastatic BCC is
Qbi'CtiVl 3· GIO,tiC Gguo"lIIng to inA'•••• !hI ""dAr.tandlng Qf yHL Iud
~(Ha.theprovlslonofgenetlccoun.ellingforaffectedandat-ri.k
family member. increased their understanding of VHl, and decreased their
anxiety concerning the adverse aspects of the dlseasen
Knowledge of VHl and anxiety concerning the disease were not formally
evaluated before the screening program was implemented. The clinical needs
of family members were so pressing when they presented to the Ocular
Genetics clinic in 1982 that the original clinical screening protocol was
designedandimplemented,andgeneticcounsellingincludingeducation about
VHl and the rationale for screening given immediately. However, observations
were made by Jane Green (who was always in close contact with the family),
at the outset, and throughout this program (Patton 1987). Relevant
information or opinions stated by family members during counselling sessions
or telephone conversations were also recorded. A medical student report
(Hogan and Sparrow 19721, written when several family members died from
what was later recognized to be VHl disease, was also reviewed. The feelings
of family members documented at that time were compared with those of
family members interviewed recently. This allowed some subjective
conclusions about the changing views of the family members towards tlie
Six affected and nine unaffected family members were interviewed,
about their knowledge of VHL and the clinical and genetic screening methods;
about the benefits and costs of the screening program, and their satisfaction
and compliance with it; and about the overall effect of screening on their
quality of life. The group interviewed included male (n = 5) and female (n = 10)
family members, and those within the reproductive (n=8) and post-
reproductive (n=7) age groups.
The interviews were conducted by Jane Green at the homes of the
family members or at the General Hospital in St. John's, depending on the
preference of the individual. The same open-ended questions were asked of
each person (Appendix B, p. 364-5). Those interviewed were free to discuss
these points in as great depth as they wished.
The first group of six affected and at-risk family members seen (and their
family doctor) did not know the name of the "family disease", nor did they
know the names of individual manifestations, and incorrectly referred to
pheochromocytomas (adrenal gland tumours) as "kidney tumours". They did
not understand the connection between the eye, brain, and adrenal gland
tumours occurring in different family members, and also thought that all family
members would develop the disease. Family members now know the main
clinical and genetic features of VHL, and they and their family doctors have
pamphlets to refer to, or geneticists to contact, if further information is
required. They regularly tell medical practitioners that they have, or are at risk
for, VHL when investigated for any medical problem.
They are now making reproductive decisions based on their knowledge
of gene carrier status rather than because of fear that everyone inthefamily
will be affected. Five family members identified as affected by clinical
screening in their teens have chosen to have sterilization rather than risk
passing on the VHL gene, and three others have had one or two children only,
rather than larger families. All family members at risk in the reproductive age
group (n = 14) chose to have genetic testing (direct mutation analysis) when
this became available, for reproductive planning as well as for clinical
management. Four family members who had chosen voluntary sterilization to
ensure that they did not have affected children, are now known to be non-
carriers. Two of these plan to have the sterilization reversed. One other family
member had only one child, and plans to have more children now that she
knows that she does not carry the VHL gene. .conversely, two affected family
members in one of the earlier generations had 10 and 12 children before the
VHL diagnosis was known, and now regret that the gene was passed on to so
many (13/221 of their offspring.
The medical student report from 1972 (Hogan and Sparrow 1972)
documents the extreme anxiety in affected and unaffected family members
caused by the frequent sudden deaths and severe disabilities within the family.
Family members still feel anxious about the devastating potential of VHL.
However, for 14 of 15 family members interviewed, this is~ except
during the period immediately before and after annual screening investigations,
or if symptoms develop, because they now trust the medical care system and
the screening program. One patient feels that VHl is a permanent cloud over
her life and prevents her enjoyment of other things. The family members also
state that their compliance with the screening program is based on an
understanding of the rationale for screening, and concern about the effect of
VHl if not detected early.
Although there was no opportunity for a formal pre- and post-
intervention evaluation of knowledge about VHl disease and of the stress
caused by this disease, it appears that the current understanding of VHl is
being used appropriately, and that the quality of life of family members has
improved because of the screening program.
Qbj'Gtiy. 4· CgnlGliO" Of data tg "finA fb, 'Cf,.ning gmtQcQI (Has the
screening program been revised when appropriate?)
literature on the natural history, screening recommendations, and
molecular genetics of VHl was monitored continuously. Clinical data were
collected retrospectively or prospectively for each family member. A summary
of the natural history of VHl in the Newfoundland families (including frequency
and order of occurrence of manifestations, and age atdiagnosisl, and of the
medical outcomes before and after the screening program was implemented,
was prepared and presented to the medical specialists. Each specialist reported
on new technology that could facilitate screening or treatment.
The availability and acceptability of molecular genetic testing for the
Newfoundland families, and the results of linkage analysis and mutation
detection conducted under a research protocol were also presented and
In 1986, renal ultrasound from the mid or late teens was included as one
of the annual investigations for affected and at-risk family members, because
of new data in the literature on earlier age at onset of renal cell carcinomathan
previously described. In 1994, it was recommended by the radiologists that
staged CTscanning of the kidney/adrenal area replace ultrasound screening.
A new, faster CT scanner had been obtained which allowed the better
sensitivity of CT scanning while minimizing the radiation exposure. Similarly,
when an MRI was obtained in 1993, MRI of the head, and spinal cord if
necessary, replaced CT scanning because MRI provides better resolution of
central nervous system tissue (Filling-Katz et a11989, Hoff et al 1993), without
exposure to radiation.
In 1994 it was recommended that genetic testing be offered to all at-risk
members of VHL families that were informative for linkage analysis or mutation
detection, because of the precision with which gene carriers and non-carriers
can now be identified, and because of the acceptability of this testing to family
members. Thus the screening program has been revised according to advances
in diagnostic and genetic technology.
A health care program should be evaluated to determine whether the
goals of the program are being achieved and, if so, whether the results can be
attributed to the program, and whether they can be generalized to other
situations (Shortell and Richardson 19781. It would take many years and the
follow-up of many families to mermine definitively the degree to which a
screening program fora hereditary cancer syndrome actually changesthelong-
term medical and psychosocial outcomes for affected individuals and members
of their families, and whether this is a cost-beneficial method of clinical
management. A preliminary evaluation, can, however, provide some guidelines
as to the effectiveness of such a program, and will allow necessary revisions
to be made (Objective 4). For this reason the Newfoundland VHL screening
program, which has been un!lerway for 12 years (for 78 affected and at-risk
members of 5 families) has been reviewed and evaluated.
Selection ofcootrg' grQups
Patients were not randomized to "treated" and "untreated" groups,since
it was considered unethical to withhold screening from a control group
(FitzGibbon and Morris 1987). Instead, a quasi-experimental design was used
with two similar comparison groups: a historical unscreened group (Cook and
Campbell 19791. and a less extensively screened group living outside
Newfoundland. There are some differences in the numbers, age profile and
disease profile of members of the experimental and comparison groupsbecause
of the variability of the disease, and because the groups were defined by the
family structure and geographic location. In fact. without extensive
investigations, the actual numberofaffected,andnumberofmanifestationsper
patient are not known.
The goals of the screening program Ii) earlier age at diagnosis of VHL to
allow reproductive decisions, ii) earlier diagnosis and treatment of individual
manifestations to decrease morbidity and mortality from the disease, iii)
increased knowledge and reduced anxiety regarding VHL to improve the quality
of life, and iv)fine-tuning of the screening protocol as new information,ornew
technology becomes available) have all been achieved since the screening
program was implemented. But, can these results be attributed to the program
rather than to otherfactors7
Threat§tQ intflrnalvalidjty
Various threats to internal validity have been considered (Shortell and
Richardson 1978, Cook and Campbell 1979):
393
al Threet of history (the effect seen could result from changes in medical
care during the past decade rather than from the InterventionI
Overall, medical care has improved and new diagnostic procedures have
become available since 1972 or even since 1982, which could result in earlier
diagnosis nowthan previously. However, without the screening protocol, these
diagnostic procedures and examinations would not be used on asymptomatic
patients. Surgical procedures have also improved so that patients with the
same degree of disease should have better outcome now than previously,
however, it is the screening program which allows early access to these
procedures.
bl Threat of maturation (the effect seen could be related to the natural
history of the disease rather than to the InterventionI
VHL is an extremely variable disease, in its manifestations and age of
onset. There is no way of knowing, for any particular patient, what the age or
order of manifestations will be. Late age at diagnosis may result from late age
of onset, rather than late detection of disease because screening was not
utilized; and good outcome of treatment may result from mild disease, rather
than from early diagnosis and treatment because of screening.
There is no reason, however, to think that the variability of the disease
is different now than it was in previous generations, or in those living in
different provinces; in each group, patients with early onset severedisease, and
others with later onset milder disease were identified.
c) Threat of instrumentation (the apparent effect could be biased by the
greater availability of current, local data)
The data for control groups (either archival data or data from another
province) may not be as complete or as accurate as data for the experimental
group. However, for this evaluation, records were available and were reviewed
for all members of the control groups.
d) Threat of selection (the effect seen could be the result of Ie.. severe
disease In the experimental group rather than the result of the Intervention)
The groups were not randomly assigned and are relatively small so may
have different representations of those with mild or severe disease, or of
different ages. Evenifthenumberswerelargeenough,patientscouldnotbe
stratified according to severity, because the number and type of manifestations
any individual will have cannot be predetermined. However, in the control
groups the two most recent deaths. and 4 of 6 disabilities during the 1980s
were because of the initial VHL manifestation. These patients had
unrecognized rather than particularly severe disease.
iii) ThrAats tg ftxtArnal VAlidity
Threats to external validity were also considered (Shortell and Richardson
1978), to determine whether these results have significance to other VHL
families, or other similar diseases.
Because VHL is so variable, both within and between families, a
comprehensive clinical screening protocol should be recommended for other
VHL families as well as for the Newfoundland families. This clinical screening
protocolisbasedonthenaturalhistoryofthediseasedescribedintheliterature
and in large well-studied families, but possibly modified for an individual family.
Earlier diagnosis and treatment of initial disease and of subsequent
manifestations should be achieved by screening members of VHL families
elsewhere with the protocol developed for the Newfoundland family.
The genetic counselling process as carried out in Newfoundland,
including counselling and educational components, is similar to that done
elsewhere. Therefore, the review of psychosocial costs and benefits, and of
the response to predietivetesting in this family should provide guidelines for
other centres developing screening programs for small or recently identified
As described in earlier chapters of this thesis, screening for other
hereditary tumour syndromes has been developed in a similar way, using a
clinical screening protocol determined by the natural history of the specific
disease. Those at risk (defined by genetic principles) are screened for the
manifestations causing significant morbidity or mortality, beginning prior to the
age that these manifestations can be recognized symptomatically, and using a
presymptomatic diagnostic procedure. Genetic screening methods to identify
gene carriers are included in the screening program when linked markers are
available. or specific mutations are known.
In conclusion. there is evidence that the outcomes identified in this study
can be attributed to the VHL screening program. It is also felt that the results
and recommendations of the Newfoundland screening program can be
generalized to similar situations elsewhere. However. one of the reasons that
the Newfoundland program works particularly well may be the special interest
of personnel involved here.
FORMATIVE EVALUATION (Is W1ere a better way to provide the VHL screening
program for those at risk. either in tarms of the type and timing of screening
investigations. or in terms of the administration of the program?)
In addition to evaluation of outcomes. a program should be evaluated in
terms of its implementation. looking at the day-to-day activities of program
personnel. the set of investigations recommended for each family member. and
the compliance of the patien~s with these investigations. This is the formative
evaluation (Shortell and Richardson 19781. answering the question of 'who is
doing what to whom. with what resources and within what period of time"
(Shortell and Richardson 1978. Sackett 1980). Formative evaluation should
taka place continuously but particularly in the early stages of implementation
in order to arrive at the most efficient and effective process (FitzGibbon and
Morris 1987, Patton 1987). Although program operation is less important than
the achievement of the medical and genetic outcomes, these outcomes cannot
be attained unless the program implementation is successful (Patton 1987).
Formative evaluation is primarily a descriptive evaluation documented
through observation of the daily activities which must take place in order for
all aspects of the screening program to proceed. Tables or flow charts should
be used to follow the personnel involved in the program, their activities related
to each major objective (Shortell and Richardson 1978), and time spent per
week or per month at these tasks. The personnel should also be interviewed
to elucidate any deficiencies or problems in the procedures and to identify areas
for improvement.
The clinical investigations of the screening protocol should be reviewed
to clarify the sensitivity and specificity (Sackett et al 1991) of these
examinations and procedures, and to determine whether recently available
investigations should replace current procedures (such as MR imaging replacing
CTscanning).
In population screening for a low-risk event, specificity is more important
than sensitivity, in order to reduce the number of false positives. However, in
very focused screening, as for those affected or at 50% risk for VHL, high
sensitivity is most important, particularly when an undetected manifestation is
associated with potential lethality. Since the ·cost· ofafalse negative is so
high, the investigation of choice may be different from that used in other
The results of genetic testing done on a research basis should be
reviewed to determine whether this should be included in the overall screening
Information was collected from appointment books and medical records
on the numberofpanicipants in the screening program and theircompliance
with appointments. The duties and time-eommitment of personnel involved
with the program were documented and monitored, and the method of
obtaining, recording and storing test results was reviewed.
Individual medical records were reviewed to identify false positive or
false negative results of screening tests, or any adverse side effects of
investigations. The results of screening (frequency of manifestations and age
at diagnosis), and the literature regarding screening recommendations from
other centres were monitored and reviewed with physicians involved so that
the type and timing of clinical investigations could be revised as necessary.
Genetic screening was introduced on a research basis in 1992 as
discussed in Chapter 6. The results of predictive testing by linkage analysis
and subsequently by direct mutation detection, and the monetary costs and
psychosocial implications of including genetic testing in the screeningprogram.
were also reviewed with the group of specialists.
Participants in the screening program were interviewed regardingtheir
satisfaction with the screening program. and reasons for compliance or non-
compliance with scheduled investigations.
The main personnel of the von Hippel-Lindau disease screening program
are the geneticist (Jane Greenl who also acts as program coordinator. a
secretary. medical specialists. and other health professionals (Table 7.31. The
geneticist oversees the whole program and provides genetic counselling for
each affected and at-risk family member in the program. when first identified
and as necessary throughout screening. These subsequent counselling sessions
havetakenplacewhenanychangeintheprotocolwasintroduced.particularly
when genetic testing became available. and to provide the results of genetic
testing for those requesting It.
The geneticist also reviews all clinical test results with the appropriate
specialists. records the data. maintains individual files. and identifies when
recall appointments are due. Relevant literature has been reviewed. so that
appropriate revisions to the protocol can be made. Educational material was
also prepared for family members. family doctors and specialists.
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The secretary books appointments that are due, in groups for those living
out of town, and notifies the participants of appointment times. The medical
specialists lincludingpediatricians, internists, ophthalmologists,andsurgeonsl
see patients in clinic, provide treatment, make referrals to other specialists as
necessary, and send reports to the coordinator. They also review relevant
areas of the literature to recommend revisions to the protocol. Other health
professionals such as laboratory and x-ray personnel conduct the investigations
that are part of the screening protocol, as booked for family members.
Affected and at-risk members of five VHl families in Newfoundland
participate in the screening program. The exact number in each category varies
as new clinical diagnoses are made, as genetic testing identifies gene carriers
or non-carriers, or as family members have moved to or from the province. In
1982, 12 affected and 34 at-risk family members were identified and entered
the program. The maximum number involved was 27 affected and 51 at risk,
and currently Isince six family members have moved, and genetic testing has
identified 24 non-carriers), 25 affected and 23 at risk participate.
The overall compliance with clinic appointments has been 78% compared
with 85% compliance for other patients booked in similar clinics. Certain
patients 15/42) have been less reliable than the majority participating in the
program. When questioned about non-compliance, they say that they are afraid
of the disease, and the only way they can handle their fear is by denying it, and
avoiding investigations which might demonstrate an actual manifestation of
VHL. Four others, now in their 40s or 50s, became less compliant after many
yearsofnormalscreeningresults-theybecameconfidentthatthey did not
havetheVHLgene.
iii)~
A file is maintained for each participant with data on all investigations,
follow-up appointments, and treatment. An overall summary is also
maintained, with date and result of each appointment for each participant, to
facilitate recall. A computerized database with automatic flagging of those due
for appointments, or for whom results have not been received, would improve
the management of files and data.
iv) Sensitivity and SQ'Gificjty Qf investigations
False positive or false negative results are rare. Four patients had renal,
cerebellarorpancreaticlesionsidentifiedwhichonretrospectwereevidenton
previous ultrasound or CT scan examinations, but which had not been reported
at that time. These patients were still asymptomatic and had successful
surgery when the diagnosis of renal cell carcinoma (n=2), cerebellar
hemangioblastoma, or pancreatic islet cell tumour was made. Two patients
had symptoms trom spinal cord hemangioblastomas which were initially
attributed to "mechanical" back problems, but were later correctly identified.
These spinal cord tumours both occurred before MRI was available in
Newfoundland for appropriate evaluation of such symptoms.
Seven patients had false positive results. Two of these patients had
surgery for "query renal cell carcinoma" identified on ultrasound screeningand
follow-up CT scanning of the abdomen, but the pathology demonstrated renal
cyst only. In VHL disease, many renal cysts have renal cell carcinoma cells
lining the wall, and solid tumours have appeared cystic on scanning. As a
result there is a high suspicion of any lesion identified. Two patients with
increased catecholaminesand three with increased blood pressuresuggesting
pheochromocytoma had normal CT and MIBG scanning, however, one of these
later had a definite pheochromocytoma. Because of the previous morbidity and
mo"ality from unidentified pheochromocytomas in this family, a false positive
result is preferable to late investigation.
v)~
In three Newfoundland families, predictive testing by linkage analysis
was introduced onaresearch basis in 1992. Linkage results were received for
24 family members at risk (20 low-risk results, 3 high-risk results and 1
uninforrnativeresultl. Regular clinical screening continued for those at high risk
(or those for whom testing was uninformative) but was reduced in frequency
The specific mutation has now been identified in each of these families.
Mutation analysis of 28 members of Family A, at a priori 50% risk but with
negative clinical screening results, has been completed and has demonstrated
that the majority (24/28 or 85.7%1 do not have the VHL mutation. This
includes all those over 15 years of age, and confirms the early age atonsetof
VHL and the efficiency with which the clinical screening has identified VHL
gene carriers.
The implications of the genetic testing to overall cost of the screening
program are discussed in the cost-benefit section of this evaluation.
vi) Sideeffect$ Qfscreening
Four patients developed allergies to the regular ionic CTscan dye, one
requiring admission to the Intensive Care Unit. Because of the severity of the
reaction this patient no longer has scanning with contrast - therefore only less
sensitive testing is possible. The other patients, with a milder reaction, now
require non-ionic dye for any investigations. One patient developed a peripheral
visual field defect after laser treatment for an enlarging angioma of the optic
disc. The treatment was considered necessary because of the danger of Ioss
of central vision if the disc angioma was not controlled.
As is recommended ill evaluation literature, the program process has
been monitored since the beginning. and revisions have been made bothinthe
activities of the program personnel and in the investigations of the screening
protocol. The geneticist has always acted as program coordinator, arid
originally was responsible for all scheduling, notifying, record ingandfiling,but
recently a secretary has become involved in these activities.
Appointment dates and results are recorded on a summary table which
has to be reviewed manually to determine which participants are due for re-
testing. A computer program has been recommended to facilitate recall of
patients but has not yet been developed. With the number of patients, the
number of investigations and the patient individualization necessary, this lack
of computerized monitoring is a major handicap and results in excessive time
spent in keeping track of the program. Another problem with the process
concerns regular receipt of copies of test results by the program coordinator.
Some come automatically but some do not. Missing reports must be searched
for (which can be a time consuming process) in order to determine whether the
appointment was missed or rescheduled, or the result not sent. A reminder to
the many specialists involved in clinical management about the benefits of
centralized coordination and monitoring of the screening program, should
improve this situation.
The clinical components of the screening program have also been
revised. Originally screening was directed towards identification of retinal
angiomas, pheochromocytomas and cerebellar hemangioblastomas only,
because in the Newfoundland families only one renal cell carcinoma (RCC) had
been previously identified (at autopsy of a 55-year-old man); and because, in
the literature, RCC was considered a late manifestation of VHL and all living
affected patients in Newfoundland were under 40 years of age. The
recommendations in the literature for screening for RCC were then revised in
the mid 1980s to include earlier screening. 8aseline screening by ultrasound
of the kidneys was introduced for affected individuals in Newfoundland and
several patients as young as 19 years of age were found to have renal cell
carcinoma. A renal ultrasound was then introduced annually from early teens
for all affected and at-risk persons.
More recently, the radiologists (Dr. Peter Collingwood and Dr. Tom
Cummings) have recommended replacing renal ultrasound by staged CT
scanning of the kidney/adrenal region. This gives better resolution than
ultrasound, and a new, more rapid CT scanner reduces radiation exposure
required for the procedure. MR imaging of the head has replaced CT scanning
for screening for cerebellar hemangioblastomas. MRI is the investigation of
choice for central nervous system lesions because of better sensitivity,andalso
because radiation is not involved (Filling-Katz et al 1987, Sato et al 1988, Hoff
et al 19931. (When dealing with an inherited precancerous condition, the
carcinogenic potential of the procedure [eg,ttjecumulativeradiationexposure
from repeat CT scanning] should be considered as well as the sensitivity and
specificity.)
Early in the screening program, there were some delays for CT scanning
as a follow-up for primary investigations because there was only one CT
scanner in Newfoundland, at the General Hospital in St. John's. Now that
other hospitals have obtained CT scanners, significant delays rarely occur. For
screening programs such as this, it is important to ensure that the follow-up
investigations and treatment are available in a timely fashion. otherwise early
diagnosis will only decrease the quality of life by labelling the patient with a
diagnosis with many negative consequences.
Even ona research basis. genetic testing has so far only been offeredto
those already participating in the clinical screening program. and these were all
over 10 years of age when genetic testing became available. (Because of
voluntary infertility. there are very few young children at risk.) Informed
consent has been required. Because genetic testing was offered to those
alreadyinvolvedinthescreeningprogram.theuptakeofgenetictestingwas
high in the three families where this testing was possible. All adults (n = 22)
informed of the possibility of testing requested it; in their opinion, the potential
for beneficial outcomes associated with low-risk or mutation-negative results
(no longer requiring annual screening. the freedom to havechildren without the
risk of passing on the VHL gene. and reduced anxiety) far outweighed the
negative implications of high-risk or mutation-positive results. For them.
continuing clinical screening. worrying about the onset of VHL disease. and
forgoing children was the status quo. They recognized from the family's
experience that even if they did inherit the VHL gene, clinical screening
provided an opportunity for early and successful treatment for gene carriers.
Two of 12 sets of parents declined genetic testing for their children
when it became available. although they had requested it beforehand. One
mother did not feel she could cope emotionally with mutation-positive results.
and one couple did not want to treat their two children differently if the results
were not the same. The children (n=3) in both families continue with annual
clinical screening.
This high uptake of predictive testing for VHL is very different from the
situation with genetic testing for Huntington disease (HD) for which uptake is
much lower (Wiggins et al 1992), and many at-risk persons feel that the
'costs' (of increased anxiety, and potential discrimination) outweigh the
benefits (Codori and Brandt 1994aI, par1icularly because HD is untreatable.
COST-BENEFIT ANALYSIS (How doe. the cost of management of VHL patients
using a screening program. with or without genetic testing. compare with the
cost of management of VHL patients without screening?)
Once the efficacy and effectiveness ofa program have been established
(Sackett 1980, Robinson 1993a), it is necessary to conduct an economic
evaluation to determine whether the program is worth doing, (Stoddart and
Drummond 1984a). Previously, health care budgets expanded to cover the
costs of new health programs, but these budgets can no longer cover the costs
of a multitude of new procedures, treatments, and programs each of which
may have some value to some patients (Stoddart and Drummond 19B4a).
Expenditures must therefore be rationalized (Williams 1974, Robinson 1993a),
ideally by using a cost-benefit (Robinson 1993e) or cost-utility analysis
(Robinson 1993d1 - comparing the cost of the program in monetary terms
with the benefits in non-monetary terms (since it is very difficult to put a dollar
value on a human life [Thompson 19871, or by a cost-effectiveness analysis
(Robinson 1993cl - comparing the cost to society of caring for VHL patients
by treating symptomatic disease, with the cost of implementing a screening
program and treating presymptomatic disease.
Health care evaluation is a complex process in which there is
considerable disagreement among the experts. The following section therefore
presents a brief review of the various approaches. a demonstration of how one
of them can be applied to the present program, some of the data needed for
such an analysis, and some tentative conclusions.
As discussed in the thesis introduction, cost-minimization analysis is
used when the outcomes of programs to be compared are the same, and the
goal is to choose the least expensive option. Cost-effectiveness analysis is
used when the outcomes of the programs are similar, but differ at least in
degree. Neither of these methods is suitable for economic evaluation of a
program as complex as the VHL screening program described, with
individualized screening protocols, and variable outcomes.
In cost-utility analysis, the outcomes vary and are converted intoquality
of life units for comparison, the most common unit being the OALY. However
QALYs have proved difficult to measure. In cost-benefit analysis, by definition.
all costs and benefits are converted into monetary units. However, many cost-
benefit studies have been published in which non-monetary units are used for
some costs or benefits, particularly relating to length and quality of life.
Several papers (Hagard and Carter 1976, Chapple et al1987, Henderson
1991) describe cost-benefit analyses of programs for prenatal diagnosis of
severe genetic disorders (eg, Down syndrome, neural tube defect, or Duchenne
muscular dystrophy). The authors estimate the costs of these programs as the
costs of genetic counselling, and of the diagnostic procedures to allow prenatal
diagnosis and therapeutic abortion of an affected fetus. They estimate the
benefits of screening as the costs not incurred for treatment, specialized
education, and extra family expenses for the relevant disorders because the
births are prevented. The assumption is that each affected fetus will be
aborted, so that either there are costs for treatment and management (status-
quosituationl,ortherearecostsforscreening(screeningprogram).
Modell and Kuliev (1991 and 1993) disagree with this approach since not
all screening programs for hereditary diseases result in such a clear-cut
"either/or" situation, particularly if the disease is of "late-onset", or if treatment
is at least partially successful.
The model for this VHl economic evaluation is Modell and Kuliev's
evaluation of programs for thalassemia management when different levels of
education and screening have been introduced (Modell and Kuliev 1993).
These authors stress that prevention and treatment are not necessarily
alternatives, but can be complementary objectives of the same program in
which the goal is to obtain a healthy family. For the VHL evaluation. the
comparison is between al the status quo situation with no screening and
patients treated when symptomatic (Program 1). and b) management and
treatment after screening is introduced (Program 2includingclinicalscreening
only. and Program 3 including genetic and clinical screening).
VHL patients will require medical care. whether or not there is a
screening program. because the VHL gene predisposes to tumour development
in mUltiple parts of the body. Without screening (Program 11. patients will
present for treatment when symptoms develop. as has been documented for
members of the large Newf,-,undland family prior to 1982. Some of these will
have treatable disease. and others will have advanced disease whichresultsin
death or disability. The monetary cost of the no-screening situation. therefore.
is the cost of treatment of symptomatic patients. and the costs incurred by
families because of death or disability from untreatable complications of VHL.
When a screening program is implemented. the cost of management and
treatment of VHL family members includes the direct and indirect costs
(Stoddart and Drummond 1984b. Robinson 1993bl of the program. and the
cost of treating patients identified by screening or any who present
symptomatically. From the review of medical outcomes of screened and
unscreenedcohorts (Chapter 6). it is expected that screened patientswillhave
treatment that is more frequent. but less complex and more successful. These
patients have been able to return to work following the postoperative recovery
period, in contrast to the many patients presenting symptomatically who could
not work subsequent to treatment.
In the first stage of the screening program (Program 2), clinical screening
was offered to all affected and at-risk family members (determined by the
position in the pedigree). Annual screening was recommended to continue until
at least 50 years of age, even for those with negative results. because of the
range of ages of onset of VHL in the literature. The cost of screening therefore
is the cost of annual screening for all who are affected and all first degree
relatives. including those who in fact do not carry the VHL gene. The direct
hospital costs and the cost of administration of the screening program, as well
as the out-of-pocket expenses for family members. must be summed for this
In the second stage of the screening program (Program 31. genetic
testing is offered to first degree relatives to distinguish gene carriers and non-
carriers. Then clinical screening is only required by those already affected or
shown to carry the VHL gene. The cost of genetic testing is added to other
costs, but the cost of clinical screening is much reduced because non-carriers
are no longer screened.
There are also indirect psychosocial costs for each of these three
programs: in the status quo situation, this is the extreme anxiety of affected
and unaffected family members because of the severe disease, the frequent
early deaths, and the poor understanding of the cause or means of control of
VHL. As has been documented through interviews, anxiety about VHL disease
is reduced for most family members by the educational and counselling
component of the screening program. However, repeated examinations for a
potentially lethal condition may induce stress, and for some individuals,
"labelling" (with the high-risk or presymptomatic diagnosis of VHL diseasel may
create a high anxiety state (Sackett et al 19911.
Balancing these costs are the medical and social benefitsofscreening,
including life-years gained (Robinson 1993cl and days of disability averted
(particularly blindness, neurological deficit, and symptomatic cancer). There is
also decreased anxiety for many family members when they have confidence
that the medical system recognizes their risks, and actively searches out and
treats problems which may exist.
The financial benefits of screening are that treatment ofearlydiseaseis
frequently less costly than treatment of late disease (Shortell and Richardson
19781, and welfare or social services costs to dependents will be decreased if
early deaths or disability are prevented.
With multisystem diseases like VHL, however, it is important to
recognize that identifying and successfully treating one manifestation does not
result in a cure. VHL is a lifetime disease and consequently has a continued
risk for subsequent manifestations which will require appropriate treatment.
The components of the alternative programs for management and
treatment of VHL family members were identified, as were the costs and
benefits of each of these programs, whether monetary or non-monetary. The
societal viewpoint (Robinson 1993a, Phatak et al 1994) was used so that costs
and benefits to the patients, to other family members, and to the medical care
system were all included (Table 7.4).
The direct costs of Program 1 are the costs of treatment of symptomatic
disease, including investigations, hospitalization and surgical procedures. For
comparison, the present-day {19941 cost was calculated for the medical care
documented in patient charts. For investigations and treatment prior to 1981,
there is no record of family members' out-of-pocket expenses. The indirect
costs of Program 1 are the costs of disability, and premature death from VHL,
and the extreme anxiety in affected and at-risk family members.
The direct costs of Program 2 are the costs of clinical screening,
including the cost of recommended investigations for affected and at-risk family
members, the cost of admini~trationof the screening program (the proportion
of salary of the geneticist and secretary attributable to the time commitment
to the program), the cost of follow-up investigations and treatment of affected
individuals, and the out-of-pocket expenses to family members participating'in
screening and treatment. The cost of screening for at-risk family members was
calculated from the number of participants and the cost of the set of annual
TABlE 7.4. IDENTIFICATION OF COSTS AND BENEFITS OF PROGRAMS FOR MANAGEMENT OF VHL DISEASE WITH OR WITHOUT
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investigations recommended in the screening protocol. The cost of screening
and treatment for affected family members was determined directly by
calculatingthecostofallappointments,investigationsandtreatmentsrecorded
in the medical records of these patients. This approach was taken because of
the variability of the disease; the treatment required is different for each patient
and even the screening protocol varies depending on the previous
manifestations of the disease. Therefore an average cost of screening and
medical care for members of this group was not known. Out-of-pocket
expenses for all family members (particularly travel expenses) were estimated
from the number of trips to the tertiary care centre required by those living out
The direct costs of Program 3 differ from that for Program 2 by al the
addition of costs of predictive testing (by mutation detection or linkage analysis
as appropriate) for at-risk family members requesting this, and b) the
subtraction of annual screening costs and ollt-of-pocket expenses for those
found not to carry the VHLgene.
The costs of medical appointments, investigations and treatments
(including hospitalization and surgery) were obtained fromthefeeschedulesof
the radiology department, the medical laboratories, and the provincial medical
care plan. If the fees quoted did not already include factors for overhead,and
for maintenance and depreciation of major equipment (such as for CT scan, MRI
and ultrasound), appropriate amounts were added to the base fees (Stoddart
and Drummond 1984b).
The indirect costs of the programs were assessed by interviewing key
participants about the psychosocial costs and benefits of the clinical and
genetic components of screening, as described in thepreviouschapter.
The costs of the three programs are summarized in Table 7.5, and the
costs estimated for the three comparison groups in Program 1 (the 1962-71
cohort from Newfoundland, the 1972-81 Cohort from Newfoundland and
Ontario, and the 1982-91 cohort from other provinces) are presented in more
detail in Tables 7.6a,7.6b, and 7.6c, respectively.
For Program 2, monetary costs for screening and treatment of affected
and at-risk family members were calculated directly, adding costs of all
investigations and procedures required during 1982-1991, a proportion of the
geneticist'sandsecretary'ssalariesforadministrationoftheprogram,andout-
of-pocket expenses of family members participating. There is no cost included
for disability or death; none of the affected members of this group are disabled
by the disease (all have been able to return to work following usual
postoperative recuperation whenever surgery was required). Although there
was one death and three instances of unilateral blindness in the group, these
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were related to delayed investigation and treatment prior to 1982 so were not
included in the cost of Program 2.
The costs of Program 3 are the predicted costs of management of the
same group of affected and at-risk family members as in Program 2, assuming
that genetic testing had been possible in 1982 as the first step of the screening
program. All of the investigations and treatment of affected members, the four
genecarriersidentifiedbypredictivetesting,andthethreechildrenforwhom
genetic testing was declined would have been necessary for Program 3, as they
were for Program 2. The cost of molecular genetic testing for all at risk is
added to the cost of Program 2, and the cost of clinical screening for those
who were later found to be mutation-negative is subtracted. Thus the
monetary costs of Program 3 are less than for Program 2, and, from the
interviewsdonepreviouslY,thepsychosocialcosts (particularly from anxiety
and lack of reproductive choice) are also less for Program 3 than for Program
The cost of management of VHL with a screening program was then
compared with the cost of management of VHL after symptomatic presentation
(Program 1). Costs of investigation and treatment, and costs relating to the
disabilities and early deaths caused by late treatment, were identified for 3
comparison groups: al the cohort in Newfoundland when VHL disease was first
recognized (1962-71) (summarized in Table 7.6a), b) the cohort of 1972-81 in
Newfoundland and Ontario (summarized in Table 7.6b), and c) the cohort of
1982-91 in Ontario and New Brunswick (summarized in Table 7.6c). There
was no screening during 1962-71, and only minimal screening during 1972-81,
or during 1982-91 for family members in other provinces.
For these groups. medical records were reviewed to identify the type and
numberof hospitalizations. investigations and procedures that were carried out.
For comparison of costs, the value used was the present day (1994) cost of
similar medical care in Newfoundland. Some medical records were incomplete,
and out-of-pocket expenses are unknown; therefore monetary costs for these
comparison groups are underestimated.
Early deaths and disabilities related to delayed diagnosis and treatment
of VHL manifestations (particularly bilateral blindness, and neurological or other
medical disabilities preventing normal employment) were then identified for
each group. Because disability pensions are typically related to previous wages
(which were unknown), disability pensions could not be calculated. In order to
provide some estimate of the financial implications of these deaths and
disabilities, values were obtained for legal awards or insurance payments for
·,oss of future wages· because of death, or similar disabilities of individuals of
comparable age but from the general public. The number and ages of children
left by death of a parent were also documented. Although the identified
monetary costs within the health care system are greater for screening and
management of VHL (Programs 2 and 3), the costs in loss of life and reduced
quality of life when patients present symptomatically, far outweigh any
apparent financial savings from not screening.
Finally, the mean age of gene carriers was calculated for the
experimental group and the two control groups in Newfoundland. For the
experimental group, this includes all those identified by symptomatic
presentation, by screening, or by direct mutation detection. In order to have
complete identification of gene carriers in the earlier groups, all those with a
diagnosis of VHL at the time, and those who subsequently developed VHL were
included. The mean age of gene carriers has increased from 23.7 and 23.4
years in the earlier decades to 31.5 years in 1992.
This cost-benefit study considers the overall costs and benefits of
screening and treating members of families with von Hippel-Lindau disease, and
compares this with the costs and benefits of treating these same individuals if
no screening program is in place (Program 1). Additionally, the costs and
benefits of the screening and treatment program are considered either as
originally implemented with clinical screening only (Program 2), or as recently
possible, with a combination of genetic and clinical screening (Program 3).
This approach is taken because those who have inherited the VHL gene
will require medical care whether or not any form of screening takes place. The
goal of the health care system is to maximize the health of the population
(Williams 1974, Robinson 1993al; more specifically, to prevent disease when
possible, and to improve the health of individuals who are ill (including patients
with VHl). Because resources are not limitless, it is desirable to control health
care expenses while pursuing this goal (Sackett 19BOI.
All costs and benefits of the three VHl programs were identified (Table
7.51. There has been no attempt, however, to convert all costs and benefits
intomonetaryunitsbecauseoftherecognizeddifficultyinvaluinghumanlife
or human disability (Modell and Kuliev 1991, Robinson 1993d, Robinson
1993e). Monetary costs, including direct and indirect costs to the patients,
their immediate families and the medical care system, for screening tests,
follow-up investigations and treatment of manifestations of VHl, were
calculated and compared. The ascertainment of costs for treatment of
members of Program 1 is less complete than for the screened group, because
of historical or geographic reasons for difficulties in obtaining complete data on
days in hospital, number of outpatient appointments, and out-of-pocket
expenses. Nevertheless,ifcostsofdeathanddisabilityareincluded,monetary
costs are greater in Program 1 than for Programs 2 or 3, in which screening has
been implemented.
Improved medical and psychosocial outcomes were demonstrated for
participants of the screening programs and members of their families,before
the cost-benefit analysis was undertaken. There was no attempt to convert
these costs and benefits into dollar values, so the cost to society for the VHl
screening and treatment program cannot be compared to the cost to society for
some other "program" within or outside the health care sector. However, if
these individuals are to be treated, then this is the most cost-beneficial way to
Mosteconomicanalysesofgeneticscreeningprogramscomparethe cost
of screening the population at risk with the cost of treatment of affected
individuals avoided, as an either/or situation (Hagard and Carter 1976,
Henderson 1991), rather than comparing the cost of treatment of affected
individuals with or without previous screening. Cost-benefit analyses of
screening for thalassemia (Modell and Kuliev 1991), and for hemochromatosis
(Phataketal1994) are the exceptions.
The main reason for the different approaches are the characteristics of
the genetic diseases being screened for. If affected individuals will have a
lethal disease, or major mental or physical handicaps despite the best
treatment, and particularly if the condition isc;ongenitalorhaS its onset in early
childhood,the reproductive choice taken is often the termination of pregnancy
involving an affected fetus (Chapple et al 1987). Therefore the goal for many
individuals being screened is to prevent the birth of affected children, and the
economic analysis of the screening program reflects this point of view.
Screening for "late-onset" genetic disease (often called adult-onset
genetic disease, although this term is notalwaysappropriatel,and particularly
screening for treatable late-onset genetic disease hasdifferentobjectives, and
therefore the evaluation must be different. Gene carriers are unaffected at birth
and for varying periods of time before one or more medical problems develop.
Frequently these medical problems (whether cardiovascular disease as in
Marfan syndrome. or a tumour as in one of the hereditary cancers1 can be
treated successfully. particularly if identified early. and the "affectedindividual"
can lead a productive life following treatment.
For some late-onset diseases such as the hereditary tumour syndromes.
including VHL. disease mutations predispose to multiple tumours. and after
successful treatment of one manifestation of disease. other tumours may
occur. Still. between the occurrence and treatment of different tumours. the
affected individuals may have no symptoms and function normally. particularly
if the tumours are identified and treated early. Therefore the main goal of the
screening program is to prevent death or disability from the disease. not to
prevent birth of affected individuals.
For late-onset diseases. it is rare for those at risk of having affected
children to consider prenatal diagnosis and therapeutic abortion as an option.
This is documented for autosomal dominant polycystic kidney disease
(Hodgkinson et al 1990. Gabow 1993) and for spinocerebellar ataxia. (Nance
et al 19941. as well as for the VHL families. and families with other hereditary
tumours described in this thesis. For the parents involved. it is difficult to
acceptelectiveterminationofapregnancythatwouldresultina normal birth.
despite the potential for severe disease in the future. Parents in the VHL
families studied, however, consider VHL to be so severe that many have
chosen to have no children rather than risk transmitting the VHL gene.
Health care evaluation provides a formal review of the need for, and
objectives, outcomes and costs of a health care program, to determine whether
it is appropriate to continue the program in its present or another form.
Needs assessment considers the reason fora program. A health care
program may have been appropriate previously, but no longer be necessary if
the risk factors, or the disease in question, have been significantly reduced or
eradicated. A continued need for a VHL screening program in Newfoundland
is indicated by the number of affected or at-risk individuals in the province, the
severity and complexity of VHL disease, and the medical and reproductive
problems resulting from late diagnosis and treatment.
Summative evaluation relates the objectives of a program to its
outcomes. Affected individuals identified by the clinical screening protocol
utilized in Newfoundland have an earlier age at onset (mean age of 16 years)
than those identified by symptomatic disease (mean age of 28 years). Clinical
screening allows the majority of affected family members to know that they
have inherited the VHL gene in time to make informed reproductive decisions.
Identification of those who~carrytheVHL gene, by clinical screening, is
not as exact, however, since those with no disease manifestation may be non-
carriers, or carriers with later onset disease. This is an important distinction for
a disease so severe that in the past family members at 50% risk chose to have
no children rather than risk passing on the VHLgene. The recent identification
of the mutation in three of the Newfoundland VHL families means that all gene
carriers and non-carriers can be identified prior to the reproductive period, if
each family member wants this information. This is of particular benefit to
those identified as non-carriers; they no longer require clinical screening, and
can have children without fear that they will transmit the VHL gene.
There have been fewer deaths, and less disability (such as blindness or
neurological handicap) in family members who have been clinically screened
than in those presenting symptomatically. Thus, early diagnosis and treatment
appears to improve the prognosis of VHL, but longer follow-up is necessary to
confirm this. VHL is, however, an unrelenting disease, and those who have
beensuccessfullytreatedfacetheprospectofothertumoursdeveloping in the
future. Individualpatientsinthescreenedgroupthereforehavemoretumours
than those who presented symptomatically and often died at a young age. An
increase in the mean age of affected individuals in the screened versus
unscreened groups provides evidence that patients who have been managed by
screening are living longer.
Based on past and present observations and recent interviews, famiiy
members participating in the screening program have a better understanding of
the clinical and genetic features of VHL, and have less anxiety about the
disease than family members before the screening program began. Relatives
in other provinces do not have the same regular screening as those in
Newfoundland. but many have benefited indirectly, particularly in their
understanding of VHL and their awareness of possible symptoms. by obtaining
copies of pamphlets and screening protocols from family members in
Newfoundland. From the point of view of the analysis. this is "contamination"
of the control group (Sackett 1980), but this dissemination of knowledge meets
the broader objectives of the VHL program. and is both impossible and
unethical to prevent.
Formative evaluation assesses the components of the screening program;
thepersonnel,the participants, and the procedures. The investigations making
up the VHL screening program have been updated regularly. Participants can
therefore benefit from new technology, and from new information about the
natural history and the molecular genetics of VHL. Although program
objectives are being met, improvements are possible in the process by which
the screening protocol is managed. Specifically. it would be more efficient to
have a computerized system of storage and recall of patient data. particularly
of the date and results of recent screening or interventions. sothat subsequent
appointments can be scheduled more efficiently. There are similar screening
programs for other hereditary cancers in Newfoundland. and a computer-based
registry (Littler and Harper 1989, Read 1990) for management of this group of
genetic diseases would be invaluable.
Finally, cost-benefit analysis compares the relative costs and benefitsof
managing VHL disease with or without screening. VHL is expensive to treat
and control, and is associated with high psychosocial costs for affected and
unaffected family members. Screening reduces monetary and non-monetary
costs to the health care system and to family members. through identification
of non-carriers who do not require screening, and through earlieridentification
and treatment of tumours in those with VHL mutations. Family members are
using the information provided in the educational and counsellingcomponents
oftheprogramtovoluntarilyreducethenumberofaffeetedindividuals in future
generations.
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Screening for genetic disease has advanced since the first programsfor
early detection and treatment of phenylketonuria were introduced in the 1960s
to prevent severe mental retardation. Although the burden of many genetic
diseases was well recognized, screening for these disorders was originally
limited because few could be identified presymptomatically (by biochemical or
physiologicaltestingl,andevenfewercouldbetreatedsuccessfully.Whenno
treatment was available, other objectives of screening programs were
substituted, including al provision of counselling regarding reproductive
options, to prevent, or prepare for, the possible birth of an affected child,and.
later, bl reduction of uncertainty when faced with the possibility of future
development of a severe untreatable disease.
An ever-increasing number of genetic diseases can now be identified
presymptomatically, using molecular genetic technology to detect specific
mutations. or markers linked to disease loci. As mapping and cloning of
disease genes accelerates, the number of potential genetic testshasincreased
rapidly. Availability of tests is no longer a limiting factor for development of
screening programs; rather. the danger is that screening may be offered
"because a test is available" without prior evaluation toestablishthatscreening
is in the best interests of those affected or at risk.
The rationale for screening, as setout by Wilson and Jungner (19681
(but adapted to suit the broader objectives of genetic screening). still provides
useful guidelines for the development of a screening program. According to this
rationale, screening is appropriate when:
thereisarecognizedburdenofdisease
the natural history of disease is known (or the gene, or map
location has been identified)
a clinical test is available to deteet presymptomaticdisease(ora
genetic test is available to identify gene carriersI
treatment is available (or reproductive options and counselling are
available, or uncertainty can be reduced)
early treatment (or counselling) improves the prognosis and/or the
quality of life
The successes and failures of previous screening programs provide
valuable lessons for those embarking on a new program. A screening test must
be partofacomplete screening program, ideally, planned with the population
tobescreened,andincludingeducationandcounselling,informedconsent,and
confidentiality of testing and. reporting for all participants; and availability of
fOllow-up investigations and treatment, or provision of reproductive options, for
those testing positive.
As for other health care programs, screening programs for hereditarv
disease must be evaluated, to assess the medical and psychosocial outcomes,
and to determine the costs and benefits so that best use can be made of health
This thesis considered the appropriateness of screening for the hereditary
tumour syndromes (variable AD diseases predisposing to benign or malignant
tumoursl. using a combined genetic and clinical screening protocol to identify
gene carriers and provide reproductive counselling. and to detect and treat
tumours early in order to improve the prognosis. This group of disorders was
first distinguished from other genetic diseases for which sereeningprograms
had already been developed. Then the need for screening. the objectives. the
choice of investigations or tests. and the medical and psychosocial outcomes
of screening for each screening program were discussed. with a more formal
evaluation. including a cost-benefit analysis. of the longest running screening
program (that for von Hippel-Lindau disease).
Capitalizing on the unique opportunity offered by the structure and
distribution of the Newfoundland population. the author had identified large
Newfoundland families with von Hippel-Lindau disease IVHL). multiple
endocrine neoplasia type 1 (MEN-1) and type 2 IMEN-21. familial adenomatous
polyposis (FAP) and hereditary non-polyposis colon cancer (HNPCCI. Extended
pedigrees were constructed. previous morbidity and mortality documented. and
relevant literature reviewed. A burden of disease was established for each
hereditary tumour syndrome (ie. previous early deaths and disabilities of
affected individuals. reduced family size. and anxiety in many affected and
unaffected membersl, and the 'population" at risk determined by the autosomal
dominant inheritance pattern.
Information on the natural history of each disease (the type and
frequency ofturnours, and their age and order of occurrencel was gathered
from the family medical records and the relevant literature. For three of the
"hereditary cancers' studied (VHl, MEN-1, FAPI, the initial data from the family
records suggested an atypical disease presentation within the Newfoundland
kindreds.Foreachdisease,specialistsmettodeterminetheappropriateclinical
investigations for presymptomatic detection of tumours. At the outset, less
genetic information was available; none of the relevant genes was cloned,
although genetic mapping strategies were in progress elsewhere, in several
cases involving Newfoundland families. Detection of gene carriers was
therefore originally provided by diagnosis of clinical disease. linked markers or
specific mutations have now been identified for predictive testing or
presymptomatic diagnosis of gene carriers for each hereditary tumour
syndrome.
Educational materials were prepared, counselling was provided, and
screening was offered to family members, first for the presymptomatic
detection of individual tumours, and later for the identification of gene carriers.
Follow-up investigations and treatment were provided for those with positive
clinical screening, and counselling regarding reproductive options was given to
those identified as gene carriers by clinical or genetic testing.
Records have been maintained throughout the development and
implementation of the screening programs, to document the identification and
treatment of tumours, and the reproductive decisions made. A full health care
evaluation has now been completed for the VHL screening program (the first
screening program initiated, and therefore the one with the most data
available). An improved prognosis (reduced morbidity and mortality), and bener
quality of life (reduced anxiety, and informed reproductive decisions) are
demonstrated. The other programs have been less formally reviewed. with
similar results. For VHL, the overall cost to society of screening and
management of presymptomatic disease is less than the combined costs of
treatment of symptomatic disease, and the costs related to early deaths and
disabilities.
Screening programs combining clinical and genetic testing methods to
identify gene carriers and provide reproductive counselling, and to identify and
treat presymptomatic tumours are therefore considered appropriate for
hereditary tumour syndromes.
As a group, these hereditary cancers differ from untreatable adult-onset
disorders (eg, Huntington disease and other neurodegenerative diseases)
because the harmful effects of the disease genes can be mitigated. Asaresult,
there is greater participation in these screening programs than in predictive
testing programs for HD. Many of the psychosocial issues related to prediction
of future rather than imminent disease, however, apply, so that the need for
counselling and support are similar for the hereditary cancers as for HD. Despite
many similarities, there are important differences within this group of hereditary
cancers (the age at onset, the severity of disease, the spectrum of disease
expression,the potential for treatment, and the state of genetic knowledge)
that have influenced the development of the screening programs.
Because the information may be helpful in the future development of
similar programs. I will summarize the ways in which these factors affected the
structure of specific programs, and influenced the attitudes of family members
towards participation in the clinical and genetic components ofscreening.lwill
then consider the relevance of the Newfoundland experience to other clinical
senings, and review the value of registers in managing screeningprograrns. I
will also address the issue of genetic testing in childhood. and finally will
restate the value of clinical and genetic screening programs for management of
hereditary tumour syndromes.
!YR' .od timing Of GlinlC" inY'ltjg,tigD'
For each screening program, the type and frequency of clinical
investigations recommended depends on the tumours that occur. and the age
range over which they have been identified. This is initially defined by the
literature. but revised as necessary according to family experience. For
hereditary tumour syndromes in general, screening is recommended to start five
years before the earliest symptomatic presentation in order to identify
presymptomatic disease (Fitzgibbons et a119871. In the following section, I
will describe how the screening programs have been modified as the unique
For FAP, the investigation recommended in the literature (annual
sigmoidoscopy starting in late childhood or early teens) is based on the
characteristic location of the premalignant stage (the mUltiple polyps) in the
sigmoid colon and rectum, and the typical age at onset in the teens or twenties.
In the Newfoundland FAP family, by contrast, the number and location of
polyps is variable, with one third of patients (including some with cancer)
having few if any polyps within view of the sigmoidoscope. The age at onset
of polyps is also variable, from the teens until at least the forties. The
recommended screening test is therefore a full colonoscopy, with screening
continuing until a later age than for typical FAP for those whose genetic risk is
not defined. Similar families have been documented elsewhere, and a
relationship between this clinical phenotype and the location of the mutations
within the APC gene has beelj established for most of these families. The APC
mutation for the Newfoundland family, however, has not yet been identified.
Thus there is evidence of clinical heterogeneity, and as a result different
screening protocols are appropriate for different families - with a large famiiy
this should be obvious, but with a small family this distinction may not be
apparent. Identifying the mutation will then be important to define the
expected phenotype,and plan clinical management.
The early data on tumour frequencies in the Newfoundland MEN-1
families were also atypical. and the families originally called the prolactinoma
variant of MEN-1. But was this because of genetic or clinical heterogeneity. or
because of greater variability of typical MEN-1 than previously recognized? The
evidence supports the latter. Large families elsewhere have since been
described with an intermediate clinical phenotype (Shepherd et a119911. and
some branches of the Newfoundland families are indistinguishable from typical
MEN-1. A more comprehensive screening protocol is, therefore, recommended
The large Newfoundland VHL family has a higher frequency of
pheochromocytomas than many other VHL families. and since these are
frequently the initial manifestation (andwereafrequentcauseofdeathinthe
past), there has been greater emphasis on screening for pheochromocytomas
in Newfoundland than at many other centres. Since the VHL gene has been
cloned and many mutations identified, a genotype/phenotype correlation has
recently been recognized between the type of mutation and ·pheo· vs ·non-
pheo· families (predominantly missense mutations in ·pheo· families, and
predominantly deletion or truncation mutations in ·non-pheo· families).
Because the genotype/phenotype correlation is not 100% and because an
undetected pheochromocytoma is acutely life-threatening, this information
should be used to emphasize screening for "pheos· in families with missense
mutations and to reduce but not exclude screening for·pheos" in familieswith
truncation mutations. Documentation of tumour frequencies with different
mutations should continue. to confirm and refine the genotype/phenotype
classification so that other modifications of screening protocols may be
possible. Conversely. knowing the clinical phenotype in a given family will
guide a search for the specific mutation. All investigations in the VHL
screening protocol now begin earlier than originally recommendedlbasedonthe
literature review) because of the identification of advanced disease at initial
screening ina number of family members.
The Newfoundland MEN-2 family may be an FMTC (familial medullary
carcinoma) family. at risk for thyroid disease only. rather than an MEN-2A
family. at risk for thyroid and adrenal disease. as originally thought. Screening
for both thyroid and adrenal disease continues. however, because of the
uncertaintyaboutthecauseofbilateraladrenalhyperplasiaintwobrotherswho
are at low risk to carry the MEN-2 mutation. Screening is initiated later in this
family than recommended for MEN-2A families 111 years of age vs 3 years of
agel because of the late age at onset of thyroid disease. Screening does.
however, begin more than five years before the earliest documented age at
diagnosis 118 years).
For HNPCC families screening is concentrated on detection of colon and
endometrial cancers. More comprehensive guidelines for screening are not yet
established, since present methods are not sensitive or specific enough for
screening for such tumours as ovarian, pancreatic, or urogenital cancers. There
is also the problem of variability in the type of tumour and age atoccurrence
within and between families. When there is extreme variability of disease
expression, as in HNPCC, it is difficult to plan a protocol that will allow early
detection of the majority of tumours without excessive false positive results or
harmful side effects of investigations, and without loss of interest in screening
after several negative tests in those who may be at high genetic risk.
Four different genes have been mapped and cloned but no
genotype/phenotype correlation has been identified which could guide the
development of different screening protocols, or the recognition of the relevant
gene in a specific family. Recent literature does recommend colonoscopy every
second year rather than less frequently (previous recommendations from some
centres were for screening every 3-5 years) since interval colon cancers have
been identified in patients screened every third year. The frequency of
screening is thus determined by the rate of growth of typical tumours.
For each hereditary tumour syndrome, the type of investigations will be
revised as new diagnostic options are available (whether new scanning
techniques such as MRI and MIBG scanning, or new laboratory assays), and the
timing of investigations may need to be altered as new information on age at
onset of tumours, in general or for a specific family, becomes available. This
may be earlier screening than recommended in the literature as for VHL, or later
screening than recommended in the literature as for the Newfoundland MEN-2
family.
Tvp' p'gAn.tiGtI,ting
The type of genetic screening available depends on the state of molecular
genetic knowledge. a rapidly changing field. Before the relevant gene is
mapped. only pedigree analysis is available. Predictive testing by linkage
analysis is possible if a gene is mapped and informative markers have been
identified. orifa gene is cloned but the specific mutation not identified for the
family in question. Presymptomatic diagnosis by mutation analysis is available
when the specific mutation is known. When the work described in this thesis
began. no genetic testing (except pedigree analysis) was available for the
Newfoundland families. Either the relevant genes were not mapped. or
informative markers had not been identified. It is interesting. therefore how
rapidly the results of research have been adapted and applied to clinical
practice.
Currently genetic testing by mutation detection or linkage analysis can
beofferedtoalmostallfamiliesstudied.Presymptomaticdiagnosisbydirect
mutation detection is possible for the large HNPCC family. and for three of five
VHL families. since the specific mutations in these families have been identified
subsequent to the cloning of the relevant genes in 1993. Predictive testing by
linkage analysis is available for the FAP family. and was used for three VHL
families before each mutation was identified. Linkage analysis has also been
used for the MEN-l families but the available markers are not informative for
all family members requesting genetic testing.
For over 80% of MEN-2A or FMTC families in the literature. the mutation
has been identified in one of five cysteine codons in the extracellular domain
of the RET proto-oncogene. Mutations in the remaining one sixth of MEN-2A
and FMTC families. including the Newfoundland family. have not yet been
identified. Linkageanalysisprovidespreliminarypredictivetestinginformation
for the MEN-2 family.
For small families with VHL. MEN-l. MEN-2. or FAP that are identified
in the future. even linkage analysis may not be possible. despite the mapping
or cloning of the relevant gene. if the mutation is not known. and if too few
affected individuals are living for the marker alleles linked to the disease gene
in the particular family to be identified.
The situation for HNPCC is even more complex because of the genetic
heterogeneity recognized - four genes have been identified (hMSH2. hMLH1.
hPMS1. and hPMS2) and at least one other gene is anticipated. No
genotype/phenotype correlation has been recognized which could predict the
gene involved in a particular family. Most families are too small to obtain the
necessary data to substantiate linkage to one of the four known map locations.
and thereby identify the relevant gene. In relatively isolated populations like
Newfoundland. however. the numberof independent mutations may be limited.
The use of detailed pedigree studies. and mutation or haplotype analysis.asin
Finland, may identify a common founder of several families, and facilitate
genetic testing.
Another limitation to the availability of genetic testing is the small
number of molecular genetics laboratories capable of doing the testing I and of
research laboratories with time and funding to search for individual mutations).
iii) Rlcgmm.ndedlp,fprg.nIUsttt'!ing
Genetic testing should be available before the typical age that clinical
screening is recommended since one rationale for genetic screening is the
identification of gene carriers requiring clinical screening. The timing of genetic
testing therefore depends on the age at onset of the disease. For VHL,genetic
testing is offered in early childhood; for MEN-1, the Newfoundland MEN-2
family, and atypical FAP, genetic testing is offered in the early teens; and for
HNPCC, genetic testing is offered in the early twenties. Except for HNPCC,
these are ngI adult-onset diseases. Many of the objections to genetic testing
in childhood. are inappropriate when applied to VHL. MEN-1. MEN-2 and FAP
since many gene carriers will have disease requiring treatment before age 18.
ivt E!p'pt,d yptak. p'pROtti, tI,ting
Although genetic screening should be offered before clinical screening
begins, some family members may not wish to participate; for these family
members. clinical screening must remain available. The reasons for interest or
disinterest in genetic screening vary according to the disease, and will be
discussed in the next section IPatient attitudes and participation). However.
extensive education and counselling regarding the advantages and
disadvantages of genetic testing are necessary for all family members, even
though some, in the end, do not wish to participate.
y) Co,t. end b.n.fig pf,gllning
A formal cost-benefit analysis was completed only for the VHl screening
program, and the other programs were reviewed informally for comparison. Of
the conditions studied, VHl is the most expensive to treat, with or without a
screening program, because of the many different tumours occurring
throughout life. Those who are treated successfully for one tumour are
unfortunately at high risk of subsequent disease. The evidence from the cost-
benefit analysis, however, is that overall costs to society (including costs within
and outside the health care system) are reduced when the management
includes a screening program, because screening decreases early death and
disability.Whengeneticscreeningisincluded,thecostsarereducedbecause
only gene carriers (or those at high riskl participate in clinical screening. Many
years of annual testing for those who are found to bemutation-negative are
The likelihood of multiple tumours is much lower for each of the other
hereditary tumour syndromes so that the overall costs of screening and
treatment are less. Nevertheless, costs of disease management are reduced by
screening. For FAP and MEN-2, the majority of those with symptomatic
disease had advanced cancer, and, despite intensive treatment, early death
frequently occurred. The majority of those identified by screening, on the other
hand, do not have cancer (or, for MEN-2, have very small cancers confined to
the thyroid gland). These patients avoid the symptoms of cancer, and rarely
require chemotherapy or radiation treatment following surgery. Therefore the
costs of treatment and discomforts of the disease are less inthoseidentified
by screening. Although the follow-up of the Newfoundland FAP and MEN-2
families after screening was implemented, has been short, the literature
supports our evidence that subsequent cancers are uncommon in FAPand
FMTC patients following screening and surgery (Farndon et al 1986, Jagelman
et al 1988). Therefore, for many affected family members, the early
identification and treatment is curative. For these diseases also, genetic
screening,whenavailable,focusesclinicalscreeningonhigh-riskormutation-
positive family members, thus reducing costs.
For MEN-', the mortality was lower than for the other hereditary tumour
syndromes studied, but many symptomatic patients had serious morbidity. Early
identification by screening markedly reduces this morbidity and early mortality,
and often decreases medical costs by allowing medical rather than surgical
treatment. The cost per person for annual screening is lower than for the other
disorders because biochemical screening isutilized,andthe bloodsamplescan
be taken locally - saving travel costs for family members. However, because
of the extremely variable age at onset of MEN-1, a long follow-up time is
required for those with negative clinical screening ifgeneticstatusisunknown.
Genetic testing will therefore reduce the costs of the screening program despite
the lower cost per person of annual clinical screening. This is important
because of the large number of family members at risk in Newfoundland.
Screening for HNPCC in Newfoundland is very recent, and therefore
difficult to evaluate. Because there is less experience with clinical screening for
HNPCC, worldwide, than for the other hereditary tumour syndromes, it is not
yet known how much the morbidity and early mortality can be reduced by
screening. This reflects the extreme variability of clinical expression of HNPCC,
and the lack of sensitive and specific tests, and of successful treatment for
some HNPCC tumours (eg, of the ovary or pancreas). However, for those
screened regularly with colonoscopy, a reduction in morbidity and mortality
from advanced colon cancer is expected, resulting in reduced costs, as well as
increased benefits in length and quality of life.
In summary, it is necessary to know the disease, including both the
medical and genetic characteristics, in order to provide an effective and cost-
beneficial screening program.
PATIENT AmTUDES AND PARTICIPATION
$av9dty Of diy'.'
VHL is the most devastating disease of those studied, from the patients'
as well as the professionals' point of view, because of the early ageatonset,
the many different tumours, the multiple recurrences in anyone individual, and
the difficulty in treating some components of VHL. Extreme anxiety occurred
in many affected and unaffected family members because of the previous early
deaths and disabilities in their families.
FAP and HNPCC also caused many early deaths in the past, and
engendered an overwhelming fear of "cancer" in many families. For both
disorders, the recommended screening (colonoscopyl adds to the stress, and
sub-total colectomy, if required, reduces the quality of life. However, because
of the variability of HNPCC, some family members (particularly those whose
close relatives hadlateronset,ortreatable disease), are less concerned about
their risk of colon or other cancers, than members of FAP families.
In the Newfoundland family reported here, MEN-2 represents a serious
burden to the older generation, but is considered a treatable disease by the
younger generation. The screening (a stimulation test), and treatment (total
thyroidectomy) are more acceptable than screening and treatment for FAP and
HNPCC. For MEN-1 family members the perception of the disease is much more
variable, and is correlated with the relationship to severely or mildly affected
in Inttrt'tloGllnlc;aI'Gr••ning
Interest in clinical screening is determined primarily by the family's
perception of the severity of the disease, and of the potential benefitsof
screening lie, the likelihood of reduction of deaths and disabilities),butmaybe
modified by any unpleasantness or inconvenience of screening.
VHL is considered a very severe disease, but family members recognize
that screening may improve the prognosis because of early diagnosis and
treatment. Most are very compliant with the many tests of the screening
protocol because they see this as their only hope for a "healthy" life. They
worry that tumours will be untreatable if not detected early because they know
ofseriousdiseaseandsevereanxietywithinthefamilybeforescreeningbegan.
A few family members, however, are non-compliant because they deal with the
stress of the disease by putting it, and the recommended screening, out of
FAP is now considered by most familv members to be a serious but
preventable disease, however, the discomfort and embarrassment of the
necessary investigation (a colonoscopy) reduces compliance, particularly in
males. Eveninthisgroup,interestinclinicalscreeningisincreasedifhigh-risk
predictive testing results are received. MEN-2 family members accept the
pentagastrin stimulation testing, despite some unpleasantsideeffects,because
they recognize the sensitivity of this procedure in identifying early treatable
thyroid disease (incontrasttotheuntreatable metastaticthyroidcancerleading
to early death present in the previous symptomatic family member).
In the MEN-1 families, where there is extremely variable disease
expression, there is also a marked difference in interest in clinical screening
depending upon the relationship to those with severe disease. Some family
members are clearly uninterested because, in their experience, MEN-1 is so
mild. However, the screening is convenient because bloodwork can be done
locally, so some family members, who would not travel for testing, do
participate.
The availability of clinical screening for the HNPCC family is more recent.
Family members are divided between those eager to participate in a screening
program, hoping to prevent advanced cancer or early death, and those not
wantingtoacknowledgethecancerrisk,andthereforedecliningany screening
or discussion of HNPCC. The uptake of clinical screening has been greatest in
close relatives of those with early death or multiple tumours, because of the
hope of a better outcome. Those with cancers recently detected by screening
and successfully treated, encourage other family members to participate. The
prospect of colonoscopy, however, is a deterrent. Despite their concern about
the cancer risk, some family members cannot bring themselves to have this
testing.
In general, compliance with clinical screening increases when the
investigations are available locally (saving time and money for travel to a
tertiarycarecentre),andwhentheteststhemselvesarenotunpleasant.Family
support also improves compliance and reduces anxiety. Persons from small
families, or without known relatives with the same disease (for instance, an
affected individual who had been adopted outside the family) have a more
stressful time participating in a screening program.
iii) Intt,t,tinqtn.tic;,c;,.tning
The extent to which individuals were interested in genetic screening also
varied. Ingeneral,theuptakeofgeneticscreeningwascorrelated with the
overall severity of the disease, the stress or unpleasantness of the clinical
screening tests, and the likely informativeness of the results.
For the most severe disease, VHL, the majority of family members at risk
have requested genetic testing. However, those studied in Newfoundland have
all participated in clinical screening fora number of years. The consequence of
genetic screening, therefore, is continuation of clinical sereening for those with
a VHL mutation, or freedom from this screening protocol for those without. A
few family members declined genetic testing for their children because they
preferred the uncertainty of 50% risk status rather than facingthepossibility
of mutation-positive results. For a newly identified family, the decision
regarding genetic testing may be more difficult to make because mutation-
positive results (for a disease as severe as VHL) could be more devastating for
those who are unprepared.
All adults at risk for VI:tL chose genetic testing for themselves because
of the importance for reproductive planning as well as for determiningtheneed
for clinical screening. Several of those at 50% risk had previously put off or
forgone having children to ensure that others were not born with thedisease.
This included family members who were actually non-carriers of the VHL gene.
Knowing that they were mutation-negative would therefore permit non-carriers
to have a family.
The numbers requesting or declining genetic testing, and the reasons,
differed for the other diseases. The results of genetic testing, however, were
used primarily to determine whether clinical screening was needed.
The uptake of genetic testing was high in the FAP family, related to the
family perception of the severity of the disease, and the discomfort of
screening. Colonoscopy is considered unpleasant and embarrassing, but
because of the lethality of FAP if not detected early, many family members
agree that colonoscopy is necessary for those at high risk. The outcome of
genetic testing is, therefore, whether regularcolonoscopy is,orisnot,required.
For HNPCC there are similar concerns about colonoscopy. Many of those
participating in clinical screening desire genetic testing to define their risk more
accurately, and clarify whether they should continue with these investigations.
Others at risk want genetic testing to decide whether to begin clinical
screening, but the possibility of insurance discrimination creates a dilemma.
The extremely variable age at onset and reduced penetrance of HNPCC means
that some gene carriers will be unaffected by HNPCC for many years yet might
become uninsurable because of the genetic testing results. In VHL families,
this situation does not arise. Because of the consistently earlier onset of
disease, any discrimination regarding insurance is due to actual disease, not
predictive testing results.
Clinical screening for MEN-l is more acceptable than for the hereditary
colon cancers since it is primarily a blood test and can be done in the local
community. Some family members were quite willing to continue clinical
screening but lacked interest in genetic testing because it was not seen to offer
a significant difference in their lifestyle. Others, whohadcloserelativeswith
severe MEN-l manifestations, were more interested in knowing whether they
were at high or low risk of being affected, and requested predictive testing
when offered. The fact that MEN-l predictive testing was not always
informative, also decreased the uptake.
All members of the MEN-2 family desired genetic screening to determine
the need for continued clinical screening but definitive genetic testing is not
possible in this family until the mutation is identified.
iv) U'IQfg,n,tic,c;r,.niog
For VHL, the results of genetic screening determine who requires clinical
screening, and also provide information for reproductive decisions. Many family
membersfeltsostronglythatthisdiseaseshouldbestoppedthat,evenwhen
at 50% risk, they chose not to have children to ensure that another generation
was not born with the disease. Genetic screening allows informed reproductive
decisions, and particularly allows those who are not gene carriers to have
children without worry.
The majority of VHL gene carriers choose to have no children because
of the risk of recurrence. None would consider prenatal diagnosis and the
possibility ofa therapeutic abortion. DespitetheseverityofVHL,theycould
not accept termination of an "affected" pregnancy when the disease was not
actually present at birth.
Some of the older affected members of the MEN-2 family said that they
would not have had children if they had known of their genetic status and the
risk of recurrence. However, younger affected family members accept MEN-2
reproductive planning.
For the other diseases in this group (FAP, HNPCC, MEN-1) the results of
genetic screening have been used to determine whether or not clinical
screening is recommended lforthose screened,or for their childrenl,buthave
not been used for reproductive planning.
In summary, it is necessary to understand the psychosocial implications
ofa disease, as well as the medical and genetic characteristics, to provide an
acceptable screening program. For some hereditary diseases, or for some
individuals,screeningmaynotbethebestapproach,althoughthis may change
as more is learned about the genetic basis of specific diseases, and new
treatments are developed. For others, such as the hereditary tumour
syndromesconsideredinthisthesis,thereisevidencethatgenetic and clinical
screening will reduce or prevent some of the serious medical and psychosocial
consequences of disease, and that a screening-based approach to disease
management is cost-beneficial.
RELEVANCE TO OTHER CENTRES AND TO OTHER DISEASES
One conclusion of this thesis is that families with hereditary tumour
syndromes in Newfoundland have benefitted medically and psychologically from
management with a clinical and genetic screening program. But does the
experience in Newfoundland have relevance to other centres; and does the
recommendation for screening apply to diseases other than those described?
RelAyInG' tg Oth" Glntrl'
The basic recommendation when screening for hereditary tumour
syndromes elsewhere is to use the same approach: ie, to develop a clinical
screening protocol based on the natural history of disease, and to add genetic
screening as current molecular genetic knowledge permits, butnotnecessarily
to use the same screening protocols as developed in Newfoundland. The
investigations of the clinical screening protocol should be determined by the
tumours that occur, should start before the earliestageatdiagnosis, and should
be repeated at an interval determined by the rate of growth of tumours in
previous studies - usually annually or every two years. The objective is to
identify the majority of tumours at a premalignant or treatable stage, but not
to overburden those at risk with too frequent testing because of the financial
and psychosocial costs of screening. Genetic screening by linkage analysis or
mutation detection, when available. should be offered before the age that
clinical screening begins to reduce the monetary and psychosocial costs of
screening.
Ideally, information on the clinical phenotype, and the mutation, or map
location, of the relevant gene, will be available for the family or families to be
screened. However. if the families are recently identified, or too small, the
spectrum of disease will be unknown, and the mutation or relevant gene may
not have been identified. Then one must rely on the literature; data on
intrafamilialandinterfamilialclinicalvariability,andthespectrumandrelative
frequency of mutations documented for families elsewhere. are valuable.
If genotype-phenotype correlations are recognized,asan increasing
number of mutations are identified. these correlations may provide guidance for
clinical screening protocols. However. these correlations are more useful for
emphasizing the need fora particular type of screening insusceptiblefamilies.
than for excluding screening investigations.
There are differences in the screening process related to the locationof
a screening centre; whether in an "isolated", primarily rural area. oran urban
centre. In Newfoundland (or Tasmania [Shepherd 198511. the initial impetus to
develop screening was the largenumberofaffeeted members of individual
families, and the impact of the morbidity and mortality previously experienced.
The impetus to continue screening is the encouragement of early results. and
the interest and expertise developed by the specialists at the single provincial
tertiary care centre, and by the family practitioners in the geographicregioris
where the families are concentrated.
In urban centres the impetus for screening is the number of unrelated
families requesting this service. The number of members of each family seen,
or accessible, is likely to be much lower than in Newfoundland, both because
of smaller family size, and because families may be scattered, with relatives or
their records unavailable. Coordination of screening for such families maybe
more difficult because of the number of different physicians and heaIthcare
centres involved, and because less is known about the clinical phenotype of
each family. A comprehensive screening protocol should then be used until the
family can be classified as a typical ora variant form of the partieularhereditary
tumour syndrome, and a more appropriate screening protocol applied.
Although there are these disadvantages, advantages of screening
programs based at a large urban centre include earlier access to new
technology, and the availability of greater molecular genetic expertise,
facilitating mutation detection and predictive testing.
Support for family members participating in screening programs may be
provided in different ways in rural areas like Newfoundland, where there are a
few large families, and in urban centres with many small families. In
Newfoundland, patient support is provided by members of the same family who
have experienced the disease and the screening process; in an urban area,
support is more likely to be provided by a support group established by
members of a number of families experiencing a particular need.
B.,.va",. to otb.rdi••••••
The features of the screening programs described are determined bythe
characteristics of the hereditary tumour syndromes, ie, severe but treatable
autosomal dominant disease with variable age at onset and variable
manifestations. As stated in the introduction, similar screening programs have
been successfully implemented for other diseases with similar features, eg, for
NF2 (MacColiin et a11993) and for Marlan disease (Bridges et a119921, and a
screening program for dysplastic nevus syndrome is administered by the
Foundation for Hereditary Tumours in the Netherlands (Vasen 1989). NF-1 and
tuberous sclerosis, although AD multisystem diseases, are less suited to this
type of screening because many patients are mildly affected and do not require
screening (Smalley et al 1994), while others have severe disease which is best
managed individually as recommended in recognized standards of care.
Although clinical screening for polycystic kidney disease has been considered,
there is no definite evidence that the prognosil! is improved by presymptomatic
detection of disease, and there is little demand for predictive testing for ADPKD
(Gabow 19931.
Many of the neurodegenerativediseasessuchasthe cerebellar ataxias
and Alzheimer disease are severe AD diseases with variable age of onset,but
are not yet treatable (Nance et al 1994). HD predictive testing or
presymptomatic diagnosis protocols serve as the prototype for offering
molecular genetic testing for these conditions when the gene or specific
mutation is known. If treatment becomes available, a clinical screening
protocol may also become appropriate.
The greatest unfilled societal demand for a clinical and genetic screening
program for identification of gene carriers, and for early diagnosis and
treatment, is for hereditary breast cancer (gene carriers being at risk for ovarian
as well as breast cancer) (Statement of the American Society of Human
Genetics 1994). Hereditary breast cancer is more common than the hereditary
cancers studied, except for HNPCC, even though the majority of breast cancer
is sporadic rather than hereditary.
Although there is a need for early diagnosis and treatment, hereditary
breast cancer does not entirely fit the guidelines for clinical screening. Those
at risk for hereditary breast cancer may not always be identified (because of
late onset, low penetrance, or transmission through males, a family with
hereditary breast cancer may be missed; or a family with a cluster of sporadic
breast cancers may be incorrectly assumed tohavehereditarydisease);atest
to reliably detect presymptomatic disease is not yet available (a mammogram,
particularly in young women, may miss early breast cancer, and screening for
ovarian cancer is even less reliable); and early treatment does not.always
improve prognosis (King et al 1993). If clinical screening is recommended for
early identification and treatment of tumours in order to improve prognosis (and
hopes of those who are affected and at risk. therefore, raised), yet tumours are
missed because of insensitivity of the tests, or the medical outcome is not
improved, serious psychological harm can be done to the participants. and
future compliance with screening will be reduced. Improvements in the ability
to identify, investigate and treat those at risk for hereditary breast cancer are
needed before a clinical screening protocol is routinely offered to members of
Molecular genetic testing is, however. available for some families. by
linkage analysis or direct mutation detection (Editorial 1994c). As with HNPCC,
there is more than one gene causing clinically similar disease which adds to the
difficulty of identifying families in which genetic testing is informative. One of
the genes (BRCA1 on chromosome 17) has been cloned (Miki et a11994), and
a range of mutations identified, and a second gene (BRCA2) mapped to
chromosome 13 (Wooster et al 1994). Predictive testing following a HD
protocol has been offered to families where the mutation or chromosomal
location is known (Lynch et aI1993d). Participants have used this information,
to reduce uncertainty, to guide clinical management, and, less often, to make
reproductive decisions (Biesecker et al 1993). Research should continue on the
clinical. molecular, and psychosocial aspects of screening for breast cancer to
determine whether a full screening program can be offered in the future (NIH
Guide 1994).
THE VALUE OF REGISTERS
One of the difficulties of managing an on-going screening program is
keeping track of all participants. Unlike screening programs for prenatal or
neonatal hereditary disease. or for carrier status of certain autosomal recessive
disorders, which are conducted once. screening for those at riskforhereditary
tumour syndromes (or for other variable multisystem diseasesl must continue
onaregularbasis. For those who are affected or identified to be gene carriers,
life-long testing is required. There may be problems, however, if the
responsibility for screening is left to the individual family practitioner or
specialist. Each of the hereditary tumour syndromes is relatively rare so
primary care physicians may not be familiar with the screening requirements;
family members may be scattered and have a number of different family
doctors; and patients or their doctors may move; any of which could disrupt
the continuity of care. Screening for affected and at-risk family members may,
therefore, be best organized through a centralized registry.
A registry can efficiently manage large numbers of participants with a
special need, by maintaining.pedigrees, and personal and medical records of
consenting affected and at-risk members of relevant families (Read 19901.
Since date and results of last screening are recorded, the registry can notify
family members when screening is due. The actual screening may also be
centralized (as at the St. Mark's Polyposis Registry in London, Englandl. or
arranged through a local specialist, as from The Foundation for the Detection
of Hereditary Tumours in the Netherlands (Vasen 1989). The registry thus
provides a means of timely recall. and also facilitates revision of risk status for
other family members when a new diagnosis is made.
Registries have been used successfully for clinical management of FAP
families since the St. Mark's Hospital Polyposis Registry was established in
London, England in 1925 (Bussey 1975. Berket al 1981, Jarvinen et a11984.
Bulow 1986, Vasen et al 199Oal, and more recently have expanded to include
other hereditary tumour syndromes, such as VHL. MEN-2 and retinoblastoma
in Wales (Littler and Harper 19891; and MEN-1, MEN-2. HNPCC, and dysplastic
nevus syndrome in the Netherlands (Vasen 19B91. Besides the main objective
of promoting and administering screening for early detection and treatment of
tumours. registries can play an important educational role, for the primary care
physicians as well as for the participants. Basic information on the disease and
on screening recommendations can be provided initially. with updates as new
clinical. molecular genetic. or technological advances occur w hichnecessitate
modifications to screening protocols.
Because results of screening tests are stored. registries also facilitate
epidemiological research. particularly prospective studies 0 fthe clinical course
of disease. and of medical and psychosocial outcomes following screening and
treatment (Vasen et al 1989. Rhodes and Bradburn 19921. Evaluation of
screening programs is also facilitated. These studies may be from individual
registries. or may be collaborative when large numbers of subjects are required.
Results of the research are then used to revise screening protocols and improve
Genetic counselling may be organized through the registry, and DNA
banking and predictive testing have been offered when the relevant genes are
mapped or cloned (Read 1990, Bulow 1991, Burn et al 1991, Rhodes and
Bradburn 1992). It has also been recommended that registries maintain a
database of the spectrum of mutations identified (Petersen et al 1993). This
information would then be available for genotype-phenotype correlations.
In the Netherlands because of small geographic size, despite a large
population, a national registry tor several hereditary tumour syndromes has
proven to be very successful (Vasen 1989). In larger countries, such as Great
Britain, and particularly Canada and the United States, regional registries may
be more efficient in maintaining close contact with physicians and participants
whom the registry is serving (Rhodes and Bradburn 1992). Regional registries
frequently have contact through national or.international organizations (eg,
Leeds Castle Polyposis Group [Thomson 1988), or International Collaborative
Group on Hereditary Non-Polyposis Colon Cancer [ICG-HNPCCI [Vasen et al
1991b)) to maintain expertise and up-to-date knowledge.
Despite the many positive features of registries, there are some
concerns, particularly regarding ethical issues. There are concerns about the
confidentiality of records. There are also fears from some family members that
they will be "labelled" with the disease in question even if only at risk, and
suffer discrimination regarding employment or insurance. To reduce these risks
consent must be given before personal or medical records are entered in the
registry, and information is only released to third parties with further consent.
There may also be a conflict of interest between family members if some do
not wish to be included; family or medical records that are withheld may be
necessary for recognition of relatives that are at risk.
Finally, a registry requires funding for a dedicated coordinator, and
preferably a dedicated computer-based system for storage of data and
automatic flagging of those requiring follow-up, if it is to functionefficiently.
CONCERNS ABOUT GENETIC TESTING IN CHILDHOOD FOR ADULT-ONSET
DISEASES
A group of hereditary diseases, including neurodegenerative disorders,
AD polycystic kidney disease, and hereditary tumour syndromes, are classified
as late-onset disorders to differentiate them from genetic diseasespresenting
at birth or in early childhood (neonatal or early-onsetdisordersl. Becausethe
typical age at diagnosis of patients presenting symptomatically was in
adulthood,thesedisordershavealsobeen referred to as "adult-onset" disorders
(Harper and Clarke 1990). With a better understanding of early signs and
symptoms of many late-onset diseases, and the use of screening to detect
presymptomatic disease, diagnosis is now typically much earlier for some of
these conditions, for example in the teens or childhood for VHL, MEN-2. or
Marfandisease. For these diseases. the designation "adult-onset" is no longer
correct. Because geneticists and ethicists, very appropriately, have established
guidelines for genetic testing of children lie, testing before the age of majority1
(Harper and Clarke 1990, Marteau 1994, Report of a Working Party of the
Clinical Genetics Society [UK) 1994), this is not just a semantic argument.
Because of the autosomal dominant inheritance pattern of many of the late-
onset disorders, the risk of recurrence within familiesishigh,and the question
of predictive testing frequently arises.
The two most important points to consider regarding whether or not
genetic testing in childhood is appropriate, are age at onset, andavailabilityof
an effective therapeutic intervention. Ifonsetistypicallyinadultyears,and/or
if no treatment is available (eg, for HD or Alzheimer disease), genetic testing of
children is not appropriate (Working Party of the Clinical Genetic Society [UK)
19941. The child's future autonomy will have been breached, and there are
dangers of discrimination (eg, for education, employment or insurance, and
even by parents or other family members), without significant benefits. If onset
is usually in childhood and early intervention will improve the outcome, then it
is good clinical practice to offer genetic testing in childhood. This is particularly
the case if clinical screening in childhood is recommended for thoseatrisk,to
allow early identification and treatment of disease manifestations, as with VHL,
FAP, MEN-1 OR MEN-2 (Gagel 1993), Petersen et a11993, Eng et a11994bl.
Similarly, genetic testing in childhood is appropriate for Marfan disease, if
predictive testing is available for the particular family. On the other hand,
because of the "'ate" and extremely variable age at onset of HNPCC, clinical
screening is not recommended before 20-25 years of age. Genetic testing of
children is therefore not appropriate. For NF-2 and hereditary breast cancer,
similarly, because onset is rarely before 20 years of age, genetictestingshould
only be offered to adults. For hereditary breast cancer, additionally, an
improved outcome because of screening is not certain (Evans 1995).
It is important to revise the classification of late-onset disease using
current knowledge of age at onset. It is also necessary to evaluate clinical
screening programs for multisystem late-onset disorders to determine whether
medical and psychosocial outcomes are improved by early diagnosis and
treatment. Both these forms of evaluation should be completed before the
ethical concerns regarding age for genetic testing are applied to a particular
disease. Some of the criticisms of genetic testing in childhood may then be
recognized as misdirected.
THE VALUE OF SCREENING FOR HEREDITARY TUMOUR SYNDROMES
The Newfoundland fa(Tlilies with hereditary tumour syndromes were
identified because of a concentration of benign or malignant tumours within
each family which had caused serious medical problems and early deaths. It
was also apparent from the time of first contact with the families, that these
diseases had an impact beyond the family members already medically affected.
There was evidence of severe anxiety and stress within families because of the
past illnesses and early deaths, fears were expressed by both affected and
unaffected family members that they or their children would develop
subsequent tumours, and reproductive plans, particularly for VHL, had been
A similar situation is documented in the literature with regard to other
families with VHL, MEN-1, MEN-2, FAP and HNPCC. Symptomatic patients
frequently have advanced disease which is difficult to treat, resulting in early
deaths and disabilities (eg, Vasen et a11987, Lamiell et a11989, Bulow 1991,
Shepherd 1991, Lynch et al 1993cl, and many family members experience
stress when there is a potentially lethal hereditary disorder within the family
(Langsley et al 1964, Yuen et a11984, Gagel 1993).
Although the numbers in each Newfoundland family are too small, and
the ages at diagnosis or death, too variable, for rigorous statistical analysis,
there is evidence that the clinical and genetic screening programsforhereditary
tumour syndromes that have been introduced in Newfoundland and at other
centres, have resulted in reduced morbidity, mortality and anxiety; and
increased understanding of the relevant disease, and of the reproductive
options available. Overall, an improved prognosis and quality of life have been
demonstrated. From the health care evaluation of the VHL screening program,
there is also evidence that the cost of managing patients with a clinical and
geneticscreeningprogramtoachievetheseoutcomes,islessthan the cost of
treating symptomatic disease if the costs related to earlydeathsanddisabilities
To summarize the conclusions and recommendations emerging from the
work described in this thesis, I will briefly recapitulate the main points,
beginning with the least complex program. that for FAP.
Flmili"'d,oom,tgu,pplypQ,i.
In the Newfoundland FAP family, 17 of 19 symptomatic patients had
invasive cancer. and 12 of these died within 6 years of diagnosis: none of the
19 patients identified by clinical screening had invasive cancer. and none died
of the disease. Clinical screening also resulted in a shift to an earlier age at
diagnosis (x of 47 years in those presenting symptomatically, compared with
xof 32 years in those detected by screening).
Successful clinical screening programs for FAP havebeendevelopedat
other centres since 1925 (Bussey 19751, because of the easily identifiable
premalignant stage of FAP (multiple colorect!ll polyps). Results of screening
similar to those of the Newfoundland program have been obtained. The
frequency of cancer, and therefore of cancer deaths. is greatly reduced for
screened vs symptomatic patients (for Denmark. 2% vs 67% [Bulow 1991]),
for Holland 4% vs 47% [Vasen et al 199Oa), for central Canada 5.5% vs 57%
[Berk et al 1987) and for England 5% vs 65% [Bussey 1975]); and there is a
shift to a younger age at diagnosis in screened patients (x, 19yr) compared
with symptomatic patients (x, 33 yrl (Bulow 1986).
It is noted that both symptomatic and screened members of the
Newfoundland family were older at the time of diagnosis than the comparable
symptomatic and screened groups reported in the literature; this is related to
the atypical disease expression in the Newfoundland family (and in a small
proportion of other FAP families [Leppert et al 1990. Spirio et al 1993b).
Although there isa difterent clinical phenotype. regarding the age at onset. and
the number and distribution of polyps. the same successful screeningresults
can be obtained if the atypical disease is recognized. and the clinicalscreening
protocol revised accordingly. With this evidence of decreased morbidity and
mortality because of the Newfoundland and ·other screening programs. there
can belittle doubt that clinical screening forFAP is beneficial.
The recommended investigation for clinical screening (sigmoidoscopy for
typical FAP. or colonoscopy for atypical FAP). however. is not acceptable to all
family members; there is. therefore. some non-compliance. Predictive testing
by linkage analysis (Maher eta11993. Rhodes and Bradburn 1992). or by direct
mutation analysis (Petersen et al 19931. however. is acceptable to many at-risk
family members. and focuses clinical screening on those at highest risk. High
risk genetic testing results may thus increase compliance with endoscopy.
Because of the large size of the APe gene. and unique mutations in the
majority of families. mutations were only identified in 30-60% of families prior
to the development of protein truncation testing (PTT) (Powell et al 1993).
With the use of PTT. and the evidence from recently described genotype-
phenotype correlations, the likelihood of finding the APC mutation is now
improved, and informative CA repeat markers in the region of the APC gene are
also available for linkage analysis if the mutation is not identified. Accurate
predictive testing should therefore be increasingly available for FAP family
Although colorectal cancer is the most frequent tumour in FAP, upper GI
cancers have been documented in approximately 5% of affected persons
(Jagelman 1987). Longer follow-up is required for the Newfoundland and other
FAP families, to determine the long-term prognosis of typical and atypical FAP,
particularly in those who have had prophylactic colectomy. Is there an
increased frequency of upper GI cancers and other tumours in these gene
carriers, now that longer survival is possible? It will also be important to study
attitudes towards clinical and genetic screening in at-risk members of younger
generations who do not have personal experience with the earlydeathsand
morbidity from symptomatic cancer.
ii) Multip'••ndgljrin.n.gpl.'iI tyg.2
Only one patient in the Newfoundland MEN-2 family had symptomatic
disease, a patient with metastatic medullary carcinoma of the thyroid who died
at age 44 within four years of diagnosis. One other patient, now age 53, who
wasidentifiedatthefirstscreeninginvestigation,hasbiochemicalevidenceof
metastatic MTC but is clinically well. Sixteen other family members were
identified by initial or subsequent screening, had MTC confined to the thyroid
or CCH only, and postoperatively have no evidence of residual disease. Vasen
et al (1987) in a more extensive series from the Netherlands, reported similar
resultsofclinicalscreeningforMEN-2,ie,amarkeddecreaseinfrequencyof
metastatic MTC, and improved survival following thyroidectomy; and also
earlier diagnosis and more successful treatment of pheochromocytoma.
Although the age at symptomatic diagnosis of MEN-2 is extremely
variable, the age at diagnosis by screening, for classic MEN-2A families, is
typically in childhood. This is documented in extensive series in Great Britain
(Easton et al 1989), Europe (Calmettes et aI1982), and the USA (Telander et
al 1989). Clinical screening is therefore recommended to begin at least by age
3, and genetic testing should be offered earlier. Later age at onset is
documented for families with FMTC (thyroid disease only), therefore clinical
screening can begin ata later age (Farndon etaI1986).
Genetic testing is available for the majority of MEN-2A and FMTC
families because, in greater than 85% of families, the mutation is found in one
of five cysteine codons near the transmembrane domain of the RET proto-
oncogene (Mulligan et al 1~94). Every MEN-2A or FMTC family identified
should therefore be tested for a mutation in one of these codons. Genetic
testing can then be integrated with clinical screening to provide a complete
management plan for MEN-2A and FMTC families (Gagel 1993, Eng et al
1994b, Ledger et al 1995), with benefits of improved medical outcome and
reduced anxiety.
Although there is a difference in the ability to identify specific mutations
and provide accurate genetic testing for MEN-2 and FAP, these two hereditary
cancersareverysimilarinthehighdisease-relatedmortalitybeforescreening
programs were introduced, and the marked reduction in mortality, morbidity,
and anxiety after screening programs are implemented. As with FAP, longer
follow-up of members of MEN-2 families who have had prophylactic surgery is
necessary, to determine the long-term prognosis, and to assess the interest in,
and compliance with, clinical and genetic screening in children of these
patients.
iii) Myltjpl••ndgGrin.n'gp'I'" 'Yp"
The Newfoundland MEN-1 families have an atypical clinical phenotype
(MEN-1 [Burinll, determined by the relative frequency, and order of occurrence
of parathyroid, pituitary, and pancreatic involvement lie, more frequent
prolactinomas which may be the first manifestation, and rare pancreatic
tumours),and an excess of carcinoid tumours, compared with typical MEN-1.
There is marked intrafamilial variability in disease expression, however, with
about 50'*' of affected family members having hyperparathyroidism only, as in
typical MEN-1. Thus the atypical phenotype cannot be recognized in individual
affected family members. Because small families with this phenotype may not
be identifiable, comprehensive screening is recommended for all MEN-1
families, rather than initial screening for parathyroid disease only as previously
recommended (Marx et aI1986).
The disease-related mortality in symptomatic MEN-1 (Burinl patients was
low compared with the other hereditary tumour syndromes studied. It was also
low compared to typical MEN-1 where mortality is primarily due to pancreatic
disease (which is rare in MEN-1 [Burin)). Disease-related morbidity, however,
was high in symptomatic patients, and was reduced by screening. Unlike for
FAP and MEN-2, immediate prophylactic surgery is not recommended for MEN-
1 patients with positive screening results. Timing of parathyroidectomy is
determined by the physicians, but the recognition of MEN-1-related
hyperparathyroidism determines the appropriate procedure, ie, a subtotal
parathyroidectomy, or total parathyroidectomy with forearm implant, instead
of removal of one parathyroid gland only. Presymptomatic prolactinomas and
gastrinomas (the most common pituitary and pancreatic islet cell tumours,
respectively) are treated medically rather than surgically. Besides the benefit
of early treatment, possible detrimental side-effects of surgery are avoided by
this approach. Carcinoid tumours of the lung or thymus, which are rare in
typical MEN-1, remain the most difficult tumours to detect or treat in MEN-1
(Burin).
Clinical screening programs in Sweden and Holland are primarily directed
at reducing morbidity and mortality from pancreatic disease (Vasen et al 1989b,
Skogseid et al 1991a), but screening for the large Tasmanian family has more
similarities to screening for MEN-1 (Burin) because of the similarities in disease
phenotype (Shepherd 1991, Shepherd et al 1993).
MEN-l and MEN-l (BurinI both map to chr 11q13 but the gene(s) has
not yet been identified. Predictive testing is available by linkage analysis
(Larsson et al 1992, Thakker et al 1993b, Teh et al 1994), however closely-
linked CA repeat markers have not been identified, so predictive testing is not
informative for all MEN-1 family members requesting this testing. The demand
for genetic testing however was lower in the MEN-l (Burin) family than for
familieswiththeotherhereditarytumoursyndromes,becauseclinical screening
is relatively convenient, and MEN-1 (Burin) is seen as a mild disease by some
family members, ie, those whose close relatives had hyperparathyroidism only,
and were successfully treated.
Family members, and their doctors, however, appreciated the education
and counselling provided with the screening program, and the availabilityof
appropriate clinical care when the underlying etiology of disease was
recognized. Thus, the screening program improves the quality of life of family
members as well as improving the medical outcomes.
As with FAP and MEN-2, it is important to continue to document the
clinical course in patients with successfully treated tumours to determinethe
long-term prognosis. When the MEN-l gene is cloned and mutations identified,
it will be possible to search forgenotype/phenotype correlationswhich on the
one hand would refine the development of appropriate screening protocols, and
on the other hand would guide the search for mutations in new MEN-1 families.
iv) H.,.ditarv Dgo-pQlynON' COIgO CloCC.r
Screening for HNPCC is more recent than for the other hereditary tumour
syndromes. in Newfoundland and in other centres. Although Lynch I and Lynch
II syndromes had been described by Henry Lynch and others (eg. Mecklin and
Jarvinen 1986a. Lynch et al 1988. Vasen et al 1990b). families with the Lynch
syndromes (now both called HNPCC) were difficult to distinguish from clusters
of sporadic colon cancer; the age at onset and type of tumours was variable;
and there was no premalignant marker. as in FAP, to reliably detect
presymptomatic disease. Clinical screening was therefore less commonly
recommended than for FAP, and until 1993 the location of the gene (or genes)
involved was unknown so that predictive testing was not an option. Because
of very rapid developments involving a Newfoundland family. this situation has
now changed.
Two independent probands were referred in 1990 for genetic counselling
,
because of an overwhelming medical and psychological burden of disease, for
these individuals and members of their extended families. due to multiple
symptomatic cancers and early cancer deaths in the families previously. A
correct diagnosis had not been made in either family. and the presence of
"hereditary cancer- had even been questioned. Through the initial pedigree
studies and medical record review, a diagnosis of Lynch II syndrome (HNPCC)
was made for each family. and a very similar pattern of cancers (type and age
at onset of tumours) was noted. The geographic origins of the two families
were each in small communities along the north-east coastline, although about
175 km apart. (Were these really two branches of one family as the similar
clinical phenotype, and geographic origin hinted7l
Because of the success of screening programs in Newfoundland for other
hereditary tumour syndromes, this same approach was taken for the HNPCC
families. Education and counselling were provided for family members; clinical
screening, particularly for colorectal and endometrial cancer, was
recommended; and this information was then summarized for the family
doctors. Five cancers (threecolorectalcancers, one endometrial cancer, and
one bladder cancer), and colorectal polyps in ten other affected and at-risk
family members, have since been identified and removed because of this
screening. Family members were extremely grateful for the clinical screening
program, and for the information leading to a bener understanding of HNPCC,
but those at risk continued to ask for a "test" to indicate whether or not they
would also be affected. In 1991, such a test was not possible because the
location of the gene (or genes) for HNPCC was unknown. However the search
was on: the APC gene for. familial adenomatous polyposis had just been
cloned. and several candidate genes for HNPCC had been excluded, but few
informative HNPCC families were available for study.
A fortuitous discussion at the short course in Medical Genetics at the
Jackson Laboratory. Bar Harbour, Maine in July 1991 with members of Bert
Vogelstein's group initiated a collaboration between the laboratoriesatJohns
Hopkins University and the University of Helsinki (with expertise and manpower
for mapping and cloning genes, but lacking informative families), and myself
(with two well-documented HNPCC families - soon to be established as two
branchesofonelargefamily-butwithouttheresourceslocallytocarryout
intensive linkage studies).
The goal of medical genetic research is ultimately to provide better
genetic services for families with hereditary disease; by developing better
methodsofprevention,treatment, and provision of reproductive options, and
by increasing knowledge. At the same time, genetic research is dependent on
individuals or families with well-characterized hereditary conditions identified
and documented by those providing genetic service. The study of hereditary
tumour syndromes in Newfoundland (particularly of HNPCC) presents a striking
example of the beneficial outcomes when genetic services, and genetic
research go hand-in-hand.
Thus, the recognition of an informative HNPCC family and the Willingness
of family members to participate in linkage studies, even though there was no
guarantee of any personal benefit, set the stage for mapping the first HNPCC
gene. Over the next several months, field trips were conducted to small
communities in central Newfoundland for further genetic counselling about the
proposed research, to extend the pedigrees (an 1882 marriage certificate seen
in one home demonstrated the connection between the families), and to collect
blood samples for DNA extraction.
It was then September 1992 - the preliminary work had taken two
years, but a clinical screening program and genetic counselling were in place
for the original and subsequent families with HNPCC, the connection between
the two original HNPCC families was established, and the intensive laboratory
studies with Newfoundland Family C and a large New Zealand family were just
beginning at Johns Hopkins University and the University of Helsinki. Three
hundred and forty-five markers later, in late March of 1993, a gene for HNPCC
was mapped to chr 2p16 (to be reported in the May 7, 1993 issue of Science)
(Peltomaki etaI1993).
As stated in Chapter 5, the first HNPCC gene (hMSH2) was cloned
barely six months later, and mutations detected in three families including
Family C; a new mechanism for predisposition to hereditary tumours was
identified (a defect in mismatch repair genes); and three other DNA repair genes
responsible for clinically indistinguishable disease in other HNPCC families soon
identified (Fishel et al 1993, Leach et a.1 1993, Bronner et al 1994,
Papadopolousetal1994, LiuetaI1994).
In the excitement of the announcements of these breakthroughs, there
were predictions of a "blood test for colon cancer" within 6-12 months. for
relevant families. Public expectations were raised. but frequently the
requirements that defined a "relevant colon cancer family" weremisunderstood;
first, an HNPCC family, and more specifically, one in which the particular
mutation. or at least the specific gene (hMSH2, hMLH1, hPMS1 or hPMS21
was known, so that predictive testing by mutation detection or linkage analysis
was possible. Even for families where the mutation was known (such as family
C), services were not necessarily immediately available to provide the genetic
testing that was requested. Further genetic counselling was necessary
regarding the implications of prediction of future disease (for Family C alone
there were 77 family members at risk over 20 years of age), and proficient
laboratorypersonnelwererequiredtodothegenetictestingonaservice basis.
Because of the rapidity with which molecular genetic progress has taken place,
the medical care system hasyetto·catch up·, and provide the funding for the
necessary manpower and facilities so that" complete programs for clinical
screening and predictive testing for late-onset multisystem diseases such as
HNPCC can be implemented, and the medical and psychosocial benefits
documented in this thesis can be more generally obtained.
For 36 members of Family C, predictive testing is now underway (some
familymemberschosenottoacceptthisoptionbecausetheypreferthatthe
risk of future serious disease remains indefinite, and others have not yet
decided). The results will be provided individually as soon as possible, and
counselling, support, and clinical screening will continue as necessary.
Affected members of other HNPCC families in Newfoundland will then be
tested for the same mutation - if two independent probands were part of one
large family, might not other families, particularly those from the north·east
coast, also be related. If so, genetic testing can immediately be offered to
other families, as has been requested.
Preliminary review of the HNPCC clinical screening program indicates
both medical and psychosocial benefits of screening. Presymptomatic cancers
have been identified and successfully treated, and polyps have been removed
which may have prevented other cancers. Family members are better informed
about HNPCC and the recurrence risks, are less anxious because of the disease
in the family, and are more confident that their physicians will provide
appropriate care. long-term follow-up of these families is required to formally
evaluate the medical and psychosocial outcomes before and after clinicaland
genetic components of the screening program were offered.
From a societal point of view, the real value of the HNPCC screening
program, however, is the research that was facilitated. Members of Family C
presented to Genetics in 1990 requesting a service (predictive testing) which
wasnotyetavaiiable.Counsellingandclinicalscreeninghoweverwere offered.
The documentation of the pedigree and medical records to confirm the
diagnosis and plan the clinical screening protocol set in train a cascade of
events leading to the mapping and cloning of four HNPCC genes, and therefore
the availability of predictive testing, not only for Family C but also for hundreds
of other HNPCC families worldwide.
Von Hipp,I-Lind,ydil"U
As discussed in Chapters 6 and 7, VHL family members presented to the
Ocular Genetics Clinic in 1982 requesting help to prevent or reduce the
disabilities and early deaths that had plagued the family. The extreme anxiety
in affected and unaffected family members was clearly evident. A multi-
disciplinary VHL interest group was formed, and a clinical screening program
was immediately established based on recommendations from the literature,
and the initial medical review of affected family members. As has been
summarized for HNPCC, provision of medical genetic services, and research on
VHL were inter-connected from the start. The large Newfoundland VHL family
was part of studies to map the VHL gene in 1988 which in turn led to
development of genetic testing for this and other VHL families (Seizinger et al
1988, Glenn et al1992, Maher et al 1992). The clinical description of this
family, from medical records and documentation of the results of clinical
screening has contributed to the recent recognition of genotype-phenotype
correlations (Crossey et al1994, Whaley et al1994, Chen et al 1995), but also
demonstrates the extensive.variability possible within a single family. This
documentation of inter- and intrafamilial variability for VHL families is resulting
in more appropriate clinical screening protocolS for individual families.
IntheNewfoundlandfamilies,earlydeathS,neurologicaldisabilities,and
blindness have been reduced by early recognition and treatment of tumours,
facilitated by the clinical screening protocol. Anxiety in affected and unaffected
familymembershasbeenreduced,becauseoftheeducationandcounselling
provided, and because of trust in the clinical screening program. Informed
reproductive choices are possible for most family members, because of early
identification of gene carriers by genetic testing, or by clinical screening if
mutation detection or linkage analysis are not available. As detailed in the
health care evaluation, all this is accomplished with decreased 0 verallcosts,
within and outside the health care system, for management of members of VHL
families because those affected with VHL (or other hereditary cancers) will
require medical care and other support, whether or not screening is provided.
The development and implementation of appropriate clinical and genetic
screening programs for management of hereditary cancers and othertreatable,
late-onset multisystem diseases is strongly recommended because of the
results of screening for hereditary tumour syndromes in Newfoundland and at
other centres. This isa multidisciplinary and preventive approach to health care
in keeping with the trends in other areas of medicine.
Medically, improved outcomes are demonstrated for each disease
studied. This is particularly dramatic for FAP and MEN-2 where in
Newfoundland or as documented in the literature, there is a very high incidence
of cancer and cancer mortality in gene carriers when patients present
symptomatically, and a curable disease for the majority of gene carriersafter
a screening program is implemented, and for VHL where morbidity and
mortality are markedly reduced, although the multiple potential tumours make
·cure" impossible.
Psychologically, there are also dramatic reductions in human anxiety and
suffering, documented in most detail for the Newfoundland VHL family,
because of the education and counselling provided with screening programs,
and the confidence in the clinical screening protocols, as well as the direct
medical benefits from this type of clinical management.
Because of individual personalities and family dynamics, and because of
past experiences, some persons at risk may require more support and
counselling before being willing or able to trust the screening program that is
offered. Patients maybe so devastated by consequences of late treatment of
previous symptomatic disease that they have no faith in the medical care
system, or may be so depressed by identification of new presymptomatic
disease that they have difficulty complying with screening recommendations.
A dedicated screening coordinator must be aware of these potential problems,
and must be available to counsel and support participants through d!fficult
times so that they can obtain maximum benefit from a screening program.
Finally,continuedsuccessofscreeningprogramsforhereditarytumour
syndromes requires financial investment at the outset, for a geneticist!
coordinator and for maintenance of a registry, for personnel and facilities to
develop and provide molecular genetic testing, and for flexibility to respond to
future research developments, so that savings in money and human suffering
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